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ABSTRACT 
Over the past 10 years, Parkinson’s Disease (PD) has been increasingly 
recognised as a disorder encompassing a diverse range of motor and nonmotor 
symptoms (Marras & Chaudhuri, 2016; Williams-Gray et al., 2013). Recent studies 
have begun to subtype mild cognitive impairment (MCI) in PD (PD-MCI) and 
highlight the negative impact of cognitive deficits on quality of life (Goldman et al., 
2015; Klepac, Trkulja, Relja, & Babić, 2008). There is currently limited evidence 
supporting pharmacological treatment for PD-MCI, which has directed the scientific 
community to explore the therapeutic potential of nonpharmacological interventions 
(cognitive training and non-invasive brain stimulation) for cognition in PD (Hindle, 
Petrelli, Clare, & Kalbe, 2013). A significant proportion of people with PD-MCI 
progress to PD-Dementia (Janvin, Larsen, Aarsland, & Hugdahl, 2006). It is 
therefore important that researchers increase their understanding of PD-MCI and 
examine the potential of interventions for alleviating and potentially halting 
cognitive impairment in PD. 
Study 1 examined the prevalence and subtypes of MCI in an Australian 
sample of people with PD. Seventy participants with PD completed 
neuropsychological assessments of their cognitive performance, using the Movement 
Disorder Society (MDS) Task Force Level II diagnostic criteria for PD-MCI. A cut-
off score of less than one standard deviation (SD) below normative data determined 
impaired performance on a neuropsychological test. Of 70 participants, 45 (64%) met 
Level II diagnostic criteria for PD-MCI. Among those with PD-MCI, 42 (93%) were 
identified as having multiple domain impairment (28 as amnestic multiple domain 
and 14 as nonamnestic multiple domain). Single domain impairment was less 
frequent (2 amnestic / 1 nonamnestic). Executive function, attention/working 
memory, and memory were the most frequently impaired domains (> 60% of 
participants). Statistically significant (p < .005) differences were found between the 
PD-MCI and Normal Cognition groups, across all cognitive domains. The results 
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from Study 1 indicate that multiple domain cognitive impairment was more frequent 
than single domain impairment in an Australian sample of people with PD. However, 
PD-MCI is heterogeneous and current prevalence and subtyping statistics may be an 
artefact of variable application methods of the criteria (e.g., cut off scores and 
number of tests). Future longitudinal studies refining the criteria will assist with 
subtyping the progression of PD-MCI, while identifying individuals who may benefit 
from pharmacological and nonpharmacological interventions.  
 
Study 2 examined cognitive training and non-invasive brain stimulation 
interventions for improving cognition in Parkinson’s disease (PD). An extensive 
search was conducted of published and unpublished studies in online databases. 
Studies were selected if they were controlled trials examining standard (not 
individualised) or tailored (individualised) cognitive training, repetitive transcranial 
magnetic stimulation (rTMS), or transcranial direct current stimulation (tDCS) in 
PD, with outcomes measured by standardised neuropsychological tests. 14 controlled 
trials met inclusion criteria. The only controlled trial of tDCS did not provide 
sufficient data for inclusion. For executive function, the pooled effect size (Hedges’ 
g) for cognitive training (standard and tailored combined) was small (g = 0.42) but 
statistically significant (95% CI 0.15 to 0.68). The pooled effect for standard 
cognitive training (alone) was medium (g = 0.51) and statistically significant (95% 
CI 0.16 to 0.85). For attention/working memory, small pooled effect sizes were 
found when combining standard and tailored cognitive training (g = 0.23; 95% CI 
0.02 to 0.44) and for standard cognitive training alone (g = 0.29; 95% CI 0.04 to 
0.53), both statistically significant. For memory, small but statistically significant 
pooled effect sizes were found when combining standard and tailored cognitive 
training (g = 0.33; 95% CI 0.06 to 0.59) and for standard cognitive training alone (g 
= 0.35; 95% CI 0.03 to 0.66). The results suggest that standard and tailored cognitive 
training may improve executive function, attention/working memory, and memory in 
PD. Future studies must adopt randomised controlled trial designs to explore the 
therapeutic potential of these interventions. 
 
Study 3 compared the efficacy of cognitive training, transcranial direct 
current stimulation (tDCS), cognitive training + tDCS for improving cognition in 
people with PD-MCI. Participants were included if they met MDS Task Force Level 
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II criteria for PD-MCI. Participants (N = 42) were randomly allocated to one of six 
groups: (1) Standard Cognitive Training, (2) Tailored Cognitive Training, (3) tDCS, 
(4) Standard Cognitive Training + tDCS, (5) Tailored Cognitive Training + tDCS, or
(6) a control group. Interventions lasted 4-weeks and participants’
neuropsychological performance was measured at baseline, post-intervention (Week 
5) and follow up (Week 12). While controlling for moderator variables (e.g.,
education, disease duration), Generalized Linear Mixed Models (GLMMs) were used 
to analyse outcomes. Compared to the control group: (1) executive function 
significantly improved in the Standard Cognitive Training + tDCS (p < .001) and 
Tailored Cognitive Training + tDCS (p = .024) groups, (2) attention/working 
memory significantly improved in the tDCS (p = .039) and Standard Cognitive 
Training + tDCS (p = .028) groups, (3) memory significantly improved in the tDCS 
(p < .001) and Tailored Cognitive Training + tDCS (p < .001) groups, (4) language 
significantly improved in the Standard Cognitive Training + tDCS (p = .008) and 
Tailored Cognitive Training + tDCS (p < .001) groups, (5) activities of daily living 
improved in the Standard Cognitive Training (p < .001) and Standard Cognitive 
Training + tDCS (p = .014) groups and (6) quality of life improved in the Standard 
Cognitive Training (p = .003) and Tailored Cognitive Training (p = .016) groups. 
Although sample size was small within groups, these preliminary results suggest that 
cognitive training, tDCS, and cognitive training combined with tDCS may improve 
cognition, activities of daily living, and quality of life in people with PD-MCI.  
Overall, this research identified that a significant proportion of people with 
PD meet formal diagnostic criteria for PD-MCI. Cognitive impairment is extremely 
heterogeneous in PD and involves deficits across all cognitive domains. Earlier 
studies examining the potential of nonpharmacological interventions, such as 
cognitive training and non-invasive brain stimulation, were limited by methodology 
(i.e., lack of controlled designs). Combined with the findings of this research, 
however, there is increasing evidence to suggest that cognitive training, tDCS, and 
cognitive training combined with tDCS may induce neural plasticity in people with 
PD-MCI, which leads to significant improvements in cognition. It is recommended 
that future studies build upon the preliminary findings from this research and 
continue to explore the potential of nonpharmacological interventions for improving 
cognition and quality of life for people with in PD and PD-MCI.
1 
OVERVIEW OF THESIS 
This thesis contains five chapters. Chapter 1 provides an overview of 
Parkinson’s Disease (PD), motor and non-motor symptoms, as well as current 
treatment options. Chapter 1 also provides a brief review of mild cognitive 
impairment and cognitive function in healthy ageing and neurodegenerative disorders 
(e.g., PD and Alzheimer’s Disease), followed by an introduction to 
nonpharmacological interventions (cognitive training and non-invasive brain 
stimulation) for mild cognitive impairment and mild cognitive impairment in PD.  
Chapter 2 presents the results of Study 1, which describe the prevalence and 
subtypes of mild cognitive impairment in PD (PD-MCI). Study 1 applied the 
Movement Disorder Society (MDS) Task Force Level II diagnostic criteria for PD-
MCI to an Australian sample of people with PD. The aim of Study 1 was to explore 
frequency differentials of PD-MCI subtypes at varying diagnostic cut off scores and 
provide recommendations for future studies administering the MDS criteria in PD. 
Chapter 3 presents the results from Study 2, which begins with a review of all 
controlled and uncontrolled cognitive training and non-invasive brain stimulation 
studies for cognition in PD. Following this, Study 2 presents the results of the first 
meta-analysis of all controlled cognitive training and non-invasive brain stimulation 
studies for cognition in PD. The aim of Study 2 was to summarise the current 
therapeutic potential of nonpharmacological interventions for cognition in PD and 
the implications of the findings for future clinical trials. 
Chapter 4 presents the results from Study 3, which was the first randomised 
controlled trial of standard cognitive training, tailored cognitive training, transcranial 
direct current stimulation (tDCS), standard cognitive training + tDCS, and tailored 
cognitive training + tDCS for PD-MCI. Previous studies had examined the potential 
of these interventions individually, but none had combined these interventions in a 
2 
 
randomised controlled trial in PD-MCI. The aim of Study 3 was to investigate which 
intervention was most efficacious for improving cognition, activities of daily living, 
and quality of life for PD-MCI.   
 
 Chapter 5 provides a general discussion of the findings from this thesis and 
integrates the findings within the context of current research. Chapter 5 concludes 
with recommendations for future prevalence and interventional studies examining 


































 Most developed countries are experiencing significant demographic changes, 
with increasingly large proportions of their population entering older age groups 
(World Health Organisation, 2015). Parkinson’s Disease (PD) predominantly affects 
individuals over the age of 50 and with an ageing population, the number of people 
with PD is expected to rise (Dorsey et al., 2007). Following diagnosis people with 
PD live approximately 7 to 14 years, but increasing age and presence of dementia are 
associated with a decreased rate of survival (Macleod, Taylor, & Counsell, 2014). 
During this time, people with PD experience a range of motor and non-motor 
symptoms (e.g., mild cognitive impairment) that are heterogeneous and negatively 
impact the health and quality of life of the individual and their family (Aarsland et 
al., 2010; Marras & Chaudhuri, 2016; Muslimović et al., 2008). It is therefore of 
paramount importance that researchers explore all avenues of pharmacological 
treatments and nonpharmacological interventions that may have the potential to 
alleviate motor and nonmotor symptoms, and improve quality of life for people with 
PD. 
 
This chapter is divided into two sections. The first half provides context for 
this research and includes a brief overview of PD, its aetiology, epidemiology, 
clinical presentation, and current treatments. The second half of the chapter focuses 
on cognition and mild cognitive impairment in PD, by providing an overview of mild 
cognitive impairment in healthy and PD populations, followed by neural and 
cognitive plasticity in older adults and neurodegenerative disorders (e.g., 
Alzheimer’s disease [AD] and PD). This chapter closes with a brief review of the 
therapeutic potential of nonpharmacological interventions for mild cognitive 
impairment and PD. 
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1.2 Nosology of Parkinson’s Disease 
 
PD is classically defined as a member of the parkinsonism group of 
movement disorders and is characterised by four cardinal motor symptoms: postural 
instability, rigidity, rest tremor, and bradykinesia (Calne, 2005). Research over the 
past two decades has led to a profound development in our understanding of PD, 
with increasing knowledge of nonmotor symptoms, discovery of biomarkers and 
their role in disease progression, as well as recognition that neural degeneration may 
precede clinical manifestation of motor symptoms (Berg et al., 2014). This increase 
in our understanding has led to a proposal for a new definition of PD (see Berg et al., 
2014). For the purpose of the current research, however, the classical definition of 




 Most cases of PD are described as idiopathic meaning the causative factor is 
unknown (Bartels & Leenders, 2009). However, post-mortem studies provide 
substantial evidence that almost all people with PD experience a death of 
dopaminergic cells in the substantia nigra pars compacta (SNc), which results in a 
severe loss of dopamine across multiple brain circuits (Bartels & Leenders, 2009). 
Dopamine depletion impacts several cortical circuits (e.g., motor, limbic, cognitive) 
and their associated behavioural representations (Alexander & Crutcher, 1990).  The 
motor circuit is most predominantly impacted by the loss of dopamine and is 
associated with the development of motor symptoms (Lewis & Barker, 2009). Large 
genome wide association studies also provide evidence linking genetic abnormalities 
and the onset of PD (Collins, Cummins, & Barker, 2015; Kasten & Klein, 2015). 
Specifically, two recent studies identified an association between a mutation of the 
glucocerebrosidase gene and earlier age onset of PD (Lill et al., 2015; Nalls et al., 
2015). The worldwide genetic risk of PD has demonstrated poor clinical prediction 
of future diagnosis, however, more studies are providing consistent evidence of 
genetic abnormalities that are associated with the aetiology of PD (Darweesh et al., 
2016). Overall, there is a current understanding that PD is individually heterogeneous 
and the consequence of several neurotransmitter and genetic abnormalities, yet 





 PD is the second most common neurodegenerative disorder, following AD, 
and affects individuals across developed and developing nations (De Lau & Breteler, 
2006). Meta-analytic evidence indicates that the prevalence of PD increases with age 
and is associated with minor gender and geographical differences (Pringsheim, Jette, 
Frolkis, & Steeves, 2014). Pringsheim (2014) and colleagues reported that the global 
prevalence of PD steadily increases from 41 people (per 100,000) within 40 to 49 
years of age, to 1903 people at 80 years and older. The incidence of PD among 
women was less than among men, however, this was only prevalent for individuals 
aged 50 to 59 years. Compared to people from North America, Europe, and Australia 
the prevalence of PD was less among those from Asia, but only between 70 to 79 
years (Pringsheim et al., 2014). In Australia, 67,000 people were living with PD in 
2011 and more than 80% of those individuals were over the age of 65 (Access 
Economics, 2011). Each day in Australia there are approximately 30 people 
diagnosed with PD and this figure will likely increase with the ageing population 
(Access Economics, 2011). Although clinical (compared to pathological) diagnoses 
are less accurate at correctly diagnosing people with PD and may falsely inflate 
prevalence statistics (Hughes, Daniel, Kilford, & Lees, 1992), there is considerable 
evidence to indicate that the prevalence of PD is relatively consistent across all main 
geographical locations and will increase with the ageing population. 
 
1.5 Clinical Presentation 
 
1.5.1 Diagnosis 
The United Kingdom Parkinson’s Disease Society Brain Bank Clinical 
Diagnostic Criteria has been used as the predominant diagnostic tool for PD (Bartels 
& Leenders, 2009). The UK criteria state that in conjunction with a response to 
levodopa medication, a minimum of two from three motor symptoms (tremor, 
bradykinesia, rigidity) must be present to satisfy a clinical diagnosis of PD (Hughes 
et al., 1992). However, the Movement Disorder Society (MDS) recently published 
updated criteria for clinical diagnosis of PD, which involve an extensive clinical 
examination and several diagnostic stages with multiple inclusion and exclusion 
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criterion (Postuma et al., 2015). The MDS-PD criteria applies the following stages to 
determine a diagnosis of PD:  
1. Establish if an individual has parkinsonism, defined as presence of 
bradykinesia in combination with either rest tremor, rigidity, or both. 
2. Following a positive diagnosis of parkinsonism there must be an absence of 
absolute exclusion criteria, for example: 
i. Dementia, aphasia, normal dopaminergic system, or no response to 
levodopa therapy. 
3. Following exclusion criteria the individual must meet two supportive criteria: 
i. A clear and dramatic response to dopaminergic therapy 
ii. Marked on/off fluctuations associated with dopaminergic therapy and 
worsening of parkinsonian symptoms during wearing off stages 
4. Following the supportive criteria there must be no presence of potential red 
flags that may compromise an accurate diagnosis of PD, for example: 
i. Absence of motor symptoms or common nonmotor symptoms, 
autonomic failure, or presence of bilateral symmetric parkinsonism.  
As noted by the authors, however, there is currently no scientific method 
available to ensure full diagnostic certainty of PD during life, with up to 95% of 
people having their diagnosis confirmed via autopsy (Postuma et al., 2015; Rajput, 
Rozdilsky, & Rajput, 1991). Nonetheless, the MDS-PD diagnostic criteria provide a 
thorough assessment of motor symptoms associated with parkinsonism and extensive 
inclusion and exclusion criteria to increase certainty in future diagnoses of PD. 
 
1.5.1 Motor Symptoms 
 As previously noted, rest tremor, rigidity, bradykinesia, and postural 
instability/gait disturbance are the four cardinal motor symptoms of PD 
(Pagonabarraga, 2010). These symptoms normally present as unilateral and remain 
most severe on this side throughout the disease course (Haaxma et al., 2010). Tremor 
is identified as involuntary movements in the limbs and (less frequently) in the lips 
and jaw (Carr, 2002). Rigidity is a tensing and stiffness that is experienced 
throughout the muscles of the body (Bartels & Leenders, 2009). The stiffness and 
tensing associated with rigidity often causes irregular movements and an inability to 
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complete continuous actions. As hallmark feature of PD, bradykinesia is 
characterised by a slowness in initiating movements and an overall reduction in the 
speed and amplitude of movement (Pagonabarraga, 2010). Clinically manifested as 
short shuffling steps, postural instability/gait disturbance limits an individual’s 
ability to move through their environment (specifically narrow spaces), and increases 
the probability of falls and associated injuries (Hanakawa et al., 1999). Although 
specific symptoms (i.e., tremor) are frequently occurring, PD is heterogeneous and 
motor subtypes have been developed in an attempt to account for the variability in 
severity and presentation of motor symptoms. These subtypes are known as tremor-
predominant or postural instability/gait disorder (PIGD)-predominant (Lewis et al., 
2005). Research suggests that rigidity and bradykinesia worsen over the disease 
course, whereas tremor severity may remain stable (Jankovic, 2008). 
 
 The Hoehn and Yahr scale is a frequently used measure of severity of PD 
progression (Goetz et al., 2004; Maetzler, Liepelt, & Berg, 2009). The Hoehn and 
Yahr scale describes five stages of PD: Stage 1, the person with PD has slowness of 
movement and unilateral tremor and rigidity. At Stage 2, there is an increase in 
slowness of movement, combined with a loss of facial expression and bilateral 
tremor and rigidity. At Stage 3, the most dominant symptoms increase in severity 
combined with a loss of balance. At Stage 4, severity of motor symptoms progress 
and the person with PD may lose physical independence, and at Stage 5 the 
individual will likely be limited to a wheelchair or be bedridden (Goetz et al., 2004). 
It is also important to note that research has identified ‘mild parkinsonian signs’ 
defined as subtle features of the motor symptoms that do not meet a formal diagnosis 
of PD, but precede onset and stage one of the disease (Louis & Bennett, 2007; 
Mahlknecht, Seppi, & Poewe, 2015).  
 
1.5.1.1 Treatments for Motor Symptoms. Anti-parkinsonian medications 
are the most common form of pharmacological treatment and reduce morbidity and 
improve motor symptoms in the early stages of PD (Chou, 2012; Fung, Herawati, & 
Wan, 2009). Levodopa is the most effective treatment option for motor symptoms of 
PD (Collins et al., 2015). Over the past 40 years, studies have demonstrated a 
significant reduction in the severity of motor symptoms following treatment with 
levodopa (Fahn et al., 2004). However, there has been a long standing debate among 
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clinicians as to when levodopa treatment is most effective for people with PD (Fahn 
& Bressman, 1984). There are considerable side effects associated with levodopa 
therapy which negatively impact quality of life (Collins et al., 2015). Evidence 
suggests that people treated with levodopa for more than 4 to 6 years increase their 
risk of living with dyskinesias (involuntary movements) by up to 40% (Ahlskog & 
Muenter, 2001). Levodopa treatment is also accompanied by ‘ON/OFF’ periods, 
which result in significant beneficial effects that reduce motor symptoms (ON 
period), followed by significant worsening of motor symptoms (OFF period). The 
rollercoaster experience of ON/OFF periods has a detrimental impact upon an 
individual’s quality of life (Rahman, Griffin, Quinn, & Jahanshahi, 2008). Those 
classified as ‘young onset’ (< 50 years of age) with the potential to live for several 
decades with PD, may consider postponing levodopa therapy to maintain their 
quality of life and only begin treatment when motor symptoms increase in severity 
(Collins et al., 2015). There is, however, an argument for starting levodopa treatment 
early in the disease course. A recent study demonstrated that compared to 
participants who delayed levodopa therapy for several years, participants who started 
treatment early reported significant improvements in functional and quality of life 
scores (PD Med Collaborative Group, 2014). Due to the diversity of motor 
symptoms in PD and the potential negative side effects that accompany levodopa 
therapy, the decision to begin this line of treatment must always be made through 
consultation with a physician or geriatrician.  
 
Other common pharmacological treatments for motor symptoms include 
dopamine agonists and monoamine-oxidase B inhibitors (Collins et al., 2015). 
Dopamine agonists are frequently only used as a first treatment option in de novo 
(newly diagnosed) PD and to precede long-term treatment with levodopa (Watts, 
1997). However, dopamine agonists have also shown efficacy as a supplemental 
therapy for people with advanced PD (Goetz, Blasucci, & Stebbins, 1999). The side 
effects associated with treatment with dopamine agonists are diverse and may 
include, impulse control disorders (e.g., gambling, hypersexuality, binge eating), 
hallucinations, nausea, and drowsiness (Chaudhuri & Schapira, 2009; Weintraub et 
al., 2010). Considering the potential consequences associated with the side effects 
(specifically, impulse control disorders) of dopamine agonists, regular clinical 
consultation and monitoring of treatment effects are recommended. Producing more 
9 
 
modest beneficial effects for motor symptoms than levodopa, MOAB inhibitors 
(selegiline and rasagiline) may also be prescribed as a therapy for PD (Marconi & 
Zwingers, 2014; Parkinson Study Group, 2004). In short, MOAB inhibitors prevent 
the breakdown of dopamine, which ensures increased levels of dopamine are 
maintained within cortical networks susceptible to dopamine depletion in PD 
(Collins et al., 2015). Few studies have examined the long-term efficacy of MOAB 
inhibitors, however, one study demonstrated slower disease progression over an 18-
month period of treatment (Olanow et al., 2009). Generally, MOAB inhibitors are 
well tolerated with few side effects (Davis et al., 2013).  
 
For people with advanced PD ( HY stages 4 to 5), apomorphine, deep brain 
stimulation (DBS), and duodopa are potential avenues for treatment of motor 
symptoms (Worth, 2013). Apomorphine is a strong dopamine agonist and is 
delivered via either bolus injections or a subcutaneous pump (Martinez‐Martin et al., 
2015). For some individuals with PD, apomorphine may cause side effects including 
psychiatric episodes and nausea/vomiting (Collins et al., 2015). Unlike the 
previously described pharmacological treatments, DBS is a neurosurgical procedure 
and often provided to individuals who have developed a resistance to the beneficial 
effects of levodopa, but maintain severe motor symptoms (Volkmann et al., 2013). 
The DBS procedure involves insertion of an electrode into the brain to stimulate the 
subthalamic nucleus during ‘OFF’ periods of levodopa use, which alleviates 
dyskinesias in PD (Williams et al., 2010). As with most neurosurgical procedures 
there are considerable risks involved with DBS (e.g., infection, haemorrhage, 
electrode wire breakage), and treatment is often only recommended to people later in 
the disease course and following unsuccessful attempts at other treatment avenues 
(Benabid, Chabardes, Mitrofanis, & Pollak, 2009). Duodopa is a system that delivers 
a levodopa gel to the small intestine and has also shown efficacy in treating motor 
symptoms in people in the later stages of PD (Nyholm, 2012). However, the cost is 
considerable (AUD$60,000 per annum) and individuals usually need to explore other 




1.5.2 Non-Motor Symptoms 
PD is not confined to motor symptoms, with non-motor symptoms often 
impacting quality of life to a greater extent (Chaudhuri, Healy, & Schapira, 2006; 
Marras & Chaudhuri, 2016). Recent studies report at least one non-motor symptom 
in up to 100% of participant groups with PD (Kim et al., 2013; Krishnan, Sarma, 
Sarma, & Kishore, 2011). As with motor symptoms, nonmotor symptoms are 
heterogeneous and prone to fluctuations in severity (Khoo et al., 2013; Witjas et al., 
2002). Non-motor symptoms can present during early stages of the disease course 
(Zis et al., 2015), such as olfactory dysfunction, which may develop among people 
with de novo PD (Chand & Litvan, 2007). Other non-motor symptoms include, 
depression, anxiety, impulse control disorders, pain, mild cognitive impairment, and 
dementia (den Brok et al., 2015; Marras & Chaudhuri, 2016; Mylius et al., 2015; 
Pfeiffer, 2016). Dementia and depression are recognised as the most detrimental 
nonmotor symptoms to impact quality of life among people with PD (Burn, 2002; 
Kadastik-Eerme et al., 2016). Meta-analytic results indicate that major depression is 
present in up to 17% of people with PD, minor depression in 22%, and dysthymia 
(mild depression) in 13% (Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008). 
Preceded by mild cognitive impairment, up to 50% of people with PD progress to 
dementia within 10 years from diagnosis (Williams-Gray et al., 2013).  
  
 1.5.2.1 Treatments for Non-Motor Symptoms. Due to the heterogeneity of 
nonmotor symptoms in PD, there are often multiple treatment options available to 
alleviate the comorbidity of these symptoms. Serotonin reuptake inhibitors (SSRIs) 
are the most common and effective treatment for depression and have shown 
beneficial effects for anxiety in PD (Chen & Marsh, 2014; Weintraub, Moberg, 
Duda, Katz, & Stern, 2003). SSRIs increase serotonin levels in the brain and have 
been used extensively in healthy and psychiatric populations (Aarsland, Påhlhagen, 
Ballard, Ehrt, & Svenningsson, 2012; Troeung, Egan, & Gasson, 2013). Tricyclic 
antidepressants are also used to treat depression and anxiety in PD (Menza et al., 
2009). There is currently no recommended treatment for impulse control disorders in 
PD. However, recent studies demonstrated that an anticonvulsant (topiramate) and 
antiepileptic (zonisamide) may benefit individuals experiencing impulse control 
disorders associated with PD (Bermejo, 2008; Bermejo, Ruiz-Huete, & Anciones, 
2010). Olfactory dysfunction is common in up to 90% of people with PD, however, 
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there is currently no therapy to alleviate this symptom (Pfeiffer, 2016). There is also 
limited evidence to support treatments of mild cognitive impairment and dementia in 
PD (Burn, 2010). Preliminary studies report that cholinesterase inhibitors and 
memantine demonstrate beneficial but limited effects on mild cognitive impairment 
and dementia (Goldman & Weintraub, 2015). In addition, DBS has shown a 
worsening effect on cognitive function, despite the potential benefits of 
neurostimulation for motor symptoms (Rothlind et al., 2014). The current lack of 
empirical evidence to support pharmacological and surgical interventions for 
cognitive impairments in PD has led researchers to explore the therapeutic potential 
of nonpharmacological interventions, such as cognitive training and non-invasive 
brain stimulation (Hindle et al., 2013). 
 
 The next half of this chapter will briefly review mild cognitive impairment 
(MCI) in healthy ageing and in PD (PD-MCI), and provide an introduction to neural 
plasticity and nonpharmacological interventions for MCI.  
 
1.6 Mild Cognitive Impairment 
 
A proportion of older adults will experience cognitive decline, typically 
characterised by memory loss (Petersen, 2011).This such decline is normal and does 
not warrant clinical intervention (Petersen, 2011; Petersen et al., 1999). However, the 
theoretical framework of ‘mild cognitive impairment’ has been developed for people 
who experience more severe cognitive deficits (Winblad et al., 2004). The 
Diagnostic and Statistical Manual for Mental Disorders (DSM-5) describes ‘mild 
neurocognitive disorder’ as increased cognitive decline from a previous 
neuropsychological assessment, with the individual conscious of decline but the 
cognitive deficits not affecting activities of daily living (American Psychiatric 
Association, 2013). Throughout this thesis mild cognitive impairment (MCI) will be 
defined as a decline in cognition that does not interfere with an individual’s daily 
activities, but is not normal for age or level of education (Gauthier et al., 2006). 
 
MCI reflects the interim stage between normal cognitive functioning and 
probable AD or another dementia (Petersen, 2011). There are four subtypes of MCI 
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(amnestic single, amnestic multiple, non-amnestic single, and non-amnestic multiple) 
and classification depends upon the affected cognitive domain (memory, attention, 
visuospatial, executive function, and language; Petersen, 2011; Winblad et al., 2004). 
Amnestic single and multiple MCI are significant memory impairments that do not 
meet the criteria for a dementia diagnosis, the latter involving more than one domain 
deficit (Petersen, 2011). Non-amnestic single and multiple MCI are a decline within 
one or multiple cognitive domains other than memory (Petersen, 2011).  
 
Petersen et al. (1999) proposed that impaired memory distinguished those 
with MCI and those without, suggesting MCI is a predictor of AD or dementia 
(Petersen et al., 1999). However, those with MCI demonstrate deficits in domains 
other than memory (Ribeiro, De Mendonca, & Guerreiro, 2006). Ribeiro and 
colleagues (2006) characterised domain deficits in MCI. Memory impairment was 
present for 63% of participants, visuospatial for 69%, and language for 34% (Ribeiro 
et al., 2006). Saunders and Summers (2011) examined non-memory cognitive 
deficits in MCI and found significant impairment in attention and executive 
functioning. These findings indicate that deficits in all cognitive domains, including 
memory, are representative of MCI.  
 
Among older adults (> 65 years old), the prevalence rate of MCI is 10 – 30%, 
and amnestic is more common than non-amnestic (Ding et al., 2015; Manly et al., 
2008; Pankratz et al., 2015; Petersen et al., 2010). MCI is more prevalent in men and 
among un-married people. Longer formal education is associated with a lower rate of 
MCI (Petersen et al., 2010). Evidence suggests that MCI is a heterogeneous 
condition, with participants with MCI performing significantly worse than controls 
on neuropsychological tests examining all cognitive domains (Nordlund et al., 2005). 
This poses a challenge for clinicians examining MCI characteristics as early 
predictors of AD/dementia (Nordlund et al., 2005; Saunders & Summers, 2011).  
 
MCI is considered a precursor to AD or dementia. However, reported 
conversion rates vary (Rasquin, Lodder, Visser, Lousberg, & Verhey, 2005). Manly 
et al. (2008) conducted a large multi-ethnic study and found 22% of participants with 
MCI at baseline were diagnosed with AD at a 24 month follow-up. Participants with 
MCI were three times more likely to later demonstrate AD than healthy older adults 
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(Manly et al., 2008). Conversely, Petersen et al. (2005) reported a conversion rate to 
dementia of more than 90% for people with amnestic MCI, suggesting that dementia 
is the inevitable endpoint of MCI (Petersen et al., 2005). To clarify these differences, 
Mitchell and Shiri‐Feshki (2009) calculated a meta-analytic annual conversion rate 
of 6.7% to dementia and 6.5% to AD, with the progression to dementia rarely 
exceeding 50% even after 10 years to follow up. These results suggest that a 
proportion of people living with MCI do not progress to AD or dementia.  
 
Many older adults experience a range of cognitive deficits over extended or 
indefinite periods of time (Gauthier et al., 2006; Nordlund et al., 2005). Development 
of the MCI construct in the healthy non-clinical population has led to its application 
in people with neurodegenerative disorders, such as PD (Litvan et al., 2011). 
However, the progression of MCI and domains of impairment in PD are markedly 
different to the healthy population and those with AD (Besser et al., 2016; Caviness 
et al., 2007). 
 
1.6.1 MCI in PD 
PD-MCI is described as “cognitive decline that is not normal for age but with 
essentially normal functional activities … even at the time of PD diagnosis and prior 
to initiation of dopaminergic therapy” (Litvan et al., 2011, p. 1815). Controversy 
surrounds the use of ‘MCI’ as a construct in PD (Dubois et al., 2007; Poletti, Emre, 
& Bonuccelli, 2011). Some researchers suggest that due to the heterogeneity of PD-
MCI and the proportion of individuals reverting back to normal cognition, 
diagnosing mild cognitive deficits in people with PD provides no current benefit to 
the individual and needs to be avoided, except for research purposes (Korczyn, 
2016). There is increasing evidence, however, supporting PD-MCI as a stage of 
cognitive functioning often present at PD onset and preceding PD-Dementia (Barone 
et al., 2011; Chahine et al., 2016). Recent studies have also identified relationships 
between cognitive impairment and the asymmetric onset of motor symptoms (Lee et 
al., 2015), the postural instability/gait disturbance subtype (Kelly et al., 2015), and 
features of biomarkers that may predict onset of cognitive decline in PD (Delgado‐




1.6.2 Epidemiology of PD-MCI 
Among people with de novo and untreated PD, up to 10% demonstrate PD-
MCI (Weintraub et al., 2015). In those with more advanced PD, Foltynie, Brayne, 
Robbins, and Barker (2004) found 36% of participants demonstrated cognitive 
impairments across four neurological subtypes: intact, frontostriatal, temporal lobe, 
and frontostriatal + temporal lobe. Three and half years later, a similar proportion of 
the participants met the criteria for MCI and 10% of the original participants had 
progressed to dementia (Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007). 
The same healthy ageing MCI subtypes (amnestic single, amnestic multiple, 
nonamnestic single, and nonamnestic multiple) have also been reported for PD-MCI 
(Litvan et al., 2011; Petersen, 2011).  
 
In a multicentre study of 1346 people with PD, Aarsland et al. (2010) found 
26% had PD-MCI; with memory impairment in 13%, visuospatial impairment in 
11%, and attention/executive function impairment in 10%. Nonamnestic MCI was 
the most common subtype (11%), in contrast to amnestic MCI being most common 
in healthy older adults (Aarsland et al., 2010). A recent systematic review found that 
26% of nondemented people with PD also have MCI and nonamnestic single domain 
is more common than amnestic single domain (Litvan et al., 2011). Litvan et al. 
(2011) concluded that people with PD-MCI are at increased risk of progression to 
PD-Dementia. 
 
1.6.3 PD-MCI as a Predictor of PD-Dementia 
The predictive value of PD-MCI to PD-Dementia emphasises the need to 
diagnose PD-MCI early. Over a 5-year follow-up from initial PD diagnosis, 
Williams-Gray et al. (2009) reported that 17% of those with PD-MCI progressed to 
PD-Dementia at a rate four times the normal population. In a 4-year longitudinal 
study, Janvin, Aarsland, and Larsen (2005) found that 69% of nonamnestic single, 
63% multiple domain, 40% amnestic single, and 20% with intact cognition had 
progressed to PD-Dementia. Irrespective of the high conversion rates, there is limited 
research into those PD-MCI subtypes which predict PD-Dementia (Barone et al., 
2011). Research suggests that impaired executive functions, verbal fluency, and 
visuospatial/language abilities are predictors of PD-Dementia (Hobson, Meara, & 
15 
 
Evans, 2013; Janvin et al., 2005; Levy et al., 2002; Mahieux et al., 1998; Ramirez-
Ruiz, Junque, Martí, Valldeoriola, & Tolosa, 2007). It is estimated that up to 80% of 
people are affected by dementia, with male gender associated with increased risk of 
dementia, and it has been identified as the most frequently associated symptom of 
increased mortality in PD (Aarsland, Zaccai, & Brayne, 2005; Cereda et al., 2016; 
Macleod et al., 2014; Reid, Hely, Morris, Loy, & Halliday, 2011). 
 
1.6.4 Heterogeneity of PD-MCI 
PD-MCI can be classified as four subtypes (amnestic single, amnestic 
multiple, nonamnestic single, and nonamnestic multiple), reflecting deficits across 
the five cognitive domains: memory, attention, language, visuospatial, and executive 
functions (Kehagia, Barker, & Robbins, 2010; Muslimovic, Schmand, Speelman, & 
De Haan, 2007). Muslimovic et al. (2007) conducted a meta-analysis examining 
patterns of cognitive impairment in people with PD. They concluded that, although 
changes in cognitive functioning are subtle, the first impaired domain may dictate the 
course of cognitive impairment (Muslimovic et al., 2007). The heterogeneity of PD-
MCI adds to the diagnostic complexity for clinicians and researchers, which has led 
to the development of standardised diagnostic criteria (Litvan et al., 2012; Verleden, 
Vingerhoets, & Santens, 2007). 
 
1.6.5 Diagnostic Criteria for PD-MCI 
Neuropsychological test batteries have been used to identify cognitive 
impairments in PD (Barone et al., 2011). However, administration often varies 
(limiting external validity) and the use of generic measures in PD reduces reliability 
of results (Barone et al., 2011). Mamikonyan et al. (2009) examined the Mini-Mental 
Status Examination’s (MMSE) ability to assess MCI in participants with PD. Thirty 
percent of participants with PD had MCI across memory, attention, and executive 
function domains. However, the same participants were classified as having ‘normal’ 
cognitive functioning according to the MMSE criteria (Mamikonyan et al., 2009). 
Although the MMSE is the most widely used measure of global cognitive 
impairment, these results highlight the need for standardised PD cognitive 
assessments and diagnostic criteria (Mamikonyan et al., 2009). 
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Diagnostic practise was to classify a person with PD-MCI if their 
performance on a neuropsychological test was 1.5 standard deviations (SDs) below 
the normative mean for that test (Barone et al., 2011). However, Litvan et al. (2011) 
suggests that PD-MCI should not be solely diagnosed by a test score, but should be 
supported by self-reported changes in cognition. Due to heterogeneity in the 
pathology and neuropsychological measures of PD-MCI, the Movement Disorders 
Society developed standardised diagnostic criteria for people with PD who present 
with cognitive impairments (Litvan et al., 2012). The diagnostic criteria increases 
uniformity across research and clinical practice and the authors urge health 
professionals to validate the criteria in the PD-MCI population (Litvan et al., 2012). 
Recent studies have begun to examine the psychometric properties and diagnostic 
accuracy of the new criteria for PD-MCI (e.g., Cholerton et al., 2014). However, no 
study has applied the diagnostic criteria to an Australian sample of people with PD 
and further validation and refinement of the criteria is required. 
 
1.6.6 Correlates of PD-MCI and Impact on Quality of Life 
Older age, more severe PD, less years of formal education, late disease onset, 
apathy, and depression are associated with more rapid cognitive decline in PD 
(Dujardin, Sockeel, Delliaux, Destée, & Defebvre, 2009; Foltynie et al., 2004; 
Mamikonyan et al., 2009; Muslimović, Post, Speelman, & Schmand, 2005; Pai & 
Chan, 2001; Starkstein, Mayberg, Leiguarda, Preziosi, & Robinson, 1992). Presence 
of hallucinations and apathy are also associated with executive function impairments 
in PD-MCI (Kulisevsky, Pagonabarraga, Pascual‐Sedano, García‐Sánchez, & 
Gironell, 2008).  
 
MCI impacts activities of daily living and quality of life in people with PD 
(Lawson et al., 2016; Litvan et al., 2012; van Uem et al., 2016) Rosenthal et al. 
(2010) examined the functional impact of cognitive deficits on activities of daily 
living in PD-MCI and PDD, and found impaired activities of daily living in both 
groups. Klepac et al. (2008) examined the relationship between health-related quality 
of life and cognitive performance in people with PD. Participants with better 
performance on measures of executive and visuospatial functions, visual 
attention/memory, and global cognitive performance reported a better health-related 
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quality of life (Klepac et al., 2008). This suggests that cognitive deficits are 
associated with poorer activities of daily living and quality of life in PD (Klepac et 
al., 2008; Rosenthal et al., 2010). 
 
1.7 Neural Plasticity 
 
At the age of 65, adults experience a decline in behavioural and cognitive 
function (Yan, 2000). The importance of neural plasticity is most apparent for this 
cohort (Cai, Chan, Yan, & Peng, 2014). Neural plasticity is the central nervous 
system’s (CNS) adaption of anatomical structures (neurons, glial cells, synapses, and 
blood vessels) and physiological processes following active engagement in cognitive 
and motor training (Ballantyne, Spilkin, Hesselink, & Trauner, 2008; Cai et al., 
2014). By maintaining an active lifestyle, older adults strengthen their neural 
plasticity and experience less cognitive and physical decline (Stein & Hoffman, 
2003). However, achieving ‘successful ageing’ is more challenging for those at risk 
of MCI and dementia (Kramer, Erickson, & Colcombe, 2006). 
 
When an individual acquires new knowledge or skills in response to training, 
the information either strengthens the existing neural pathways and networks 
(building upon existing knowledge) or develops a new series of neural circuits and 
synapses (Wall, Xu, & Wang, 2002). During cognitive training an individual is 
exposed to repeated stimuli or required to practice cognition focused exercises (Cai 
et al., 2014). Neurons related to that exercise are simultaneously activated, which 
strengthens/modifies their firing in response to the learning experience (Cai et al., 
2014). The strengthening of neuronal connections is known as synaptogenesis and is 
fundamental to neural plasticity (Ponti, Peretto, & Bonfanti, 2008). Synaptic changes 
in cerebral cortex activation occur in response to experience-dependent learning and 
have been demonstrated across the life-span into older age (Hill, Kolanowski, & Gill, 
2011; Wall et al., 2002).  
 
Experience-dependent neural plasticity (learning) is a complex process, 
influenced by age and pathology, which relies upon different cortical regions and the 
type of stimulus used (Cai et al., 2014; Johnson, 2003; Kim & Kim, 2014). Belleville 
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and colleagues (2011) investigated the potential of neural plasticity to reverse brain 
changes associated with MCI. Functional magnetic resonance imaging (fMRI) was 
used to monitor the pattern of neural activation among older adults with and without 
MCI, while completing a verbal memory task (Belleville et al., 2011). Patterns of 
increased activation after the memory training were observed in those participants 
with MCI (Belleville et al., 2011). These results suggest that the ageing and impaired 
brain maintains neural plasticity and the ability to learn.  
 
1.7.1 Cognitive Capacity 
Previous research demonstrates that individuals are able to learn and can 
improve their level of cognitive functioning as they age (Baltes & Mayer, 2001; 
Calero & Navarro, 2004; Verhaeghen, 2000).  Cognitive capacity is described as the 
difference between an individual’s baseline performance on a measure of cognition 
and their performance on the same measure after a period of cognition focused 
training/practise (Baltes, 1987). The potential of older adults with MCI to improve 
cognitive functioning following a cognitive training intervention has been 
demonstrated in “testing-the-limits” studies  (Baltes, 1987; Sales-Galán, Meléndez-
Moral, & Mayordomo-Rodríguez, 2013). “Testing-the-limits” of cognitive capacity 
involves three stages: (a) baseline performance, (b) baseline reserve capacity, and (c) 
developmental reserve capacity (Baltes, 1987). Testing-the-limits is comparable to 
pre-test assessment (baseline performance) – cognitive intervention (baseline reserve 
capacity) – post-test assessment (developmental reserve capacity).  
 
Calero and Navarro (2004) examined whether older adults with MCI were 
able to learn and whether reduced cognitive capacity was a diagnostic marker of 
cognitive decline. Following an auditory learning intervention, both healthy 
participants and the participants with MCI improved their learning (Calero & 
Navarro, 2004). Furthermore, Sales-Galán et al. (2013) demonstrated that although 
healthy older participants performed better on a verbal learning test, those with MCI 
retained capacity for learning. It is fair to conclude that an individual’s potential to 
learn is unequally reduced depending on their age and level of cognitive functioning 
(Calero & Navarro, 2004). Baltes and Mayer (2001) found that 17% of older adults 
aged 70 report cognitive impairment and the rate increases to 50% by the age of 90. 
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The effect of age is also compounded by its relationship with an increased rate of 
cognitive decline (Petersen, 2000). However, improvements in cognitive capacity are 
not eliminated as MCI and dementia progress.  
 
1.7.2 Cognitive Capacity from MCI to AD 
Research has demonstrated that older adults with MCI and mild AD can 
improve their performance in visuospatial abilities, executive functioning, and verbal 
fluency (Cai et al., 2014; Fernández-Ballesteros, Zamarrón, Tárraga, Moya, & 
Iñiguez, 2003). Fernández-Ballesteros et al. (2003) compared the performance of 
healthy older adults and those with MCI and AD, on the Verbal Memory Learning 
Potential (VMLt) training program to investigate differences in cognitive capacity. 
Results showed people in both MCI and AD groups improved their performance 
post-training (Fernández-Ballesteros et al., 2003). Fernández-Ballesteros et al. (2012) 
examined the contributions of age and pathology to learning performance in people 
with MCI and AD. Across all ages (55 to 102 years) and levels of pathology (MCI 
and AD), participants demonstrated learning after five trials of the VMLt 
(Fernández-Ballesteros et al., 2012). Although significant differences in learning 
ability were found between age and pathology groups, these results support the 
existence of cognitive capacity in older adults with a neurodegenerative disorder 
(Fernández-Ballesteros et al., 2012).  
 
1.7.3 Cognitive Reserve in PD 
Although there has been considerable research of cognitive capacity in 
healthy ageing, MCI, and AD, there is limited research in PD. Preliminary findings 
indicate that those with PD-MCI can improve their performance on 
neuropsychological tests after nonpharmacological training interventions, using 
cognitive reserve (Hindle, Martyr, & Clare, 2014; Poletti et al., 2011). However, it is 
important to distinguish between cognitive capacity and cognitive reserve. The 
former is inherent to the underlying biological process involving the strengthening 
and adaption of neuronal networks to increase learning ability (Cai et al., 2014). The 
latter is a description of the impact of lifelong experiences (e.g., education and 
occupational attainment) on an individual’s cognitive resources, which result in their 
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ability to withstand greater pathology by relying on increased levels of cognitive 
reserve (Stern, 2012). Nonpharmacological interventions for PD-MCI include 
cognitive training (standard and tailored) and non-invasive brain stimulation 
(transcranial magnetic stimulation [TMS] and transcranial direct current stimulation 
[tDCS]), which rely upon cognitive capacity and reserve in people with PD (Hindle 
et al., 2013). 
 
1.8 Nonpharmacological Interventions for MCI 
 
The effectiveness of nonpharmacological interventions (cognitive training 
and non-invasive brain stimulation) for ameliorating cognitive decline has been 
explored (Kim & Kim, 2014; Walton, Mowszowski, Lewis, & Naismith, 2014). 
Research has demonstrated that older adults benefit from cognitive training and brain 
stimulation techniques (Berry et al., 2010; Kelly et al., 2014; Willis et al., 2006). 
However, the positive effect of cognitive training in older adults with MCI was 
comparable to that observed in controls (Martin, Clare, Altgassen, Cameron, & 
Zehnder, 2011; Zehnder, Martin, Altgassen, & Clare, 2009). This suggests that 
specific cognitive training provides no additional benefit to cognitive functioning 
than non-specific daily activities (e.g., physical exercise; Martin et al., 2011; Zehnder 
et al., 2009). Conflicting results have raised questions about the effectiveness of 
stimulation and compensation-focussed interventions for older adults with cognitive 
impairment.  
 
Stimulation-focussed interventions involve the presentation of external novel 
stimuli that encourages neural plasticity by rewiring or strengthening synaptic 
connectivity in the brain (Kim & Kim, 2014). The external stimuli are either specific 
(visual, auditory, or motor) or non-specific (social interactions/physical activities; 
Kim & Kim, 2014). Optale et al. (2010) used specific visual and auditory stimuli, 
such as a computer-generated beach walk, to improve memory functions in older 
adults with MCI. Muscari et al. (2010) demonstrated that 12 months of non-specific 
endurance exercise training reduced age related cognitive decline in healthy older 
adults. Stimulation-focused interventions with and without specific stimuli can 
improve global and domain specific cognitive functioning, strengthening the brain’s 
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existing synaptic networks to reduce the adverse effects of neurological ageing and 
neurodegenerative disorders (Kim & Kim, 2014).  
 
Compensation-focussed interventions seek to improve frontal functions 
and/or enhance the brain’s ability to compensate for impairments in cognitive 
domains (Kim & Kim, 2014). Compensatory techniques include meta-cognitive 
strategies, and executive control and speed of processing (Kim & Kim, 2014). The 
most common compensation-focused interventions are memory training in older 
adults (Kim & Kim, 2014). Memory training involves teaching participants new 
mnemonics to encode and organise information in a way that compensates for age-
related memory decline. Kaci-Fairchild and Scogin (2010) showed that older adults 
improved their ability to remember names, faces, and locations of household items 
after completing an in-home memory enhancement program. The program 
emphasised the importance of subjective memory beliefs and objective memory 
abilities, thereby implementing a new mnemonic to compensate for memory deficits 
(Kaci-Fairchild & Scogin, 2010).  
 
Depending on the cortical region for stimulation, non-invasive brain 
stimulation techniques (e.g., rTMS and tDCS) may also act as compensation-
focussed interventions to alleviate cognitive deficits. The Scaffolding Theory of 
Ageing and Cognition proposes that as older adults experience a decline in cognition, 
the brain provides ‘scaffolds’ to compensate for inefficient function of specific 
cognitive abilities (Goh & Park, 2009). Predominantly occurring in the prefrontal 
cortices, scaffolds recruit secondary neural circuits to support the performance of the 
primary (but diminished) neural circuits (Park & Reuter-Lorenz, 2009). When 
targeting prefrontal cortices, rTMS and tDCS may therefore enhance the 
‘scaffolding’ of secondary neural circuits by providing increased activation of these 
cortical regions as a compensation-focussed intervention for older adults with MCI. 
 
Both stimulation and compensation-focused interventions improve cognitive 
functions in people with MCI. However, Kim and Kim (2014) suggest that merging 
the stimuli mechanisms from stimulation interventions with the cognitive needs of 
compensation interventions will improve participant outcomes to a greater extent. 
22 
 
Tailoring cognitive training and non-invasive brain stimulation to strengthen the 
neural networks of a specific cognitive domain may result in improved cognition. 
 
1.8.1 Cognitive Training and General Mental Stimulation for MCI 
The lack of consensus regarding pharmacological treatment (e.g., 
cholinesterase inhibitors) for people with MCI suggests that cognitive training or 
general mental stimulation may be therapeutic options for those showing early signs 
of cognitive impairment (Teixeira et al., 2012). Cognitive training is a structured 
programme of tasks designed to target the use of specific cognitive domains, in an 
attempt to improve cognitive functioning through repeated training sessions (Kelly et 
al., 2014; Martin et al., 2011). General mental stimulation is described as non-
specific activities (e.g., exercise, socialising) that improve cognitive functioning 
(Kelly et al., 2014). In a review of cognitive training in  MCI and AD, Mowszowski, 
Batchelor, and Naismith (2010) concluded that, for people with MCI, cognitive 
training has the potential to improve cognitive functioning and act as a therapeutic 
technique to delay progression of cognitive decline. Tappen and Hain (2014) 
compared an in-home cognitive training program with general mental stimulation of 
a life story interview. Only participants who completed the cognitive training 
program demonstrated improvements in cognitive functioning that were specifically 
related to the trained domain (Tappen & Hain, 2014). These results suggest that 
specific cognitive training is more effective than general mental stimulation at 
improving cognitive functioning (Tappen & Hain, 2014).  
 
1.8.2 Brain Stimulation for MCI and AD 
Transcranial magnetic stimulation (TMS) is a non-invasive tool which 
employs an electromagnetic coil to excite or inhibit cortical functions (Barker, 
Jalinous, & Freeston, 1985; Guse, Falkai, & Wobrock, 2010). In a systematic review, 
Guse et al. (2010) examined studies using high frequency rTMS to induce long-term 
potentiation (LTP) of neuronal firing to improve cognitive function in healthy 
participants and those with MCI. High-frequency rTMS (10 to 20 Hz) applied over 
the left dorsolateral prefrontal cortex significantly improved executive function, 
learning, and memory in people with MCI (Guse et al., 2010). The improvement in 
cognition was greater in MCI compared to healthy participants (Guse et al., 2010). 
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These results support the use of brain stimulation to improve cognitive function in 
people with MCI and provide evidence of neural plasticity in this population (Cai et 
al., 2014).  
 
The limited benefits of pharmacological treatments for people with MCI are 
mirrored in AD (Birks, 2006; Nardone et al., 2012). This has led researchers to 
investigate the effectiveness of rTMS and tDCS for modifying and delaying cortical 
degeneration in people with AD (Nardone et al., 2012). tDCS can be used to 
modulate neuronal activity by delivering low intensity (1 mA or 2 mA) electrical 
currents to a specific cortical region (Creutzfeldt, Fromm, & Kapp, 1962; Nardone et 
al., 2012). Anodal tDCS and high frequency rTMS increase, whereas, cathodal tDCS 
and low frequency rTMS decrease cortical excitability. Both rTMS and tDCS impact 
cortical excitability, although it is not known if one method induces greater long-
term change (Nardone et al., 2012; Nitsche & Paulus, 2000; Pascual-Leone et al., 
1998). 
 
To compare the long-term effect of high and low frequency rTMS on 
cognitive function, Ahmed, Darwish, Khedr, and Ali (2012) applied bilateral trains 
of contrasting rTMS frequencies over the left dorsal lateral prefrontal cortex of 
people with AD. Those who received high frequency rTMS improved in global 
cognitive functioning and activities of daily living, significantly more than the low 
frequency group (Ahmed et al., 2012). These improvements were maintained at a 
three-month follow up assessment (Ahmed et al., 2012). Boggio et al. (2009) 
compared the effect of anodal tDCS over the left temporal cortex and the left dorsal 
lateral prefrontal cortex in people with mild and moderate AD. Stimulation over both 
cortical areas led to significant improvement in visual recognition memory (Boggio 
et al., 2009). However, the authors did not report any long-term effect (Boggio et al., 
2009). Bentwich et al. (2011) investigated whether combining high-frequency rTMS 
interlaced with cognitive training (rTMS-COG) improved cognitive functioning in 
people with AD. Participants demonstrated improved cognitive functioning after a 
six-week intervention and the improvements were maintained for 4.5 months 
(Bentwich et al., 2011). The authors concluded that rTMS-COG is an effective 
treatment for AD (Bentwich et al., 2011). The previous studies demonstrate that 
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noninvasive brain stimulations improve cognitive functioning in older adults with a 
neurodegenerative disorder. 
 
1.8.3 Nonpharmacological Interventions for PD  
The efficacy of nonpharmacological interventions for people with PD and 
PD-MCI is ambiguous (Hindle et al., 2013). Initial research suggests that cognitive 
training interventions may reduce the rate of cognitive decline for people with PD-
MCI and PDD (Burn, 2010; Kehagia et al., 2010). Studies using rTMS and tDCS 
have reported positive, but variable, effects on cognitive functioning in people with 
PD and there is a lack of consensus regarding the administration methods for brain 
stimulation in PD (Benninger et al., 2010; Hindle et al., 2013). Following a review of 
the prevalence and subtypes of MCI in PD, chapter 3 will provide a thorough review 
of all controlled and uncontrolled trials of cognitive training and non-invasive brain 
stimulation for cognition in PD. 
 
1.9 Chapter Summary 
 
 PD is a heterogeneous neurodegenerative disorder accompanied by many 
motor and nonmotor symptoms. Cognitive deficits are now increasingly recognised 
as a nonmotor symptom affecting a significant proportion of people with PD and 
these impairments impact activities of daily living and quality of life. Preliminary 
evidence suggests that nonpharmacological interventions, such as cognitive training 
and non-invasive brain stimulation, may benefit PD and PD-MCI (Hindle et al., 
2013). Recent development of the MDS diagnostic criteria for PD-MCI (Litvan et al., 
2012) provides future studies with recommendations for standardised assessment of 
cognition in PD, and may increase consistency across studies examining cognitive 
subtypes that may predict progression to PD-Dementia.  
 
 The next chapter reports prevalence and subtyping statistics of PD-MCI when 





Study 1. Prevalence and 
Subtypes of Mild Cognitive 






Parkinson’s disease (PD) is now understood as a multifaceted 
neurodegenerative disorder presenting with heterogeneous motor and non-motor 
symptoms (Williams-Gray et al., 2013). Approximately 30% of people with PD 
experience cognitive impairment and up to 50% progress to PD-Dementia after more 
than 10 years (Cosgrove, Alty, & Jamieson, 2015; Litvan et al., 2011). Cognitive 
impairments in PD comprise four subtypes: amnestic single, amnestic multiple, 
nonamnestic single and nonamnestic multiple.  The four subtypes reflect deficits 
across five cognitive domains: memory, attention/working memory, language, 
visuospatial, and executive functions (Kehagia et al., 2010; Muslimovic et al., 2007).  
 
Several biological and epidemiological risk factors are associated with 
cognitive deficits in PD, with studies reporting cognitive impairment even at time of 
diagnosis (Pedersen, Larsen, Tysnes, & Alves, 2013; Williams-Gray et al., 2009). To 
standardise assessment, the Movement Disorder Society (MDS) Task Force  
developed new diagnostic criteria for PD-MCI (Litvan et al., 2012). Preceding the 
criteria, most studies adopted the method proposed by Petersen (2011) which 
specifies a decline in memory. However, PD-MCI is heterogeneous and many people 
demonstrate impairments across the spectrum of cognitive domains (Goldman et al., 
2013). The MDS diagnostic criteria specifies the following guidelines for Level I 
                                                          
1 This chapter is published in Scientific Reports, reference: Lawrence, BJ, et al. (2016). Prevalence and Subtypes of Mild Cognitive 
Impairment in Parkinson’s Disease. Scientific Reports, 6, e33929. doi: 10.1038/srep33929. See Appendix A for a signed 
statement from each co-author confirming the candidates’ contribution to the publication. 
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(abbreviated assessment) and Level II (comprehensive assessment) categories of PD-
MCI (Litvan et al., 2012): 
A. Level I (abbreviated assessment) 
a. Impairment on a scale of global cognitive abilities validated for use in PD 
or 
b. Impairment on at least two tests, when a limited battery of 
neuropsychological tests is performed (i.e., the battery includes less than 
two tests within each of the five cognitive domains, or less that five 
cognitive domains are assessed).  
B. Level II (comprehensive assessment) 
a. Neuropsychological testing that includes two tests within each of the five 
cognitive domains (i.e., attention and working memory, executive, 
language, memory, and visuospatial). 
b. Impairment on at least two neuropsychological tests, represented by either 
two impaired tests in one cognitive domain or one impaired test in two 
different cognitive domains. 
c. Impairment on neuropsychological tests may be demonstrated by: 
i. Performance approximately 1 to 2 SDs below appropriate norms 
or 
ii. Significant decline demonstrated on serial cognitive testing  
or 
iii. Significant decline from estimated premorbid levels. 
 
Recent studies adopting the new MDS diagnostic criteria report variable 
results (Cholerton et al., 2014; Marras et al., 2013). These studies also applied 
varying diagnostic cut off scores and number and weighting of tests per cognitive 
domain, which may influence the reported prevalence of cognitive impairment in PD. 
The significant impact of cognitive impairment on quality of life for people with PD 
indicates that any standardised criteria developed for international use needs to be 
validated and examined across multiple populations of PD. To date, no study has 
applied the MDS criteria for PD-MCI to an Australian sample. This study provides a 
novel application of the MDS Task Force PD-MCI Level II diagnostic criteria to an 
Australian sample of people with PD. This study also examined the PD-MCI 
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frequency differentials at varying diagnostic cut off scores to explore subtype 




2.2.1 Research design  
This study used a cross-sectional design to measure cognitive performance of 
people with PD. A cross-sectional design allowed the researcher to assess a large 
sample of participants with the new MDS Task Force diagnostic criteria for PD-MCI 
(Litvan et al., 2012). Neuropsychological assessments were completed at Curtin 
University’s Neuroscience Laboratory between March and September, 2015.  
 
2.2.2 Participants  
2.2.2.1 Power analysis and sample size. Previous PD-MCI studies recruited 
between 72 and 139 participants (Cholerton et al., 2014; Goldman et al., 2013; 
Janvin et al., 2006; Marras et al., 2013; Sollinger, Goldstein, Lah, Levey, & Factor, 
2010). However, most participants recruited for this study also completed Study 3 
(Chapter 4). Therefore, it was necessary to determine the number of participants 
required for Study 3 to inform Study 2. Paris et al. (2011) and Naismith et al. (2013) 
found moderate to large effect sizes for cognitive outcomes (Cohen, 1992).  An a 
priori power analysis for an analysis of covariance (ANCOVA) was calculated using 
G*Power (Faul, Erdfelder, Lang, & Buchner, 2007) and 54 participants with PD-
MCI were required to detect moderate effects in Study 3 (power = .80, α = .05). To 
reduce the impact of potential participant attrition on power, 90 participants with PD-
MCI were targeted for recruitment. 
 
2.2.2.2 Inclusion and exclusion criteria. Participants were adults (> 18 
years of age) with PD and living in Western Australia. The following inclusion 
criteria were used: (1) diagnosed with idiopathic PD by a neurologist or geriatrician 
in accordance with the United Kingdom Parkinson’s Disease Society Brain Bank 
Clinical Diagnostic Criteria and (2) a stable response to antiparkinsonian medication 
for a minimum period of 2 months and (3) cognitive deficits that do not interfere 
with functional independence. Exclusion criterion was presence of PD-Dementia to 
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ensure all included participants understood the purpose of the study and were able to 
provide informed consent. 
 
2.2.3 Measures 
Neuropsychological assessments were conducted in two phases. Participants 
were first screened over the telephone for the presence of dementia and then 
completed an extensive neuropsychological assessment at Curtin University. In 
accordance with the MDS Task Force Level II diagnostic criteria for PD-MCI, two 
measures were selected to assess each of the five cognitive domains (executive 
function, attention/working memory, memory, language, and visuospatial abilities) 
involved in PD-MCI (Litvan et al., 2012). The following measures have been 
recommended by the MDS Task Force for use in PD and were used to assess 
functioning across all cognitive domains.  
 
2.2.3.1 Screening measures. The Telephone Interview for Cognitive Status-
30 (TICS-30) was used to assess cognitive functioning and presence of dementia 
over the telephone (Brandt, Spencer, & Folstein, 1988). Development of the TICS-30 
was based on the ‘gold standard’ test of cognition, the Mini Mental State 
Examination (Folstein, Folstein, & McHugh, 1975). The TICS-30 contains eight 
items assessing orientation, mathematical skills, short-term memory, 
attention/working memory and language. Items include “What month of the year is 
this?”, “Please spell the word WORLD backwards”, and “What do people usually 
use to cut paper?”. TICS-30 scores range 0 to 30 with the following severity ratings 
corresponding to the MMSE: 0 to 12 (severe cognitive impairment), 13 to 17 (mild 
cognitive impairment), and 18 to 30 (unimpaired cognitive ability). Participants were 
required to score 13 or higher to be included in the study (Fong et al., 2009). 
Although there is limited psychometric information for the TICS-30, it has a strong 
correlation (r = .80) with the MMSE (Fong et al., 2009). 
 
2.2.3.2 Demographic questionnaire. Following telephone screening and 
preceding formal neuropsychological assessment, participants completed a 
demographic questionnaire. The demographic questionnaire asked participants to 
report their personal and health information, age, gender, disease duration (years), 
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and current daily levodopa dopaminergic medication dosage. Participants were asked 
to bring the completed questionnaire to their assessment. 
 
2.2.3.2 Executive function. The Cambridge Neuropsychological Test of 
Automated Batteries (CANTABTM) Stockings of Cambridge (SOC) subtest was used 
to assess executive function. SOC is a spatial planning test based upon the Tower of 
London task (Lezak, Howieson, & Loring, 2012). SOC tests executive function skills 
such as simultaneous use of rule learning, planning, and execution. Participants were 
shown a computerised touch screen tablet which presented two horizontal displays of 
coloured balls sitting in stockings (see Figure 1). Participants were instructed to 
rearrange the balls in the lower display to match the configuration of balls in the 
upper display. The goal was to rearrange the coloured balls using the least number of 
moves, with task difficulty (number of moves) increasing as participants progressed. 
Patterns completed within minimum moves was used as the outcome variable in this 
study (higher scores represent greater executive function). There is limited 
psychometric data for the CANTABTM tests (Lezak et al., 2012), but the SOC subtest 
has shown modest test-retest reliability (r = .60) in older adults (Lowe & Rabbitt, 




Figure 1. Example Activity from the Stockings of Cambridge Test. 
 
The Controlled Oral Word Association Task (COWAT) was also used to 
assess executive function (Benton, 1968). The COWAT measures phonemic and 
semantic verbal fluency. The MDS Task Force recommend the use of only one 
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verbal fluency test to diagnose cognitive impairment, due to high correlations 
between similar tests (Litvan et al., 2012). Semantic verbal fluency has shown 
relative stability in people with PD-MCI compared to those with PD-Dementia 
(Kehagia et al., 2010; Williams-Gray et al., 2007). Phonemic verbal fluency was 
therefore used to measure executive function. Participants were given 60 seconds to 
provide as many words as possible beginning with a specified letter (e.g., F, A, or S). 
Prior to each trial, instructions were provided to ensure participants did not provide 
incorrect words (e.g., proper nouns, repetitions, variants of the same word). Total 
scores were calculated as the sum of correct words across trials with higher scores 
demonstrating greater verbal fluency (Lezak et al., 2012). The COWAT has shown 
high internal (r = .83) and test-retest (r = .74) reliabilities (Tombaugh, Kozak, & 
Rees, 1999), as well as high convergent validity (r = .72 to .81) with other verbal 
fluency tasks (Cohen & Stanczak, 2000). Furthermore, meta-analytic results show 
significant differences in verbal fluency performance between people with PD and 
healthy controls (Henry & Crawford, 2004). Impairment was assessed using 
normative data by Tombaugh et al. (1999).  
 
2.2.3.3 Attention/working memory. The Letter-Number Sequencing (LNS) 
subtest from the Wechsler Adult Intelligence Scale-IV (WAIS-IV) was used to assess 
attention/working memory (Wechsler, 2008). The WAIS-IV includes 13 subtests and 
is used to measure general intellectual functioning in older adolescents and adults (16 
to 89 years). For the LNS subtest, participants were read a randomised combination 
of letters and numbers (e.g., 6-F-2-B) and asked to recall the list in ascending order 
and numbers first (Wechsler, 2008). LNS contains 10 items with three trials per item 
and items were discontinued when a participant scored three incorrect responses in 
one item. Scores ranged from 0 to 30 with higher scores indicating greater attentional 
and working memory abilities. The LNS subtest has shown high internal consistency 
(r = .80 to .89) and adequate test-retest reliability (r = .70 to .79; Wechsler, 2008). 
When administered independently, the LNS subtest has shown sufficient specificity 
(Kaufman & Lichtenberger, 1999). Previous studies have used the LNS subtest to 
examine cognitive functioning in PD (Higginson et al., 2003; McKinlay, Grace, 
Dalrymple-Alford, & Roger, 2010). Raw and scaled scores were computed for each 
participant, with scaled scores compared to WAIS-IV normative data to establish 




Attention/working memory was also measured using the Stroop (Colour-
Word) Test (Golden & Freshwater, 2002; Jensen & Rohwer, 1966; Stroop, 1935). 
The Stroop (Colour-Word) Test involves selective attention and inhibition, whereby 
participants are presented with an incongruent colour naming task (e.g., the word 
‘GREEN’ printed in the colour BLUE). Participants were shown an A4 sheet of 
paper containing a set of 100 words arranged in five vertical columns (20 words per 
column). Participants were given 45 seconds to name what colour ink each word was 
printed in as they read down each column (Golden & Freshwater, 2002). Slow 
performance on this task demonstrates poor concentration, inhibition and attentional 
abilities (Lezak et al., 2012). Scores range from 0 to 100 and total scores were 
calculated as number of correct words in 45 seconds. The Stroop (Colour-Word) Test 
has shown adequate test-retest reliability (r = .73) and convergent validity (r = .55) 
with other attention tests (Golden, 1975; May & Hasher, 1998). Studies have found 
impaired colour-word performance in PD (Hanes, Andrewes, Smith, & Pantelis, 
1996) and in people with deficits in prefrontal (dorsolateral and ventrolateral) 
cortices (Demakis, 2004). Scores were compared against normative data from Fisher, 
Freed, and Corkin (1990). 
 
2.2.3.4 Memory. The Hopkins Verbal Learning Test-Revised (HVLT-R) was 
used to measure memory (Brandt & Benedict, 2001). The HVLT-R comprises 12 
noun words drawn from three semantic categories (e.g., animals, dwellings, and 
precious stones). Participants were read the randomised list of words and asked to 
repeat the words they remembered in any order (Brandt & Benedict, 2001). Three 
consecutive trials were completed using the same list of words. Total scores were 
calculated as the sum of correct words across all trials, with higher scores 
representing greater retention. Benedict and Zgaljardic (1998) reported adequate test-
retest reliability (r = .66) among older adults. In addition, adequate convergent 
validity (r = .60) was shown between the HVLT-R and the California Verbal 
Learning Test in AD (Lacritz, Cullum, Weiner, & Rosenberg, 2001). The HVLT-R 
has been used to assess memory impairment (Weintraub, Moberg, Culbertson, Duda, 
& Stern, 2004) and the relationship between impaired memory and motor symptoms 
in PD (Foster et al., 2010). Degree of memory impairment was compared to 
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normative data from Brandt and Benedict (2001) and Hester, Kinsella, Ong, and 
Turner (2004). 
 
The Paragraph Recall subtest of the Rivermead Behavioural Memory Test 
(RMBT) was also used to assess memory (Wilson, Cockburn, Baddeley, & Hiorns, 
1989). The RMBT was initially developed to examine memory impairment in people 
with acquired neurological damage (Cockburn & Keene, 2001) and contains 11 
subtests measuring immediate and delayed recall abilities (Strauss, Sherman, & 
Spreen, 2006). During the Paragraph Recall subtest, participants were read a short 
story (5 to 6 lines) and asked to immediately recall the ‘ideas/details’ as they 
remembered them. This task has no time limit, although most participants provided 
details within 60 seconds following the story. Scores ranged 0 to 21 with higher 
scores demonstrating greater memory recall (Wilson et al., 1989). The total number 
of correct ‘ideas/details’ was used as the score for this outcome. There is limited 
psychometric information for the RBMT subtests, but the full battery has shown high 
internal consistency (Cronbach’s α = .86) and test-retest reliability (r = .89), as well 
as moderate convergent validity with other memory tests (Fennig, Mottes, Ricter-
Levin, Treves, & Levkovitz, 2002; Man & Li, 2002). Pérez and Godoy (1998) found 
the RBMT correctly classified AD, older adults with cognitive complaints, epilepsy 
and controls at a rate of 72.5%. Paragraph recall tests have been successfully used to 
assess memory impairment in PD (Cummings, 1988; Taylor, Saint-Cyr, & Lang, 
1986). Scores were examined against normative data from Wilson et al. (1989) and 
Strauss et al. (2006). 
 
2.2.3.5 Visuospatial. The Judgement of Line Orientation (JLO) test measures 
orientation/spatial perception and was used to assess visuospatial abilities (Benton, 
Hamsher, & Sivan, 1994). The JLO test was initially developed to measure left 
versus right visual hemisphere superiority in people who were right hand dominant. 
The test is now used across many clinical groups including schizophrenia, AD, and 
PD (Finton, Lucas, Graff-Radford, & Uitti, 1998; Hardoy et al., 2004; Montse, Pere, 
Carme, Francesc, & Eduardo, 2001). Participants were shown a series of cards and 
asked to estimate the angles of lines on an upper card by comparing them to a set of 
numbered angled lines on a lower card. The JLO test comprises 30 items (one pair of 
angled lines per item) and is scored 0 to 30 (Benton et al., 1994). The following 
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scores represent visuospatial deficits: < 17 (severe impairment), 17 to 23 (mild 
impairment), and > 23 (no impairment). The JLO test has shown high internal (r = 
.90) and test-retest (r = .90) reliability (Benton et al., 1994; Qualls, Bliwise, & 
Stringer, 2000), as well as adequate convergent validity (r = .69) with WAIS-R 
visuospatial tests (Trahan, 1998). The JLO test has also been used to assessed 
impaired visuospatial abilities in PD (Montse et al., 2001). Normative data from 
Glamser and Turner (1995) and Ska, Poissant, and Joanette (1990) were used to 
interpret results. 
 
The Hooper Visual Organisation Test (HVOT) was also used to measure 
visuospatial abilities (Hooper, 1983). Similar to the JLO test, the HVOT was 
originally developed to discriminate between people with and without cortical 
damage (Hooper, 1958). The HVOT is now often used to assess visuospatial deficits 
in AD and PD (Caselli et al., 2014; Cholerton et al., 2014). Participants were 
presented with a series of cards which contained common objects/animals that were 
cut into two or more illogical pieces. Participants were instructed: “As you can see 
here, this is an object that has been cut into pieces. Tell me what you think the object 
would be if the pieces were put back together again.” The HVOT includes 30 items 
with increasing ambiguity (Strauss et al., 2006). Scores range 0 to 30, with a score 
less than 23 indicative visuospatial impairment. The HVOT has shown high internal 
(r ≥ .80) and test-rest (r = .86) reliabilities (Lezak, Howieson, & Loring, 2004; 
Lopez, Lazar, & Oh, 2003). Also, Ricker and Axelrod (1995) found that 48% of the 
variance in HVOT scores was accounted for by the WAIS perceptual subtests, 
supporting the HVOT as a valid measure of visuospatial abilities. Normative data 
from Tamkin and Jacobsen (1984) was used to interpret results. 
 
2.2.3.6 Language. The Boston Naming Test-Short Form (BNT-Short Form) 
was used to assess language (Kaplan, Goodglass, & Weintraub, 2001). The BNT-
Short Form is a revised 15-item version of the original 60-item test (Mack, Freed, 
Williams, & Henderson, 1992). Participants were shown a series of line drawings of 
objects of increasing difficulty, ranging from simple, high frequency vocabulary 
words (e.g., house) to rare words (e.g., sphinx). Scores range 0 to 15 with higher 
scores demonstrating greater language proficiency (Kaplan et al., 2001). Tombaugh 
and Hubiey (1997) reported adequate internal consistency (α = .49) for the BNT-
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Short  Form in people with AD. The BNT-Short Form has also shown high 
convergent validity with the full 60-item BNT (r = .72 to .82) and with the Visual 
Naming Test (r = .76 to .86) (Axelrod, Ricker, & Cherry, 1994; Tombaugh & 
Hubiey, 1997). The BNT has been used extensively in AD and PD research (Henry 
& Crawford, 2004; Henry, Crawford, & Phillips, 2004). Scores were compared 
against normative data by Fastenau, Denburg, and Mauer (1998). 
 
Another test from the WAIS-IV battery, the Similarities subtest was used to 
assess language (Wechsler, 2008). The Similarities subtest assesses language and 
abstract reasoning, and participants were instructed as follows: “Now I’m going to 
say two words and ask you how they are alike. For example, in what way are TWO 
and SEVEN alike?” Instructions were read verbatim to each participant, with 
stimulus words increasing in difficulty (e.g., ‘horse and tiger’ to ‘poem and statue’) 
across the 18 items (Wechsler, 2008). Total scores range from 0 to 36 with higher 
scores representing greater language proficiency. The Similarities subtest showed 
high internal and test-retest reliabilities (r = .80 to .89; Wechsler, 2008), as well as 
sufficient subtest specificity when used independently (Kaufman & Lichtenberger, 
1999). As with the LNS subtest, Similarities raw and scaled scores were computed 
for each participant, with scaled scores compared to WAIS-IV normative data to 
determine the degree of language impairment (Wechsler, 2008). 
 
2.2.3.7 Global cognition. The Parkinson’s Disease – Cognitive Rating Scale 
(PD-CRS) was used to assess global cognitive impairment (Pagonabarraga et al., 
2008). The PD-CRS examines the full spectrum of cognitive functioning in PD, from 
cognitively intact to PD-MCI and PDD (Kulisevsky & Pagonabarraga, 2009). The 
PD-CRS contains nine items assessing attention, executive functions, verbal 
fluency/memory, visuospatial abilities and language. Examples include, word recall 
(memory) and copying a clock drawing (visuospatial). Total scores were calculated 
by summing individual item scores and recommended cut-offs suggest: < 64 
(dementia), 64 to 82 (mild cognitive impairment) and > 81 normal cognition 
(Pagonabarraga et al., 2008). The authors report high internal consistency (α = .85) 
and the PD-CRS has shown strong discriminant validity (p < .001) when 
administered to healthy controls, cognitively intact PD, PD-MCI and PDD groups 




The Mini Mental State Examination (MMSE) was also used as a measure of 
global cognition (Folstein et al., 1975). Designed to distinguish cognitive functioning 
between neurological and psychiatric patients (Folstein et al., 1975), the MMSE is 
the most widely used screening measure of global cognition. The test is attractive 
due to its brevity and ease in administration and scoring. The MMSE includes five 
items assessing orientation, immediate recall, attention/calculation, (slight) delayed 
recall and language (Strauss et al., 2006). Total scores range 0 to 30 and the 
following cutoffs were used: 0 to 9 (severe impairment), 10 to 20 (moderate 
impairment), 21 to 24 (mild impairment) and 25 to 30 (normal cognition; Folstein et 
al., 1975). This study calculated total scores using the serial 7s method by Strauss et 
al. (2006).  
 
2.2.3.8 Premorbid intelligence. The Australian version of the National Adult 
Reading Test (AUSNART) was used to measure premorbid intelligence (Hennessey 
& Mackenzie, 1995). The AUSNART assesses an individual’s ability to read a list of 
words that do not conform to the regular rules of reading (Hennessy & Mackenzie, 
1995). For example, coelacanth is pronounced see-luh-kanth. Participants were 
instructed to pronounce each word on a series of cards and total scores were recorded 
as the number of errors (incorrectly pronounced words). Items were discontinued 
when a participant provided 12 incorrect responses within their previous 13 attempts. 
AUSNART scores were used to calculate premorbid intelligence using the Sullivan, 
Senior, and Scarcia (2000) regression equation: 
 
110.15 −  .48(AUSNARTerr) + 2.97(Education) − 3.01(Sex) 
 
where:                         AUSNARTerr :  incorrect responses 
 
Education : less than 9 years = 1; 9 to 10 years = 2; 11 to 12 
years = 3; 13 to 15 years = 4; 16 years or more = 5 
 
                                    Sex : Male = 1; Female = 2 
 
2.2.3.9 Functional independence. The Unified Parkinson’s Disease Rating 
Scale (section II) was used to measure functional independence (Goetz et al., 2008). 
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The UPDRS-II includes 13 items that assess the impact of parkinsonian symptoms 
on an individual’s ability to complete activities of daily living, independently. Items 
include: “Over the past week, have you usually had problems dressing?” and “Over 
the past week, have you usually had trouble doing your hobbies or other things that 
you like to do?” Each item is scored between ‘0 = Normal’ and ‘4 = Severe’. Total 
scores were then computed into a summary index score by summing the 13 items and 
dividing the total score by 13. The MDS Task Force PD-MCI inclusion criteria 
require individuals to present with cognitive deficits that do not significantly impact 
upon their functional independence. Therefore, an UPDRS-II summary index score 
greater than three was used to exclude participants reporting significantly impaired 
activities of daily living.  
 
2.2.3.10 Depression. The Depression, Anxiety, and Stress Scale -21 (DASS-
21) was used to assess presence of depression that may have impacted cognitive 
functioning (Lovibond & Lovibond, 1995). The DASS-21 measures depression, 
anxiety and stress. Participants were asked to report the degree to which they 
experienced a range of psychological symptoms over the past week, using a 4-point 
Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very 
much). Example items include “I couldn’t seem to experience any positive feeling at 
all” and “I felt that I wasn’t worth much as a person” (Lovibond & Lovibond, 1995). 
For each dimension, scores may range from 0 to 21, with higher scores indicating 
greater experience of respective symptoms (e.g., depression). Henry and Crawford 
(2005) reported strong internal consistency (α = .88) for the depression subscale of 
the DASS-21. Comorbid depression significantly impacts cognitive functioning, 
activities of daily living and quality of life in PD (Lawrence, Gasson, Kane, Bucks, 
& Loftus, 2014; Weintraub & Burn, 2011). Depression was therefore included to 
examine whether participants with PD-MCI reported increased depressive symptoms 
when compared to those with normal cognition. 
 
2.2.4 Procedure 
2.2.4.1 Ethical and clinical registration. This research was approved by 
Curtin University’s Research Ethics Committee prior to contact with participants 
(approval number: HR 189/2014). This study, as part of the larger study (Chapter 4), 
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was registered with the Australian New Zealand Clinical Trials Registry (ACTR 
number: 12614001039673). 
 
2.2.4.2 Recruitment. Participants were recruited through several avenues. 
Print advertisements for the study were published in the Parkinson’s Western 
Australia (PWA) newsletter and the ‘Have-A-Go’ News, a community newspaper 
popular among older adults in the metropolitan area of Western Australia. Curtin 
University released a media statement targeting television networks, which led to a 
national news health story on the Channel Nine News Network. The news story 
included an interview with a participant explaining their experience in the study and 
an interview with the lead researcher outlining the details of the study. After this 
news release, the lead researcher completed a live television interview during the 
following morning’s Channel Nine News broadcast. The study was also registered on 
the Michael J Fox Foundation’s Fox Trial Finders website, an international registry 
of clinical trials being conducted in PD. Individuals self-referred and were sent an 
information pack (e.g., information sheet, consent form, inclusion criteria, 
demographic questionnaire, Curtin University map). 
 
2.2.4.3 Neuropsychological assessment, diagnosis and subtypes. Potential 
participants who contacted the researcher were screened via telephone (Brandt et al., 
1988), and were sent an information pack. Individuals who met inclusion criteria 
were scheduled for a neuropsychological assessment. Neuropsychological 
assessments were conducted by the primary researcher and two assistant researchers 
who have extensive clinical training in the delivery, scoring, and interpretation of 
neuropsychological tests. Each assessment took 2 to 3 hours to complete (depending 
on performance) and were conducted during participants’ ‘ON’ stage of medication 
use. At completion of the assessment participants were reimbursed for their travel 
costs and thanked for their participation with a $10 gift card. Following each 
assessment, results were scored and interpreted using standardised normative data 
from healthy older adults (see Appendix B). PD-MCI was diagnosed as less than one 
standard deviation (SD) below normative scores on two or more neuropsychological 
tests (Litvan et al., 2012). The MDS Task Force suggest the use of 1 to 2 SD cut offs 
below normative scores. A cut off of 1 SD was used in this study to account for the 
likelihood that the community based cohort may include higher functioning adults 
38 
 
living independently, who may not report cognitive deficits but demonstrate 
impairment during formal neuropsychological assessment. Also, subjective report of 
cognitive decline has shown low accuracy in PD (Copeland, Lieberman, 
Oravivattanakul, & Tröster, 2016). Therefore, individuals in this study were not 
required to meet the criteria of reporting cognitive decline.  
 
The following PD-MCI subtype classifications were applied: (1) amnestic 
single domain (impairment on two memory tests); (2) nonamnestic single domain 
(impairment on two or more non-memory tests); (3) amnestic multiple domain 
(impairment on two or more tests, including memory) and (4) nonamnestic multiple 
domain (impairment on two or more tests, not including memory). Raw scores were 
used to determine impairment on all tests, excluding the LNS and Similarities tests. 
The LNS and Similarities raw scores were converted into scale scores (as per WAIS-
IV instructions), and then compared to normative data (Wechsler, 2008).  
 
2.2.4.4 Data collection. Neuropsychological assessments were completed at 
a time convenient for each participant and data collected for this study forms part of 
the pre-intervention (baseline) data for Study 3 (see Chapter 4). 
2.2.5 Data analysis 
The Statistical Package for the Social Sciences (SPSS) 22.0 was used to 
complete statistical analyses. Descriptive statistics (e.g., means and SDs) for 
demographic data and neuropsychological test scores were computed, and frequency 
estimates were calculated to describe the prevalence of cognitive impairment and 
PD-MCI subtypes. Independent samples t tests and Mann-Whitney U tests examined 
outcome differences between the ‘PD-MCI’ and ‘Normal Cognition’ groups (Field, 
2013; Howell, 2013). An alpha level of .05 was applied to demographic variables 
and a Bonferroni-adjusted alpha level for multiple comparisons was applied to 
cognitive outcomes per domain (i.e., p < .025).  
 
2.2.5.1 Between-group comparisons. Independent samples t tests and 
Mann-Whitney U tests (for non-parametric outcomes) determined if there was a 
statistically significant difference between the ‘PD-MCI’ and ‘Normal Cognition’ 




2.2.5.2 Assumption testing. Two statistical assumptions pertain to 
independent samples t tests: normality and homogeneity of variance (Howell, 2013). 
Normality refers to the distribution of scores on outcome variables demonstrating a 
relatively symmetrical inverted U-shape distribution, with most participant scores 
grouped in the center of the distribution and less scores at either end of the 
distribution (Field, 2013). The normality assumption was assessed using visual 
inspection of histograms and Quantile-Quantile (Q-Q) Plots and the Shapiro-Wilk 
statistic, which is suitable for group sizes less than 50 (Tabachnick & Fidell, 2013). 
Homogeneity of variance assumes that each group’s scores are homogeneous (equal) 
in their variability (Field, 2013). Levene’s Test for Equality of Variances was used to 
examine homogeneity of variance across groups. For outcomes that violated 
homogeneity of variance, ‘equal variances not assumed’ results were reported. All 
assumptions (independence, scale of measurement) for Mann-Whitney U tests were 
met prior to analysis. 
 
2.2.5.3 Internal reliability. A test’s internal reliability reflects the extent to 
which items within a test measure one latent cognitive/psychological construct 
(Strauss et al., 2006). Where possible, internal reliability was computed using two 
methods: (1) the Kuder-Richardson 20 (KR-20) and (2) Cronbach’s α (Anastasi & 
Urbina, 1997; Cronbach, 1951). Both methods produce estimates of internal 
consistency, though the KR-20 assesses tests with dichotomous response items (e.g., 
‘correct’ or ‘incorrect’) and Cronbach’s α examines tests with any response scale 
(Cortina, 1993). For cognitive tests, internal consistency of  ≥ .70 is acceptable for 
research purposes (Field, 2013).  
 
2.3 Results 
2.3.1 Missing data 
Participants who completed neuropsychological assessments provided data 
for all demographic and outcome variables, excluding one participant who did not 
report years of disease duration. Missing values analysis was conducted and Little’s 
Missing Completely at Random (MCAR) test showed this missing datum was not 
systematically linked to included variables, χ² (19) = 18.70, p = .48. Expectation 
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Maximisation (EM) was used to replace this missing value (Tabachnick & Fidell, 
2013). 
 
2.3.2 Demographic and cognitive characteristics 
In total, 70 participants completed neuropsychological assessments, with 
64.3% (N = 45) classified as PD-MCI and remaining participants classified as 
Normal Cognition (N = 25). Levodopa equivalent dose (LED) was calculated using 
the Tomlinson et al. (2010) method. 
 
2.3.3 PD-MCI versus Normal Cognition results 
2.3.3.1 Assumption testing. Normality was violated (Shapiro-Wilk = p < 
.05) for several demographic and outcome variables. For the Normal Cognition 
group, age, premorbid IQ, disease duration, depression, SOC, Paragraph Recall, 
BNT, and JLO showed non-normal distributions. For the PD-MCI group, age, 
premorbid IQ, disease duration, depression, LED, TICS, MMSE, LNS (scale score), 
Paragraph Recall, BNT, Similarities (scale and raw scores), and JLO showed non-
normal distributions. Visual inspection of histograms revealed negatively skewed 
distributions for cognitive outcomes (e.g., MMSE, BNT) and positively skewed 
distributions for demographic variables (e.g., disease duration, LED). However, these 
distributions may accurately represent this higher functioning cohort. It is possible 
that people with less daily LED and more years of education will have less years of 
disease duration (positive skewness) and likely perform within the top range of a 
cognitive test (negative skewness). Q-Q plots showed data to cluster relatively close 
to diagonal lines across all outcomes and t tests are robust in the face of normality 
violations (Tabachnick & Fidell, 2013). Therefore, no data transformation technique 
was applied. Between-groups homogeneity of variance was violated (Levene’s test: p 
< .05) in six outcomes (MMSE, PD-CRS, LNS, BNT, JLO, and HVOT). 
Consequently, ‘equal variances not assumed’ results were reported for these 
outcomes. Assumption test results for all outcomes can be found in Appendix C. 
 
2.3.3.2 Internal reliability of outcomes. Internal reliability varied between 
excellent (> .90) to adequate ( .40 to .50) and was computed for 10 outcomes: 
UPDRS-II (α = .80), DASS (α = .88), TICS (KR-20 = .47), MMSE (KR-20 = .54); 
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PD-CRS (α = .84), LNS (KR-20 = .92), Stroop (Colour-Word) Test (KR-20 = .96), 
BNT (KR-20 = .54),  Similarities (α = .68), JLO (KR-20 = .90) and HVLT (KR-20 = 
.78). Low internal reliability scores were identified for the TICS, MMSE, BNT and 
Similarities outcomes. However, due to the diversity of cognitive constructs, using 
cut off scores for Cronbach’s α may subtract from the scale’s primary purpose in the 
context of the research (Kline, 1999). All outcomes were therefore reported in this 
study and the current authors suggest interpreting the outcomes with low reliability 
with caution. 
 
2.3.3.3 Group differences. For demographic variables and depression, 
independent samples t tests showed no statistically significant differences (p > .05) 
between the PD-MCI and Normal Cognition groups (see Table 1). However, there 
were significant differences between groups on all cognitive outcomes (excluding 
SOC). Compared to the Normal Cognition group the PD-MCI group performed 
worse on the TICS (p = .004), MMSE (p = .001) and PD-CRS (p < .001) measures of 
global cognition. For executive function, the PD-MCI Group performed worse on the 
COWAT (p < .001) but not SOC (p = .76). For attention/working memory, the PD-
MCI Group performed worse on LNS (scale, p < .001; raw, p = .001) and the Stroop 
(Colour-Word) Test (p < .001). For memory, the PD-MCI group performed worse on 
HVLT (p < .001) and Paragraph Recall (p < .001). For language, the PD-MCI group 
performed worse on the BNT (p < .001) and Similarities (scale, p < .001; raw, p < 
.001). For visuospatial abilities the PD-MCI group performed worse on the JLO test 















Comparison of demographic and neuropsychological test scores for PD-MCI and 
Normal Cognition groups 
  
PD-MCI  
(N = 45) 
NC  
(N = 25) 
Diff. of means 
Domain Outcome M SD M SD t p 
 Gender (% ♀) 62.2% (N = 28) 64% (N = 16) – .88+ 
 Age++ 68.53 9.92 64.12 7.10 -1.96 .05 
 Education++ 13.60 3.10 14.52 2.87 1.22 .23 
 Premorbid IQ 106.97 8.01 106.81 21.71 -.04 .97 
 Disease Durat.++ 5.81 4.58 5.90 4.99 .08 .94 
 Depression 2.84 3.24 2.45 2.19 -.52 .60 
 LED 398.43 350.33 335.19 254.15 -.79 .43 
 UPDRS-II 1.08 0.62 0.89 .54 -1.30 .20 
Global TICS 22.42 2.95 24.48 2.47 2.96 .004* 
 MMSE 25.56 2.95 27.84 1.62 3.57× .001* 
 PD-CRS 81.07 19.48 100.28 12.10 4.47× .001** 
EF COWAT 32.24 15.01 45.80 12.36 3.85 .001** 
 SOC 6.22 2.08 7.24 2.06 1.96 .60 
Atten.WM LNS (SS) 8.36 3.64 11.56 2.16 4.02 .001** 
 LNS (RS) 16.09 5.88 20.52 2.43 3.59× .001* 
 Stroop Test 24.51 12.19 38.24 10.05 4.80 .001** 
Memory HVLT 21.60 6.82 28.80 5.48 4.53 .001** 
 Para. Recall 4.56 2.31 7.08 1.79 4.71 .001** 
Language BNT 13.27 1.66 14.32 .80 2.98× .001** 
 Similarities (SS) 8.76 1.88 10.84 1.52 4.74 .001** 
 Similarities (RS) 21.09 3.97 26.40 2.75 5.93 .001** 
VS JLO 21.29 7.62 26.64 3.49 3.31× .001* 
 HVOT 22.11 3.96 25.24 2.10 4.32× .001** 
Note. M = mean; SD = standard deviation; EF = executive function; Atten.WM = attention/working memory; VS = visuospatial 
abilities; Global = global cognition; ADL = activities of daily living; QOL = quality of life; COWAT = Controlled Oral Word 
Association Test; SOC = Stockings of Cambridge; LNS = Letter-Number Sequencing; HVLT = Hopkin’s Verbal Learning 
Test; BNT = Boston Naming Test; JLO = Judgement of Line Orientation; HVOT = Hooper’s Visual Orientation Test; MMSE = 
Mini-Mental State Examination; PD-CRS = Parkinson’s Disease – Cognitive Rating Scale; UPDRS-II = Unified Parkinson’s 
Disease Rating Scale – section II (ADL); PDQ-39 = Parkinson’s Disease Questionnaire-39; SS = Scaled score; RS = Raw 
score; + = non-parametric Mann-Whitney U test; ++ = years; × = equal variances not assumed; * = p < .05; ** = p < .001. 
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2.3.4 PD-MCI subtypes according to MDS criteria 
Most participants who met the MDS Task Force criteria for PD-MCI 
presented with multiple domain impairment compared to single domain (see Figure 
2). Multiple domain impairment was present in 93.4% of participants, with 6.6% 






Figure 2. Distribution of PD-MCI Subtypes.  
 
 
Cognitive deficits were heterogeneous among participants with multiple 
domain PD-MCI. In total, 62.2% (N = 28) of participants were classified as amnestic 
multiple domain with 11 different patterns of impairments identified (see Table 2). 
Moreover, 31.20% (N = 14) of participants were classified as nonamnestic multiple 
domain and nine sets of impairments were identified. When comparing individual 
cognitive domains for all PD-MCI (see Figure 3), executive function was impaired in 
62.2% (N = 28) of participants, attention/working memory in 66.7% (N = 30), 
memory in 66.7% (N = 30), visuospatial in 31.2% (N = 14) and language in 44.4% 







Distribution of PD-MCI subtypes and domain impairments using a one standard 
deviation cut off score.  
PD-MCI Subtype Domains Impaired N (%) 
Amnestic Multiple All domains 5 (11.1) 
 Memory + EF 5 (11.1) 
 Memory + Attention/WM 5 (11.1) 
 Memory + EF + Attention/WM 3 (6.7) 
 Memory + Attention/WM + Language 3 (6.7) 
 Memory + EF + Attention/WM + Language 2 (4.4) 
 Memory + EF + Attention/WM + Visuospatial 1 (2.2) 
 Memory + Attention/WM + Visuospatial 1 (2.2) 
 Memory + Language 1 (2.2) 
 Memory + EF + Language 1 (2.2) 
 Memory + Language + Visuospatial 1 (2.2) 
 Subtotal 28 (62.2) 
Nonamnestic Multiple  EF + Attention/WM 4 (8.8) 
 EF + Language 3 (6.7) 
 EF + Visuospatial 1 (2.2) 
 EF + Attention/WM + Language 1 (2.2) 
 
EF + Attention/WM + Language + 
Visuospatial 
1 (2.2) 
 EF + Attention/WM + Visuospatial 1 (2.2) 
 Attention/WM + Language  1 (2.2) 
 Attention/WM + Visuospatial 1 (2.2) 
 Attention/WM + Language + Visuospatial 1 (2.2) 
 Subtotal 14 (31.2) 
Amnestic Single  Memory 2 (4.4) 
Nonamnestic Single Visuospatial 1 (2.2) 
 Total  45 (100) 
Note. PD-MCI = Parkinson’s Disease-Mild Cognitive Impairment; EF = executive function; 





Figure 3. Percentage of Participants with Cognitive Impairment by Domain. 
 
2.3.5 Post-hoc analyses.  
Following the high frequency of PD-MCI (64.3%) when using a 1 SD cut-off 
below normative data, post-hoc analyses were conducted to examine whether using a 
2 SD cut off would result in frequency differentials (Table 3). The frequency of PD-
MCI decreased from 64.3% to 28.6% (N = 20). Among participants with PD-MCI, 
however, the frequency of subtype classifications remained relatively stable. Overall, 
90% (N = 18) of participants with PD-MCI demonstrated multiple domain 
impairment and only 10% showed single domain impairment (N = 1 for memory and 
N = 1 for attention/working memory). Amnestic multiple domain remained most 
frequent (N = 10, 50%) with five different patterns of impairments, followed by 
nonamnestic multiple domain (N = 8, 40%) with five different patterns of 
impairments. Both amnestic single and nonamnestic single domains showed the least 
frequency of impairment (N = 1, 5% individually). Following the 2 SD cut off, 
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executive function was impaired in 75% (N = 15) of participants, attention/working 
memory in 45% (N = 9), memory in 50% (N = 10), visuospatial in 45% (N = 9) and 
language in 10% (N = 2). 
 
Table 3 
Distribution of PD-MCI subtypes and domain impairments using a two standard 
deviation cut off score. 
PD-MCI Subtype Domains Impaired N (%) 
Amnestic Multiple Memory + EF 4 (20) 
 Memory + EF + Attention/WM + Visuospatial 3 (15) 
 Memory + EF + Attention/WM 1 (5) 
 Memory + Attention/WM  1 (5) 
 Memory + Language 1 (5) 
 Subtotal 10 (50) 
Nonamnestic Multiple  EF + Visuospatial 4 (20) 
 EF + Attention/WM 1 (5) 
 EF + Language 1 (5) 
 EF + Attention/WM + Visuospatial 1 (5) 
 Attention/WM + Visuospatial 1 (5) 
 Subtotal 8 (40) 
Amnestic Single  Memory 1 (5) 
Nonamnestic Single Attention/WM 1 (5) 
 Total 20 (100) 
Note. PD-MCI = Parkinson’s Disease-Mild Cognitive Impairment; EF = executive function; 





2.4.1 Main findings 
This study is the first application of MDS Task Force criteria for PD-MCI in 
an Australian sample of people with PD. In accordance with criteria, 64.3% of 
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participants were diagnosed as PD-MCI. Among those with PD-MCI, 93.4% 
presented with multiple domain impairments (i.e., deficit test results in more than 
one cognitive domain), and 6.6% with single domain impairment. For individual 
domains, attention/working memory, executive function and memory impairments 
were most frequently impaired. Language and visuospatial abilities demonstrated 
less impairment. These results are consistent with Cholerton et al. (2014) and 
Goldman et al. (2013) who found 63% to 67% of their samples had PD-MCI and 
91.5% to 95% of those participants had multiple domain impairments. Marras et al. 
(2013) reported that 93% of their sample with PD-MCI had multiple domain PD-
MCI, despite an overall prevalence of only 33%. Recent application of the new 
criteria also revealed that attention/working memory, executive function and memory 
domains were most frequently impaired in PD-MCI (Cholerton et al., 2014; Goldman 
et al., 2013). These results, however, conflict with prevalence statistics preceding the 
new diagnostic criteria. Earlier studies reported a significantly lower prevalence 
(19% to 38%) of PD-MCI, and some studies identified single domain impairment 
more common than multiple domain impairment (Caviness et al., 2007; Goldman, 
Weis, Stebbins, Bernard, & Goetz, 2012; Litvan et al., 2011).  
 
Several reasons have been proposed for the varying frequency of PD-MCI 
across studies. Compared to methods used in earlier studies, the new diagnostic 
criteria is less stringent when diagnosing multiple domain (i.e., impairment on one 
test per domain) compared to single domain (i.e., impairment on two tests in one 
domain) subtypes, which will invariably identify more people with multiple domain 
impairment (Goldman et al., 2013). Introducing a more conservative criterion for the 
multiple domain subtype (e.g., impairment on two tests per domain) will likely 
reduce the biased frequency of multiple domain impairment. In addition, several 
verbal memory, visuospatial, and attention tests have demonstrated appropriate 
diagnostic specificity for PD-MCI (Biundo et al., 2013), and administering these 
tests in future research may provide a more accurate estimate of the multiple domain 
subtype. 
 
In studies preceding the MDS Task Force criteria, variable use of SD cut offs 
increased the heterogeneity of the frequency of PD-MCI and this issue is yet to be 
resolved (Liepelt-Scarfone et al., 2011). The new diagnostic criteria suggest 1 to 2 
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SD cut offs when establishing cognitive impairment with normative data (Litvan et 
al., 2012), but Liepelt-Scarfone et al. (2011) have shown PD-MCI diagnoses vary 
between 56.4% (using < 1 SD) and 9.9% (using < 2 SDs). A study recently identified 
2 SDs as the most sensitive and specific cut off for diagnosing PD-MCI using the 
new criteria (Goldman et al., 2013). Using a 2 SD cut off in the current study reduced 
the frequency of PD-MCI from 64.3% (using 1 SD) to 28.6%, but the frequency of 
subtype classifications remained relatively stable (i.e., multiple domain impairment 
remained more frequent than single domain). Language impairment, however, 
reduced from 44.4% (N = 20) using a 1 SD cut off to 10% (N = 2) using a 2 SD cut 
off. Compared to other cognitive domains, this result suggests that language 
impairment may be less frequent in PD-MCI. Impairment across all cognitive 
domains was prevalent among 11.1% (N = 5) of participants using a 1 SD cut off, but 
this reduced to nil participants using a 2 SD cut off. This finding supports the current 
characterisation of PD-MCI, with most individuals demonstrating impairment within 
multiple, but not all, cognitive domains (e.g., executive function and memory; 
Cholerton et al., 2014). Using a 1 SD cut off may, however, be too liberal and not 
sufficiently specific for identification of PD-MCI subtypes (Goldman et al., 2013). 
Overall, the reduction in the frequency of PD-MCI is similar to previous prevalence 
estimates that adopted more conservative 1.5 SD (Marras et al., 2013), and 2 SD 
(Muslimović et al., 2005) cut off scores. The MDS Task Force, however, suggest 
using a 1 SD cut off to detect impaired cognition in higher functioning individuals, 
who may have noticed a decline in their cognitive functioning but do not meet the 
stricter criteria of 1.5 to 2 SDs (Litvan et al., 2012).  
 
The inconsistent use and weighting of cognitive tests per domain may also 
bias diagnosis and subtyping of PD-MCI. The MDS Task Force recommends two 
tests per cognitive domain to ensure consistency across studies and reliable external 
validity of results (Litvan et al., 2012). Recent studies adopting the criteria have used 
between 3 and 7 tests/subtests per domain, more than recommended (Cholerton et al., 
2014; Goldman et al., 2013). Inclusion of more tests in any one domain increases the 
risk of a Type I error and may falsely inflate the prevalence of PD-MCI (Loftus et 
al., 2015). A recent study showed that when using MDS Task Force 
recommendations (10 or more neuropsychological tests), approximately 13% of 
people with PD and normal cognition will demonstrate impaired performance on two 
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or more tests (Loftus et al., 2015). The recent increase in prevalence of PD-MCI 
may, therefore, be associated with inclusion of more neuropsychological tests which 
may lead to more false-positive diagnoses of cognitive impairment. As previously 
noted, a more conservative use of tests (e.g., impairment on two tests per domain) 
when diagnosing multiple domain PD-MCI and applying a more stringent cut off 
score (e.g., < 2 SDs below normative data) may reduce the risk of Type 1 errors in 
research and clinical settings. While acknowledging these issues, further refinement 
of the PD-MCI criteria will determine the ideal classification method, appropriate cut 
off scores and optimal number and selection of tests for diagnosis. 
 
Although recent studies have used variable cut off scores, subtype 
classifications in this study are consistent with recent findings (Geurtsen et al., 2014). 
Most participants were classified as multiple domain PD-MCI, which included 20 
different combinations of impaired domains. Cholerton et al. (2014) also found 19 
combinations of impaired domains within their multiple domain subtype. Although 
this may be an artefact of the diagnostic criteria (i.e., 1 SD cut off has shown low 
specificity; Goldman et al., 2013), this heterogeneous distribution across multiple 
domains is a hallmark feature of PD-MCI (Kehagia et al., 2010). Research has 
identified diverse pathophysiological changes and characteristics that underline the 
heterogeneous presentation of PD-MCI (Cosgrove et al., 2015).  
 
Most participants in this study showed memory and executive function 
impairments, but there were considerable concomitant deficits across domains. The 
variability of PD-MCI has been associated with protein/neurotransmitter 
abnormalities and genetic characteristics (Cosgrove et al., 2015). Specifically, 
catecholaminergic changes involving frontostriatal dopaminergic deficits are 
associated with executive function impairment and deficiency of acetylcholine is 
associated with impaired posterior cortical function of memory, language and 
visuospatial abilities (Cosgrove et al., 2015; Svenningsson, Westman, Ballard, & 
Aarsland, 2012; Williams-Gray et al., 2009). In addition, alpha-synuclein infiltration 
(as Lewy based pathology) of the limbic system and neocortex has been associated 
with amnestic cognitive impairment in PD (Compta et al., 2011). Diverse 
neurotransmitter changes demonstrate the complex pathology of different cognitive 




Kehagia et al. (2010) suggest that genetic characteristics may account for 
patterns of decline in PD-MCI. The ‘dual syndrome hypothesis’ proposes two 
distinct genetic syndromes (executive and posterior cortical) that affect executive 
function and memory/visuospatial abilities in PD, and often present in early disease 
stages (Kehagia et al., 2010). A recent study tested the hypothesis and found 
associations between a genetic variation (rs4680 polymorphism of the COMT gene) 
which modulated executive function and two genetic variations (APOE allelic and 
MAPT haplotype) which independently modulated posterior cortical functions of 
memory and visuospatial abilities, respectively (Nombela et al., 2014). These studies 
provide initial support for subtyping of PD-MCI, indicating that frontal or posterior 
cortical deficits are associated with specific genetic and neurotransmitter 
abnormalities. Neuroimaging was beyond the scope of the present study, but the 
heterogeneity of multiple domain PD-MCI in this study does not support the ‘dual 
syndrome hypothesis’. That being said, research shows considerable overlap between 
the executive and posterior cortical syndromes and further clinical trials combining 
neuroimaging and neuropsychological testing are required (Kehagia, Barker, & 
Robbins, 2013). 
 
Participants with PD-MCI performed significantly worse (compared to 
participants with ‘Normal Cognition’), across all cognitive domains, including 
measures of global cognition. Similar results were reported by Goldman et al. (2013) 
and Marras et al. (2013). In both of these studies, PD-MCI groups performed worse 
on cognitive outcomes compared to the unimpaired groups. Group allocation was 
determined by cognitive performance, and as such, significant differences between 
group scores were to be expected. However, a conflicting result was reported for 
executive function. Compared to the Controlled Oral Word Association Test 
(COWAT), scores on the Stockings of Cambridge (SOC) test demonstrated no 
difference between groups, indicating comparative performance between those with 
and without PD-MCI. A recent systematic review and meta-analysis highlighted the 
multifaceted nature of executive function and challenges in researching this cognitive 
domain in PD (Kudlicka, Clare, & Hindle, 2011). Executive function is often 
referred to as an ‘umbrella’ concept used to described many subcomponent abilities, 
including purposive action (execution), volition, planning, effective performance, 
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attentional control, set-shifting, abstract reasoning, and managing behaviour (Lezak 
et al., 2012; Smith & Jonides, 1999; Stuss & Alexander, 2007). Consequently, 
individual neuropsychological tests are often unable to capture and measure the full 
spectrum of executive function. Predominantly, the SOC test involves rule learning, 
planning and execution, whereas the COWAT requires set shifting (between trials) 
and attentional control. In addition, studies have shown separation of ‘hot’ and ‘cold’ 
executive function abilities. ‘Cold’ cognitive tasks are described as neutrally 
affective and involve cognitive flexibility, while ‘hot’ cognitive tasks are influenced 
emotion and motivated reasoning (Zelazo & Carlson, 2012). Due to the complexity 
of executive function and the inherent specificity of neuropsychological tests, people 
with PD may show impaired performance on individual tests which do not represent 
impairment across the entire domain (Kudlicka et al., 2011). Therefore it is important 
that the exact tests used for diagnosis are standardised. 
 
When examining demographic variables, there were no significant 
differences between groups. Participants in the PD-MCI group were slightly older 
and had slightly less years of education, but differences were not significant. Recent 
studies have reported no educational difference between people with and without 
cognitive impairments in PD (Caviness et al., 2007; Cholerton et al., 2014; Goldman 
et al., 2013; Marras et al., 2013). But other studies reported older age and less years 
of education associated with cognitive decline in PD (Elgh et al., 2009; Hu et al., 
2014; Williams-Gray et al., 2009). These conflicting results suggest future 
longitudinal research is required to determine the long-term relationship between 
years of education and cognitive impairment in PD. Motor symptom severity was not 
measured in the current study, however, other factors such as daily levodopa 
equivalent dose and disease duration did not differ between groups, which suggests 
severity of motor symptoms may have been similar across groups (Fahn et al., 2004) 
and no worse for participants with PD-MCI. 
 
2.4.2 Limitations and recommendations for future research 
The primary limitation of this study was the cross sectional design, involving 
only baseline cognitive assessments. Collecting data at one time-point limits 
examination of which neuropsychological tests are most appropriate and which 
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domains of impairment are most predictive of cognitive decline in PD. Also, this 
sample had relatively high educational levels and low years of disease duration. 
These characteristics are comparable to cohorts from recent studies (Cholerton et al., 
2014; Marras et al., 2013), but may limit the generalisability of the results to the 
wider PD population. Some measures included in this study may have not been 
appropriate for detecting cognitive impairments in PD. For example, the COWAT is 
classified as a measure of executive function, but the timed nature of the test also 
requires participants’ use of processing speed (Lezak et al., 2012). Processing speed 
is frequently impaired in PD (Litvan et al., 2011; Muslimovic et al., 2005). 
Participants may therefore demonstrate impaired performance on the COWAT, as a 
result of impaired processing speed, rather than deficits in executive function. In 
addition, the Similarities test was included as a measure of language abilities but it 
also involves higher-order cognitive skills such as, conceptualisation and abstract 
reasoning (Wechsler, 2008). When completing tasks involving these higher-order 
cognitive skills the prefrontal cortex is predominantly activated, yet people with PD 
are known to experience frontostriatal dopaminergic deficits, which adversely impact 
associated cognitive abilities (Cosgrove et al., 2015). Poor performance on the 
Similarities test may therefore represent impaired conceptualisation and abstract 
reasoning, as opposed to deficits with language abilities. Lastly, the statistical 
assumptions of normality and homogeneity of variance were violated for some 
outcomes, and there was low internal consistency for some cognitive measures. 
Although outcome distributions were representative of this cohort, these caveats 
must be noted when interpreting the results. 
 
Future studies should adopt longitudinal designs to validate and provide 
suggestions for the refinement of the MDS Task Force diagnostic criteria for PD-
MCI. Future studies need to determine which neuropsychological tests are most 
reliable and valid over time, the most appropriate number of tests per cognitive 
domain (to control inflation of Type I errors), tests most suitable for detecting 
cognitive impairment in PD (e.g., additional processing speed and language tests), 
and the most sensitive and specific cut off scores for diagnostic purposes. The MDS 
criteria also needs to be applied to different age groups with varying degrees of 
cognitive impairment, disease severity and cognitive reserve (educational/ 
occupational attainment). Recent and ongoing longitudinal studies are examining 
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biomarker, epidemiological and neuropsychological risk factors associated with 
cognitive decline in PD (Dujardin et al., 2015; Hu et al., 2014; Loftus et al., 2015; 
Nombela et al., 2014; Williams-Gray et al., 2009). However, future studies need to 
adopt an interdisciplinary approach by integrating clinical neuroscience, 
neuroimaging and neurobiology with the MDS criteria, to provide a greater 
understanding of PD-MCI. Moreover, studies must be transparent in their reporting 
of the normative datasets used to establish diagnoses of PD-MCI. As explained by 
Strauss et al. (2006), selection of appropriate normative data is equally as important 
as choosing a reliable and valid neuropsychological test. Using a normative dataset 
that is not a demographical match to a participant’s characteristics is problematic, 
given that norm-referenced scores are directly tied to measurable consequences such 
as prevalence rates, diagnosis, and pharmacological/nonpharmacological 
interventions (Mitrushina, Boone, Razani, & Delia, 2005).  
 
The etiology and profile of PD-MCI is heterogeneous with some people 
reverting back to normal cognition and many others progressing to PD-Dementia 
(Pedersen et al., 2013). Currently, there is no known therapeutic intervention to halt 
or delay cognitive decline in PD (Goldman & Weintraub, 2015). While clinical trials 
are examining the potential of pharmacological treatments, two recent studies found 
no improvements in cognition (Frakey & Friedman, 2014; Mamikonyan, Xie, 
Melvin, & Weintraub, 2015). This limited empirical support of pharmacological 
treatment has led to an increase in research assessing nonpharmacological 
interventions for cognition in PD (Hindle et al., 2013). Specifically, cognitive 
training and non-invasive brain stimulation have demonstrated improved cognition in 
PD (Pal, Nagy, Aschermann, Balazs, & Kovacs, 2010; París et al., 2011). However, 
most studies included participants without cognitive impairment and significant 
methodological heterogeneity has limited the reliability of results (Goldman & 
Weintraub, 2015). Despite current limitations, nonpharmacological interventions 
may be a therapeutic alternative for people with PD-MCI who are already burdened 






2.5 Chapter Summary 
 
When applying the MDS Task Force diagnostic criteria for PD-MCI, this 
study found 64% of participants (using a 1 SD cut off) were cognitively impaired 
(i.e., demonstrated PD-MCI), and this figure reduced to 28% with PD-MCI when 
using a 2 SD cut off. Despite the change in frequency of impairments, most 
participants with PD-MCI were classified as multiple domain subtype which is 
consistent with recent findings (Geurtsen et al., 2014). Although further validation 
and refinement of the diagnostic criteria is required, the significant prevalence and 
heterogeneous nature of PD-MCI is now documented in an Australian sample. 
Neurotransmitter abnormalities, genetic biomarkers and epidemiological risk factors 
are associated with cognitive deficits in PD. The limited evidence supporting 
pharmacological treatments for PD-MCI, indicates that future studies need to 
integrate the MDS criteria with randomised controlled trials of nonpharmacological 
interventions (e.g., cognitive training and non-invasive brain stimulation), and 
explore the potential beneficial effects of these therapies for people with cognitive 
impairment and PD. The next chapter is a review and meta-analysis of cognitive 
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Whilst PD is classified as a movement disorder, up to 64% (see Chapter 
2.3.2) of people with PD may experience cognitive deficits which negatively impact 
quality of life (Litvan et al., 2011). Whilst there is limited evidence supporting 
pharmacological treatment (e.g., cholinesterase inhibitors and memantine) for people 
with comorbid cognitive impairments and PD (Goldman & Weintraub, 2015; Wang 
et al., 2014), nonpharmacological interventions are being considered as potential 
therapeutic techniques for improving cognition (Hindle et al., 2013). 
 
Initial research suggests that cognitive training may reduce cognitive decline 
for people with PD-Mild Cognitive Impairment and PD-Dementia (Burn, 2010; 
Kehagia et al., 2010). Studies using rTMS and tDCS have reported positive, but 
variable, effects on cognitive functioning in PD and there is a lack of consensus 
regarding administration methods for brain stimulation in PD (Benninger et al., 2010; 
Hindle et al., 2013). Sindhi and Leroi (2013) suggested that future research 
concerning cognitive training interventions for PD-MCI and PDD should be 
specifically adapted to the needs of the individual. People with PD often develop 
deficits in non-amnestic cognitive domains, such as executive functions and 
visuospatial abilities (Aarsland et al., 2010; Sindhi & Leroi, 2013). Any effective 




This chapter begins with a review of all controlled and uncontrolled trials of 
standard (non-specific) cognitive training, tailored (domain specific) cognitive 
training, repetitive transcranial magnetic stimulation (rTMS), and transcranial direct 
current stimulation (tDCS) for cognition in PD. This chapter concludes with a meta-
analysis of all controlled trials of standard cognitive training, tailored cognitive 
training, and rTMS for cognition in PD. A meta-analysis uses statistical methods to 
pool multiple intervention trials into an individual standardised intervention effect 
(Borenstein, Hedges, Higgins, & Rothstein, 2011). Meta-analytic results provide a 
more accurate estimate of an intervention effect and allow for efficacy comparisons 
to determine whether there is consistency or heterogeneity across intervention 
outcomes (Borenstein et al., 2011). A recent meta-analysis of cognitive training in 
PD found cognitive training improves select cognitive domains in PD (Leung et al., 
2015). However, this study is the first meta-analysis to stratify cognitive training into 
standard or tailored interventions and meta-analyse brain stimulation in PD. This 
chapter provides an accurate review of the empirical research and recommendations 
for future nonpharmacological interventions. 
 
3.2 A Review of Cognitive Training and Brain Stimulation Interventions for 
Cognition in PD 
 
3.2.1 Cognitive Training for Cognition in PD 
As noted in Chapter 1 (section 8.3), recent clinical trials of cognitive training 
have demonstrated improved cognition in PD and PD-MCI (Hindle et al., 2013). For 
the purpose of this review, cognitive training was broadly defined as “…structured 
practice on tasks relevant to aspects of cognitive functioning … and tasks may be 
presented in various modalities, including pencil/paper or computerised versions.” 
(Martin et al., 2011, p. 3). Standard cognitive training (not individualised) refers to a 
set of cognitive tasks administered to participants regardless of their individually 
different cognitive deficits. Tailored cognitive training (individualised) is customised 
to address specific cognitive deficits. 
 
3.2.1.1 Standard Cognitive Training. Three uncontrolled trials have 
explored standard cognitive training in PD (Mohlman, Chazin, & Georgescu, 2011; 
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Sinforiani, Banchieri, Zucchella, Pacchetti, & Sandrini, 2004; Zimmermann et al., 
2014). Sinforiani et al. (2004) examined the effect of standard computer-based 
cognitive training in people with cognitive impairments and PD. The standard 
cognitive training program involved the use of attention, abstract reasoning, and 
visuospatial abilities. Performance improved on measures of abstract reasoning, 
verbal fluency, and visuospatial abilities post-training and effects were maintained 
for six months (Sinforiani et al., 2004). Mohlman et al. (2011) assessed the feasibility 
and acceptance of a computer-based cognitive training program designed to train 
attentional abilities for people with PD. Executive functioning improved post-
training, which was significantly related to the participant’s subjective ratings of the 
training (Mohlman et al., 2011). Zimmermann et al. (2014) compared whether 
cognition-specific training and non-specific computer game training improved 
cognitive performance in PD. Although nonspecific computer-based training 
improved attention to a greater extent, both forms of training improved cognitive 
functioning (Zimmermann et al., 2014).  
 
There have been eight controlled trials of standard cognitive training in PD 
(Costa et al., 2014; Edwards et al., 2013; Ell, 2013; Nombela et al., 2011; París et al., 
2011; Pena et al., 2014; Petrelli et al., 2014; Pompeu et al., 2012). Nombela et al. 
(2011) examined whether six months of daily Sudoku puzzle training improved 
attention and working memory in people with cognitive impairments and PD, while 
neural activity was monitored by fMRI. Participants significantly improved on the 
Stroop test, which aligned with reduced patterns of frontal and parietal cortical 
activation (Nombela et al., 2011). In an RCT, París et al. (2011) examined whether 
standard multimedia and paper/pencil cognitive training improved cognitive 
functioning, quality of life, and activities of daily living in people with PD. 
Participants were randomised to a ‘trained’ or ‘speech therapy’ group (París et al., 
2011). Compared to the control group, the trained group improved their performance 
across all cognitive domains (except language). However, no improvement was 
found on quality of life and activities of daily living measures (París et al., 2011). To 
examine whether standard cognitive training improved global cognition and activities 
of daily living in people with PD, Pompeu et al. (2012) compared Nintendo Wii-
based cognitive and motor training (trained group) against balance exercise therapy 
(control group) in people with PD. Both groups significantly improved in global 
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cognition and activities of daily living, which were maintained for 60 days (Pompeu 
et al., 2012).  
 
Ell (2013) compared targeted and non-targeted decision-rule training with a 
control group in people with PD. Trained groups completed 80 computer-based trials 
in which they were presented with a single stimulus and instructed to categorise the 
stimulus based on predetermined labels (Ell, 2013). The targeted group were 
presented with a stimulus relevant to the dimension and the non-targeted group were 
presented with both stimuli relevant and non-relevant to the dimension (Ell, 2013). 
Results showed that compared to the control and non-targeted groups, the targeted 
group improved in executive functions (Ell, 2013). In a RCT, Edwards et al. (2013) 
examined whether cognitive training improved speed of processing in PD. 
Participants completed 20 hours of computer-based cognitive training that focused 
on speed of processing skills. There were significant improvements in speed of 
processing for those with mild/moderate PD (Edwards et al., 2013). Costa et al. 
(2014) conducted a controlled trial of attentional shifting training for improvement of 
prospective memory in PD. Following 12 sessions of cognitive training, participants 
demonstrated improvements in event-based prospective memory and executive 
functions (Costa et al., 2014). 
 
In a RCT, Petrelli et al. (2014) compared structured cognitive training 
(targeting specific cognitive domains) and unstructured cognitive training (random 
cognitive tasks) with a control group for improvements in cognition, depression, and 
quality of life in PD. Participants were assessed using a series of neuropsychological 
tests pre and post-intervention, and completed 12 sessions of cognitive training. 
Compared to the control and unstructured training groups, participants in the 
structured training group significantly improved their working memory (Petrelli et 
al., 2014). The structured group also significantly improved short-term memory, 
whereas the control group did not (Petrelli et al., 2014). The unstructured training 
group demonstrated improved control of attention, short and long-term memory, 
working memory, and executive functions (Petrelli et al., 2014). Pena et al. (2014) 
examined the impact of cognitive training on processing speed, verbal memory, 
visual memory, executive functions, and theory of mind in PD. Compared to the 
control group, participants in the training group demonstrated significant 
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improvements in processing speed, visual memory, theory of mind, and functional 
disability following three months of cognitive training (Pena et al., 2014). 
 
3.2.1.2 Tailored Cognitive Training. Three uncontrolled studies have 
examined tailored cognitive training in PD (Disbrow et al., 2012; Milman, Atias, 
Weiss, Mirelman, & Hausdorff, 2014; Reuter, Mehnert, Sammer, Oechsner, & 
Engelhardt, 2012). Disbrow et al. (2012) conducted a computer-based cognitive 
training intervention to improve motor-related executive function in people with PD. 
Participants were divided into groups based on baseline motor-related executive 
function assessments and task difficulty was tailored to individual performance 
(Disbrow et al., 2012). Compared to the participants without motor impairment, there 
were significantly greater improvements in motor-related executive function for the 
participants with motor impairment (Disbrow et al., 2012). In a multimodal study, 
Reuter et al. (2012) compared three interventions for people with PD-MCI: cognitive 
training (Group A), cognitive training and transfer training (Group B), and cognitive 
training, transfer training, and motor training (Group C). Cognitive training was 
individually tailored based on baseline neuropsychological results and involved 
practicing executive function tasks (Reuter et al., 2012). Transfer training involved 
the practice of daily activities (e.g., prepare a meal, pay a bill) that had practical 
relevance to participants, and motor training was adapted from training traditionally 
used to enhance working memory and visuospatial abilities in children (Reuter et al., 
2012). After four weeks of training, significant improvements in executive function 
tasks were evident for all groups. However, Group C improved significantly more 
than the other groups (Reuter et al., 2012). At a six month follow-up the 
improvements of Groups A and B were diminished, whereas improvements of Group 
C were maintained (Reuter et al., 2012). Milman et al. (2014) examined whether 12 
weeks of in-home cognitive training improved gait, mobility (primary outcomes), 
and cognitive functioning (secondary outcome) in people with PD. Significant 
improvements were found in global cognitive scores at one and four-weeks post-
training, but there were no improvements in executive function, attention, memory, 
and visuospatial abilities (Milman et al., 2014). 
 
There are three published controlled trials of tailored cognitive training in PD 
(Cerasa et al., 2014; Naismith, Mowszowski, Diamond, & Lewis, 2013; Sammer, 
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Reuter, Hullmann, Kaps, & Vaitl, 2006). Sammer et al. (2006) compared the effect 
of tailored executive function training and standard physical therapy on cognitive 
performance in people with PD. Both groups demonstrated improved performance in 
executive functions post-training, but those who received the tailored training 
improved to a greater extent (Sammer et al., 2006). To accentuate the positive results 
of executive function training in PD, Naismith et al. (2013) conducted a tailored 
cognitive training program to improve memory. Cognitive training comprised of 
two-hour sessions twice a week and involved psychoeducation and tailored 
computer-based tasks (Naismith et al., 2013). Episodic memory and learning 
retention were significantly improved post-training (Naismith et al., 2013). Cerasa et 
al. (2014) examined neurofunctional correlates between trained cognitive domains 
and synaptic plasticity of those domains in people with PD. Participants completed 
12 hours of computer-based cognitive training tailored to their pre-training cognitive 
impairments. Compared to the control group, participants in the training group 
demonstrated attentional improvements which increased neural resting state (fMRI) 
activity in the superior parietal and prefrontal dorsolateral cortices (Cerasa et al., 
2014). Both cortices are associated with attention and executive functions, indicating 
that tailored cognitive training improves cognition in PD (Cerasa et al., 2014).  
 
3.2.1.3 Summary of Cognitive Training. Most controlled and uncontrolled 
trials of standard and tailored cognitive training improved cognition in people with 
PD. Specifically, attention/working memory improved in six standard cognitive 
training and one tailored cognitive training study (Cerasa et al., 2014; Edwards et al., 
2013; Nombela et al., 2011; París et al., 2011; Pena et al., 2014; Petrelli et al., 2014; 
Zimmermann et al., 2014). Significant improvements in executive functions were 
reported in five standard cognitive training and three tailored cognitive training 
studies (Costa et al., 2014; Ell, 2013; Mohlman et al., 2011; París et al., 2011; Pereira 
et al., 2013; Reuter et al., 2012; Sammer et al., 2006; Sinforiani et al., 2004). 
Visuospatial functions and memory improved in two and five studies, respectively 
(Costa et al., 2014; Naismith et al., 2013; París et al., 2011; Pena et al., 2014; Petrelli 
et al., 2014; Sinforiani et al., 2004). Despite recent studies demonstrating language 
impairments in PD-MCI (Cholerton et al., 2014; Goldman et al., 2013) no cognitive 
training study reported language improvements. Results from these studies suggest 
that as a nonpharmacological intervention, cognitive training may alleviate cognitive 
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deficits in PD. As noted by Hindle et al. (2013), however, intervention methodology 
has varied considerably across studies which may undermine the efficacy of these 
findings. 
 
3.2.2 Brain Stimulation for Cognition 
There are two main non-invasive brain stimulation procedures: repetitive 
transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation 
(tDCS). rTMS employs an electromagnetic coil to excite or inhibit cortical functions 
(Barker et al., 1985; Guse et al., 2010). tDCS can be used to modulate neuronal 
activity by delivering low intensity (1 mA or 2 mA) electrical currents to a specific 
cortical region (Creutzfeldt et al., 1962; Nardone et al., 2012). Anodal tDCS and high 
frequency rTMS increase cortical excitability, whereas, cathodal tDCS and low 
frequency rTMS decrease cortical excitability (Nardone et al., 2012). Both rTMS and 
tDCS impact cortical excitability, although it is not known if one method induces 
greater long-term change (Nardone et al., 2012; Nitsche & Paulus, 2000; Pascual-
Leone et al., 1998). The limited benefits of pharmacological treatments for people 
with PD and cognitive impairments has led researchers to investigate the 
effectiveness of rTMS and tDCS for modifying and delaying cortical degeneration in 
people with PD (Hindle et al., 2013; Wang et al., 2014). 
 
3.2.2.1 Repetitive Transcranial Magnetic Stimulation. Although there is 
limited research examining the efficacy of brain stimulation interventions for 
cognitive impairments in PD, preliminary results are encouraging. Nine uncontrolled 
trials have examined the impact of rTMS on cognition in PD (Benninger et al., 2009; 
Epstein et al., 2007; Fregni et al., 2004; Furukawa, Izumi, Toyokura, & Masakado, 
2009; Kimura et al., 2011; Mally & Stone, 1999; Sedláčková, Rektorová, 
Srovnalová, & Rektor, 2009; Srovnalova, Marecek, Kubikova, & Rektorova, 2012; 
Srovnalova, Marecek, & Rektorova, 2011).  
 
In a preliminary study, Mally and Stone (1999) administered rTMS (1 Hz) 
over the skull’s vertex once or twice a day to people with PD. Motor and short-term 
memory assessments were completed at baseline and three, seven, 30, and 90 days 
following stimulation (Mally & Stone, 1999). There were no improvements in short-
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term memory. Fregni et al. (2004) compared rTMS and antidepressant medication 
(fluoxetine) on cognitive function in PD. Participants were randomised to either 
receiving rTMS (15 Hz) over their left dorsolateral prefrontal cortex and a placebo 
drug, or sham rTMS and fluoxetine (20mg; Fregni et al., 2004). Although depression 
was the primary outcome of this study, significant improvement in global cognition 
(measured by MMSE) was reported for both the rTMS and fluoxetine groups at 2-
weeks post-intervention. In an open study, Epstein et al. (2007) examined the impact 
of rTMS on global cognition, attention, and memory in PD. Participants completed 
10 sessions of rTMS (10 Hz) applied over their left dorsolateral prefrontal cortex. 
Global cognition and memory improved at two-weeks post-intervention. But 
improvements were not maintained at the three and six week follow-up assessments 
(Epstein et al., 2007). Sedláčková et al. (2009) investigated whether one session of 
rTMS (10 Hz) applied over the left dorsal premotor cortex and/or left dorsal lateral 
prefrontal cortex affected reaction time and executive functions in people with PD. 
The results did not indicate any improvements related to rTMS (Sedláčková et al., 
2009).  
 
As previous studies used 25 Hz rTMS or less, Benninger et al. (2009) 
investigated whether rTMS (50 Hz) could be safely delivered to people with PD and 
whether increased rTMS frequency would lead to improvements in cognitive and 
motor functions. Participants received one session of rTMS over the left primary 
motor cortex. Significant improvements were found in right and left-hand 
movements, but participants demonstrated no improvements in cognition (Benninger 
et al., 2009). Comparatively, Furukawa et al. (2009) examined whether low 
frequency rTMS (0.2 Hz) improved working memory and executive functions in PD. 
Six participants completed 12 stimulation sessions over 12 weeks. Significant 
improvements were reported for working memory and executive functions 
(Furukawa et al., 2009). 
 
Srovnalova et al. (2011) examined whether rTMS over the inferior frontal 
gyrus improved executive functions in PD without cognitive impairment. 
Participants completed one active and one sham rTMS (25 Hz) session, and 
performed the Stroop test and Frontal Assessment Battery (FAB) prior to and 
immediately following each session (Srovnalova et al., 2011). Stroop test 
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performance improved, but FAB performance did not (Srovnalova et al., 2011). In a 
eight-week cross-over study of sham rTMS followed by real rTMS, Kimura et al. 
(2011) examined the impact of 0.2 Hz stimulation on motor symptoms, activities of 
daily living, depression, cerebral blood flow, and cognition in PD. Post-rTMS, only 
motor symptom improvements were found (Kimura et al., 2011). Another study by 
Srovnalova et al. (2012) compared rTMS (25 Hz) applied over either the left or right 
dorsolateral prefrontal cortices to examine its impact on an executive function task 
(Tower of London). Participants demonstrated improvements in Tower of London 
problem-solving time when rTMS was applied over the right, but not the left, 
dorsolateral prefrontal cortex (Srovnalova et al., 2012). 
 
There are four published controlled trials of rTMS for cognition in PD 
(Benninger et al., 2011; Benninger et al., 2012; Boggio et al., 2005; Pal et al., 2010). 
Similar to Fregni et al.’s (2004) uncontrolled trial, Boggio et al. (2005) compared the 
effects of rTMS (15 Hz) over the left dorsal lateral prefrontal cortex or antidepressant 
medication (fluoxetine) on cognitive function in PD. Both interventions led to 
improvements in executive functions and visuospatial abilities post-treatment, which 
were maintained for eight weeks (Boggio et al., 2005). Pal et al. (2010) compared the 
effect of rTMS (5 Hz) over the left dorsal lateral prefrontal cortex and sham rTMS in 
PD and comorbid depression. After 10 sessions of rTMS, Stroop performance 
significantly improved and these improvements were maintained for 30 days (Pal et 
al., 2010). Although depression was the primary outcome in these studies, high 
frequency rTMS over the left dorsal lateral prefrontal cortex improved executive and 
visuospatial functions in people with PD (Boggio et al., 2005; Pal et al., 2010). 
 
To examine the safety and efficacy of intermittent theta-burst (iTBS) rTMS, 
Benninger et al. (2011) conducted a RCT of eight 5 Hz sessions over two weeks. 
Participants received bilateral iTBS-rTMS to the primary motor and dorsolateral 
prefrontal cortices. Results showed decreased verbal fluency for the iTBS-rTMS 
group (compared to control), but no significant differences were found for executive 
functions (as measured by the Frontal Assessment Battery). Furthering these results, 
Benninger et al. (2012) conducted another RCT to examine the safety and efficacy of 
rTMS (50 Hz) for improving motor symptoms in PD. Executive function (FAB) was 
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included as a secondary outcome, but no improvements were reported (Benninger et 
al., 2012). 
 
3.2.2.2 Transcranial Direct Current Stimulation. Two uncontrolled trials 
(Boggio et al., 2006; Pereira et al., 2013) and one controlled trial (Doruk, Gray, 
Bravo, Pascual-Leone, & Fregni, 2014) have examined the impact of tDCS on 
cognition in PD. Boggio et al. (2006) tested whether tDCS over the left dorsal lateral 
prefrontal cortex (DLPFC) improved working memory performance (three-back 
letter paradigm) in PD. Participants were assigned to one of three tDCS conditions; 
(i) stimulation of the left DLPFC, (ii) stimulation of the primary motor cortex, and 
(iii) sham tDCS. Participants were then allocated to one of two tDCS intensity 
groups, 1 mA or 2 mA (Boggio et al., 2006). Two mA tDCS over the left DLPFC 
improved working memory, whereas 1mA and sham tDCS did not improve working 
memory. Pereira et al. (2013) examined whether 20 minutes of counterbalanced 2 
mA tDCS over the left dorsolateral prefrontal and left temporo-parietal cortices 
improved executive functions (phonemic and semantic fluency) in PD. Significant 
improvements were found in executive functions immediately following tDCS. In the 
only randomised controlled trial of tDCS in PD, Doruk et al. (2014) compared 2 mA 
tDCS applied over the left (group one) or right (group two) dorsolateral prefrontal 
cortex with sham stimulation (control group) for executive function in PD. 
Compared to the control group, significant improvements in the Trail Making Test 
(Part B) were found for both tDCS groups immediately following the two-week 
intervention and at a one-month follow-up assessment (Doruk et al., 2014). 
 
3.2.2.3 Summary of Brain Stimulation. Most brain stimulation 
interventions improved cognitive functioning in PD. Attention/working memory 
improved in one rTMS and one tDCS study (Boggio et al., 2006; Furukawa et al., 
2009). Executive function improvement was found in five rTMS and two tDCS 
studies (Boggio et al., 2005; Disbrow et al., 2012; Doruk et al., 2014; Furukawa et 
al., 2009; Pal et al., 2010; Srovnalova et al., 2012; Srovnalova et al., 2011). 
Improvements were also found in memory (Epstein et al., 2007) and visuospatial 
functions (Boggio et al., 2005). No brain stimulation study measured language 
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improvements. These studies provide preliminary evidence in support of non-
invasive brain stimulation for improving cognitive function in PD. 
 
3.2.3 Summary of Previous Research 
Hindle and colleagues (2013) conducted a systematic review examining 
nonpharmacological enhancement of cognitive functions in PD. They concluded that 
although a large number of studies demonstrated improvements in cognitive function 
(predominantly executive functions) for people with PD and PD-MCI, there was a 
lack of methodological rigour which reduced the quality of the results (Hindle et al., 
2013). rTMS studies have varied by intervention length (1 to 12 sessions), 
stimulation frequency (0.2 Hz to 50 Hz), target locations (dorsolateral prefrontal or 
motor cortices) and approach to stimulation: intermittent theta-burst or repetitive 
TMS (Benninger et al., 2011; Benninger et al., 2012; Benninger et al., 2009; Boggio 
et al., 2005; Epstein et al., 2007; Furukawa et al., 2009). Consequently, studies 
administering lower frequency (e.g., 5 Hz) rTMS over the left dorsolateral prefrontal 
cortex (impacting executive function) will likely produce different cortical effects 
compared to higher frequency (e.g., 50 Hz) rTMS over the motor cortices (impacting 
motor function). Most studies have also assessed cognitive domains as secondary 
outcomes, rather than targeting interventions to the primary improvement of 
cognition (Boggio et al., 2005; Fregni et al., 2004). For tDCS, more consistent 
methodology has been adopted (e.g., 2 mA stimulation of prefrontal cortices) but 
findings are limited by lack of controlled designs (Boggio et al., 2006; Pereira et al., 
2013). The methodological differences across studies indicates a need to meta-
analyse results to provide a more accurate estimate of an overall intervention effect. 
 
Recent, controlled trials have adopted more stringent methodological designs 
and support cognitive training and brain stimulation for improved cognition in PD 
(Doruk et al., 2014; Petrelli et al., 2014). In addition, a recent meta-analysis of 
cognitive training in PD found improvements in working memory, processing speed 
and executive function (Leung et al., 2015). It remains unclear, however, whether 
standard or tailored cognitive training, rTMS, or tDCS are beneficial for cognition in 
PD. The present study builds upon the recent meta-analysis by examining the 
efficacy of controlled, standard cognitive training, tailored cognitive training, tDCS, 
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and rTMS studies in PD and provides a synthesis of current results with 
recommendations for future, nonpharmacological interventions. 
 
3.3 A Meta-Analysis of Controlled Nonpharmacological Interventions for 
Cognition in PD 
 
This meta-analysis systematically examines the efficacy of standard cognitive 
training, tailored cognitive training, tDCS, and rTMS studies for improving cognition 
in PD and provides a synthesis of current results with recommendations for future 
nonpharmacological interventions in PD. This meta-analysis was conducted in 
accord with the Preferred Reporting of Systematic Reviews and Meta-Analyses 
(PRISMA) statement (Moher, Liberati, Tetzlaff, & Altman, 2009). 
 
 
3.4 Search Strategy 
 
An extensive literature search revealed intervention studies for cognition in 
PD. The following key words attention, brain, brain stimulation, cognition, 
cognitive, cognitive impairment, cognitive rehabilitation, cognitive therapy, cognitive 
training, cerebral cortex, cortex, current, direct, dorsal, dorsolateral, dorsolateral 
prefrontal cortex, electric stimulation, episodic memory, executive, executive 
function, explicit memory, function, implicit memory, intervention, language, 
language tests, learning, long-term memory, magnetic, memory, mild cognitive 
impairment, motor cortex, neuronal plasticity, neuropsychological, noninvasive, 
parietal lobe, Parkinson disease, prefrontal, prefrontal cortex, premotor, 
psychomotor, performance, rehabilitation, semantic memory, short-term memory, 
spatial memory, stimulation, tests, therapy, training, transcranial, transcranial direct 
current stimulation, transcranial magnetic stimulation,  verbal memory, visual 
perception, visuospatial, visuospatial ability, visuospatial memory, and working 
memory were systematically searched in online databases for published studies 
(Medline, PubMed, Proquest, ScienceDirect, PsycInfo, Web of Science, Wiley 
Online Library, EMBASE, and Cochrane Library) and grey literature (OpenGey and 
NTIS). Search parameters were from first date of publication to May 27, 2016. 
Reference lists of selected articles were also searched. 
67 
 
3.5 Study Selection 
 
Studies were included in the meta-analysis if they: 
1. Included participants with idiopathic PD diagnosed by a neurologist or 
geriatrician in accord with the United Kingdom’s Parkinson’s Disease 
Society Brain Bank Clinical Criteria (UKPDSBBC). 
2. Evaluated repetitive transcranial magnetic stimulation, transcranial direct 
current stimulation, or cognitive training interventions in PD. 
3. Used a controlled design. 
4. Measured primary outcomes with standardised neuropsychological tests. 
5. Provided data to calculate an effect size (means, SDs, t or F values, and 
probability values). 
 
The primary researcher (B.J.L) systematically screened article titles and 
abstracts in-line with selection criteria, and identified preliminary articles for 
inclusion. The primary researcher (B.J.L) and supervisory researcher (A.M.L) then 
independently screened selected articles to determine the final studies for inclusion. 
Any disagreements were resolved through discussion.  
 
3.6 Statistical Analysis 
 
Comprehensive Meta-Analysis (CMA) version 3.3.070 was used to complete 
data analyses in accordance with recommendations by Borenstein et al. (2011), 
Hedges and Olkin (1985), Ray and Shadish (1996), and DerSimonian and Kacker 
(2007). 
 
3.6.1 Effect Size Calculation 
Hedge’s 𝑔 was used to represent the effect size for each study (Hedges & 
Olkin, 1985). Hedge’s 𝑔 removes the overestimate effect size bias of Cohen’s 𝑑 by 
applying the correction factor (𝐽). Cohen’s 𝑑 is the standardised mean difference 
between control and intervention groups at post-intervention (Cohen, 1992) and was 
calculated before applying 𝐽 to compute 𝑔 (Borenstein et al., 2011). When a study 
reported sufficient data (pre and post-intervention means and standard deviations 
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[SDs] for intervention and control groups), effect sizes were calculated using change 
scores with the following formula:  
 
𝑑 =  
𝑀𝐼𝛥  −  𝑀𝐶𝛥
 𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑  
 
 
where:                          𝑀𝐼𝛥   =  mean change in intervention group from  
                                                 pre-intervention to post-intervention  
                                    𝑀𝐶𝛥    =  mean change in control group from  
                                                 pre-intervention to post-intervention  
 
 
and                               𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑 = √
(𝑛𝐼 – 1) (𝜎𝐼)
2 +  (𝑛𝐶 – 1) (𝜎𝐶)
2 
𝑛𝐼  +  𝑛𝐶  − 2
 
 
where:                            𝑛𝐼 = number of participants (intervention group) 
                                       𝑛𝐶  = number of participants (control group) 
                                       𝜎𝐼 = standard deviation (intervention group) 
                                       𝜎𝐶 = standard deviation (control group) 
 
Rather than computing pooled effect sizes with post-intervention means and 
SDs, the change score method provides a more precise estimate of an ‘intervention 
vs. control’ effect by accounting for pre-intervention group differences. Change 
scores ensure the within-groups absolute magnitude of change is used to calculate 
pooled effect sizes in a meta-analysis. Leung et al. (2015) recently used the change 
score method.  
 
In some studies, underlying population standard deviations are the same 
across groups. However, in this meta-analysis it was unlikely that, 𝜎𝐼 =  𝜎𝐶 =  𝜎. 
Therefore within-groups standard deviations were pooled across groups to provide a 
more accurate estimate of their combined value (Borenstein et al., 2011). For studies 




𝑉𝑑 =  
 𝑛𝐼  +  𝑛𝐶
  𝑛𝐼  ×  𝑛𝐶   
 +  
𝑑2
2(𝑛𝐼 +  𝑛𝐶)
 
(Hedges & Olkin, 1985) 
 
Then, each study’s Cohen’s 𝑑 was converted to Hedge’s 𝑔 using the below 
correction factor  (𝐽) formula: 





Then,                                                   𝑔 = 𝐽 × 𝑑 
 
and                                                    𝑉𝑔 = 𝐽
2  ×  𝑉𝑑  
 
with                                                   𝑆𝐸𝑔 =  √𝑉𝑔 
 
where:                                             𝑑𝑓 = (𝑛𝐼  +  𝑛𝐶) − 2  
                                                      𝑆𝐸𝑔 = Standard Error of 𝑔 
                                                         𝑉𝑔 = Variance of 𝑔 
 
(Borenstein et al., 2011; Hedges & Olkin, 1985) 
 
When studies did not report means, standard deviations, t or F statistics, 
effect sizes were calculated using probability levels from a one-way two-group test 
(ANOVA or ANCOVA) based on post-intervention scores (Ray & Shadish, 1996). 
Corresponding t-values for reported probability levels were computed using CMA 
and substituted into the below formula to calculate an estimate of Hedge’s 𝑔: 
 
𝑔 = 𝐽 × 𝑑 
 
where:                                    𝑑 =
𝑡
(√𝐻𝑎𝑟𝑚𝑜𝑛𝑖𝑐 𝑁 / √2)
 
 
and                                    𝐻𝑎𝑟𝑚𝑜𝑛𝑖𝑐 𝑁 =  






producing:                         𝑔 =  𝐽 × 
𝑡
[√





(Borenstein, Hedges, Higgins, & Rothstein, 2014) 
 
Where studies reported adjusted means and standard error (𝑆𝐸) values at pre 
and post-intervention, standard error values were converted into standard deviations 
(𝑆𝐷) using the following formula: 
 
𝑆𝐷 = 𝑆𝐸 × √𝑛 
(Altman & Bland, 2005) 
 
3.6.1.1 Multiple outcomes per study. Studies often report multiple outcomes 
that are conceptually related and measure an overarching domain (e.g., memory, 
executive function). Selecting individual outcomes from each study to pool effect 
sizes may induce a selection bias towards statistically significant results or the most 
frequently used outcomes across studies. Borenstein et al. (2011) therefore 
recommend including all outcomes from all studies, by first computing composite 
domain effects within studies and then using the composite domain effects to pool 
effect sizes across studies. However, including multiple outcomes from each study 
within each pooled effect will produce (often high) intercorrelations between the 
conceptually related outcomes (Olkin & Gleser, 2009). High correlations will lead to 
less precise estimates of the pooled effects (Borenstein et al., 2011). Thus to account 
for intercorrelations between conceptually related outcomes, composite domain 
effects were calculated by computing the mean effect and variance within each 
domain within each study, and adjusting the mean variance by a factor of .80 using 
the below formula: 
 
𝑉?̅? =  
1
𝑚
 𝑉 (1 + (𝑚 − 1) 𝑟) 
 
where:                                𝑉 = mean variance 
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                                           𝑚 = number of conceptually related outcomes 
                                            𝑟 = correlation factor 
 
(Borenstein et al., 2011; Leung et al., 2015) 
 
3.6.1.2 Multiple treatment conditions. To ensure even distribution of 
participants, studies including two or more intervention groups and one control group 
had participants in the control group divided into multiple sub-control groups. This 
ensured that each participant’s data was included only once in the meta-analysis 
(Borenstein et al., 2011).  
 
3.6.2 Pooled Effect Size Calculation 
There are two dominant statistical models for pooling effect sizes in a meta-
analysis: a fixed-effect model and a random-effects model (Borenstein et al., 2011). 
The fixed-effect model assumes one true effect size among included studies and any 
study effect differences are due to sampling error (Borenstein et al., 2011). However, 
it is unlikely that all studies in a meta-analysis produce the same effect. Most studies 
pooled using meta-analytic techniques differ in various ways (e.g., research design, 
participant demographics, type and length of intervention) and despite examining the 
same phenomenon, this heterogeneity produces varying effects (Borenstein et al., 
2011). Nonetheless, as long as studies included in a meta-analysis demonstrate a 
degree of similarity and combining their results will provide a valuable synthesis of 
information, the random-effects model accounts for differences across study effect 
sizes using the Hedges and Vevea (1998) ‘weighting by inverse variance’ method. 
Although less powerful than a fixed-effect model, a random effects model applies a 
weight to each study using both within and between-study variance to ensure that the 
weight (small or large Ns) of an individual study does not over influence the pooled 
effect (Borenstein, Hedges, Higgins, & Rothstein, 2010). For this meta-analysis, 
pooled effect sizes were calculated using a random-effects model (Borenstein et al., 
2010).  
 
3.6.2.1 Within-study variance. Within-study variance (𝑣𝑖) was calculated 




𝑣𝑖 =  
 𝑛𝐼  +  𝑛𝐶
  𝑛𝐼  ×  𝑛𝐶   
 +  
𝑑2
2(𝑛𝐼 +  𝑛𝐶)
 
 
where:                               𝑛𝐼 = number of participants (intervention group) 
                                          𝑛𝐶  = number of participants (control group) 
                                           𝑑 = effect size 
(Hedges & Olkin, 1985) 
 
3.6.2.2 Between-study variance. The general method-of-moments estimate 
was used to calculate between-study variance (𝑇2):  
 





with:       𝑄 =  ∑  
(𝑑 – ?̅? )²
𝑣𝑖














producing:                            𝑇2 =  
∑  
















(DerSimonian & Laird, 1986)  
 
Where 𝑑 = effect size, ?̅? = mean effect size, 𝑛 = number of studies and 𝑣𝑖 = 
within-study variance. Where the value of  𝑇2 was negative, 𝑇2 was set to zero as 
variance cannot be negative (Borenstein et al., 2011). 
 
3.6.2.3 Weighted effect size. Each outcome effect size was weighted by the 
inverse of its within and between-study variance. The formula below was used to 




𝑊𝑖 =  
1
𝑣𝑖 +  𝑇2
 
(Hedges, 1983)  
 
3.6.2.4 Pooled effect size. After computing weighted effect sizes for each 
outcome, weighted mean effect sizes were calculated to produce pooled effect sizes 
(𝑀𝑊) for each intervention modality (rTMS, standard cognitive training, and tailored 
cognitive training). The below formula was used:  
 






3.6.2.5 Statistical significance. In accord with recommendations from 
Borenstein et al. (2011) 95% confidence intervals were calculated to test the 
statistical significance of each pooled effect size. The pooled effect size and standard 
error of the pooled effect size was used in the formula: 
 
       𝐿𝑜𝑤𝑒𝑟 𝐿𝑖𝑚𝑖𝑡 =  𝑀𝑊 − 1.96 × 𝑆𝐸𝑀𝑊  
      𝑈𝑝𝑝𝑒𝑟 𝐿𝑖𝑚𝑖𝑡 =  𝑀𝑊 + 1.96 × 𝑆𝐸𝑀𝑊  
 




     





where:                                    𝑀𝑊 = pooled effect size 
                                           𝑆𝐸𝑀𝑊  = standard error of the pooled effect size  
                                              𝑉𝑀𝑊 = variances of the pooled effect size  
 
3.6.3 Publication Bias 
Publication bias occurs when researchers selectively publish significant 
results that support a priori hypotheses and neglect to report non-significant or 
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contradictory results (Rosenthal, 1979). Scientific journals often favour statistically 
significant and/or large effect results and this bias can influence a researcher’s 
decision to report their results (Easterbrook, Gopalan, Berlin, & Matthews, 1991). 
Unfortunately, researchers often selectively report their findings (omitting non-
significant or small effect sizes) and may change what they declare as a priori 
hypotheses (Chan, Hróbjartsson, Haahr, Gøtzsche, & Altman, 2004). Publication bias 
often results in a large amount of grey literature (unpublished results), which is 
challenging for the meta-analyst to source and therefore provide a more accurate 
synthesis of all existing scientific evidence (Borenstein et al., 2010). A meta-analysis 
based on published and statistically significant results has the potential to produce a 
pooled effect size, which may overestimate the true effect (Thornton & Lee, 2000).  
 
In this meta-analysis, funnel plots, Egger’s (1997) regression asymmetry test, 
and R. Rosenthal’s (1979) Fail-Safe 𝒩 method assessed publication bias. Funnel 
plots are a scatter plot estimate of a study’s effect size (on the x-axis) against a 
measure of study size (usually the standard error of effect size on the y-axis) with 
larger sample sizes providing greater precision of intervention effect estimates 
(Sterne, Egger, & Smith, 2001). Therefore, a funnel plot without bias should 
resemble a symmetrical inverted funnel shape with small studies scattered more 
widely at the bottom and larger studies gathered closer together at the top (Sterne et 
al., 2001). The presence of publication bias is shown by an asymmetrical distribution 
indicating a bias towards a particular result irrespective of study size or precision. 
Egger’s (1997) test of regression asymmetry uses a simple linear regression between 
the funnel plot effect sizes (x-axis) and their standard errors (y-axis), with a 
statistically significant result indicating the meta-analysis is impacted by publication 
bias.  
 
R. Rosenthal’s (1979) Fail-Safe 𝒩 method was also used to examine 
publication bias. Described as the File Drawer Problem, Rosenthal (1979) stated that 
published studies are the Type 1 errors and only represent 5% of all studies 
conducted, while 95% of all research is left in ‘file drawers’ as unpublished due to 
non-significant results. Fail-Safe 𝒩 refers to the number of unpublished studies 
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needed to reduce the significance of a meta-analytic pooled-effect size to non-
significant. This formula was used to calculate Rosenthal’s (1979) Fail-Safe 𝒩:  
 
𝐹𝑎𝑖𝑙 − 𝑠𝑎𝑓𝑒 𝑁 =  [ 
𝑘
𝑍𝐶²
 ]  ×  [𝑘 ( 𝑍𝑘̅̅ ̅ )² −  𝑍𝐶²] 
 
 
where:                                              𝑘 = number of studies 
      𝑍𝐶  = critical Z value 
                𝑍𝑘̅̅ ̅ = mean Z for K studies 
 
Rosenthal (1979) asserts that a Fail-Safe 𝒩 value greater than 5k +10 
indicates a low likelihood of publication bias within a meta-analysis.  
 
3.6.4 Heterogeneity Analysis 
Heterogeneity of intervention effects in a meta-analysis suggests that 
individual interventions produce different effects across studies (Higgins, Thompson, 
Deeks, & Altman, 2003). A large degree of heterogeneity limits external validity and 
generalisability of pooled effect sizes (Higgins et al., 2003). Heterogeneity was 
explored using Cochrane’s Q and I2 statistics. In a meta-analysis a statistically 
significant Q statistic suggests a difference between an observed and true effect 
(Huedo-Medina, Sánchez-Meca, Marín-Martínez, & Botella, 2006). However, the Q 
statistic may overestimate this difference in small sample sizes. Therefore, if Q was 
significant the I² statistic, which is an estimate of the total proportion of variance in 
the pooled effect size, was used to examine heterogeneity between studies. Values 
for I² are expressed as a percentage with suggested values of 25% (low), 50% 
(moderate), and 75% (high) used to categorise levels of heterogeneity (Huedo-
Medina et al., 2006). The I² statistic was calculated using the following formula: 
 









                                         = ∑ 𝑊𝑖  (𝑑 − ?̅?)² 
 
giving:                                 𝐼2 = 100% × 
[ ∑ 𝑊𝑖 (𝑑− ?̅?)² ]−𝑑𝑓
∑ 𝑊𝑖 (𝑑− ?̅?)²
 
3.6.5 Meta-Regression Analysis 
Meta-regression assesses whether moderator variables explain variance in 
heterogeneity of pooled effect size estimates (Borenstein et al., 2010). Similar to 
multiple regression at the participant level, where independent or covariate variables 
are used to predict variance in dependent variables, meta-regression uses covariate 
variables at the study level and dependent variables are pooled effect sizes 
(Borenstein et al., 2010). As with meta-analysis, there are fixed-effect and random-
effects models for meta-regression. This meta-regression adopted a random-effects 
model with unrestricted maximum-likelihood analysis (UML) and CMA was used to 
conduct each meta-regression. A Z-test determines the statistical significance of the 
relationship between moderator variables and pooled effect sizes (Borenstein et al., 
2010). Statistical significance is defined as Z-values beyond +1.96 to -1.96 limits and 
is calculated using this equation: 
 





where:                                 𝐵 = unstandardised regression coefficient 
                                       𝑆𝐸𝐵 = standard error of B 
 
3.6.6 Risk of Bias Assessment 
The Cochrane Collaboration tool was used to assess risk of bias among 
studies included in this meta-analysis (Higgins & Green, 2008). The risk of bias 
assessment tool classifies individual studies as having low, high, or unclear risk of 
bias across six domains; sequence generation, allocation concealment, blinding, 




3.6.7 Data Extraction 
The data extracted from each study included participants, interventions, 
comparisons, outcomes, and study design (PICOS). Cognitive outcomes were 
categorised in accordance with the Movement Disorder Society (MDS) Task Force 
recommendations for cognitive domains:  executive function, attention/working 
memory, memory, visuospatial abilities, language and global cognition (Litvan et al., 
2012). The MDS Task Force does not describe attention, processing speed, and 
working memory as individual domains. Outcomes assessing these cognitive abilities 
were therefore categorised within the single ‘attention/working memory’ domain, in 
accord with MDS recommendations. 
 
3.7 Results 
3.7.1 Search Results 
In total, 13,162 titles and abstracts were systematically screened in online 
databases. Seventy one studies examined nonpharmacological interventions in PD. 
Fifty seven were excluded as they were not rTMS, tDCS, or cognitive training 
interventions (13), multiple interventions (e.g., cognitive training combined with 
physical exercise) (4), study protocols (3), case studies (2), not assessing cognition 
with standardised measures (9), not all participants diagnosed with PD (1), provided 
insufficient data to be meta-analysed (e.g., conference abstracts and authors did not 
respond to a follow up contact) (6), or not controlled trials (17). Two additional 
studies were excluded as the researcher was unsuccessful in obtaining missing data 
from the authors. Boggio et al. (2005) were contacted to provide control group means 
and standard deviations at Week 2. Doruk et al. (2014) were contacted to provide 
raw means and standard deviations. The authors did not respond and the studies were 
excluded. Therefore, tDCS was not included in this meta-analysis due to only one 


























Figure 4. PRISMA Flow Chart of Search Results 
 
3.7.2 Study Characteristics  
Fourteen controlled trials met inclusion criteria (see Table 4). There were 3 
rTMS (Benninger et al., 2011; Benninger et al., 2012; Pal et al., 2010), 3 tailored 
cognitive training (Cerasa et al., 2014; Naismith et al., 2013; Sammer et al., 2006), 
and 8 standard cognitive training studies (Costa et al., 2014; Edwards et al., 2013; 
Ell, 2013; Nombela et al., 2011; París et al., 2011; Pena et al., 2014; Petrelli et al., 
2014; Pompeu et al., 2012). Publication dates ranged from 2006 to 2014, with all but 
one published in the past five years. For the purpose of this meta-analysis, Petrelli et 
al. (2014) was split into two studies, as the study compared two intervention groups 
against a control group. Throughout this chapter, Petrelli et al. (2014) will be referred 
to as two studies and referenced once. 
Titles and abstracts screened 
(n = 13,162) 
Data analysis: 
Calculated individual and pooled effect sizes 




Attention, brain, brain stimulation, cognition, cognitive, cognitive impairment, cognitive rehabilitation, cognitive therapy, 
cognitive training, cerebral cortex, cortex, current, direct, dorsal, dorsolateral, dorsolateral prefrontal cortex, electric stimulation, 
episodic memory, executive, executive function, explicit memory, function, implicit memory, intervention, language, language 
tests, learning, long-term memory, magnetic, memory, mild cognitive impairment, motor cortex, neuronal plasticity, 
neuropsychological, noninvasive, parietal lobe, Parkinson disease, prefrontal, prefrontal cortex, premotor, psychomotor, 
performance, rehabilitation, semantic memory, short-term memory, spatial memory, stimulation, tests, therapy, training, 
transcranial, transcranial direct current stimulation, transcranial magnetic stimulation, verbal memory, visual perception, 
visuospatial, visuospatial ability, visuospatial memory, and working memory. 
Electronic Databases searched: 
Medline (n = 4776), PubMed (n = 1182), Proquest (n = 2368), ScienceDirect (n = 1849), PsycInfo (n = 2166),  
Web of Science (n = 38), Wiley Online Library (n = 417), EMBASE (n = 267), Cochrane Library (n = 48) 
Grey Literature: 
OpenGrey (n  = 0), NTIS (n = 1239) 
N = 13,162 
Abstracts excluded 
(n = 13,091) 
Full text copies retrieved for evaluation  
(n = 71) Studies excluded (n = 57) 
Reasons: 
•  Not rTMS, tDCS, or cognitive training 
interventions  
  (n = 13) 
•  Multiple interventions (n = 4) 
•  Study protocol (n = 3) 
•  Case studies (n = 2) 
•  No standardised cognitive outcome (n = 9) 
•  Not all participants diagnosed with PD (n = 1) 
•  Insufficient data (n = 6) 
•  Not placebo-controlled trials (n  = 17) 
•  Insufficient data after contacting authors (n = 2) 
Extracted descriptive data  
(n = 14): authors, year of publication, study design, 
sample size, participant details, intervention length, 





Participant Characteristics of all Controlled Trials included in Meta-Analysis 









rTMS Pal (2010) 22 68 50 6.25 –– 
 Benninger (2011) 26 63.85 69 8.65 –– 
 Benninger (2012) 26 64.1 77 8.95 –– 
       
Standard CT Nombela (2011) 20 60.65 50 8.10 7.60 
 Paris (2011) 28 65.09 53.80 7.60 9.69 
 Pompeu (2012) 32 67.40 53.13 –– –– 
 Ell (2013)* 36 66.13 –– 4.70 16.33 
 Edwards (2013) 73 68.78 62.07 6.94 15.15 
 Costa (2014) 17 68.50 –– 9.10 10.90 
 Petrelli (2014) 65 69.05 43.08 5.63 13.17 
 Pena (2014) 44 67.84 61.36 6.50 10.40 
       
Tailored CT Sammer (2006) 26 69.65 –– –– –– 
 Naismith (2013) 50 66.70 70.50 7.05 14.45 
 Cerasa (2014) 15 59.70 –– 3.35 8 
M  34 66.10 58.99 6.90 11.74 
Note. M  = mean; Yrs = years; CT = cognitive training; * = only participants with PD. 
 
Table 5 
Characteristics of all Controlled Trials included in Meta-Analysis 















rTMS Pal (2010) No CI n.a n.a SH 10 .30 












n.a n.a n.a SH 8 .08 
50Hz / 
M1 
         
Standard CT Nombela (2011) CI P/P I Act. 182 45.63 n.a 




Act. 12 9 n.a 
 Pompeu (2012) No CI Comp. I Act. 14 7 n.a 
 Ell (2013) No CI Comp. I Act. 1 .13 n.a 
 Edwards (2013) No CI Comp. I W 20 20 n.a 
 Costa (2014) CI Comp. I Act. 12 9 n.a 
 Petrelli (2014) No CI Comp. I & G Act. 12 18 n.a 
 Pena (2014) No CI Comp. G Act. 36 36 n.a 
        n.a 
Tailored CT Sammer (2006) No CI P/P I Act. 10 5 n.a 
 Naismith (2013) No CI 
Comp. 
& P/P 
G W 14 14 n.a 
 Cerasa (2014) No CI Comp. I Act. 12 12 n.a 
M  n.a n.a n.a n.a 25.10 12.59 n.a 
Note. CT = cognitive training; CG = control group; Sess. = sessions; Stimul. = stimulation; Hz = hertz; M1 = primary motor 
cortex; DLPFC = dorsal lateral prefrontal cortex; CI = cognitive impairment; Comp. = computerised training; P/P = paper and 
pencil tasks; I = individual; G = group; SH = sham control group; W = waitlist control group; Act. = active control group. 
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3.7.3 Assessment of Risk of Bias 
Two studies had low risk of bias (Pena et al., 2014; Petrelli et al., 2014), 5 
had high risk of bias (Costa et al., 2014; Edwards et al., 2013; Naismith et al., 2013; 
Nombela et al., 2011; Sammer et al., 2006), and 7 had unclear risk of bias (Benninger 
et al., 2011; Benninger et al., 2012; Cerasa et al., 2014; Ell, 2013; Pal et al., 2010; 
París et al., 2011; Pompeu et al., 2012). Of the 5 studies with high risk of bias, 3 did 
not use a randomisation sequence for allocating participants (Costa et al., 2014; 
Naismith et al., 2013; Nombela et al., 2011), 3 did not blind outcome assessments 
(Edwards et al., 2013; Nombela et al., 2011; Sammer et al., 2006), and 1 did not 
conceal participant group allocation (Nombela et al., 2011).  Of the 7 studies with 
unclear risk of bias, 5 did not clearly describe the randomisation sequence generation 
(Cerasa et al., 2014; Ell, 2013; Pal et al., 2010; París et al., 2011; Pompeu et al., 
2012), 3 did not sufficiently describe blinding of outcome assessments (Benninger et 
al., 2011; Benninger et al., 2012; Ell, 2013), and 2 did not adequately describe 
concealment of group allocation (Ell, 2013; Pompeu et al., 2012). Only 3 of the 
cognitive training studies were double-blind (Costa et al., 2014; Pena et al., 2014; 
Petrelli et al., 2014).  
 
3.7.4 Primary Effect on Executive Function 
Ten studies assessed executive functions pre and post-intervention 
(Benninger et al., 2011; Benninger et al., 2012; Cerasa et al., 2014; Costa et al., 
2014; Ell, 2013; Naismith et al., 2013; París et al., 2011; Petrelli et al., 2014; 
Sammer et al., 2006). Figure 5 shows a forest plot of effect sizes, 95% confidence 
limits and heterogeneity results.  
 
3.7.4.1 Pooled effect sizes. Pooled effect sizes were calculated for rTMS, 
combined cognitive training and independently for tailored and standard cognitive 
training. The pooled effect for rTMS (N = 2) was small (𝑔 = .40) and in support for 
rTMS, yet non-significant (95% CI = -.14 to .93). The pooled effect for combined 
cognitive training (N = 8) was small (𝑔 = .42), statistically significant (95% CI = .15 
to .68) and in support of cognitive training. The pooled effect for standard cognitive 
training (N = 5) was medium (𝑔 = .51), statistically significant (95% CI = .16 to .85) 
and in support of standard cognitive training. Finally, the pooled effect for tailored 
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cognitive training (N = 3) was small (𝑔 = .30) and not statistically significant (95% 
CI = -.16 to .76). There was no heterogeneity in rTMS, combined and standard 
pooled effect sizes, I² = 0.00%, p >.05. A small and not statistically significant 
degree of heterogeneity was found in the tailored cognitive training pooled effect, I² 
= 15.49%, p >.05. 
 
 
Figure 5. Forest Plot of Effect Sizes for Executive Function. 
 
 
3.7.5 Secondary Effect on Attention/Working Memory 
Eight from 10 cognitive training effects favoured the intervention, ranging 






Figure 6. Forest Plot of Effect Sizes for Attention/Working Memory.  
 
3.7.5.1 Pooled effect sizes. One rTMS study (Pal et al., 2010) examining 
attention/working memory was included in the meta-analysis. Therefore, only 
combined cognitive training and individual tailored and standard cognitive training 
pooled effect sizes were calculated. The pooled effect for combined cognitive 
training (N = 10) supported the intervention with a small (𝑔 = .23) and statistically 
significant effect (95% CI = .02 to .44). The pooled effect for standard cognitive 
training (N = 7) was also small (𝑔 = .29) and statistically significant (95% CI = .04 to 
.53). Lastly, the pooled effect for tailored cognitive training (N = 3) was very small 
(𝑔 = .08) and not statistically significant (95% CI = -.32 to .48). There was no 
heterogeneity within combined, standard, or tailored cognitive training effect 
estimates, I² = 0.00%, p >.05. 
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3.7.6 Secondary Effect on Memory 
All studies examining the effect of cognitive training on memory favoured 
the intervention, with effect sizes ranging .03 to .42 (Cerasa et al., 2014; Naismith et 
al., 2013; París et al., 2011; Pena et al., 2014; Petrelli et al., 2014). However, no 




Figure 7. Forest Plot of Effect Sizes for Memory.  
 
3.7.6.1 Pooled effect sizes. No rTMS studies included memory as a primary 
outcome. Therefore, pooled effect sizes were only calculated for cognitive training 
studies. The pooled effect for combined cognitive training (N = 6) was small (𝑔 = 
.33) and statistically significant (95% CI = .06 to .59) in support of the intervention. 
The pooled effect for standard cognitive training (N = 4) was small (𝑔 = .35) and 
statistically significant (95% CI = .03 to .66). In addition, the pooled effect for 
tailored cognitive training (N = 2) was small (𝑔 = .28) and in support for tailored 
cognitive training, but not statistically significant (95% CI = -.20 to .76). There was 
no heterogeneity among pooled cognitive training studies, I² = 0.00%, p >.05. 
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3.7.7 Secondary Effect on Visuospatial abilities.  
Four studies examined visuospatial abilities (Cerasa et al., 2014; París et al., 
2011; Petrelli et al., 2014), with all but Cerasa et al. (2014) supporting the 
intervention. Results are shown in Figure 8. 
 
 
Figure 8. Forest Plot of Effect Sizes for Visuospatial Abilities. 
 
3.7.7.1 Pooled effect size. The pooled effect for combined cognitive training 
(N = 4) was small (𝑔 = .25) and in support for cognitive training, but not statistically 
significant (95% CI = -.13 to .63). The pooled effect for standard cognitive training 
was also small (𝑔 = .32) and in support of the intervention, but not statistically 
significant (95% CI = -.12 to .76). There was a small and non-significant degree 
heterogeneity within the standard cognitive training effect estimate, I² = 10.08%, p 
>.05.  No heterogeneity was identified within the combined cognitive training pooled 
effect, I² = 0.00%, p >.05. 
 
3.7.8 Secondary Effect on Global Cognition. 
Five studies in this meta-analysis examined the effect of cognitive training on 
global cognition in PD, with effect sizes between .04 and .48 (Cerasa et al., 2014; 
París et al., 2011; Petrelli et al., 2014; Pompeu et al., 2012). One rTMS study (Pal et 
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al., 2010) examined global cognition with results favouring the control group. Figure 
9 shows the results for global cognition.  
 
 
Figure 9. Forest Plot of Effect Sizes for Global Cognition. 
 
3.7.8.1 Pooled effect sizes. The pooled effect for combined cognitive training 
(N = 5) was small (𝑔 = .32) and not statistically significant (95% CI = -.01 to .64). In 
addition, the pooled effect for standard cognitive training (N = 4) was small (𝑔 = .32) 
and not statistically significant (95% CI = -.02 to .67). There was no heterogeneity 
within cognitive training effects, I² = 0.00%, p >.05.  
 
3.7.9 Publication Bias 
Publication bias statistics were calculated for significant, pooled effect sizes 
by cognitive domain. Despite a non-significant Egger’s regression for combined 
cognitive training effects on executive function, p = 0.25, only 14 non-significant 
results would be required to render this effect zero, suggesting publication bias. 
Likewise, Egger’s regression for standard cognitive training effects on executive 
function was not significant (p = 0.54), but needing only 7 non-significant results 
suggests publication bias. For attention/working memory, Fail-Safe Ns for combined 
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cognitive training (N = 2) and standard cognitive training (N = 2) suggest publication 
bias. However, Egger’s regressions were not significant for combined (p = 0.77) or 
standard training (p = 0.58). Finally for memory, Egger’s regression was significant 
for combined cognitive training (p = 0.006) and only 3 non-significant results would 
be needed to undermine this significant pooled effect. Also for memory, Egger’s 
regression for standard cognitive training effects was not significant (p = 0.27), yet a 
low Fail-Safe N (N = 1) suggests publication bias.  
 
3.7.10 Sensitivity Analyses 
Petrelli et al. (2014) reported means and standard error values adjusted for 
covariates and not raw data, Sammer et al. (2006) did not report pre/post data and 
effect sizes were computed using probability values from post-intervention 
outcomes, and Ell (2013) conducted a short cognitive training intervention (8 
minutes) compared to the longer interventions included in this meta-analysis. 
Therefore, three sensitivity analyses were conducted to determine if removing these 
studies would significantly impact pooled effect estimates. After removing Petrelli et 
al. (2014), the pooled effect for combined cognitive training (N = 6) on executive 
function increased to medium (𝑔 = 0.50) and statistically significant (95% CI 0.19 to 
0.81). Standard cognitive training (N = 3) remained medium (𝑔 = 0.77) and 
statistically significant (95% CI 0.30 to 1.24). For attention and working memory, 
the pooled effect for combined cognitive training (N = 8) remained small (𝑔 = 0.22) 
but reduced to not significant (95% CI -0.01 to 0.45). Attention/working memory 
effects for standard cognitive training (N = 5) remained small (𝑔 = 0.29) and 
statistically significant (95% CI 0.004 to 0.57). For memory, the effect for combined 
cognitive training (N = 4) remained small (𝑔 = 0.35) and statistically significant 
(95% CI 0.03 to 0.66). The memory effect for standard cognitive training (N = 2) 
remained small (𝑔 = 0.40) and reduced to not significant (95% CI -0.02 to 0.82). For 
visuospatial function, the effect for combined cognitive training (N = 2) remained 
small (𝑔 = 0.37) and not significant (95% CI -0.52 to 1.25). Standard cognitive 
training (N = 1) increased to medium (𝑔 = 0.76) and statistically significant (95% CI 
0.05 to 1.48). For global cognition the effect for combined cognitive training (N = 3) 
remained small (𝑔 = 0.22) and reduced to not significant (95% CI -0.21 to 0.66), 
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while standard cognitive training (N = 2) remained small (𝑔 = 0.21) and not 
significant (95% CI -0.28 to 0.70).  
 
After removing Sammer et al. (2006), the pooled effect for combined 
cognitive training (N = 7) on executive function remained small (𝑔 = 0.37) and 
statistically significant (95% CI 0.08 to 0.66). Tailored cognitive training (N = 2) 
remained small (𝑔 = 0.08) and not significant (95% CI -0.43 to 0.58). For attention 
and working memory, the pooled effect for combined cognitive training (N = 9) 
remained small (𝑔 = 0.25) and statistically significant (95% CI 0.04 to 0.47). 
Attention/working memory effects for tailored cognitive training (N = 2) remained 
small (𝑔 = 0.12) and not significant (95% CI -0.36 to 0.60). Lastly, after removing 
Ell (2013) from the pooled effect for combined cognitive training (N = 7) on 
executive function, the effect size remained small (𝑔 = 0.38) and statistically 
significant (95% CI 0.10 to 0.65). Standard cognitive training (N = 4) reduced to 
small (𝑔 = 0.45) but remained statistically significant (95% CI 0.07 to 0.82). 
 
3.7.11 Meta-Regression Analysis 
According to Borenstein et al. (2011) a minimum of 10 studies per moderator 
variable is required before conducting meta-regression. Age, years of education, 
duration of illness, and length of intervention were identified as potential moderators 
of effect estimates. However, meta-regression of four moderator variables would 
require 40 studies to be included in each pooled effect. Therefore, meta-regression 




3.8.1 Main Findings 
This meta-analysis is the first to provide distinct pooled effect sizes for 
standard and tailored cognitive training and rTMS interventions for cognition in PD. 
When considered together, standard and tailored cognitive training studies appear to 
improve executive function, albeit only by a small amount (𝑔 = .42; 95% CI = .15 to 
.68). When analysed separately, perhaps because of the small number of studies, 
executive function was no longer improved by tailored cognitive training (𝑔 = .30, 
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95% CI = -.16 to .76), but standard cognitive training appeared to have a more 
moderate effect (𝑔 = .51, 95% CI = .16 to .85). This nonsignificant effect for tailored 
cognitive training may represent a Type II error, given that a small effect size was 
observed but only three tailored cognitive training studies were included in this meta-
analysis. There were insufficient studies for a formal comparison of the relative 
effects of standard and tailored cognitive training. Thus more controlled trials of 
tailored cognitive training are needed to determine if this modality is more or less 
efficacious than a standard intervention. Executive function did not appear to 
improve (𝑔 = .40, 95% CI = -.14 to .93) in the two rTMS studies investigated 
(Benninger et al., 2011; Benninger et al., 2012). Given that preliminary results of 
controlled (Pal et al., 2010) and uncontrolled (Boggio et al., 2005) rTMS trials report 
improvements in cognition, more detailed exploration of this therapeutic technique is 
required.  
 
People with PD and cognitive impairment demonstrate deficits in 
attention/working memory (Cholerton et al., 2014). When considered together, 
attention/working memory was improved by standard and tailored cognitive training 
(𝑔 = .23, 95% CI = .02 to .44) and by standard training alone (𝑔 = .29, 95% CI = .04 
to .53). This finding conflicts with those of Leung et al. (2015) who reported a 
medium and significant effect for working memory, but a small and non-significant 
negative effect for attention. Unlike this meta-analysis, however, Leung et al. (2015) 
included one study that had a large negative effect on attention (Zimmermann et al., 
2014). This study compared computerised cognitive training (intervention group) to 
computerised sport-related video gaming (control group), but sport-related video 
games have improved cognition in older adults (Basak, Boot, Voss, & Kramer, 
2008), which Zimmermann et al. (2014) also reported. Inclusion of this study in the 
previous meta-analysis led to inclusion of a large negative effect for cognitive 
training on attention, but inversely included a large positive effect for computerised 
sport-related gaming on attention (rather than an effect favouring a control group). 
The current meta-analysis excluded this study to ensure only controlled comparisons 
were included in pooled effects, and this approach found positive effects for 





Only one controlled rTMS study (Pal et al., 2010) examined 
attention/working memory in PD and this study produced a small and non-significant 
effect (𝑔 = .34, 95% CI = -.42 to 1.11). However, several uncontrolled rTMS studies 
have shown improvements in cognition (Epstein et al., 2007; Fregni et al., 2004; 
Furukawa et al., 2009; Srovnalova et al., 2011). Before concluding whether rTMS is 
or is not helpful in alleviating cognitive deficits in PD, more controlled rTMS studies 
are needed. 
 
Whilst the primary cognitive impairments in PD are characterised by frontal 
dysfunction, memory impairment is also common (Domellof, Ekman, Forsgren, & 
Elgh, 2015). Both standard and combined cognitive training studies offered small 
improvements in memory (standard: 𝑔 = .35, 95% CI = .03 to .66; combined: 𝑔 = 
.33, 95% CI = .06 to .59). This corresponds with a meta-analysis of memory training 
in healthy older adults, which found significant memory improvements post-training 
(Zehnder et al., 2009).  
 
Due to the heterogeneous nature of cognitive impairment in PD, individuals 
may demonstrate deficits in visuospatial and language domains (Cholerton et al., 
2014). There was no impact of cognitive training on visuospatial abilities across the 
four studies examined in this analysis (combined: 𝑔 = .25, 95% CI = -.13 to .63; 
standard: 𝑔 = .32, 95% CI = -.12 to .76). No controlled studies evaluated language 
impairment. Although language deficits are rare in PD, recent research suggests 
impaired functioning in language and visuospatial domains (Goldman et al., 2013). 
For that reason, future studies should include standardised neuropsychological 
assessment of these domains, in line with MDS Task Force recommended tests 
(Litvan et al., 2012). 
 
The final outcome of this meta-analysis was global cognition, which showed 
small and non-significant effects for both combined (𝑔 = .32, 95% CI = -.01 to .64) 
and standard cognitive training (𝑔 = .32, 95% CI = -.02 to .67). This is not consistent 
with the finding of improved global cognition following cognitive training for those 
with MCI (Li et al., 2011). Compared to larger cognitive training trials improving all 
cognitive domains in healthy older adults (Lampit, Hallock, & Valenzuela, 2014), the 
presently included studies may have been underpowered (i.e., small N) which 
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resulted in non-significant effects. Future studies need to recruit larger samples to 
ensure sufficient statistical power in cognitive training trials in PD. 
 
In addition to the cognitive outcomes, sensitivity analyses examined whether 
removing Petrelli et al.’s (2014) covariate adjusted results impacted corresponding 
effect estimates. The effect of combined cognitive training on executive function 
remained significant, even increasing slightly, and the effect of standard cognitive 
training on visuospatial function increased to medium and statistically significant. 
However, the effect of combined cognitive training on attention/working memory 
and standard cognitive training on memory, reduced to non-significance. These 
variations suggest that this study’s adjusted results had a large impact on 
attention/working memory, visuospatial, memory and global cognition effects 
(Petrelli et al., 2014). Pooling effect sizes with adjusted results may not, however, 
demonstrate an accurate effect of standard cognitive training on these cognitive 
domains in PD. Adjusting results for the effect of covariates will likely under-
represent the true effect of an intervention (e.g., cognitive training), by accounting 
for a proportion of variance in outcome variables. Sensitivity analyses also examined 
whether removing Sammer et al.’s (2006) effect sizes (computed with probability 
statistics) or Ell’s (2014) results from a short cognitive training intervention, would 
impact pooled effect estimates. No changes in statistical significance of effects were 
observed. 
 
3.8.2 Limitations and Directions for Future Research 
There are some limitations to this meta-analysis. Most studies selected 
neuropsychological tests representative of each intervention’s proposed mechanism 
of action (i.e., cognitive training to improve executive function matched with 
executive function tests as primary outcomes). However, Cerasa et al. (2014) used a 
domain-specific intervention (attention) and measured pre/post performance in other 
cognitive domains (e.g., visuospatial abilities). This study measured a cognitive 
domain that was not theoretically related to the domain-specific intervention, which 
may have contributed to the non-significant pooled effect size for visuospatial 
abilities. This result suggests the effect of cognitive training may have been specific 
to the domain targeted by the intervention. 
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For rTMS, methodological differences between studies may have resulted in 
the initial nonsignificant effect for executive function. Benninger et al. (2011) 
administered 50 Hz intermittent theta burst rTMS over the primary motor and 
dorsolateral prefrontal cortices, whereas Benninger et al. (2012) applied 50 Hz rTMS 
over primary motor cortices. Both studies were sham-controlled but delivered fewer 
than 10 minutes of stimulation and differed in type of stimulation and target 
locations. Compared to the short-term effects found in rTMS studies, intermittent 
theta burst rTMS has been shown to increase the duration of synaptic plasticity by 
delivering three shorter pulses of stimulation (every 200 milliseconds) to specific 
neuronal groups (Huang, Edwards, Rounis, Bhatia, & Rothwell, 2005). Conversely, 
earlier studies delivered longer stimulation (20 to 30 minutes) and showed significant 
improvements in cognition in PD (Boggio et al., 2005; Fregni et al., 2004; Pal et al., 
2010). Length and frequency of stimulation may, therefore, produce variable effects 
on synaptic connections and associated cognitive functions. Moreover, Benninger et 
al. (2012) assessed executive function but stimulated primary motor cortices not 
associated with executive function improvement. Having said this, rTMS has been 
shown to be relatively nonfocal, often activating a combination of cortical systems 
that may have interacting effects (Huang et al., 2005). In their earlier study, 
Benninger et al. (2011) used the 5 cm rule to target the dorsolateral prefrontal cortex, 
which provides widespread stimulation across motor and prefrontal sites (Pascual-
Leone, Wassermann, Grafman, & Hallett, 1996). Consequently, rTMS over primary 
motor cortices may activate broader cortical systems that impact prefrontal areas 
(thus affecting executive function). Despite these differences, both studies reported 
positive effects in support of rTMS for improving cognition in PD. Future studies 
should build on these preliminary results by exploring the therapeutic potential of 
this non-invasive intervention for people with cognitive impairment and PD. 
 
A lack of sensitivity of executive function and attention/working memory 
measures for detecting change in PD may also have contributed to the null rTMS 
pooled effect sizes. For Pal et al. (2010), the Trail Making Test-Part A (TMT-A) was 
one of three outcomes used to compute an attention/working memory effect (Reitan, 
1992). However, a meta-analysis comparing TMT-A performance between people 
with frontal deficits to those with posterior deficits found no significant difference 
between groups (Demakis, 2004). This suggests the TMT-A is unable to discriminate 
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between frontal and nonfrontal cognitive impairments, yet impairments in PD are 
associated with deficits in prefrontal (dorsolateral and ventrolateral) cortices (Lewis, 
Dove, Robbins, Barker, & Owen, 2003). In addition, both rTMS (Benninger et al., 
2011; Benninger et al., 2012) studies assessing executive function used the Frontal 
Assessment Battery (FAB) (Dubois, Slachevsky, Litvan, & Pillon, 2000). The FAB 
has, however, low sensitivity (66.3%) in detecting executive function impairments 
related to dementia in PD (Kaszás et al., 2012). Also, neither participant group were 
classified as cognitively impaired which may have resulted in a ceiling effect when 
administering rTMS to produce improvements in cognition in PD. These limiting 
factors may account for the non-significant executive function and attention/working 
memory effect estimates and must be acknowledged when interpreting the results.  
 
A further limitation was the heterogeneous application of neuropsychological 
tests for cognitive outcomes in the current literature. Test selection bias was 
accounted for in the present study by first coding all tests from each study into 
cognitive domains, computing composite domain effects and adjusting for 
intercorrelations between tests, then pooling effects. This method included 65 
neuropsychological tests across pooled effect sizes. Borenstein et al. (2011) 
recommends using this method to pool effects when studies report multiple 
conceptually related outcomes. However, conceptually related outcomes must be 
adjusted for high intercorrelations, which produce a less precise estimate of a pooled 
effect. It is recommended that future studies adopt a more homogenous use of 
neuropsychological tests (e.g., MDS Task Force recommended tests; Litvan et al., 
2012) to reduce the impact of multiple outcomes in meta-analysis and improve the 
precision of future pooled effects. 
 
Variable length of cognitive training interventions also limited this meta-
analysis. Jean, Bergeron, Thivierge, and Simard (2010) recommend 6 to 20 cognitive 
training sessions (up to 15 hours) completed within 12 weeks to be most effective, 
when compared to longer and more costly interventions. However, included studies 
ranged between 8 minutes (computer-based rule learning task; Ell, 2013) and 45 
hours (Sudoku puzzle every day for 6 months; Nombela et al., 2011). Having said 
this, removing Ell (2013) from pooled effects resulted in no changes in 
corresponding effect estimates and recent cognitive training studies have 
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implemented more homogenous interventions (9 to 18 hours; Costa et al., 2014; Pena 
et al., 2014; Petrelli et al., 2014). Future trials need to build upon current scientific 
evidence to establish the most efficacious parameters (e.g., length, frequency, and 
type of training) for cognitive interventions in PD. 
 
The literature relating to the impact of either rTMS or tDCS in PD on 
cognitive function is limited, and very few studies employed a controlled design. In 
addition to a small N, there was evidence of bias within trials and bias in publication 
for combined and standard cognitive training effects on executive function, 
attention/working memory, and memory. Although violation of Rosenthal’s Fail-
Safe N suggests included studies may not be a true representation of the population 
effect, 13,162 studies were systematically searched in published and unpublished 
databases and only 14 met inclusion criteria. This extensive search, inclusive of grey 
literature, suggests these significant Fail-Safe N results may not be an accurate 
indication of publication bias. 
 
This study highlights the need for controlled trials of cognitive training 
(standard and tailored), rTMS, and tDCS for improving cognition in PD. Future 
studies need to conduct randomised controlled trials in accordance with the 
CONSORT statement to provide reliable and externally valid evidence of these 
nonpharmacological interventions (Boutron, Moher, Altman, Schulz, & Ravaud, 
2008).  Future interventions need to compare standard (not individualised) and 
tailored (individualised) cognitive training, and examine whether combining 
cognitive training with brain stimulation further improves cognition in PD. Studies 
should also compare interventions between participant groups with varying severity 
of cognitive impairment, to provide insight into which stages of disease progression 
are most likely to benefit from cognitive training and brain stimulation. In addition, 
future studies need to include activities of daily living and quality of life as primary 






3.9 Chapter Summary 
 
This meta-analysis builds upon previous results to provide the first individual 
pooled effect sizes for standard and tailored cognitive training and brain stimulation 
interventions for cognition in PD. Despite the significant prevalence of cognitive 
impairment in PD, there is a considerable lack of empirical evidence to support the 
improvement of cognitive functioning. An extensive literature search uncovered 14 
controlled trials, three rTMS, three tailored cognitive training, and eight standard 
cognitive training. The only controlled trial of tDCS did not provide sufficient data 
for inclusion. Based on the available studies, there is evidence to support the use of 
standard and tailored cognitive training for improving executive function, 
attention/working memory, and memory in PD. More controlled cognitive training, 
rTMS, and tDCS interventions are needed to establish a reliable and valid estimate of 
their therapeutic potential in PD. Although limited by available studies, the results of 
this meta-analysis provide a promising starting point for future nonpharmacological 
interventions in PD.  
 
The next chapter will examine the efficacy of cognitive training and tDCS 
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Over the past five years, there has been a considerable increase in research 
examining cognitive impairments in PD and the potential of nonpharmacological 
interventions (e.g., cognitive training and non-invasive brain stimulation) for 
improving cognitive function in people with PD and PD-MCI (Goldman & 
Weintraub, 2015). It remains unknown whether cognitive training (standard or 
tailored), transcranial direct current stimulation (tDCS), or cognitive training 
(standard or tailored) combined with tDCS is most efficacious for improving 
cognition in this population. 
 
This chapter presents the findings of the first randomised controlled trial of 
standard cognitive training, tailored cognitive training, tDCS, standard cognitive 
training + tDCS, and tailored cognitive training + tDCS for improving cognition, 
activities of daily living, and quality of life in people with PD-MCI. The first half of 
this chapter outlines the study methodology, followed by the results and a thorough 
discussion of the findings with recommendations for future clinical trials. 
 
Overall, statistically significant improvements in executive function, 
attention/working memory, memory, language, activities of daily living, and quality 
of life were observed across and/or within intervention groups. The results suggest a 
theoretically additive benefit for combining cognitive training with tDCS to improve 
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cognition and practical outcomes in PD-MCI. However, several outcomes did not 
respond to intervention effects and the implications of this are discussed. 
 
4.2 Methodology 
4.2.1 Research Design and Study Setting 
This study was a randomised controlled trial (RCT) comparing standard 
cognitive training, tailored cognitive training, tDCS, standard cognitive training + 
tDCS, and tailored cognitive training + tDCS against a control group, to determine 
which modality was more efficacious for improving cognition, quality of life and 
activities of daily living in PD. The study was completed in the School of 
Psychology and Speech Pathology at Curtin University, Perth, Western Australia. 
Participant recruitment, neuropsychological testing and interventions were completed 
between March and December 2015. Data was collected at pre-intervention, post-
intervention (Week 5), and follow-up (Week 12). This study was conducted in 
accordance with the CONSORT requirements for nonpharmacological interventions 
(Boutron et al., 2008). 
 
4.2.2 Participants 
4.2.2.1 Inclusion and exclusion criteria. Participants were adults (> 18 years 
of age) with PD living in Western Australia. The following inclusion criteria was 
used: (1) participants diagnosed with idiopathic PD by a neurologist or geriatrician in 
accordance with the United Kingdom Parkinson’s Disease Society Brain Bank 
Clinical Diagnostic criteria, (2) presence of MCI in accordance with the MDS PD-
MCI Level II diagnostic criteria (from Chapter 2), (3) a stable response to 
antiparkinsonian medication for a minimum period of 2 months preceding the study, 
and (4) cognitive deficits that do not interfere with functional independence.  
 
As for Chapter 2, the same exclusion criteria applied to this study with 
exception of additional tDCS exclusion conditions. Participants were excluded from 
the study on the basis of the following criteria: (1) presence of PD-Dementia (TICS 
total score < 12) (2) recent history of brain surgery, (3) Deep Brain Stimulation 
(DBS) implant, (4) active skin disease on the scalp, (5) history of migraine, (6) 
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history of epilepsy, (7) unstable medical condition (e.g., uncontrolled diabetes), (8) 
history of asthma, (9) metal implants in the head/brain, and (10) currently using a 
hearing aid. All participants who met inclusion/exclusion criteria provided informed 
consent prior to participation in this study. 
 
4.2.3 Interventions 
4.2.3.1 Cognitive training. The website version of Smartbrain ProTM 
(www.smartbrain.net) was used for cognitive training. Smartbrain ProTM is an 
interactive computer-based cognitive training program designed to train each 
cognitive domain (executive function, attention/working memory, memory, language 
and visuospatial abilities). Smartbrain ProTM has been used in trials which have 
demonstrated improvements in global cognitive functioning in AD (Tárraga et al., 
2006), and improvements in attention, information processing speed, memory, 
visuospatial abilities, verbal fluency, and executive functions in PD (París et al., 
2011).  
 
4.2.3.2 Standard cognitive training and standard cognitive training + 
tDCS groups. Participants in the standard cognitive training and standard cognitive 
training + tDCS groups completed a pre-determined program comprising of 10 
activities. Each cognitive domain was trained by two activities per domain (see Table 5).  
 
Table 6 
Smartbrain ProTM Activities for Standard and Tailored Cognitive Training 





1. Remembering faces 
2. Remembering words 




3. Finding symmetries 





5. Finishing sentences 




7. Ordering the steps of an action 





9. Identifying coordinates 
10. Clicking static items 
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4.2.3.3 Tailored cognitive training and tailored cognitive training + tDCS 
groups. Participants in the tailored cognitive training and tailored cognitive training 
+ tDCS groups completed the same activities as the standard cognitive training 
groups. However, activities in the tailored groups were customised to each 
participant’s pre-intervention neuropsychological test results. For example, a 
participant who demonstrated memory and executive function impairment at pre-
intervention, completed only two memory and two executive function activities on 
Smartbrain ProTM. 
 
4.2.3.4 Brain stimulation. tDCS was used as the brain stimulation 
intervention. tDCS is a noninvasive brain stimulation procedure delivering low 
intensity electrical currents (0.5 mA to 2mA) to specific cortical regions in the brain 
(Creutzfeldt et al., 1962; Nardone et al., 2012). tDCS modulates neuronal activity, 
with anodal tDCS used to increase excitability and cathodal tDCS decreases 
excitability in the cortex.  
 
4.2.3.6 tDCS, standard cognitive training + tDCS, and tailored cognitive 
training + tDCS groups. In addition to the cognitive training, participants allocated 
to the tDCS, standard cognitive training + tDCS, and tailored cognitive training + 
tDCS groups completed 4-sessions of tDCS stimulation over 4-weeks (one session 
per week).  
 
4.2.3.7 Control group. Participants in the control group completed post-
intervention and 12-week follow-up neuropsychological assessments, but they did 
not complete cognitive training or tDCS interventions. Participants in the control 
group were provided with the opportunity to complete cognitive training or tDCS 




4.2.4.1 Ethical and clinical registration. Curtin University’s Human 
Research Ethics Committee provided ethical approval prior to study commencement 
(Approval number: HR 189/2014). This study was also registered with the Australian 
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New Zealand Clinical Trials Registry (ANZCTR: 12614001039673).  
 
4.2.2.2 Recruitment. Participants were given the opportunity to participate 
in this study if they met the MDS Task Force diagnostic criteria for PD-MCI and 
tDCS inclusion criteria. 
 
4.2.4.3 Randomisation. To limit selection bias, a computer-generated 
randomisation list was used to allocate participants to groups using block 
randomisation at a ratio of 1:1 (Schulz & Grimes, 2002). Participants in the cognitive 
training and tDCS groups were informed of intervention start dates and participants 
in the control group were advised of a 4-week waiting period before a second 
neuropsychological assessment (post-intervention). Following post-intervention 
assessments, participants completed the 12-week follow-up assessments. 
 
4.2.4.4 Cognitive training format. Jean et al. (2010) suggest that for people 
with mild cognitive impairment, 6 to 20 cognitive training sessions completed in less 
than 12 weeks are as efficacious as longer and more costly interventions. Smartbrain 
ProTM creators also suggest that participants may experience fatigue after 35 to 45 
minutes of cognitive training which may impact their performance 
(www.smartbrain.net). Cognitive training groups completed three 45-minute in-home 
training sessions each week for 4-weeks (total of 12 sessions). Participants were 
requested to structure their training sessions each week. For example, completing 
cognitive training on Mondays, Wednesdays and Fridays. Participants were asked to 
complete training sessions in a quiet location free from distractions. Each participant 
was provided with a unique ‘USER ID’ and ‘PASSWORD’ to log into the training 
program. Smartbrain ProTM was streamed directly from the internet onto participant’s 
home computers or onto AcerTM Aspire E3-112 portable computers via OptusTM 
E5251 Mini Wifi Modems (provided by the researcher). Following completion of 
each 45-minute training session, the program terminated. Performance was 
automatically monitored by the program to adjust individual difficulty levels for each 
activity. For example, if a participant scored one incorrect answer on Level 5 of an 
executive function activity, the program decreased the difficulty of that activity to 
Level 4 in the following rotation. Conversely, if a participant scored all correct 
answers on Level 5, the program increased the difficulty of that activity to Level 6 in 
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the following rotation. Participants began the program on ‘Level 1’ (least 
challenging) and progressed through the levels to a maximum of ‘Level 15’ (most 
challenging).  
 
On the first day of each intervention the researcher visited participants’ 
homes to set up the program (and equipment if necessary), ensure the program was 
working appropriately, and provide written and verbal instructions. Participants were 
instructed to contact the researcher if they required assistance with the program, or if 
they experienced technical difficulties with the software during the intervention. All 
participant homes were within a 70 kilometer radius of Perth metropolitan area.  
 
4.2.4.6 Brain stimulation format. Four sessions of anodal tDCS, one per 
week for 4-weeks, were administered to participants in the tDCS groups. Stimulation 
session times were arranged individually and scheduled for the same day and time 
each week. During each session, participants completed 20 minutes of constant 
current 1.5 mA stimulation over the left dorsal lateral prefrontal cortex. tDCS was 
delivered using the TCTTM tDCS stimulator (http://www.trans-cranial.com/) and 
administered with two 50 x 70 mm2 sponge electrodes, soaked in saline solution. 
There was a period of 30 seconds at the start and end of the tDCS for ramp up/ramp 
down of the stimulator. 
 
To stimulate the left dorsal lateral prefrontal cortex, the anode electrode was 
placed over F3 according to the 10–20 international system for EEG electrodes 
placement (see Figure 10). The F3 anode location was determined by measuring over 
a participant’s centre line of their scalp, from the Inion (occipital protuberance) to the 
Naison (bridge of the nose), recording the total length, then using a felt-tip pen to 
mark the centre point of that length on the scalp. The researcher then measured over 
the mark on the scalp from a participant’s right preauricular point (middle of the ear) 
to their left preauricular point and marked the middle of that length on their scalp. 
This central point is known as ‘Cz’ and was used to locate F3. From Cz, 20% of the 
total Naison to Inion length was measured toward the front of the scalp and marked 
as ‘Fz’. From Fz, 20% of the preauricular to preauricular length was measured to the 
left of the scalp and marked as F3, the anode electrode location. The cathode 
electrode was placed on the forehead above the left eye to ensure stimulation was 
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delivered to the left dorsal lateral prefrontal cortex. The 10–20 system of electrode 
placement has been used in tDCS studies (Boggio et al., 2006; Doruk et al., 2014) 
and is established as an accurate method of localization by neuronavigation 
techniques (Herwig, Satrapi, & Schönfeldt-Lecuona, 2003). tDCS sessions were 




Figure 11. The 10–20 International System for EEG Electrodes Placement 
 
 
4.2.4.7 Data collection. The neuropsychological assessments conducted in 
Chapter 2 were used as pre-intervention (Week 0) results. Identical assessments were 
conducted post-intervention (Week 5) and follow-up (Week 12). All 
neuropsychological assessments, cognitive training, and brain stimulation were 
completed during participants’ ‘ON’ stage of medication use, to ensure they were 
feeling their best. Participants were reimbursed for travel costs and given a $10 gift 
card for completing pre-intervention assessments and a $15 gift card for completing 





4.2.5.1 Measures. Neuropsychological assessment measures for this study 
were the same as for Chapter 2 and were used at the post-intervention and 12-week 
follow-up assessments. Recommended by the MDS Task Force (Litvan et al., 2012), 
the following measures were used to assess outcome variables: (1) executive function 
was assessed with the Stockings of Cambridge (SOC) subtest from the Cambridge 
Neuropsychological Test of Automated Batteries (CANTABTM) and the phonemic 
verbal fluency subtest of the Controlled Oral Word Association Task (COWAT), (2) 
attention and working memory was assessed with the Letter-Number Sequencing 
(LNS) subtest from the Wechsler Adult Intelligence Scale-IV (WAIS-IV) and the 
Stroop (Colour-Word) Test, (3) memory was assessed with the Hopkins Verbal 
Learning Test-Revised (HVLT-R) immediate recall subtest and the Paragraph Recall 
subtest of the Rivermead Behavioural Memory Test (RMBT), (4) visuospatial 
abilities were assessed with the Judgement of Line Orientation (JLO) test and the 
Hooper Visual Organisation Test (HVOT), and (5) language was assessed with the 
Boston Naming Test-Short Form (BNT-Short Form) and the Similarities subtest 
from the WAIS-IV battery. Global cognition was assessed with the Parkinson’s 
Disease – Cognitive Rating Scale (PD-CRS) and the Mini Mental State Examination 
(MMSE). Premorbid intelligence and activities of daily living were assessed by the 
Australian version of the National Adult Reading Test (AUSNART) and Unified 
Parkinson’s Disease Rating Scale (section II), respectively. As measured in Chapter 
2, depression was assessed by the depression subscale of the DASS-21 and pre-
intervention scores were included as covariates. In addition to cognitive and practical 
outcomes, quality of life was assessed using the measure described below.  
 
4.2.5.3 Health-related quality of life. The Parkinson’s Disease 
Questionnaire-39 (PDQ-39) was used to measure quality of life (Peto, Jenkinson, & 
Fitzpatrick, 1998). The PDQ-39 contains 39 items assessing eight health-related 
dimensions: mobility, daily living, emotional wellbeing, stigma, social support, 
cognition, communication and bodily discomfort. Participants were asked, “Due to 
having Parkinson’s Disease, how often during the last month have you…” and rated 
the impact of their PD symptoms on their experiences in daily life. Example items 
include “Had difficulty carrying bags of shopping?” and “Avoided situations which 
involve eating and drinking in public?”. A summary index score was used as the 
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outcome variable for the PDQ-39 and was calculated by dividing the sum total of the 
eight dimension scores by eight (Jenkinson, Fitzpatrick, Peto, Greenhall, & Hyman, 
1997). Summary index scores range between 0 (no problems with quality of life) and 
100 (maximum problems with quality of life). The PDQ-39 has shown strong 
internal consistency across the eight dimensions (α = .72 to .95), as well as strong 




H1: Compared to participants in the Control group, participants in the Standard 
Cognitive Training, Tailored Cognitive Training, tDCS, Standard Cognitive 
Training + tDCS, and Tailored Cognitive Training + tDCS groups will 
demonstrate statistically significantly larger improvements in (i) cognitive 
functioning, (ii) ADL, and (iii) QOL, from pre-intervention (Time 1) to 
post-intervention (Time 2), and pre-intervention to three-month follow-up 
(Time 3) assessments. 
 
H2: Compared to participants in the Standard Cognitive Training group, 
participants in the Tailored Cognitive Training, tDCS, Standard Cognitive 
Training + tDCS, and Tailored Cognitive Training + tDCS groups will 
demonstrate statistically significantly larger improvements in (i) cognitive 
functioning, (ii) ADL, and (iii) QOL, from pre-intervention (Time 1) to 
post-intervention (Time 2), and pre-intervention to three-month follow-up 
(Time 3) assessments. 
 
H3: Compared to participants in the Tailored Cognitive Training group, 
participants in the tDCS, Standard Cognitive Training + tDCS, and Tailored 
Cognitive Training + tDCS groups will demonstrate statistically 
significantly larger improvements in (i) cognitive functioning, (ii) ADL, and 
(iii) QOL, from pre-intervention (Time 1) to post-intervention (Time 2), and 




H4: Compared to participants in the tDCS group, participants in the Standard 
Cognitive Training + tDCS and Tailored Cognitive Training + tDCS groups 
will demonstrate statistically significantly larger improvements in (i) 
cognitive functioning, (ii) ADL, and (iii) QOL, from pre-intervention (Time 
1) to post-intervention (Time 2), and pre-intervention to three-month 
follow-up (Time 3) assessments. 
 
H5: Compared to participants in the Standard Cognitive Training + tDCS group, 
participants in the Tailored Cognitive Training + tDCS group will 
demonstrate statistically significantly larger improvements in (i) cognitive 
functioning, (ii) ADL, and (iii) QOL, from pre-intervention (Time 1) to 
post-intervention (Time 2), and pre-intervention to three-month follow-up 
(Time 3) assessments. 
 
4.4 Data analysis 
 
4.4.1 Statistical Hypothesis Testing 
Generalised linear mixed models (GLMMs) were used to test statistical 
hypotheses (Bryk & Raudenbush, 1987). All GLMMs were performed using a syntax 
file procedure in SPSS 22.0. GLMMs control for outcome variables with non-normal 
distributions and include both random and fixed effects (McCulloch, 2006). For the 
present study, there was one random effect (participant) and three fixed effects: 
Group (standard training vs tailored training vs tDCS vs standard training + tDCS vs 
tailored training + tDCS vs control), time (pre, post, follow-up) and the Group x 
Time interaction (McCulloch, 2006). Separate GLMMs were run for each outcome 
variable to optimise the likelihood of convergence (McCulloch, 2006). Independently 
analysing outcome variables increased the Type 1 error rate. Therefore, outcome 
variables were grouped in accordance with cognitive domains (e.g., executive 
function measures, memory measures), and a more stringent alpha level was applied 
(to interaction effects) to conserve statistical power (i.e., p < .025). Unlike repeated 
measures ANOVA, GLMMs do not rely on participants providing data at pre/post-
intervention and follow-up. GLMMs use all data available at time intervals which 
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reduces the impact of participant attrition on statistical power. Moreover, GLMMs 
are rigorous against unequal groups (Krueger & Tian, 2004).  
 
Each GLMM was first assessed for a statistically significant Group x Time 
interaction effect. A significant interaction effect indicated a differential rate of 
change in the outcome variable, between the control and intervention groups, across 
the time intervals. In accordance with the proposed hypotheses (see section 4.3), it 
was therefore predicted that there would be significant Group x Time interactions for 
all outcomes. Significant interaction effects were then examined for significant 
simple main effects of Time, for each group. A significant simple main effect of 
Time (per group) indicated that there was a change in outcome scores across the pre-
intervention, post-intervention, and/or follow-up intervals. Significant simple main 
effects of Time were then examined for significant pairwise contrasts between time 
intervals, for each group. Statistically significant pairwise contrasts indicated a 
group’s outcome scores had changed between time intervals. These pairwise 
contrasts were used to determine which groups demonstrated significant 
improvements on outcome variables.  
 
Statistically significant simple main effects of Group were not of interest for 
this study. Significant simple main effects of Group indicate a significant difference 
between group outcome scores at either pre-intervention, post-intervention or follow-
up time intervals. However, this study investigated whether there was a significantly 
different degree of change (over time) on outcome variables, between groups. 
Therefore, pre-intervention, post-intervention, or follow-up group differences 
provided no statistical evidence to support the effect of interventions (or no effect of 
the control group) on outcome variables. 
 
4.4.1.1 Assumption testing. Similar to repeated measures ANOVA, three 
statistical assumptions pertain to GLMMs: normality, homogeneity of variance, and 
sphericity (Field, 2013). Each assumption was tested individually, per outcome 
variable. Normality refers to the distribution of scores on outcome variables 
demonstrating a relatively symmetrical inverted U-shape distribution, with most 
participant scores grouped in the center and less scores at either end of the 
distribution. Normality was assessed using the Shapiro-Wilk and skewness/kurtosis 
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statistics (Tabachnick & Fidell, 2013). A non-significant (p > .05) Shapiro-Wilk 
statistic and skewness/kurtosis statistics within ± 1.96, suggested that scores were 
normally distributed. Homogeneity of variance assumes that each group’s scores are 
homogeneous (equal) in their variability (Field, 2013). Homogeneity of variance was 
assessed using the Fmax method, where the largest sample variance was divided by 
the smallest sample variance. Largest and smallest sample variances were calculated 
by squaring the largest standard deviation and then squaring the smallest standard 
deviation. Tabachnick and Fidell (2013) recommend that homogeneity of variance 
can be assumed if Fmax is less than 10. Lastly, the assumption of sphericity was 
assessed using Mauchly’s Test of Sphericity. Sphericity assumes that the variances 
between the differences of outcome scores, at any two time intervals (e.g., pre to 
post, pre to follow-up, or post to follow-up), are approximately equal (Field, 2013). 
A non-significant (p > .05) Mauchly’s result indicated that sphericity was met. 
 
4.4.1.2 Power analysis and sample size. The sample for this study was 
determined during Study 1 (see Chapter 2.2.2.1). But for ease of exposition, an a 
priori power analysis was calculated using G*Power 3 (Faul et al., 2007). Power 
analysis was computed for an analysis of covariance (ANCOVA) as there is 
currently no statistical software available to determine an a priori sample size for 
GLMMs. To detect a moderate effect (power = .80 and α = .05), 54 participants were 
required for analysis. To reduce the impact of potential participant attrition on 
statistical power, 90 participants (15 per group) were targeted for recruitment. 
 
4.4.1.3 Effect size calculation. Effect sizes (Hedge’s g) were calculated 




4.5.1 Preliminary Analyses 
4.5.1.1 Missing data. No data was missing at pre-intervention. At post-
intervention, however, one participant’s data was missing for the depression subscale 
of the DASS-21 (DASS-D) and the PDQ-39, and five participants’ data were missing 
for the SOC. This missing data equates to 6.7% of the DASS-D and the PDQ-39, and 
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33.5% of the SOC at post-intervention. Missing values analysis was conducted and 
Little’s Missing Completely at Random (MCAR) test showed data missing at post-
intervention was not systematically linked to included variables, χ² (27) = 23.80, p = 
.64. At follow-up assessments, seven participants’ data were missing for the DASS-
D and PDQ-39, and four participants’ data were missing for the SOC. In addition, 
four participants withdrew from the study before follow-up assessments, providing 
no data across all outcomes. This missing data equates to 26.8% of the SOC and 
46.9% of the DASS-D and PDQ-39. Little’s MCAR test showed data missing at 
follow-up was not systematically linked to included variables, χ² (27) = 40.34, p = 
.05. Reasons for missing data included participants’ failing to return completed 
questionnaires (despite follow up contact), and software malfunction with the 
CANTABTM program. Given that GLMMs account for missing data by using all data 
available at each time interval and that missing data analyses were not statistically 
significant, no data transformation or replacement technique was used prior to 
analysis (Krueger & Tian, 2004). Means and standard deviations calculated in the 
GLMMs at post-intervention and follow-up were therefore slightly adjusted by each 
model and do not reflect the raw data at those time points. 
 
4.5.1.2 Participant flow. A total of 70 participants completed pre-
intervention neuropsychological assessments, and 42 participants met inclusion 
criteria for this RCT. Participants were excluded for two reasons: (1) demonstrating 
cognitive functioning above MDS Task Force Level II criteria for PD-MCI (N = 25) 
and (2) severe cognitive impairment (N = 3). The researcher determined severe 
cognitive impairment as meeting MDS criteria, but demonstrating cognitive deficits 
that would have restricted a participant’s ability to complete the cognitive training 
intervention.  The 42 participants who completed the study were randomly allocated 
to an intervention group or the control group, resulting in 7 participants per group 
(see Figure 11). All participants completed their allocated interventions and post-
intervention neuropsychological assessments. However, 4 participants (9.5%) did not 
complete follow-up assessments. Reasons for this attrition included an inability to 
travel due to disease progression (N = 2) and a lack of time to complete the follow-up 
































Figure 11. Flow Diagram of Participant Allocation 
 
4.5.1.3 Statistical power. To provide sufficient power (.80, α = .05), this 
study required 54 participants (9 per group). However, only 42 participants (7 per 
group) met the inclusion criteria. This study was somewhat underpowered and the 
results should be interpreted as preliminary findings. 
 
 4.5.1.4 Demographic statistics. Table 6 provides demographic results for 
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Standard Cognitive Training + tDCS, Tailored Cognitive Training + tDCS, and 
Control groups. 
 
Table 7                                                                      
Demographic information for the intervention and control groups  
 
Standard CT Tailored CT tDCS  
Outcome M SD M SD M SD 
 
Gender (% ♀) 43% (N = 3) 57% (N = 4) 71% (N = 5) 
 
Age++ 68.14 8.69 65.57 5.20 72 6.45 
 
Education++ 13.57 2.64 12.21 2.83 13.57 3.69 
 
Premorbid IQ 103.29 6.96 107.21 12 108.21 5.83 
 
Disease Duration++ 5.29 4.23 5.79 4.97 5.50 5.66 
 
LED 295 313.40 383 178.62 573.29 586.25 
 
DASS-D 2.29 2.56 1.29 1.50 3 2 
 
 Standard CT + tDCS Tailored CT + tDCS Control 
 
Outcome M SD M SD M SD 
 
Gender (% ♀) 71% (N = 5) 71% (N = 5) 57% (N = 4) 
 
Age++ 63.57 15.68 67.43 6.37 72.29 6.21 
 
Education++ 15.50 3.35 15.86 1.35 11.71 2.98 
 
Premorbid IQ 111.96 4.37 111.08 3.59 103.64 7.53 
 
Disease Duration++ 6.79 4.60 4.43 2.70 5.36 4.14 
 
LED 350.71 322.37 464.29 358.78 292.88 274.51 
 
DASS-D 3 5.07 3.29 4.11 2.71 3.15 
 
Note. ♀ = male gender; ++ = years; CT = cognitive training; M = mean; SD = standard deviation; IQ = 
intelligence quotient; LED = levodopa equivalent dose; DASS-D = depression subscale of the 
Depression, Anxiety, and Stress Scale. 
 
4.5.1.5 Pre-intervention correlations and covariate variables.  Bivariate 
correlations were conducted to determine whether age, gender, years of education, 
premorbid IQ, disease duration, LED, and depression significantly correlated with 
outcome variables at pre-intervention. Age significantly correlated with the HVLT (r 
= -.43, p = .004), MMSE (r = -.43, p = .005), and PD-CRS (r = -.37, p = .018), and 
so was included as a covariate for these outcomes. Gender significantly correlated 
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with the Stroop test (r = .35, p = .025), and so was included as a covariate for this 
outcome. Years of education significantly correlated with Similarities (r = .31, p = 
.043) and MMSE (r = .34, p = .026), and so was included as covariate for these 
outcomes. Premorbid IQ significantly correlated with Similarities (r = .44, p = .003), 
JLO (r = .33, p = .034) and MMSE (r = .38, p = .014), and so was included as a 
covariate for these outcomes. Disease duration significantly correlated with the 
HVOT (r = -.32, p = .044) and was included as a covariate for this outcome. LED 
significantly correlated with Similarities (r = .33, p = .032) and was included as a 
covariate for this outcome. Lastly, depression significantly correlated with 
Similarities (r = -.39, p = .011) and the PDQ-39 (r = .59, p < .001), and so was 
included as a covariate for these outcomes. No other significant correlations were 
found. 
 
4.5.2 Generalised Linear Mixed Models 
4.5.2.1 Assumption testing. No outcomes violated the assumption of 
sphericity. The assumption of normality was violated for five outcomes (MMSE, 
HVLT, JLO, BNT, and LNS) according to Shapiro-Wilk (p < .05; see Appendix D). 
However, three outcomes (MMSE, HVLT, and JLO) showed skewness/kurtosis 
statistics within the acceptable range (± 1.96), suggesting these variables were 
normally distributed. Two outcomes (BNT and LNS) showed large kurtosis statistics 
(BNT = 3.02; LNS = 2.83), suggesting these variables were not normally distributed. 
Eight outcomes (MMSE, PD-CRS, JLO, BNT, Paragraph recall, LNS, COWAT, and 
UPDRS-II) violated the homogeneity of variance assumption, with Fmax values 
greater than 10. GLMMs are, however, robust against violations of normality and 
homogeneity of variance when group sizes are relatively equal (Krueger & Tian, 
2004). Therefore, no data transformation technique was used to account for 
assumption violations. 
 
4.5.2.2 Hypothesis testing. To address each hypothesis, outcomes were 
examined for statistically significant Time x Group interaction effects, simple main 
effects of Time (per group), and group pairwise contrasts. Raw outcome scores for 
each group at pre-intervention, post-intervention, and follow-up are in Appendices E, 
111 
 
F, and G. Effect sizes in accordance with each hypothesis are reported in Appendix 
H. To ease exposition, each hypothesis is summarised here:  
H1: Compared to participants in the Control group, participants in the Standard 
Cognitive Training, Tailored Cognitive Training, tDCS, Standard Cognitive 
Training + tDCS, and Tailored Cognitive Training + tDCS groups will 
demonstrate statistically significantly larger improvements for all outcomes 
across all assessment intervals. 
 
H2: Compared to participants in the Standard Cognitive Training group, 
participants in the Tailored Cognitive Training, tDCS, Standard Cognitive 
Training + tDCS, and Tailored Cognitive Training + tDCS groups will 
demonstrate statistically significantly larger improvements for all outcomes 
across all assessment intervals. 
 
H3: Compared to participants in the Tailored Cognitive Training group, 
participants in the tDCS, Standard Cognitive Training + tDCS, and Tailored 
Cognitive Training + tDCS groups will demonstrate statistically 
significantly larger improvements for all outcomes across all assessment 
intervals. 
 
H4: Compared to participants in the tDCS group, participants in the Standard 
Cognitive Training + tDCS and Tailored Cognitive Training + tDCS groups 
will demonstrate statistically significantly larger improvements for all 
outcomes across all assessment intervals. 
 
H5: Compared to participants in the Standard Cognitive Training + tDCS group, 
participants in the Tailored Cognitive Training + tDCS group will 
demonstrate statistically significantly larger improvements for all outcomes 
across all assessment intervals. 
 
4.5.2.2.1 Executive function. For Stockings of Cambridge (SOC), H1, H2, 
H3, and H4 were partially supported. H5 was not supported. Figure 12 shows groups 







Figure 12. Trajectory of change in SOC total scores for intervention groups with 
statistically significant improvement and for the control group. Note: 95% confidence 
interval bars have been omitted from each data point to ease interpretation of the figure. 
 
A significant interaction effect was observed for SOC, indicating a 
differential rate of change in executive function between groups, F (10, 95) = 3.82, p 
< .001. A significant simple main effect of Time was observed for the Standard 
Cognitive Training + tDCS group, F (2, 95) = 10.73, p < .001. Pairwise contrasts 
revealed significant improvement in executive function from pre-intervention to 
post-intervention, t (95) = 2.15, p < .001, 𝑔 = .41, and from pre-intervention to 
follow-up, t (95) = 1.71, p = .024, 𝑔 = .23. A significant simple main effect of Time 
was observed for the Tailored Cognitive Training + tDCS group, F (2, 95) = 12.00, p 
< .001. Pairwise contrasts revealed significant improvement in executive function 
from pre-intervention to post-intervention, t (95) = 1.71, p = .024, 𝑔 = .19, and from 
pre-intervention to follow-up, t (95) = 3.29, p < .001, 𝑔 = .92. No significant simple 
main effects of Time were observed for the Standard Cognitive Training group (F [2, 
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95] = 2.00, p = .14), Tailored Cognitive Training group (F [2, 93] = .96, p = .39), 
tDCS group (F [2, 93] = 2.38, p = .10), or Control group (F [2, 93] = 3.15, p = .05).  
 
For the Controlled Oral Word Association Test (COWAT), the interaction 
effect was not significant and indicated no differential rate of change between 
groups, F (10, 104) = 1.65, p = .10. Therefore, no hypotheses were supported for this 
outcome. 
 
4.5.2.2.2 Attention/working memory. For the Stroop test, H1, H2, and H3 
were partially supported. H4 and H5 were not supported. Figure 13 shows groups 





Figure 13. Trajectory of change in Stroop total scores for intervention groups with 
statistically significant improvement and for the control group.  
 
A significant interaction effect was observed for the Stroop test, indicating a 
differential rate of change in attention/working memory between groups, F (10, 103) 
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= 2.91, p = .003. A significant simple main effect of Time was observed for the tDCS 
group, F (2, 103) = 4.06, p = .020. Pairwise contrasts revealed significant 
improvement in attention/working memory from pre-intervention to post-
intervention, t (103) = 6.29, p = .039, 𝑔 = .65, and from pre-intervention to follow-
up, t (103) = 5.14, p = .018, 𝑔 = .01. A significant simple main effect of Time was 
observed for the Standard Cognitive Training + tDCS group, F (2, 103) = 35.05, p < 
.001. Pairwise contrasts revealed significant improvement in attention/working 
memory from pre-intervention to post-intervention, t (103) = 6.00, p = .028, 𝑔 = .60 
and from pre-intervention to follow-up, t (103) = 9.29, p < .001, 𝑔 = .24. No 
significant simple main effects of Time were observed for the Standard Cognitive 
Training group (F [2, 103] = 1.61, p = .20), Tailored Cognitive Training group (F [2, 
103] = 1.08, p = .34), Tailored Cognitive Training + tDCS group (F [2, 103] = 1.45, 
p = .24), and Control group (F [2, 103] = .56, p = .57).  
 
For Letter-Number Sequencing (LNS), H1, H2, H4, and H5 were partially 
supported. H3 was not supported. A significant interaction effect was observed for 
LNS, indicating a differential rate of change in attention/working memory between 
groups, F (10, 95) = 4.53, p < .001. A significant simple main effect of time was 
observed for the Standard Cognitive Training group, F (2, 95) = 16.41, p < .001. 
However, pairwise contrasts revealed no significant differences from pre-
intervention to post-intervention, or to follow-up. A significant simple main effect of 
time was observed for the Tailored Cognitive Training group, F (2, 95) = 6.62, p = 
.002. Pairwise contrasts revealed a significant improvement in attention/working 
memory from pre-intervention to follow-up, t (95) = 2.42, p = .001, 𝑔 = .34. No 
improvements were observed from pre-intervention to post-intervention. A 
significant simple main effect of time was observed for the Tailored Cognitive 
Training + tDCS group, F (2, 95) = 5.11, p = .008. Pairwise contrasts revealed a 
significant improvement in attention/working memory from pre-intervention to 
follow-up, t (95) = 1.61, p = .030, 𝑔 = .22. No improvements were observed from 
pre-intervention to post-intervention. No significant simple main effects of Time 
were observed for the tDCS group (F [2, 95] = 1.83, p = .17), Standard Cognitive 
Training + tDCS group (F [2, 95] = .09, p = .91), and Control group (F [2, 95] = .58, 








Figure 14. Trajectory of change in LNS total scores for intervention groups with 
statistically significant improvement and for the control group.  
 
4.5.2.2.3 Memory. For Paragraph recall, H1, H3, and H5 were partially 
supported. H2 and H4 were not supported. A significant interaction effect was 
observed for Paragraph recall, indicating a differential rate of change in memory 
between groups, F (10, 104) = 2.51, p = .010. A significant simple main effect of 
Time was observed for the Standard Cognitive Training group, F (2, 104) = 5.24, p = 
.007. Pairwise contrasts revealed a significant improvement in memory from pre-
intervention to follow-up, t (104) = 2.09, p = .002, 𝑔 = 1.30. No improvements were 
observed from pre-intervention to post-intervention. A significant simple main effect 
of Time was observed for the tDCS group, F (2, 104) = 17.82, p < .001. Pairwise 
contrasts revealed a significant improvement in memory from pre-intervention to 
post-intervention, t (104) = 2.29, p < .001, 𝑔 = 1.11. No improvements were 
observed from pre-intervention to follow-up. A significant simple main effect of 
Time was observed for the Tailored Cognitive Training + tDCS group, F (2, 104) = 
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12.09, p < .001. Pairwise contrasts revealed a significant improvement in memory 
from pre-intervention to post-intervention, t (104) = 2.50, p < .001, 𝑔 = 1.36, and 
from pre-intervention to follow-up, t (104) = 3.21, p = .002, 𝑔 = 1.75. No significant 
simple main effects of Time were observed for the Tailored Cognitive Training 
group (F [2, 104] = 2.87, p = .06), Standard Cognitive Training + tDCS group (F [2, 
104] = 2.86, p = .06), and Control group (F [2, 104] = .97, p = .38). Figure 15 shows 




Figure 15. Trajectory of change in Paragraph recall total scores for intervention 
groups with statistically significant improvement and for the control group.  
 
For Hopkins Verbal Learning Test (HVLT), the interaction effect was not 
significant and indicated no differential rate of change between groups, F (10, 103) = 
.87, p = .56. Therefore, no hypotheses were supported for this outcome. 
 
4.5.2.2.4 Language. For Similarities, H1, H2, H3, and H4 were partially 
supported. H5 was not supported. A significant interaction effect was observed for 
Similarities, indicating a differential rate of change in language between groups, F 
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(10, 92) = 3.25, p = .001. A significant simple main effect of Time was observed for 
the Standard Cognitive Training + tDCS group, F (2, 92) = 5.23, p = .007. Pairwise 
contrasts revealed a significant improvement in language from pre-intervention to 
post-intervention, t (92) = 1.92, p = .008, 𝑔 = .59. But no improvements were 
observed from pre-intervention to follow-up. A significant simple main effect of 
Time was observed for the Tailored Cognitive Training + tDCS group, F (2, 92) = 
17.43, p < .001. Pairwise contrasts revealed a significant improvement in language 
from pre-intervention to post-intervention, t (92) = 3.13, p < .001, 𝑔 = 1.06. But no 
improvements were observed from pre-intervention to follow-up. No significant 
simple main effects of Time were observed for the Standard Cognitive Training 
group (F [2, 92] = 1.55, p = .22), Tailored Cognitive Training group (F [2, 92] = .29, 
p = .75), tDCS group (F [2, 92] = 1.41, p = .25), and Control group (F [2, 92] = 1.78, 





Figure 16. Trajectory of change in Similarities total scores for intervention groups 
with statistically significant improvement and for the control group.  
For the Boston Naming Test (BNT), the interaction effect was not significant 
and indicated no differential rate of change between groups, F (10, 104) = 1.24, p = 




4.5.2.2.4 Visuospatial abilities. A significant interaction effect was observed 
for Judgement of Line Orientation (JLO), indicating a differential rate of change in 
visuospatial abilities between groups, F (10, 103) = 3.76, p < .001. A significant 
simple main effect of Time was observed for the Standard Cognitive Training group, 
F (2, 103) = 6.57, p = .002. However, pairwise contrasts revealed a significant 
decline in visuospatial abilities from pre-intervention to follow-up, t (103) = 5.00, p 
= .004, 𝑔 = -.32. No improvements were observed from pre-intervention to post-
intervention. A significant simple main effect of Time was observed for the Control 
group, F (2, 103) = 7.46, p = .001. However, pairwise contrasts revealed no 
significant differences from pre-intervention to post-intervention, or to follow-up. No 
significant simple main effects of Time were observed for the Tailored Cognitive 
Training group (F [2, 103] = 3.19, p = .05), tDCS group (F [2, 103] = 2.85, p = .06), 
Standard Cognitive Training + tDCS group (F [2, 103] = 1.87, p = .16), and Tailored 
Cognitive Training + tDCS group (F [2, 103] = .21, p = .81). These results indicate 
that no hypotheses were supported for this outcome.  
 
For Hooper’s Visual Organisation Test (HVOT), the interaction effect was 
not significant and indicated no differential rate of change between groups, F (10, 
99) = 1.18, p = .32. Therefore, no hypotheses were supported for this outcome. 
 
4.5.2.2.5 Global cognition. Interaction effects were not significant for the 
Mini Mental State Examination (MMSE), F (10, 101) = 1.74, p = .08, and the 
Parkinson’s Disease-Cognitive Rating Scale (PD-CRS), F (10, 103) = 2.06, p = .035 
(using a Bonferroni adjusted alpha level, p = .025). These results indicate no 
differential rate of change in global cognition between groups, and so no hypotheses 
were supported for these outcomes. 
 
4.5.2.2.6 Activities of daily living. For the Unified Parkinson’s Disease 
Rating Scale – section II (UPDRS-II), H1, H3, and H4 were partially supported. H2 
and H5 were not supported. Figure 17 shows groups with statistically significant 






Figure 17. Trajectory of change in UPDRS-II total scores for intervention groups 
with statistically significant improvement and for the control group.  
 
A significant interaction effect was observed for the UPDRS-II, indicating a 
differential rate of change in activities of daily living between groups, F (10, 104) = 
1.96, p = .045. A significant simple main effect of Time was observed for the 
Standard Cognitive Training group, F (2, 104) = 11.29, p < .001. Pairwise contrasts 
revealed a significant improvement in activities of daily living from pre-intervention 
to post-intervention, t (104) = -.23, p < .001, 𝑔 = .33. No improvements were 
observed from pre-intervention to follow-up. A significant simple main effect of 
Time was observed for the Standard Cognitive Training + tDCS group, F (2, 104) = 
3.40, p = .037. Pairwise contrasts revealed a significant improvement in activities of 
daily living from pre-intervention to post-intervention, t (104) = -.38, p = .014, 𝑔 = 
.55. No improvements were observed from pre-intervention to follow-up. A 
significant simple main effect of Time was observed for the Tailored Cognitive 
Training + tDCS group, F (2, 104) = 16.96, p < .001. However, pairwise contrasts 
revealed no significant differences from pre-intervention to post-intervention, or to 
follow-up. No significant simple main effects of Time were observed for the Tailored 
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Cognitive Training group (F [2, 104] = .48, p = .62), tDCS group (F [2, 104] = 2.54, 
p = .08), and Control group (F [2, 104] = .57, p = .57).  
 
4.5.2.2.7 Quality of life. For the Parkinson’s Disease Questionnaire-39 
(PDQ-39), H1 was partially supported. H2, H3, H4, and H5 were not supported. 




Figure 18. Trajectory of change in PDQ-39 total scores for intervention groups with 
statistically significant improvement and for the control group.  
 
A significant interaction effect was observed for the PDQ-39, indicating a 
differential rate of change in quality of life between groups, F (10, 95) = 2.96, p = 
.003. A significant simple main effect of Time was observed for the Standard 
Cognitive Training group, F (2, 95) = 7.21, p = .001. Pairwise contrasts revealed a 
significant improvement in quality of life from pre-intervention to post-intervention, 
t (95) = -3.52, p = .003, 𝑔 = .24. No improvements were observed from pre-
intervention to follow-up. A significant simple main effect of Time was observed for 
the Tailored Cognitive Training group, F (2, 95) = 12.48, p < .001. Pairwise contrasts 
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revealed a significant improvement in quality of life from pre-intervention to post-
intervention, t (95) = -3.32, p = .016, 𝑔 = .26, and from pre-intervention to follow-up, 
t (95) = -3.20, p = .017, 𝑔 = .12. A significant simple main effect of Time was 
observed for the Tailored Cognitive Training + tDCS group, F (2, 95) = 3.85, p = 
.025. However, pairwise contrasts revealed no significant differences from pre-
intervention to post-intervention, or to follow-up. No significant simple main effects 
of Time were observed for the tDCS group (F [2, 95] = .63, p = .54), Standard 
Cognitive Training + tDCS group (F [2, 95] = 1.73, p = .18) and Control group (F [2, 




This study was the first randomised controlled trial of standard cognitive 
training, tailored cognitive training, tDCS, standard cognitive training + tDCS, and 
tailored cognitive training + tDCS for mild cognitive impairment in PD. In support of 
the therapeutic potential of these nonpharmacological interventions, differential rates 
of statistically significant improvements in cognition, activities of daily living, and 
quality of life were observed across various intervention groups. The control group 
did not improve on outcome measures. 
 
4.6.1 Main Findings and Implications 
Standard cognitive training involves the repetitive presentation of external 
stimuli to induce synaptic plasticity by altering neural connectivity at a cellular level 
(Kim & Kim, 2014). Within Kim and Kim’s (2014) theoretical framework, standard 
cognitive training is a stimulation-focussed intervention that broadly enhances 
cognitive function by changing existing neural connections in the brain. In this study, 
the Standard Cognitive Training group improved on memory, but no improvements 
were found for any other cognitive domains. Improvements were observed on the 
Paragraph recall test (𝑔 = .62) from pre-intervention to post-intervention, but 
improvements were not maintained at follow-up neuropsychological assessments. 
These results are supported by previous studies, with standard cognitive training 
improving memory in PD (París et al., 2011; Pena et al., 2014; Petrelli et al., 2014). 
Two previous studies, however, reported improvement in visuospatial related 
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memory abilities (París et al., 2011; Pena et al., 2014) and no improvement on 
paragraph recall tasks that primarily assess logical memory. This discrepancy 
between studies may be explained by the ‘dual syndrome hypothesis’ (Nombela et 
al., 2014). The dual syndrome hypothesis suggests that distinct genetic variations are 
associated with memory (APOE allelic) and visuospatial (MAPT haplotype) deficits 
in PD (Kehagia et al., 2010). If the majority of participants in the previous studies 
had the MAPT haplotype genetic abnormality (associated with visuospatial 
impairment), and participants in the current study had the APOE allelic abnormality 
(associated with memory impairment), then standard cognitive training would likely 
produce stimulation-focussed effects to improve abilities associated with specific 
cognitive deficits and their corresponding genetic abnormality. Functional magnetic 
resonance imaging (fMRI) was beyond the scope of the present study, but future 
clinical trials need to integrate cognitive training with neuroimaging to assist with 
understanding the neurobiological processes involved during these interventions. 
 
For the Standard Cognitive Training group, activities of daily living (𝑔 = .33) 
and quality of life (𝑔 = .24) also improved from pre-intervention to post-intervention, 
but improvements were not maintained at follow-up assessments. One standard 
cognitive training study has reported improvements in activities of daily living 
(Pompeu et al., 2012), but the current study is the first to report significant 
improvements in quality of life in PD from pre to post-intervention. París et al. 
(2011) used the same computer-based cognitive training program (Smartbrain ProTM) 
and the same quality of life outcome measure (PDQ-39), but their participants did 
not improve on quality of life. Half of the participants in Paris et al.’s (2011) 
cognitive training group were, however, classified as having normal cognition. 
Participants with normal cognitive functioning may have experienced a ceiling 
effect, which limits the therapeutic potential of cognitive training and associated 
improvements in quality of life. Despite limited evidence to support the findings of 
the current study, quality of life and activities of daily living are frequently impaired 
in PD and are associated with cognitive decline (Klepac et al., 2008; Lawrence et al., 
2014; Muslimović et al., 2008). The current results indicate that standard cognitive 
training may provide improvements in activities of daily living and quality of life for 
people with PD-MCI, and future cognitive training studies need to include these 




Building upon standard cognitive training, tailored cognitive training also 
uses external stimuli to alter neural connectivity and target specific cognitive 
impairments, to compensate for deficits in these domains. Theoretically, tailored 
cognitive training is a stimulation and compensation-focussed intervention aimed at 
improving specific cognitive functions that have been impacted by neural 
degeneration (Kim & Kim, 2014). In the present study, the Tailored Cognitive 
Training group improved on attention/working memory (measured by LNS, 𝑔 = .34) 
from pre-intervention to follow-up, but no improvements were observed at post-
intervention assessments. That is, no immediate post-intervention improvement was 
evident. The improvement in attention/working memory was delayed and only 
presented 12-weeks post-intervention cessation. One other tailored cognitive training 
study has reported immediate post-intervention ‘attentional improvements’, 
evidenced by increased neural resting state (measured by fMRI) activity in the 
superior parietal and prefrontal dorsolateral cortices following training (Cerasa et al., 
2014). In the current study, however, improvements in attention/working memory 
were not observed until the 12-week follow-up assessment. Methodological 
differences may account for the discrepancy between results. Compared to the 
current study, Cerasa et al. (2014) administered 12-sessions of tailored cognitive 
training in a supervised group setting. Group-based cognitive training has shown 
greater efficacy than in-home cognitive training in healthy-older adults (Lampit et 
al., 2014). Group-based training may provide additional benefits including trainer 
supervision, encouragement in performance, and social interaction among 
participants (Lampit et al., 2014). Participants may therefore adhere to and benefit 
from a group-based intervention to a greater extent. In addition, several participants 
in the current study’s tailored cognitive training group provided feedback (albeit 
anecdotally) suggesting that the training was, at times, monotonous and too 
repetitive. Compared to the standard cognitive training format, those randomised to 
tailored cognitive training only completed activities targeting their impaired 
cognitive domains (i.e., a less diverse and engaging cognitive training program). 
These methodological parameters may be associated with the lack of post-
intervention improvement in the current study. Nonetheless, the Tailored Cognitive 
Training Group did improve on attention/working memory at the follow-up 
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assessment, which provides some preliminary evidence to support future tailored 
cognitive training studies.  
 
The Tailored Cognitive Training group also improved on quality of life from 
pre-intervention to post-intervention (𝑔 = .26), and improvements were maintained at 
follow-up assessment (𝑔 = .12). This is the first study to report improvements in 
quality of life following tailored cognitive training in people with PD or PD-MCI. 
Despite limited evidence in PD, a Cochrane review of cognitive training for people 
with mild to moderate dementia reported positive effects of cognitive training for 
quality of life (Woods, Aguirre, Spector, & Orrell, 2012). From the 15 RCTs 
included in the review, participants with dementia demonstrated improvements in 
self-reported quality life (as well as cognitive function) following cognitive training 
(Woods et al., 2012). An earlier study of cognitive training in dementia reported 
improvements in quality of life were mediated by improvements in cognition 
(Woods, Thorgrimsen, Spector, Royan, & Orrell, 2006). This result suggests that the 
beneficial effects of cognitive training for quality of life may be reliant upon 
cognitive improvement during training, and quality of life is less likely to improve if 
no cognitive benefits are observed. It is currently not known whether there is 
individual or multiple neurobiological mechanisms associated with improved quality 
of life following cognitive training. However, the positive results in the present study 
and those reported in dementia indicate that future studies need to explore the 
potential of tailored cognitive training for improving quality of life in PD-MCI.  
 
tDCS modulates neuronal activity by delivering low intensity electrical 
currents to specific cortical regions (Creutzfeldt et al., 1962; Nardone et al., 2012). 
Several neuroimaging studies report increased activation of the prefrontal cortices 
when older adults complete tasks involving attention/working memory and/or 
executive skills (Spreng, Wojtowicz, & Grady, 2010). That is, older adults 
experience greater activation of frontal cortical networks during complex cognitive 
tasks to compensate for impaired performance in other cortical regions (Goh & Park, 
2009). Within Kim and Kim’s (2014) theoretical framework, anodal tDCS used in 
this study was a compensation-focussed intervention to improve cognitive 
impairments associated with compensatory activation of the left DLPFC in people 
with PD-MCI. The tDCS group improved on attention/working memory (Stroop test) 
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from pre-intervention to post-intervention (𝑔 = .65), and improvements were 
maintained at follow-up assessments (𝑔 = .01). To date, one tDCS study has reported 
significant improvement on attention/working memory in PD (Boggio et al., 2006) 
and two studies reported improvement on executive function (Doruk et al., 2014; 
Pereira et al., 2013). As described in section 3.8.2, however, recent tDCS (and 
cognitive training) studies have heterogeneously applied neuropsychological tests to 
the measurement of cognitive domains, which leads to variability in the reporting of 
intervention effects for improving cognitive functions. 
 
In this study, the MDS Task Force criteria for PD-MCI was used to 
categorise neuropsychological tests (Litvan et al., 2012). The MDS criteria suggest 
using the Stroop test to measure attention/working memory and in the current study, 
the tDCS group demonstrated significant improvements on this domain. However, 
the Stroop test’s incongruent colour-word naming task (which was used in this study) 
primarily assesses an individual’s ability to inhibit a prepotent word response (Fisk 
& Sharp, 2004). Inhibition has been proposed as an executive function ability (Fisk 
& Sharp, 2004; Miyake et al., 2000), which suggests that the tDCS group may have 
improved an executive function skill other than attention/working memory. Further 
discrepancies between test classifications are also highlighted when comparing the 
methods employed by Doruk et al. (2014) and the formal test classification methods 
recommended by Strauss et al. (2006) and the MDS criteria. Doruk et al. (2014) 
administered tDCS and reported improvement in ‘executive abilities’ as measured by 
the Trail Making Test-Part B (TMT-B). Strauss et al. (2006) and the MDS criteria 
classify the TMT-B as a measure of attention/working memory, which is consistent 
with Baddeley (2003) suggestion that the ‘central executive’ involves the use of 
attentional control and is one underlying component of the broader working memory 
domain. The method used to classify specific cognitive skills and neuropsychological 
tests within a cognitive domain, will therefore determine which domain is described 
as improved during a clinical trial. Despite the heterogeneous use of 
neuropsychological tests in PD, the results of this study suggest that tDCS can 





The tDCS group demonstrated significant improvements on memory 
(Paragraph recall, 𝑔 = 1.11) from pre-intervention to post-intervention, but 
improvements were not maintained at follow-up assessments. The current study is 
the first to report memory improvement following tDCS in PD-MCI. Several studies 
in AD have reported improvements in memory following tDCS. Boggio et al. (2009) 
compared the effect of anodal tDCS over the left temporal cortex and left DLPFC, 
against sham tDCS in AD. Anodal stimulation over both cortical sites led to 
significant improvement in visual recognition memory immediately following 
stimulation, but no long-term effect was reported (Boggio et al., 2009). Ferrucci et al. 
(2008) compared anodal, cathodal, and sham tDCS applied over the temporoparietal 
areas in AD. Significant improvement in recognition memory was observed 
immediately following anodal tDCS (Ferrucci et al., 2008), without long-term 
improvements. In a follow up study, Boggio et al. (2012) reported improvement in 
visual recognition memory following anodal tDCS over the temporal cortex and 
effects were maintained one month post-stimulation. The results observed in AD 
provide empirical support for the positive effects demonstrated in the current study, 
suggesting that anodal tDCS over both temporal and dorsolateral cortices may induce 
compensatory activation of neural networks associated with improvements in 
memory for individuals with a neurodegenerative disorder (i.e., PD-MCI). As 
previously noted, participants in the current study may have had the APOE allelic 
genetic abnormality associated with memory deficits in the posterior cortex 
(Nombela et al., 2014). In accordance with the Scaffolding Theory of Ageing and 
Cognition (Goh & Park, 2009), impaired posterior cortical function may have 
resulted in compensatory activation of the prefrontal cortices (i.e., left DLPFC), to 
account for increased cognitive demand during complex tasks (i.e., 
neuropsychological assessments). Anodal tDCS therefore enhanced compensatory 
activation of the left DLPFC, leading to increased neural activity of frontal functions 
that were associated with improved memory performance in PD-MCI. 
 
This study was the first controlled trial in PD or PD-MCI to combine standard 
cognitive training with tDCS. In accord with Kim and Kim’s (2014) model, 
combining standard cognitive training with tDCS ensured participants in this group 
received a stimulation and compensation-focussed intervention. In the present study, 
the Standard Cognitive Training + tDCS group demonstrated significant 
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improvement on executive function (SOC, 𝑔 = .41) and attention/working memory 
(Stroop test, 𝑔 = .60) from pre-intervention to post-intervention, and improvements 
were maintained at follow-up assessment (SOC, 𝑔 = .23; Stroop test, 𝑔 = .24). A 
number of uncontrolled studies have combined standard cognitive training with 
noninvasive brain stimulation, but the results vary. In the only study of PD-MCI, 
Biundo et al. (2015) examined the effect of combining standard cognitive training 
with either real or sham tDCS. For participants in the real tDCS group, a significant 
decline in executive skills but significant improvements in attention and memory 
were observed (Biundo et al., 2015). Improvements were not maintained at 16-week 
follow up assessments and this study did not include a control group, which limits 
interpretation of the results. Two studies in AD paired repetitive transcranial 
magnetic stimulation (rTMS) with standard cognitive training and reported 
significant improvement in global cognition at an 18-week follow up assessment 
(Bentwich et al., 2011; Rabey et al., 2013). Although they are different methods of 
non-invasive stimulation, both anodal tDCS and high frequency rTMS increase 
cortical excitability to improve cognitive functioning in these neurodegenerative 
disorders (Nardone et al., 2012). According to Mowszowski et al. (2010), combining 
standard cognitive training with tDCS in the current study may have resulted in 
‘positive plasticity’ to alleviate executive function and attention/working memory 
deficits in PD-MCI. Standard cognitive training may have stimulated and strengthen 
existing neural connections (i.e., synaptogenesis; Ponti et al., 2008), while tDCS 
provided compensatory activation of a cortical region (i.e., left DLPFC) associated 
with higher-order cognition (i.e., executive function and working memory). In 
combination, these nonpharmacological interventions produced beneficial effects on 
cognition for people with PD-MCI. 
 
Among studies administering cognitive training or tDCS independent of one 
another, most report short-term cognitive improvement immediately following 
interventions (Boggio et al., 2006; Costa et al., 2014; París et al., 2011; Pereira et al., 
2013), with one study reporting improvements were maintained up to 4-weeks post-
tDCS (Doruk et al., 2014). Combining standard cognitive training and tDCS in the 
present study resulted in maintenance of executive function and attention/working 
memory improvements for 12-weeks post cessation of intervention. Pairing anodal 
tDCS applied to the left DLPFC with 12-sessions of standard cognitive training may 
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induce stimulation and compensation-focussed neuronal plasticity in people with PD-
MCI, and lead to long-term improvements in cognition. 
 
The Standard Cognitive Training + tDCS group improved on language 
(Similarities, 𝑔 = .59) from pre-intervention to post-intervention, but improvements 
were not maintained at follow up assessment. This study is the first standard 
cognitive training and tDCS study to report language improvements in PD-MCI. This 
significant improvement in language abilities may be explained by the overlap 
between the language skills needed to complete the Similarities test (pre and post-
intervention) and the language skills employed during the cognitive training 
program. When completing the language activities (Smartbrain ProTM), participants 
were required to finish sentences by selecting an appropriate word and determine the 
relationship between a group of words by applying a semantic category to those 
words. Successful completion of the Similarities test also involves application of 
semantic word categories to describe the most appropriate relationship between a set 
of words (Wechsler, 2008). Participants in the Standard Cognitive Training + tDCS 
group may have trained and improved language skills that were most beneficial for 
successful performance on the Similarities language test. As described in sections 
3.2.1.3 and 3.2.2.3, however, very few cognitive training and no rTMS or tDCS 
studies have included a standardised measurement of language abilities, as language 
deficits are not typically associated with PD (Litvan et al., 2011). Only recent studies 
adopting the MDS criteria have begun to report language impairment (Cholerton et 
al., 2014; Goldman et al., 2013), with earlier studies describing PD-MCI as a decline 
in memory and frontal (attention/executive) functions (Aarsland et al., 2010). 
Whether variability in the prevalence of language deficits in PD-MCI is an artefact of 
the new MDS criteria, or reflects a cognitive domain not extensively assessed in 
preceding studies, is a direction for future research. Nonetheless, there is mounting 
evidence to indicate that people with PD-MCI demonstrate language impairment and 
the current study suggests that combining standard cognitive training with tDCS may 
alleviate this deficit. 
 
The Standard Cognitive Training + tDCS group also improved on activities 
of daily living (𝑔 = .55) from pre-intervention to post-intervention, but 
improvements were not maintained at follow up. One study has reported improved 
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activities of daily living following standard cognitive training in PD (Pompeu et al., 
2012). However, no tDCS studies have observed improvements in activities of daily 
living. Kim and Kim (2014) suggest that for older adults, compensation-focussed 
interventions will often induce frontally-mediated executive skills that transfer to 
practical improvements in daily activities. Specifically, Willis et al. (2006) found that 
compensation-focussed cognitive training of reasoning abilities in healthy older 
adults was associated with significantly less decline in activities of daily living for up 
to five years post-intervention. For the current study, anodal tDCS provided 
compensatory activation of the left DLPFC. This, paired with standard cognitive 
training, may have evoked improved frontally mediated executive skills (i.e., 
executive function improved in this group) that transferred into practical 
improvements in activities of daily living (e.g., eating tasks, dressing, doing 
hobbies). 
 
The final intervention group in this study completed tailored cognitive 
training and tDCS. This group were therefore exposed to the stimulation and 
compensation-focussed aspects of tailored cognitive training, paired with the 
additional compensation-focussed aspects of tDCS (Kim & Kim, 2014). The Tailored 
Cognitive Training + tDCS group demonstrated significant improvement on 
executive function (SOC) from pre-intervention to post-intervention (𝑔 = .41), and 
these improvements were maintained at follow up (𝑔 = .23). Among studies that 
have examined these interventions independently, executive function improvements 
have been observed following tailored cognitive training and tDCS in PD (Disbrow 
et al., 2012; Pereira et al., 2013; Sammer et al., 2006). Reuter et al. (2012) compared 
the multimodal efficacy of cognitive training (Group A), cognitive training + transfer 
training (Group B), and cognitive training + transfer training + motor training (Group 
C) for people with PD-MCI. Post-intervention, Group C demonstrated the greatest 
significant improvement on executive function tasks (Reuter et al., 2012). At a 6-
month follow up, only Group C had maintained improvements in executive function. 
Reuter et al.’s (2012) study did not include tDCS, but these findings suggest that 
combining tailored (compensation-focussed) cognitive training, with tailored 
(compensation-focussed) transfer training, and standard (stimulation-focussed) motor 




The Tailored Cognitive Training + tDCS group also improved on 
attention/working memory (LNS) from pre-intervention to follow up (𝑔 = .22), but 
no immediate post-intervention improvements were observed. As previously noted 
when describing results for the Tailored Cognitive Training group, one tailored 
cognitive training study reported significant improvement in attention in PD (Cerasa 
et al., 2014). Their study implemented group-based cognitive training, which may 
have accounted for the difference between their immediate beneficial effects and the 
current study’s delayed effects on attention/working memory. For the Tailored 
Cognitive Training + tDCS group, however, there is evidence from healthy older 
adults to support the delayed effects of tDCS on cognition. Hsu, Zanto, Anguera, 
Lin, and Gazzaley (2015) reported that compared to participants who experienced 
sham followed by real-tDCS (1-hour apart) over the left DLPFC, those who received 
real followed by sham-tDCS demonstrated increased multitasking abilities. This 
finding suggests a delay in cognitive improvement following real-tDCS. Conversely, 
one study in PD has reported significant improvement on attention/working memory 
immediately following tDCS (Boggio et al., 2006). Several reasons have been 
suggested to account for the variability in results. Namely, tDCS is relatively 
nonfocal and when targeting a cortical region associated with many complex 
cognitive functions (e.g., DLPFC) in people with a neurodegenerative disorder (e.g., 
PD-MCI), their impaired cognitive networks may alter the responsiveness of the 
brain to tDCS (Olma et al., 2013) and the extent to which beneficial effects are 
observed (Barbey, Koenigs, & Grafman, 2010). For people with PD-MCI, anodal 
tDCS may temporarily affect cognitive networks associated with specific domains of 
impairment, resulting in improved cognition (Biundo et al., 2015). Conversely, 
individuals with PD but without MCI may experience minimal or limited beneficial 
effects of tDCS to their unimpaired cognitive networks, and consequently 
demonstrate no improvements in cognition. It is apparent, however, that tDCS may 
induce immediate or delayed beneficial effects on attention/working memory, which 
are associated with an individual’s degree of neurodegeneration and presentation of 
cognitive impairment. 
 
Memory (Paragraph recall) improved from pre-intervention to post-
intervention (𝑔 = 1.36) for the Tailored Cognitive Training + tDCS group, and 
improvements were maintained at follow up assessment (𝑔 = 1.75). This is the first 
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study to report significant improvement in memory following tailored cognitive 
training and tDCS. Standard cognitive training paired with tDCS has recently shown 
memory improvements in PD-MCI, suggesting that combining these 
nonpharmacological interventions may alleviate memory deficits for people with PD 
(Biundo et al., 2015). To date, no studies administering tDCS independently have 
reported improvements in memory in PD or PD-MCI. Although from three published 
studies, only one (Pereira et al., 2013) included a standardised neuropsychological 
measurement of memory performance. Currently, one tailored cognitive training 
study has reported memory improvements in people with PD and PD-MCI (Naismith 
et al., 2013). All other published trials (excluding Reuter et al., 2012) have 
implemented interventions designed to train specific cognitive domains other than 
memory (e.g., executive function training to improve executive function; Sammer et 
al., 2006). Including a neuropsychological outcome (e.g., for memory) that is not 
representative of an intervention’s proposed mechanism of action (e.g., cognitive 
training involving visuospatial skills), will be less likely to improve post-
intervention. Memory impairment is common in PD-MCI (see Chapter 2.3.4) and 
may predict progression to PD-Dementia (Muslimovic et al., 2007). Future clinical 
trials of tDCS and tailored cognitive training need to include standardised memory 
outcomes and design interventions to target memory impairment in PD-MCI. 
 
Lastly, the Tailored Cognitive Training + tDCS group demonstrated 
significant improvement on language (Similarities, 𝑔 = 1.06) from pre-intervention 
to post-intervention, but improvements were not maintained at follow up. As with the 
Standard Cognitive Training + tDCS group, this is first study to report significant 
improvement in language following a combined tailored cognitive training and tDCS 
intervention for PD-MCI. For the Tailored Cognitive Training + tDCS group, there 
may be a specific reason as to why language improved in this group. Language 
improvements were observed on the Similarities test, but not the BNT. The MDS 
Task Force classify the Similarities test as a measure of language abilities (Litvan et 
al., 2012). However, the Similarities test is a subtest of the verbal IQ index of the 
WAIS battery of cognitive performance and involves abstract reasoning (Wechsler, 
2008). Abstract reasoning is a higher-order cognitive ability associated with 
executive function and involves ordering, comparing, analysing, and synthesizing 
information to arrive at an answer (Lezak et al., 2012). When completing the 
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Similarities test, participants need to describe in what way are two concepts/words 
alike (e.g., “...in what way are ‘acceptance’ and ‘denial’ alike?”), and this task 
requires the use of abstract reasoning (an executive skill) to synthesise information 
related to both concepts/words. As a task requiring executive function, completing 
the Similarities test may involve increased activation of the left DLPFC, which was 
also the target of tDCS for this group of participants. Compared to participants who 
completed the other interventions, participants in this group demonstrated the lowest 
baseline score for the SOC test (i.e., greatest potential to benefit from the 
intervention), and demonstrated significant post-intervention improvement on this 
executive function outcome. Participants in this group demonstrated impaired 
executive function and completed cognitive training tasks tailored to executive 
function skills. Pairing this form of tailored cognitive training with tDCS applied to 
the left DLPFC may have increased cortical activity associated with improved 
performance on SOC and Similarities, tasks involving executive and language 
abilities. 
 
To summarise, the Standard Cognitive Training group improved on three 
outcomes (memory, activities of daily living, and quality of life), the Tailored 
Cognitive Training group improved on two outcomes (attention/working memory 
and quality of life), the tDCS group improved on two outcomes (attention/working 
memory and memory), the Standard Cognitive Training + tDCS group improved on 
four outcomes (executive function, attention/working memory, language, and 
activities of daily living), the Tailored Cognitive Training + tDCS group improved 
on four outcomes (executive function, attention/working memory, memory, and 
language), and the control group did not improve on any outcome measures. A 
greater number of outcomes improved for the groups that received standard cognitive 
training combined with tDCS and tailored cognitive training combined with tDCS. 
Combining these interventions targeted impaired cognitive domains with potential 
for improvement, while stimulating neuronal plasticity in otherwise unimpaired 
domains (Kim & Kim, 2014). These results suggest that the theoretically additive 
benefits of stimulation and compensation-focussed interventions may lead to greater 
improvements in cognition and practical outcomes for people with PD-MCI. In other 
words, combining cognitive training with tDCS may provide optimal conditions for 




Several outcomes did not improve across intervention groups, which may be 
due to a number of reasons. Despite selecting outcomes in accordance with MDS 
Task Force recommendations (Litvan et al., 2012), a lack of sensitivity of some 
cognitive tests for detecting change in PD may have contributed to nonsignificant 
improvement for those tests. No improvements were observed on the Hopkin’s 
Verbal Learning Test (HVLT). The HVLT has been predominantly validated for 
detection of severe cognitive decline in dementia populations (Strauss et al., 2006). 
For example, the total score from the HVLT has shown to be more sensitive than the 
MMSE in detecting dementia (Hogervorst et al., 2001), and using a diagnostic cut off 
of 1 SD below normative data has demonstrated to be 95% sensitive and 83% 
specific in detecting dementia (Shapiro, Benedict, Schretlen, & Brandt, 1999). In 
addition, several recent cognitive training studies in PD and PD-MCI reported no 
improvements on similar verbal memory tests (París et al., 2011; Pena et al., 2014; 
Zimmermann et al., 2014). Therefore, the HVLT may not be sensitive to mild 
changes in cognition following an intervention in PD.  
 
No improvements were observed on the Boston Naming Test (BNT) or the 
Controlled Oral Word Association Test (COWAT). The COWAT is highly sensitive 
to frontally mediated deficits associated with PD, while the BNT is less sensitive and 
a more reliable indicator of moderate to severe dementia (Lezak et al., 2012). For the 
purpose of the current study, the BNT and COWAT were classified as language and 
executive function tests, respectively (Litvan et al., 2012). However, meta-analytic 
results identified a common use of semantic memory to complete both tasks, and 
individuals often demonstrate an equal and associated magnitude of impairment, on 
both tests in PD (Henry & Crawford, 2004). It is therefore possible that the BNT is 
not sensitive to mild language deficits or improvements in PD-MCI, but also that 
participants in the current study did not demonstrate a significant degree of semantic 
memory impairment or improvement (on the BNT or COWAT), following the 
cognitive training, tDCS, or cognitive training + tDCS interventions. The results 
from the current and previous studies suggest that the BNT may not be suitable for 
measuring subtle changes in language abilities in PD, suggesting that the MDS Task 
Force may need to reevaluate their recommendations for suitable language tests in 
PD-MCI (Litvan et al., 2012). 
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Recognised as the most widely used measure of global cognition, the Mini 
Mental State Examination (MMSE) was included as a primary outcome in this study. 
No intervention groups improved on the MMSE. The MMSE was first developed to 
assess frank dementia (Folstein et al., 1975) and has shown to be insensitive when 
detecting mild cognitive impairment in PD (Mamikonyan et al., 2009). 
Recommendations suggest that when using the MMSE to assess cognitive function in 
PD, it must be administered in conjunction with other cognitive tests, due to the 
MMSE’s suboptimal specificity (54%) at the recommended screening cutoff point 
(Hoops et al., 2009). Results of this study suggest that the MMSE may have not been 
sensitive to improvements in global cognition following the cognitive training and 
tDCS interventions. The Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) was 
also included as a measure of global cognition, but following a Bonferroni correction 
due to multiple comparisons, post-intervention improvements were not statistically 
significant. Compared to the Control group, however, several intervention groups 
demonstrated improvements of medium effect on the PD-CRS, post-intervention 
(e.g., tDCS group, 𝑔 = .53; Standard Cognitive Training + tDCS group, 𝑔 = .71; see 
Appendix H). In addition, the PD-CRS has been designed to reliably discriminate 
between healthy controls, cognitive intact PD, PD-MCI and PDD groups 
(Pagonabarraga et al., 2008) and is recommended by the MDS Task Force to assess 
global cognition in PD. Interpretation of improvements on this outcome were 
therefore limited by statistical constraints (a Bonferroni correction), and not 
necessarily due to limitations of the PD-CRS or a lack of beneficial effects of 
cognitive training or tDCS on this outcome. 
 
A limitation of this study was the lack of alternate forms for 
neuropsychological tests. Although common practice in many studies examining  
cognitive training and tDCS in PD (e.g., Doruk et al., 2014; Paris et al., 2011; Pena et 
al., 2014), the same neuropsychological tests were used at pre-intervention, post-
intervention, and follow up. Using the same tests across assessment intervals may 
induce practice effects during the course of a clinical trial (Benedict & Zgaljardic, 
1998). Participants may therefore demonstrate improvement on a neuropsychological 
test due to previous exposure to that test rather than improvement in the cognitive 
function being assessed (Troster, Woods, & Morgan, 2007). Although most 
participants in the current study provided anecdotal evidence indicating that they did 
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not remember completing the same neuropsychological tests at pre-intervention, this 
methodological limitation needs to be considered when interpreting the results. 
 
The cognitive training and tDCS parameters used in this study may have 
impacted nonsignificant results. No improvements were observed for visuospatial 
abilities, as measured by Hooper’s Visual Orientation Test (HVOT) and Judgement 
of Line Orientation (JLO). Successful completion of HVOT requires the use of 
perceptual organisation to rearrange pieces of an object (Strauss et al., 2006) and 
JLO primarily involves visual estimation of angled lines (Benton et al., 1994). The 
visuospatial activities administered as part of the computer-based cognitive training 
intervention in this study required identification of coordinates on a numbered grid 
and remembering time ranges on analog clocks following a perceptual delay 
(Smartbrain ProTM). It is possible that the visuospatial cognitive training tasks did not 
directly align with the visuospatial skills needed to complete HVOT and JLO. In 
addition, several hemispheric and lesion studies report more dominant involvement 
of the right posterior hemisphere (compared to the left) during completion of HVOT 
(Nadler, Grace, White, Butters, & Malloy, 1996) and JLO (Gur et al., 2000; Ng et al., 
2001; Ng et al., 2000). In this study, tDCS was applied to a cortical region that is not 
associated with visuospatial performance (the left DLPFC). Stimulation of the left 
DLPFC was therefore not likely to improve visuospatial abilities. The current results 
support recent cognitive training studies (Cerasa et al., 2014; Petrelli et al., 2014; 
Zimmermann et al., 2014) and a tDCS study (Doruk et al., 2014), which also 
reported no improvement in visuospatial tasks. It is recommended that future trials 
match visuospatial cognitive training activities with the visuospatial abilities assessed 
by standardised cognitive tests, and explore the potential of noninvasive brain 
stimulation over the right posterior hemisphere for improving visuospatial function 
in people with PD-MCI.  
 
The current study was limited by the lack of neuroimaging (e.g., fMRI) to 
examine whether the different interventions were associated with homogeneous or 
heterogeneous patterns or changes in cortical activation. One tDCS study in PD has 
administered fMRI immediately following stimulation and reported functional 
network changes in left DLPFC and left temporo-parietal cortex, which were 
associated with verbal fluency performance (Pereira et al., 2013). fMRI has also been 
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administered following cognitive training in PD. Cerasa et al. (2014) reported 
activation of the superior parietal cortex associated with increased attentional 
performance and activation of the DLPFC associated with increased executive 
function. It could be inferred that similar networks of activation may have been 
present in the cognitive training, tDCS, and cognitive training + tDCS groups in the 
current study. However, definitive conclusions cannot be made about whether 
stimulation focussed or compensation focussed interventions induce the greatest 
degree of synaptic plasticity and associated improvement in cognitive function for 
people with PD-MCI.  
 
Identifying PD-MCI using a cutoff of one standard deviation (SD) below 
normative data may have been a limitation in the current study. Although within 
recommendations of the MDS Task Force, PD-MCI is highly heterogeneous and a 
proportion of individuals often return back to normal cognition, due to normal 
fluctuations and effects of medication on cognitive functioning (Loftus et al., 2015; 
Yarnall, Rochester, & Burn, 2013). Using the most liberal (<1 SD) cutoff may have 
resulted in false-positive diagnoses of PD-MCI (i.e., including participants with 
normal cognition), when participants were experiencing a mild and temporary 
fluctuation in their cognitive functioning. Capturing false-positive diagnoses at pre-
intervention assessments may then result in people ‘reverting’ back to normal 
cognition at post-intervention and follow-up assessments, which compromises the 
reliability of the interventional effects. Having said this, daily levodopa equivalent 
dose was controlled in statistical analyses and all neuropsychological assessments 
were completed during participants’ ‘ON’ stage of medication use. Controlling these 
factors would limit the likelihood of false-positive diagnoses. 
 
Final limitations of this study were the sample size and the lack of matching 
exposure between intervention groups. For sufficient statistical power, 54 
participants (9 per group) were needed to detect moderate effects (Faul et al., 2007). 
However, only 42 participants met inclusion criteria and 4 participants dropped out 
prior to follow up assessment. Although larger than the average sample size (N = 34, 
see Chapter 3) of previous controlled trials of cognitive training and non-invasive 
brain stimulation in PD, this study was somewhat underpowered which may have 
impacted the nonsignificant results. Participants allocated to the cognitive training 
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groups (standard or tailored) completed 12 sessions of training. Whereas, participants 
in the cognitive training + tDCS groups completed 12 sessions of cognitive training 
and 4 sessions of tDCS. Completing both interventions exposed participants to a 
greater number of therapeutic sessions designed to improve cognition. Additional 
therapeutic sessions may have therefore produced purely additive beneficial effects 
on neuropsychological outcomes due to increased exposure during the intervention. 
Lastly, six outcomes demonstrated no significant improvement following the 
intervention and several hypotheses were either not, or only partially, supported. As 
noted in Chapter 3, research examining nonpharmacological interventions for PD-
MCI is in its relative infancy and the results of this study need to be interpreted as 
preliminary findings. 
 
4.6.3 Directions for Future Research 
Future studies examining the therapeutic potential of cognitive training and 
tDCS need to include neuropsychological outcomes that are sensitive to changes in 
cognition in PD-MCI. Goldman et al. (2015) reported the first recommendations for 
the most optimal number (10 tests, 2 per domain) and selection of tests for measuring 
cognitive performance in PD. However, the Trail Making Test (Part A) was 
recommended as a better performing measure of attention/working memory deficits, 
which conflicts with previous studies reporting low sensitivity of the Trail Making 
Test (Part A) for detecting frontal impairments in PD (Kaszás et al., 2012). More 
studies are needed to determine which neuropsychological tests are most appropriate 
for identifying impairments and measuring change in PD-MCI, and future 
researchers need to ensure that alternate forms of neuropsychological tests are used 
to limit potential practice effects in clinical trials (for exhaustive compendiums of 
tests see: Lezak, Howieson, & Loring, 2012 and Strauss et al., 2006). 
 
Methodological parameters of cognitive training and tDCS interventions need 
to be considered in future clinical trials. The results of this study suggest that the 
visuospatial outcomes may have not been representative of the visuospatial skills 
needed to complete the computer-based visuospatial activities. In addition, applying 
tDCS to the left DLPFC was not likely to improve visuospatial abilities that are 
predominantly mediated by the right posterior hemisphere. Future studies need to 
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implement cognitive training modalities (e.g., standard and/or tailored) and tDCS 
locations (e.g., DLPFC, posterior cortices) which consider the outcomes most 
representative of each intervention’s cognitive functions targeted for improvement. 
 
Neuroimaging (molecular, structural, and functional) has significantly 
expanded our understanding of the complex neurobiological changes associated with 
PD (Weingarten, Sundman, Hickey, & Chen, 2015). For example, imaging 
techniques discovered the cortico-basal ganglia-thalamocortical dorsolateral 
prefrontal cortex loop, which is implicated by dopamine depletion from the putamen 
to the dorsal caudate, and associated with executive function decline in PD 
(Weingarten et al., 2015; Xu et al., 2016). Studies utilising imagine techniques have 
also demonstrated the important impact of hippocampal degeneration which often 
leads to memory impairment in the later stages of PD (Calabresi, Castrioto, Di 
Filippo, & Picconi, 2013). Including neuroimaging as a primary outcome in future 
cognitive training and tDCS studies will provide evidence of any cognitive changes 
indicated by neuropsychological tests, and explore whether individuals with single or 
multiple domain cognitive impairments demonstrate greater cortical activation post-
intervention and are more likely to benefit from these therapeutic effects. 
 
Future studies may want to implement a more conservative cut off score (e.g., 
< 2 SDs below normative data) for identification of PD-MCI. A more conservative 
diagnostic criterion would reduce the possibility of including participants who 
demonstrate a temporary and mild decline in cognition, and whom do not meet a 
formal identification of PD-MCI (Yarnall et al., 2013). The use of 2 SDs below 
normative data as an indicator of impaired performance on a neuropsychological test 
has demonstrated good sensitivity and specificity in PD-MCI (Goldman et al., 2013). 
It is important to note, however, that severe cognitive decline can negatively impact 
cognitive abilities beyond the potential of cognitive training or tDCS, resulting in 
participants that may not respond to nonpharmacological interventions (Kim & Kim, 
2014).  It is therefore suggested that future studies examine the potential of these 
interventions within populations of varying age, cognitive impairment, years of 
education, disease duration, and severity of Parkinsonian symptoms. Conducting 
rigorous RCTs of cognitive training and tDCS across the spectrum of the disease 
course (e.g., de novo to advanced PD) has the potential to determine if and when 
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these interventions (stimulation and compensation focussed) are most efficacious for 
preventing, alleviating, and potentially halting, the progression of cognitive decline 
in PD-MCI. 
 
Results from this study suggest that tailored cognitive training, tDCS, tailored 
cognitive training + tDCS, and standard cognitive training + tDCS can lead to long-
term improvements (12 weeks) in executive function, attention/working memory, 
memory, and quality of life. As explained, very few previous trials of these 
interventions have included long-term follow-up assessments of cognition and 
practical outcomes. It is therefore recommended that future studies include follow-up 
assessments (e.g., 3, 6 and 12 months) to build upon the current results, and to 
explore whether the individual or combined therapeutic potential of these 
interventions are more likely to lead to long-term improvements cognition, activities 
of daily living, and quality of life for people with PD-MCI.  
 
4.7 Chapter Summary 
 
This chapter presented the findings of the first randomised controlled trial of 
standard cognitive training, tailored cognitive training, tDCS, standard cognitive 
training + tDCS, and tailored cognitive training + tDCS for mild cognitive 
impairment in PD. This study had several strengths. First, this clinical trial was 
conducted in accordance with the CONSORT statement for RCTs of 
nonpharmacological interventions (Boutron et al., 2008) and provides Level III 
evidence in support of cognitive training, tDCS, and cognitive training + tDCS for 
PD-MCI. Second, the rate of participant attrition was low (< 10%) with only 4 
participants dropping out of the study prior to follow-up assessments. Third, 
cognitive performance was measured using an extensive battery of 
neuropsychological tests, in-line with MDS Task Force recommendations for Level 
II diagnostic criteria of PD-MCI. Results of this study supported previous clinical 
trials suggesting that cognitive training and tDCS can improve executive function, 
attention/working memory, and memory in PD. However, this study was the first to 
explore the combined therapeutic potential of cognitive training and tDCS. Results 
indicated that combining these therapeutic techniques may increase their potential to 
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alleviate deficits in cognition, activities of daily living, and quality of life for people 
with PD-MCI, as opposed to administering these interventions independently. It is 
recommended that future studies examine the effects of standard and tailored 
cognitive training and different parameters of tDCS (e.g., cortical site of stimulation), 
in combination with neuroimaging techniques, and among individuals at variable 
stages of PD, to determine the long-term efficacy of these nonpharmacological 































The overarching aim of this research was to examine the therapeutic potential 
of nonpharmacological interventions for mild cognitive impairment in Parkinson’s 
Disease (PD-MCI). Three studies were conducted and the corresponding chapters 
provide a thorough discussion of each study’s rationale, methodology, results, 
implications, limitations, and recommendations for future research. This final chapter 
will provide a summary of the research findings, followed by a discussion of the 
findings within the context of the current literature. This chapter will also provide 
recommendations for future studies examining cognitive training and brain 
stimulation interventions for people with PD-MCI. 
 
5.2 Summary of Research Findings 
 
5.2.1 Study 1: Prevalence and Subtypes of Mild Cognitive Impairment in PD 
Study 1 was the first application of the Movement Disorder Society (MDS) 
Task Force criteria for PD-MCI in an Australian sample of people with PD. There 
were several main findings from Study 1. First, 64.3% of participants met MDS Task 
Force criteria for PD-MCI when applying a 1 SD cut off to classify cognitive 
impairment on a neuropsychological test. Among those with PD-MCI, 93.4% 
presented with multiple domain impairment (i.e., impaired test performance in more 
than one cognitive domain). When examining individual cognitive domains, 
attention/working memory (66.7%), executive function (62.2%), and memory 
(66.7%) were most frequently impaired. The overall frequency of PD-MCI decreased 
from 64.3% to 28.6% after applying a 2 SD cut off to classify cognitive impairment. 
The frequency of subtype classifications remained stable, with multiple domain 
impairment maintained as the most frequent subtype (90%) even when using this 




The second main finding from Study 1 was that compared to participants with 
normal cognition, participants classified as PD-MCI performed significantly worse 
across all cognitive domains (excluding one test of executive function, Stockings of 
Cambridge, p = .76). However, participant groups (PD-MCI vs Normal Cognition) 
did not differ on demographic variables (e.g., age, years of education, disease 
duration). The findings from Study 1 provide evidence to support the heterogeneous 
presentation of cognitive impairments in PD-MCI. Compared to individuals with 
normal cognition and PD, those with PD-MCI may perform significantly worse 
across the spectrum of cognitive domains.  
 
5.2.2 Study 2: A Meta-Analysis of Cognitive Training and Non-Invasive Brain 
Stimulation for Cognition in PD 
Study 2 was the first meta-analysis of randomised controlled trials of standard 
and tailored cognitive training and non-invasive brain stimulation for the 
improvement of cognition in PD. The only controlled trial of tDCS did not provide 
sufficient data for inclusion and was therefore excluded from the study. There were 
several main findings in Study 2. First, improvements in executive function were 
observed when standard and tailored cognitive training studies were combined (𝑔 = 
.42; 95% CI = .15 to .68). When standard and tailored cognitive training were 
considered separately, the tailored effect estimate reduced to non-significance (𝑔 = 
.30; 95% CI = -.16 to .76). Two rTMS studies were included in the meta-analysis 
(Benninger et al., 2011; Benninger et al., 2012), but did not statistically improve 
executive function (𝑔 = .40, 95% CI = -.14 to .93). Second, significant pooled effects 
for attention/working memory were observed when standard and tailored cognitive 
training were combined (𝑔 = .23, 95% CI = .02 to .44) and for standard cognitive 
training alone (𝑔 = .29, 95% CI = .04 to .53). Similar to the results for executive 
function, only one rTMS study examined attention/working memory and the effect 
was not significant (𝑔 = .34, 95% CI = -.42 to 1.11). The third and final significant 
finding from Study 2 was that both standard and combined cognitive training studies 
improved memory in PD (standard: 𝑔 = .35, 95% CI = .03 to .66; combined: 𝑔 = .33, 
95% CI = .06 to .59). No significant pooled effects were identified for visuospatial 




Study 2 provided a synthesis of results from all published controlled trials of 
standard cognitive training, tailored cognitive training, tDCS, and rTMS studies in 
PD. The findings from Study 2 indicated that standard and tailored cognitive training 
may improve executive function, attention/working memory, and memory.  
 
5.2.3 Study 3: A Randomised Controlled Trial of Cognitive Training and 
Transcranial Direct Current Stimulation in PD-MCI 
Study 3 was the first randomised controlled trial comparing standard 
cognitive training, tailored cognitive training, tDCS, standard cognitive training + 
tDCS, and tailored cognitive training + tDCS for mild cognitive impairment in PD. 
Overall, differential rates of statistically significant improvements in cognition, 
activities of daily living, and quality of life were observed across the intervention 
groups.  
 
The Standard Cognitive Training group improved on memory (F [2, 104] = 
5.24, p = .007), activities of daily living (F [2, 104] = 11.29, p < .001), and quality of 
life (F [2, 95] = 7.21, p = .001), and the Tailored Cognitive Training group improved 
on attention/working memory (F [2, 95] = 6.62, p = .002) and quality of life (F [2, 
95] = 12.48, p < .001). Study 3 was the first randomised controlled trial to report 
improved quality of life following standard or tailored cognitive training in people 
with PD-MCI. 
 
The tDCS group improved on attention/working memory (F [2, 103] = 4.06, 
p = .020) and memory (F [2, 104] = 17.82, p < .001), and the Standard Cognitive 
Training + tDCS group improved on executive function (F [2, 93] = 10.70, p < .001), 
attention/working memory (F [2, 103] = 35.05, p < .001), language (F [2, 92] = 5.23, 
p = .007), and activities of daily living (F [2, 104] = 3.40, p = .037). The final 
intervention group completed tailored cognitive training + tDCS and improved on 
executive function (F [2, 93] = 12.00, p < .001), attention/working memory (F [2, 
95] = 5.11, p = .008), memory (F [2, 104] = 12.09, p < .001), and language (F [2, 92] 
= 17.43, p < .001). Study 3 was the first RCT of cognitive training and/or tDCS to 




The findings from Study 3 suggest that cognitive training, tDCS, and 
cognitive training combined with tDCS may improve executive function, 
attention/working memory, memory, language, activities of daily living, and quality 
of life for people with PD-MCI.  
 
5.3 Mild Cognitive Impairment in PD: Contribution of Research Findings to the 
Current Literature 
 
In addition to the cardinal motor symptoms of PD, it is now acknowledged 
that a significant proportion of people with PD experience impaired cognitive 
functioning (Goldman & Weintraub, 2015). Cognitive deficits are associated with a 
multitude of symptoms that worsen quality of life in PD (Zhang et al., 2016), and the 
increasing prevalence of PD-MCI, highlights the need for research to explore the 
potential of pharmacological and nonpharmacological interventions for alleviating 
and potentially halting the progression of cognitive impairments in PD. 
 
5.3.1 Heterogeneity of PD-MCI 
Research indicates that cognitive impairment is highly heterogeneous in PD 
(Goldman & Weintraub, 2015; Kehagia et al., 2010). Individuals often present with 
differing combinations of impairments across the spectrum of cognitive domains 
(Cholerton et al., 2014; Marras et al., 2013). The findings from Study 1 support and 
extend the understanding of PD-MCI. Study 1 demonstrated that at a 1 SD cut off or 
2 SD cut off below normative data, 64% (at a 1 SD cut off) and 28% (at a 2 SD cut 
off) of participants met the diagnostic criteria for PD-MCI. At both cut off levels, 
multiple domain impairment was more prevalent (93% to 90%) than single domain 
impairment (7% to 10%). Furthermore, 20 different patterns of impairments were 
identified at 1 SD and 10 different patterns of impairments identified at 2 SDs. 
Irrespective of the severity of cognitive impairments in Study 2, PD-MCI was 
heterogeneous and included deficits across all cognitive domains.  
 
Studies examining neuropsychological and cognitive deficits in PD-MCI 
describe and subtype behavioural representations of cognitive impairments (Kalbe et 
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al., 2016), but these studies do not explore the underlying pathophysiological 
processes that lead to the development of cognitive impairments in PD.  Research is 
beginning to address the role of genetic characteristics and protein/neurotransmitter 
abnormalities, and their association with PD-MCI (Cosgrove et al., 2015). For 
example, Williams-Grey (2009) and colleagues examined longitudinal (5 year) 
changes of catecholaminergic and cholinergic deficits in PD. For those with PD-
MCI, executive function impairment was associated with catecholaminergic changes 
involving frontostriatal dopaminergic deficits, but limited cholinergic interaction. For 
those with PD-Dementia, early cholinergic deficits were the prominent factor 
associated with severe cognitive decline (Williams-Gray et al., 2009). A review of 
biomarkers and treatments of cognitive impairment in PD (Svenningsson et al., 
2012), reported acetylcholine deficiency in posterior cortical regions as a biomarker 
contributing to memory, language and visuospatial deficits. In addition, Kehagia et 
al. (2010) proposed the ‘dual syndrome’ hypothesis to describe how two distinct 
genetic syndromes (executive and posterior cortical) may be associated with 
executive function and memory/visuospatial abilities in PD. Nombela et al. (2014) 
recently supported this hypothesis by demonstrating that a specific genetic variation 
(rs4680 polymorphism of the COMT gene) modulated executive function and two 
other genetic variations (APOE allelic and MAPT haplotype) independently 
modulated posterior cortical functions of memory and visuospatial abilities, 
respectively. These studies provide preliminary evidence to suggest that 
neurotransmitter abnormalities and genetic characteristics are associated with 
cognitive impairments in PD, and that these factors may predispose the onset of 
cognitive decline in PD and other neurodegenerative disorders. 
 
The findings from Study 1 support the results from recent neuropsychological 
and pathophysiological studies indicating that PD-MCI is highly heterogeneous.  PD-
MCI involves complex pathological changes across multiple cortical regions, and 
those changes may present as mild, moderate, and severe deficits in cognitive 




5.3.2 Diagnostic criteria for PD-MCI 
Due to the heterogeneous presentation of cognitive deficits in PD, a 
Movement Disorder Society (MDS) Task Force developed diagnostic criteria in 
attempt to standardise assessment of cognitive impairments (Litvan et al., 2012). 
Since the development of the PD-MCI criteria, several studies have examined its 
potential to accurately diagnose and subtype PD-MCI (Bezdicek et al., 2016; 
Goldman et al., 2013). Any standardised criteria developed for international use 
needs to be validated and examined across multiple populations, and Study 1 of this 
thesis was the first application of the MDS criteria for PD-MCI in an Australian 
sample.  
 
Study 1 applied the Level II (comprehensive assessment) MDS criteria and 
identified the previously described presentation of cognitive impairments in PD-
MCI. In summary, more than 60% of the sample met PD-MCI diagnostic criteria and 
the multiple domain subtype was significantly more prevalent than the single domain 
subtype. Studies preceding the MDS criteria often reported a much lower overall 
prevalence of PD-MCI (19% to 38%), and single domain impairment was reported as 
more frequent than multiple domain impairment (Caviness et al., 2007; Goldman et 
al., 2012; Litvan et al., 2011).  
 
Study 1 identified several issues with the MDS criteria that may account for 
this variability between prevalence estimates and subtyping frequencies of PD-MCI. 
First, the new diagnostic criteria is less stringent when diagnosing multiple domain 
compared to single domain subtypes, which will invariably identify more people 
with multiple domain impairment (Goldman et al., 2013). The results of Study 1 
accentuated this issue, with almost all participants with PD-MCI meeting the criteria 
for the multiple domain subtype. Second, variable use of SD cut off scores will 
produce varying estimates of the prevalence of PD-MCI. The findings from Study 1 
accentuate this issue, with a significant proportion of participants (64%) meeting PD-
MCI diagnosis at the 1 SD cut off and this figure reduced (28%) when using the 2 
SD cut off. Third, differential weighting and selection of tests per cognitive domain 
will likely bias subtyping statistics of PD-MCI. Study 1 did, however, control for this 
issue by administering an even number of tests (two) per cognitive domain. Several 
recent studies, however, administered an unequal number of tests (3 to 7) in an 
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attempt to validate the diagnostic criteria (Cholerton et al., 2014; Goldman et al., 
2013). Using an unequal number of tests will increase the risk of Type 1 errors and 
may falsely inflate the frequency of PD-MCI (Loftus et al., 2015). 
Despite the issues raised regarding the use of the MDS diagnostic criteria to 
identify PD-MCI, findings from Study 1 supported recent applications of the criteria 
(e.g., Geurtsen et al., 2014) and provided evidence to support its future refinement 
and utility (Bezdicek et al., 2016). Section 5.4.1 provides recommendations to 
address the issues with the current diagnostic criteria for PD-MCI. 
 
5.3.3 Nonpharmacological interventions for PD and PD-MCI 
Current research exploring pharmacological treatments (e.g., cholinesterase 
inhibitors and memantine) for PD-MCI provides preliminary evidence in support of 
their potential to alleviate cognitive impairments in PD (Goldman & Weintraub, 
2015; Wang et al., 2014). Many people with PD are, however, burdened by 
polypharmacy and experience a range of adverse side effects due to pharmacological 
treatments (Lai et al., 2011). Recent clinical trials have examined the potential of 
nonpharmacological interventions (e.g., cognitive training and non-invasive brain 
stimulation) for cognitive impairments in PD, and provide evidence to support their 
beneficial effects on cognition (Boggio et al., 2005; París et al., 2011). Study 2 
reviewed all controlled and uncontrolled trials of standard cognitive training, tailored 
cognitive training, tDCS, and rTMS. Significant methodological differences were 
identified across studies, which limited interpretation of the beneficial effects of 
these interventions. Study 2 therefore included a meta-analysis of all controlled trials 
to provide an accurate estimate of the potential of these interventions for improving 
cognition in PD. 
 
Study 2 identified that standard and tailored cognitive training may improve 
executive function, attention/working memory, and memory in PD. No beneficial 
effects were identified for rTMS on cognition in PD, and the only controlled trial of 
tDCS did not provide sufficient data to be included in the meta-analysis. Overall, the 
findings from Study 2 suggested that cognitive training may alleviate deficits in 
executive function, attention/working memory, and memory in PD, but the findings 
were limited by the few controlled trials available for meta-analysis. In accordance 
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with the conclusions from Study 2 and as recommended by Hindle et al. (2013), 
“...there is an urgent need for rigorous RCTs of nonpharmacological, noninvasive 
treatments for cognitive impairment and dementia in PD” (p. 1048).  
 
To address this gap in the literature, Study 3 used an RCT design to compare 
standard cognitive training, tailored cognitive training, tDCS, standard cognitive 
training + tDCS, and tailored cognitive training + tDCS for improvement of 
cognition, activities of daily living, and quality of life in PD-MCI. In accordance 
with Kim and Kim’s (2014) theoretical framework, standard cognitive training is a 
stimulation-focussed intervention that broadly enhances cognitive function by 
changing existing neural connections in the brain. Tailored cognitive training is a 
stimulation and compensation-focussed intervention aimed at improving specific 
cognitive functions that have been impacted by neural degeneration (Kim & Kim, 
2014). The tDCS used in this study was a compensation-focussed intervention to 
increase cortical activity in the left DLPFC. The Scaffolding Theory of Ageing and 
Cognition suggests that older adults experience increased compensatory activation 
(i.e., ‘scaffolding’) of secondary neural circuits in the prefrontal cortices, when 
primary neural circuits are diminished during a complex cognitive task (Goh & Park, 
2009). tDCS therefore provided additional compensatory activation of the left 
DLPFC for people with PD-MCI. In Study 3, standard cognitive training combined 
with tDCS and tailored cognitive training combined with tDCS were stimulation and 
compensation focussed interventions, designed to provide optimal conditions for 
neural plasticity and associated improvements in cognition.  
 
5.3.3.1 Standard Cognitive Training. In Study 3, the Standard Cognitive 
Training group improved on memory, activities of daily living, and quality of life. 
Previous studies had demonstrated significant improvements in memory and 
activities of daily living following standard cognitive training in PD (Petrelli et al., 
2014; Pompeu et al., 2012). Study 3 was the first RCT to report improved quality of 
life. París et al. (2011) administered the same cognitive training software (Smartbrain 
ProTM), but found no change in quality of life outcomes. This null result may have 
been impacted by a ceiling effect during cognitive training, given that Paris et al.’s 
(2011) sample included participants without cognitive impairments (i.e., participants 
without the ability to improve their cognition). Nonetheless, cognitive impairment is 
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associated with worsened quality of life for people with PD (Klepac et al., 2008), and 
Study 3 was the first clinical trial to provide evidence in support of standard 
cognitive training for improving this domain. 
 
5.3.3.2 Tailored Cognitive Training. The Tailored Cognitive Training group 
improved on attention/working memory and quality of life. The beneficial effect of 
tailored cognitive training on attention/working memory was delayed with no 
immediate post-intervention improvement, but presented 12-weeks post-intervention 
cessation. One tailored cognitive training study has reported immediate 
improvements in attentional abilities post-intervention (Cerasa et al., 2014). This 
study, however, conducted group-based cognitive training which may have provided 
additional therapeutic effects (e.g., social interaction) leading to immediate (as 
opposed to delayed) improvements in attention/working memory. The Tailored 
Cognitive Training group also improved on quality of life and Study 3 was the first 
trial in PD to report improvements in this domain following tailored cognitive 
training. The neurobiological mechanism responsible for improvement in quality of 
life following cognitive training is currently not known. Research in dementia 
suggests that the beneficial effects of cognitive training for quality of life may be 
reliant upon cognitive improvement during training, and quality of life is less likely 
to improve if no cognitive benefits are observed (Woods et al., 2006). Study 3 
provides preliminary evidence to suggest that tailored cognitive training, a 
stimulation and compensation-focussed intervention, may induce neural plasticity 
that acts to improve attention/working memory and quality of life in people with PD-
MCI. 
 
5.3.3.3 Transcranial Direct Current Stimulation (tDCS). In Study 3, the 
tDCS group improved on attention/working memory and memory. These results 
were supported by earlier studies examining the effects of tDCS in PD and AD. 
Boggio et al. (2006) demonstrated improvements in attention/working memory 
following tDCS in PD, and three studies in AD reported improved memory following 
tDCS (Boggio et al., 2012; Boggio et al., 2009; Ferrucci et al., 2008). For Study 3, 
the proposed mechanism of action for tDCS was considered in accordance with 
Scaffolding Theory of Ageing and Cognition (Goh & Park, 2009). These findings 
therefore suggest that anodal tDCS over left DLPFC may induce compensatory 
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activation of cortical networks associated with attention/working memory and 
memory in PD-MCI, and thereby alleviate impairment in these cognitive domains. 
 
5.3.3.4 Standard Cognitive Training + tDCS. The Standard Cognitive 
Training + tDCS group improved on executive function, attention/working memory, 
language, and activities of daily living. A number of studies have combined 
cognitive training with non-invasive brain stimulation (tDCS and rTMS) in AD and 
one study has explored the combination of these interventions in PD. These studies 
reported improvements in attention and memory (Biundo et al., 2015) and global 
cognition (Bentwich et al., 2011; Rabey et al., 2013), but no beneficial effects for 
executive function, language, or activities of daily living. Study 3 was the first RCT 
of cognitive training and tDCS to report improvements in language abilities and 
activities of daily living in PD-MCI. The novelty of these findings may be the 
consequence of no cognitive training, rTMS or tDCS studies having included a 
standardised measurement of language abilities in PD (Litvan et al., 2011). In 
addition, only one previous cognitive training study has provided evidence to support 
a nonpharmacological intervention for improving activities of daily living (Pompeu 
et al., 2012). Despite the limited evidence available to support these results, Study 3 
demonstrated that standard cognitive training combined with tDCS may have 
induced stimulation and compensation-focussed effects on neural activity to improve 
cognitive function and activities of daily living in PD-MCI. 
 
5.3.3.5 Tailored Cognitive Training + tDCS. In Study 3, the final 
intervention group completed tailored cognitive training + tDCS and improved on 
executive function, attention/working memory, memory, and language domains. 
Several studies examining the potential of cognitive training and tDCS 
independently, have also reported improvements in executive function (Pereira et al., 
2013), attention/working memory (Boggio et al., 2006; Cerasa et al., 2014), memory 
(Naismith et al., 2013). Study 3 was the first RCT of tailored cognitive training and 
tDCS to report improvements in language abilities in PD-MCI. As noted in Chapter 
4.6.1, the improvement in language abilities in this group may be attributed to the 
increased activation of the left DLPFC following tDCS and the use of executive 
skills (i.e., abstract reasoning) to complete the language task (Similarities test), which 
are also mediated by cortical networks within the left DLPFC. Tailored cognitive 
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training + tDCS may therefore induce neural plasticity as a stimulation and 
compensation-focussed intervention, thereby alleviating cognitive deficits in PD-
MCI. 
Overall, Study 3 demonstrated that compared to the groups that received 
cognitive training or tDCS independently, a greater number of outcomes improved 
for the groups that received cognitive training combined with tDCS. This result 
suggests that combining stimulation and compensation-focussed interventions may 
lead to greater improvements in cognition and practical outcomes for people with 
PD-MCI. These findings add to the current literature to support nonpharmacological 
interventions as potential therapies for improving deficits in cognition, activities of 
daily living, and quality of life for people with PD-MCI.  
 
5.4 Recommendations for Future Research 
 
Comprehensive recommendations and directions for future research were 
discussed in the preceding chapters. These recommendations are summarised in the 
following section. 
 
5.4.1 Assessment and subtyping of cognition in PD-MCI 
The findings from the research in this thesis highlighted several issues 
associated with the assessment and subtyping of PD-MCI. Specifically, future studies 
need to: 
1. Examine and report PD-MCI frequency statistics at differing 
diagnostic cut off scores. This research identified that applying different 
standard deviation cut off scores to classify PD-MCI significantly 
influences the frequency statistics used to describe the prevalence of PD-
MCI. Future studies need to report PD-MCI frequency statistics at 1, 1.5, 
and 2 SD cut off scores to explore whether cognitive impairments and 
subtype classifications are associated with increasing severity of PD-MCI. 
Reporting these statistics will ensure future studies are transparent in their 
assessment of PD-MCI and will increase the broader understanding of 
these cognitive impairments in PD. This will also translate to the allied 
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health setting in terms of informing diagnosis of PD-MCI.  
 
2. Report sources of normative data that are used to establish diagnoses 
of PD-MCI. Selecting appropriate normative data is equally as important 
as choosing a reliable and valid neuropsychological test (Strauss et al., 
2006). Using normative data that is not a demographic match to a 
participant’s characteristics may lead to false-positive or false-negative 
classifications of PD-MCI, impacting the accuracy of prevalence and 
subtyping statistics. Therefore, future studies need to provide a 
description and reference list of their normative data sets to ease 
exposition and interpretation of their results. Reporting sources of 
normative data sets in peer-reviewed journals will also provide physicians 
and geriatricians with comparative statistics for accurate diagnoses and 
potentially increase community and government awareness of mild 
cognitive impairment in PD. 
 
3. Explore the diagnostic accuracy of a more conservative criterion for 
the multiple domain subtype of PD-MCI. The current MDS criteria for 
PD-MCI classifies individuals as the multiple domain subtype if they 
demonstrate impaired performance on one neuropsychological test in any 
two or more cognitive domains. The single domain subtype applies a 
more conservative criterion and requires impaired performance on two 
neuropsychological tests in any one domain. The more liberal criterion for 
the multiple domain subtype may be associated with the recent increase in 
the frequency of multiple domain PD-MCI. Among participants classified 
as PD-MCI, Study 1 identified more than 90% of those participants as the 
multiple domain subtype. Future studies need to explore what effect a 
conservative criterion (i.e., impairment on two tests in any two or more 
domains) will have on frequency estimates of multiple domain PD-MCI 
and whether this criterion will increase diagnostic accuracy of cognitive 
impairments in PD.  
4. Administer a consistent and equal number of neuropsychological 
tests to each cognitive domain. Study 1 addressed this issue by including 
two neuropsychological tests per cognitive domain. However, recent 
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studies have applied an inconsistent number and weighting of tests to 
cognitive domains (e.g., Cholerton et al., 2014), which increases the risk 
of Type I errors and may inflate the frequency of PD-MCI. In accordance 
with recommendations by Goldman et al. (2015), future studies should 
administer two tests per cognitive domain to limit biases in the diagnosis 
and subtyping of PD-MCI.  
 
5. Apply consistent classifications of neuropsychological tests used to 
measure cognitive domains. This research identified that recent studies 
often varied when classifying neuropsychological tests to specific 
cognitive domains. There is considerable overlap across many cognitive 
abilities (e.g., executive function and working memory) and 
neuropsychological tests often involve the use of more than one cognitive 
ability. For research purposes, however, consistent classification of 
neuropsychological tests will increase the generalisability of research 
findings and assist with standardised examination of cognitive 
impairments in PD-MCI. For health professionals, consistency across 
research will provide evidence to increase uniformity of cognitive 
assessments in clinical settings and assist with referrals to appropriate 
specialist and treatment services for people with PD-MCI.  
 
6. Include standardised assessment of processing speed. The MDS 
criteria for PD-MCI does not identify processing speed as an independent 
cognitive domain (Litvan et al., 2012), yet impaired processing speed is 
often associated with worse performance on specific neuropsychological 
tests (e.g., for executive function) in PD. It is recommended that future 
studies include standardised assessment of processing speed to account 
for potential comorbid associations between cognitive domains and 





5.4.2 Methodological Parameters of Cognitive Training and tDCS Interventions 
Studies 2 and 3 identified a number of methodological parameters as limiting 
factors. Future clinical trials need to: 
1. Recruit a large sample to ensure sufficient statistical power in RCTs. 
Study 3 required 54 participants (9 per group) to ensure sufficient 
statistical power. Only 42 participants (7 per group) met inclusion criteria. 
Study 3 was somewhat underpowered and this factor may have affected 
the non-significant results. It is difficult to recruit large groups of 
participants for clinical trials in PD, specifically in the advanced stages of 
the disease when individuals lose their ability to function independently 
(i.e., a caregiver is required for travel and daily activities). It is 
recommended, however, that future RCTs exploring the potential of 
cognitive training and tDCS ensure they recruit participant samples to 
satisfy the requirements of sufficient statistical power. 
 
2. Ensure cognitive outcomes align with the proposed mechanisms of 
action of cognitive training interventions. This research identified that 
computer-based cognitive training programs include many cognitive tasks 
that require the use of different abilities, across the spectrum of cognitive 
domains. It is important that future researchers align the proposed 
mechanism of action of a cognitive training intervention (e.g., working 
memory) with those outcomes that actually assess the corresponding 
cognitive domain. Implementing this method will likely increase the 
probability of significant improvements in cognitive outcomes following 
cognitive training interventions. Determining which cognitive outcomes 
are most responsive to change following cognitive training interventions, 
will provide evidence for clinicians to recommend potential cognitive 
training programs and regimes to alleviate cognitive deficits and improve 
quality of life for people with PD-MCI. 
 
3. Use neuropsychological outcomes that are sensitive to changes in 
cognition in PD-MCI. This research highlighted that some 
neuropsychological outcomes used in previous studies and recommended 
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by the MDS Task Force, may not be sensitive to changes in cognition in 
PD-MCI. Including these outcomes in RCTs of cognitive training and 
tDCS will often result in null post-intervention effects and potentially 
underestimate the beneficial effects of these interventions on cognition. It 
is recommended that future researchers consult Strauss et al. (2006) and 
Lezak et al. (2012) for more detailed recommendations of 
neuropsychological tests that are most appropriate for detecting changes 
in cognition in PD. It is also recommended that practising 
neuropsychologists remain informed of the refinement and future changes 
to the MDS criteria (Goldman et al., 2015), and consult specialized 
compendiums of neuropsychological tests to ensure the most appropriate 
tests are administered during standardised assessments of cognition in PD 
and PD-MCI. 
 
4. Explore the efficacy of cognitive training and tDCS with varying 
lengths and frequency of interventions. This research identified that 12 
sessions of cognitive training and 4 sessions of tDCS over 4 weeks led to 
improvements in cognition, activities of daily living, and quality of life in 
PD-MCI. However, there is currently no formal consensus regarding the 
most efficacious parameters of these interventions. Future clinical trials of 
cognitive training and tDCS need to explore the effects of differing 
intervention lengths (e.g., 20 to 40 sessions), frequency (e.g., daily or 
weekly), and intensity (e.g., 20 minutes or 2 hours) to increase our 
understanding of the effects of these therapies in PD-MCI. Combining 
cognitive training with tDCS was most efficacious in the current research. 
Therefore, future studies may wish to explore the effects of a longer 
intervention (e.g., 12 weeks of cognitive training and tDCS) to examine 
the potential benefits and feasibility of combining these interventions over 
an extended period of time.  
 
5. Explore the efficacy of group-based cognitive training interventions 
in PD-MCI. Study 3 involved cognitive training that was completed 
individually by participants in their homes. However, a number of 
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participants reported that the training was monotonous and too repetitive. 
Group-based cognitive training has shown greater efficacy than in-home 
cognitive training in healthy-older adults (Lampit et al., 2014), and may 
provide additional benefits (e.g., trainer supervision, social interactions). 
It is recommended that future studies examine the effects of group-based 
cognitive training in PD-MCI and include social engagement as a primary 
outcome (Mor et al., 1995). 
 
6. Examine the therapeutic effects of tDCS over different cortical sites. 
The cortical site of tDCS will influence which cognitive domains are most 
likely to benefit from stimulation. Study 3 administered tDCS over the 
left DLPFC which resulted in improvements in executive function, but no 
improvements in visuospatial abilities. Visuospatial abilities are mediated 
by the right posterior hemisphere (not the left DLPFC). Future studies 
may therefore want to examine the effects of tDCS over different cortical 
sites in PD-MCI, with intention of improving cognitive functions 
associated with those regions in the brain. 
 
7. Ensure exposure to interventions is equal across groups. Participants 
in the cognitive training + tDCS groups completed a greater number of 
intervention sessions, compared to the groups that completed 
interventions independently. Increased exposure to an intervention may 
therefore produce biased beneficial effects, which compromise the 
internal validity of results. Researchers need to implement 
nonpharmacological interventions that are matched for methodological 
parameters (e.g., intensity, length, time) to ensure any future findings are 
supported by rigorous empirical design.  
 
8. Use alternate forms for neuropsychological tests administered at 
post-intervention and follow up assessments. In Study 3 the same 
neuropsychological tests were administered at pre-intervention, post-
intervention, and follow up assessments. Using the same tests may result 
in practice effects during the course of an intervention, which limits the 
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interpretation of potential therapeutic effects. Future clinical trials should 
therefore include alternate forms for neuropsychological tests (see Lezak 
et al., 2012), which eliminate practice effects and maintain standardised 
assessment of cognitive function at post-intervention and follow up 
assessments. 
 
9. Include quality of life and activities of daily living as primary 
outcomes. This research provides preliminary evidence to suggest that 
cognitive training and tDCS may improve activities of daily living and 
quality of life in PD-MCI. Difficulties with activities of daily living 
(Rosenthal et al., 2010) and worsened quality of life (van Uem et al., 
2016) are well documented in PD, but there is limited evidence to suggest 
that cognitive training and tDCS can improve functioning in these 
domains. Future studies need to build upon the findings of Study 3 and 
explore the potential of these nonpharmacological interventions for 
improving activities of daily living and quality of life in PD-MCI.  
 
10. Include neuroimaging data as primary outcomes. Neuroimaging 
techniques are uncovering the complex neurobiological processes that are 
associated with cognitive impairments in PD (e.g., Xu et al., 2016). Using 
neuroimaging to measure cortical activity pre and post cognitive training 
and tDCS interventions will provide evidence to indicate which cortical 
regions are most activated following these interventions, and whether 
increased cortical activity is associated with improvements on 
neuropsychological tests. There is also potential for neuroimaging to 
assist in determining whether stimulation or compensation-focussed 
interventions produce the greatest adaptive neural plasticity in people 
with PD-MCI.  
 
11. Include follow up assessments at 3, 6, and 12 months post-
intervention. Study 3 was the first clinical trial of cognitive training and 
tDCS to report long-term (12 week) improvements in cognition and 
quality of life in PD-MCI. Very few studies have included long-term 
follow up assessments, and it is not known whether the beneficial effects 
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of these interventions are maintained beyond intervention cessation. It is 
therefore recommended that future studies build upon the findings from 
this research and include assessments of cognition, activities of daily 
living, and quality of life at 3, 6, and 12 months post-intervention.  
 
12. Explore the efficacy of cognitive training and tDCS among groups of 
participants at varying stages of PD-MCI and with differing 
demographic characteristics. This research explored the effects of 
cognitive training and tDCS in people identified with PD-MCI at the most 
liberal cut off (i.e., < 1 SD below normative data). Future studies may 
want to use a more conservative cut off score (e.g., < 2 SDs below 
normative data) to examine if cognitive training and tDCS can elicit 
neural plasticity and improvements in cognitive function in people with 
more severe cognitive impairments. Future researchers may also wish to 
explore the effects of these interventions in people with varying levels of 
education (i.e., varying levels of cognitive reserve), age cohorts, severity 
of Parkinsonian symptoms, and across the spectrum of the disease course 

















5.5 Closing Words 
 
It took 150 years from James Parkinson’s ‘An Essay on the Shaking Palsy’ 
for the development of the first effective therapy for the motor symptoms of 
Parkinson’s Disease (PD) – high-dosage levodopa (Fahn, 2015). It is undeniable that 
the motor symptoms of PD infiltrate every aspect of a person’s life and need to be 
targeted as the primary symptom of treatment. As described in this thesis, PD is now 
recognised as a disorder that encompasses many motor and non-motor symptoms, 
including mild cognitive impairment. 
 
Over the past 5 years, the scientific community has increased their focus on 
nonpharmacological therapies for cognitive impairments in PD and to complement 
the pharmacological benefits of levodopa for motor symptoms. This thesis explored 
the therapeutic potential of nonpharmacological interventions for improving 
cognition and quality of life for people with PD. It is hoped that the findings 
presented in this thesis will add to and expand the current evidence base in support of 
cognitive training and transcranial direct current stimulation for mild cognitive 
impairment in PD, and motivate fellow researchers to continue to explore the 
potential of these interventions to improve the quality of life for the many millions of 
people living with PD.  
 
To close this thesis, I would like to extend the most whole hearted thank you 
to the people with Parkinson’s who volunteered their time to contribute to this 
research. This research would not exist if it wasn’t for the altruistic effort contributed 














Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., 
Kulisevsky, J., . . . Allcock, L. (2010). Mild cognitive impairment in 
Parkinson disease: A multicenter pooled analysis. Neurology, 75, 1062-1069. 
doi:10.1007/s11910-011-0203-1 
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012). 
Depression in Parkinson disease—epidemiology, mechanisms and 
management. Nature Reviews Neurology, 8, 35-47. 
doi:10.1038/nrneurol.2011.189 
Aarsland, D., Zaccai, J., & Brayne, C. (2005). A systematic review of prevalence 
studies of dementia in Parkinson's disease. Movement Disorders, 20, 1255-
1263. doi:10.1002/mds.20527 
Access Economics. (2011). Living with Parkinson's Disease - update (Trans. ed. 




Ahlskog, J. E., & Muenter, M. D. (2001). Frequency of levodopa‐related dyskinesias 
and motor fluctuations as estimated from the cumulative literature. Movement 
Disorders, 16, 448-458. doi:10.1002/mds.1090 
Ahmed, M. A., Darwish, E. S., Khedr, E. M., & Ali, A. M. (2012). Effects of low 
versus high frequencies of repetitive transcranial magnetic stimulation on 
cognitive function and cortical excitability in Alzheimer’s dementia. Journal 
of Neurology, 259, 83-92. doi:10.1007/s00415-011-6128-4 
Alexander, G. E., & Crutcher, M. D. (1990). Functional architecture of basal ganglia 
circuits: neural substrates of parallel processing. Trends in Neurosciences, 13, 
266-271.  
Altman, D. G., & Bland, J. M. (2005). Standard deviations and standard errors. 
British Medical Journal, 331, 903. doi:10.1136/bmj.331.7521.903 
American Psychiatric Association. (2013). Diagnostic and statistical manual of 




Anastasi, A., & Urbina, S. (1997). Psychological Testing (Trans. 7th ed ed. Vol.). 
Upper Saddle River, NJ: Prentice Hall. 
Axelrod, B. N., Ricker, J. H., & Cherry, S. A. (1994). Concurrent validity of the 
MAE visual naming test. Archives of Clinical Neuropsychology, 9, 317-321. 
doi:10.1093/arclin/9.4.317 
Baddeley, A. (2003). Working memory: Looking back and looking forward. Nature 
Reviews: Neuroscience, 4, 829-839. doi:10.1038/nrn1201 
Ballantyne, A. O., Spilkin, A. M., Hesselink, J., & Trauner, D. A. (2008). Plasticity 
in the developing brain: Intellectual, language and academic functions in 
children with ischaemic perinatal stroke. Brain, 131, 2975-2985. 
doi:10.1093/brain/awn176 
Baltes, P. B. (1987). Theoretical propositions of life-span developmental psychology: 
On the dynamics between growth and decline. Developmental Psychology, 
23, 611-626. doi:10.1037/0012-1649.23.5.611 
Baltes, P. B., & Mayer, K. U. (2001). The Berlin aging study: Aging from 70 to 100 
(Trans. ed. Vol.). Cambridge University Press. 
Barbey, A. K., Koenigs, M., & Grafman, J. (2010). Orbitofrontal contributions to 
human working memory. Cerebral Cortex, 1-7. doi:10.1093/cercor/bhq153 
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985). Non-invasive magnetic 
stimulation of human motor cortex. The Lancet, 325, 1106-1107. 
doi:10.1016/S0140-6736(85)92413-4 
Barone, P., Aarsland, D., Burn, D., Emre, M., Kulisevsky, J., & Weintraub, D. 
(2011). Cognitive impairment in nondemented Parkinson's disease. 
Movement Disorders, 26, 2483-2495. doi:10.1002/mds.23919 
Bartels, A. L., & Leenders, K. L. (2009). Parkinson's disease: The syndrome, the 
pathogenesis and pathophysiology. Cortex, 45, 915-921. 
doi:10.1016/j.cortex.2008.11.010 
Basak, C., Boot, W. R., Voss, M. W., & Kramer, A. F. (2008). Can training in a real-
time strategy video game attenuate cognitive decline in older adults? 
Psychology and Aging, 23, 765-777. doi:10.1037/a0013494 
Belleville, S., Clément, F., Mellah, S., Gilbert, B., Fontaine, F., & Gauthier, S. 
(2011). Training-related brain plasticity in subjects at risk of developing 
Alzheimer’s disease. Brain, 134, 1623-1634. doi:10.1093/brain/awr037 
162 
 
Benabid, A. L., Chabardes, S., Mitrofanis, J., & Pollak, P. (2009). Deep brain 
stimulation of the subthalamic nucleus for the treatment of Parkinson's 
disease. The Lancet Neurology, 8, 67-81. doi:10.1016/S1474-4422(08)70291-
6 
Benedict, R. H., & Zgaljardic, D. J. (1998). Practice effects during repeated 
administrations of memory tests with and without alternate forms. Journal of 
Clinical and Experimental Neuropsychology, 20, 339-352. 
doi:10.1076/jcen.20.3.339.822 
Benninger, D. H., Berman, B., Houdayer, E., Pal, N., Luckenbaugh, D., Schneider, 
L., . . . Hallett, M. (2011). Intermittent theta-burst transcranial magnetic 
stimulation for treatment of Parkinson disease. Neurology, 76, 601-609. 
doi:10.1212/WNL.0b013e31820ce6bb 
Benninger, D. H., Iseki, K., Kranick, S., Luckenbaugh, D. A., Houdayer, E., & 
Hallett, M. (2012). Controlled study of 50-Hz repetitive transcranial magnetic 
stimulation for the treatment of Parkinson disease. Neurorehabilitation and 
Neural Repair, 26, 1096-1105. doi:10.1177/1545968312445636 
Benninger, D. H., Lomarev, M., Lopez, G., Wassermann, E. M., Li, X., Considine, 
E., & Hallett, M. (2010). Transcranial direct current stimulation for the 
treatment of Parkinson's disease. Journal of Neurology, Neurosurgery & 
Psychiatry, 81, 1105-1111. doi:10.1136/jnnp.2009.202556 
Benninger, D. H., Lomarev, M., Wassermann, E. M., Lopez, G., Houdayer, E., 
Fasano, R. E., . . . Hallett, M. (2009). Safety study of 50Hz repetitive 
transcranial magnetic stimulation in patients with Parkinson’s disease. 
Clinical Neurophysiology, 120, 809-815. doi:10.1016/j.clinph.2009.01.012 
Benton, A. L. (1968). Differential behavioral effects in frontal lobe disease. 
Neuropsychologia, 6, 53-60.  
Benton, A. L., Hamsher, K. D., & Sivan, A. B. (1994). Multilingual aphasia 
examination: Manual of instructions (Trans. 3rd ed. Vol.). Iowa City: AJA. 
Bentwich, J., Dobronevsky, E., Aichenbaum, S., Shorer, R., Peretz, R., Khaigrekht, 
M., . . . Rabey, J. M. (2011). Beneficial effect of repetitive transcranial 
magnetic stimulation combined with cognitive training for the treatment of 
Alzheimer’s disease: A proof of concept study. Journal of Neural 
Transmission, 118, 463-471. doi:10.1007/s00702-010-0578-1 
163 
 
Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T., . . . Lang, A. 
E. (2014). Time to redefine PD? Introductory statement of the MDS Task 
Force on the definition of Parkinson's disease. Movement Disorders, 29, 454-
462. doi:10.1002/mds.25844 
Bermejo, P. E. (2008). Topiramate in managing impulse control disorders in 
Parkinson's disease. Parkinsonism & Related Disorders, 14, 448-449. 
doi:10.1016/j.parkreldis.2007.11.008 
Bermejo, P. E., Ruiz-Huete, C., & Anciones, B. (2010). Zonisamide in managing 
impulse control disorders in Parkinson’s disease. Journal of Neurology, 257, 
1682-1685. doi:10.1007/s00415-010-5603-7 
Berry, A. S., Zanto, T. P., Clapp, W. C., Hardy, J. L., Delahunt, P. B., Mahncke, H. 
W., & Gazzaley, A. (2010). The influence of perceptual training on working 
memory in older adults. PLoS One, 5, e11537. 
doi:10.1371/journal.pone.0011537 
Besser, L. M., Litvan, I., Monsell, S. E., Mock, C., Weintraub, S., Zhou, X.-H., & 
Kukull, W. (2016). Mild cognitive impairment in Parkinson's disease versus 
Alzheimer's disease. Parkinsonism & Related Disorders, 27, 54-60. 
doi:10.1016/j.parkreldis.2016.04.007 
Bezdicek, O., Nikolai, T., Michalec, J., Růžička, F., Havránková, P., Roth, J., . . . 
Růžička, E. (2016). The diagnostic accuracy of Parkinson's Disease mild 
cognitive impairment battery using the Movement Disorder Society Task 
Force criteria. Movement Disorders Clinical Practice, 
doi:10.1002/mdc3.12391 
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer’s disease (Review). 
Cochrane Database of Systematic Reviews, 1, 
doi:10.1002/14651858.CD005593 
Biundo, R., Weis, L., Fiorenzato, E., Gentile, G., Giglio, M., Schifano, R., . . . 
Bisiacchi, P. (2015). Double-blind randomized trial of t-DCS versus sham in 
Parkinson patients with mild cognitive impairment receiving cognitive 






Biundo, R., Weis, L., Pilleri, M., Facchini, S., Formento-Dojot, P., Vallelunga, A., & 
Antonini, A. (2013). Diagnostic and screening power of neuropsychological 
testing in detecting mild cognitive impairment in Parkinson’s Disease. 
Journal of Neural Transmission, 120, 627-633. doi:10.1007/s00702-013-
1004-2 
Boggio, P. S., Ferrucci, R., Mameli, F., Martins, D., Martins, O., Vergari, M., . . . 
Priori, A. (2012). Prolonged visual memory enhancement after direct current 
stimulation in Alzheimer's disease. Brain Stimulation, 5, 223-230. 
doi:10.1016/j.brs.2011.06.006 
Boggio, P. S., Ferrucci, R., Rigonatti, S. P., Covre, P., Nitsche, M., Pascual-Leone, 
A., & Fregni, F. (2006). Effects of transcranial direct current stimulation on 
working memory in patients with Parkinson's disease. Journal of the 
Neurological Sciences, 249, 31-38. doi:10.1016/j.jns.2006.05.062 
Boggio, P. S., Fregni, F., Bermpohl, F., Mansur, C. G., Rosa, M., Rumi, D. O., . . . 
Rigonatti, S. P. (2005). Effect of repetitive TMS and fluoxetine on cognitive 
function in patients with Parkinson's disease and concurrent depression. 
Movement Disorders, 20, 1178-1184. doi:10.1002/mds.20508 
Boggio, P. S., Khoury, L. P., Martins, D. C., Martins, O. E., De Macedo, E., & 
Fregni, F. (2009). Temporal cortex direct current stimulation enhances 
performance on a visual recognition memory task in Alzheimer disease. 
Journal of Neurology, Neurosurgery & Psychiatry, 80, 444-447. 
doi:10.1136/jnnp.2007.141853 
Borenstein, M., Hedges, L., Higgins, J., & Rothstein, H. (2014). Comprehensive 
meta-analysis version 3. Trans.). In (Ed.),^(Eds.), In (ed., Vol. pp.)  
Englewood, NJ: (Biostat). 
Borenstein, M., Hedges, L. V., Higgins, J., & Rothstein, H. R. (2010). A basic 
introduction to fixed‐effect and random‐effects models for meta‐analysis. 
Research Synthesis Methods, 1, 97-111. doi:10.1002/jrsm.12 
Borenstein, M., Hedges, L. V., Higgins, J. P., & Rothstein, H. R. (2011). 
Introduction to meta-analysis (Trans. ed. Vol.). UK: John Wiley & Sons. 
Boutron, I., Moher, D., Altman, D. G., Schulz, K. F., & Ravaud, P. (2008). 
Extending the CONSORT statement to randomized trials of 
nonpharmacologic treatment: Explanation and elaboration. Annals of Internal 
Medicine, 148, 295-309. doi:10.7326/0003-4819-148-4-200802190-00008 
165 
 
Brandt, J., & Benedict, R. H. (2001). Hopkins Verbal Learning Test-Revised: 
Professional Manual (Trans. ed. Vol.). Lutz, FL: Psychological Assessment 
Resources. 
Brandt, J., Spencer, M., & Folstein, M. (1988). The telephone interview for cognitive 
status. Cognitive and Behavioral Neurology, 1, 111-118.  
Bryk, A. S., & Raudenbush, S. W. (1987). Application of hierarchical linear models 
to assessing change. Psychological Bulletin, 101, 147-158.  
Burn, D. (2002). Depression in Parkinson's disease. European Journal of Neurology, 
9, 44-54. doi:10.1046/j.1468-1331.9.s3.6.x 
Burn, D. (2010). The treatment of cognitive impairment associated with Parkinson's 
disease. Brain Pathology, 20, 672-678. doi:10.1111/j.1750-
3639.2009.00367.x 
Cai, L., Chan, J. S., Yan, J. H., & Peng, K. (2014). Brain plasticity and motor 
practice in cognitive aging. Frontiers in Aging Neuroscience, 6, In PRESS. 
doi:10.3389/fnagi.2014.00031 
Calabresi, P., Castrioto, A., Di Filippo, M., & Picconi, B. (2013). New experimental 
and clinical links between the hippocampus and the dopaminergic system in 
Parkinson's disease. The Lancet Neurology, 12, 811-821. doi:10.1016/S1474-
4422(13)70118-2 
Calero, M. D., & Navarro, E. (2004). Relationship between plasticity, mild cognitive 
impairment and cognitive decline. Archives of Clinical Neuropsychology, 19, 
653-660. doi:10.1016/j.acn.2003.08.008 
Calne, D. (2005). A definition of Parkinson's disease. Parkinsonism & Related 
Disorders, 11, S39-S40. doi:10.1016/j.parkreldis.2005.01.008 
Carr, J. (2002). Tremor in Parkinson's disease. Parkinsonism & Related Disorders, 8, 
223-234. doi:10.1016/S1353-8020(01)00037-2 
Caselli, R. J., Locke, D. E., Dueck, A. C., Knopman, D. S., Woodruff, B. K., 
Hoffman-Snyder, C., . . . Reiman, E. M. (2014). The neuropsychology of 
normal aging and preclinical Alzheimer's disease. Alzheimer's & Dementia, 
10, 84-92. doi:10.1016/j.jalz.2013.01.004 
Caviness, J. N., Driver‐Dunckley, E., Connor, D. J., Sabbagh, M. N., Hentz, J. G., 
Noble, B., . . . Adler, C. H. (2007). Defining mild cognitive impairment in 




Cerasa, A., Gioia, M. C., Salsone, M., Donzuso, G., Chiriaco, C., Realmuto, S., . . . 
D’amelio, M. (2014). Neurofunctional correlates of attention rehabilitation in 
Parkinson’s disease: An explorative study. Neurological Sciences, 1-8. 
doi:10.1007/s10072-014-1666-z 
Cereda, E., Cilia, R., Klersy, C., Siri, C., Pozzi, B., Reali, E., . . . Tesei, S. (2016). 
Dementia in Parkinson's disease: Is male gender a risk factor? Parkinsonism 
& Related Disorders, 26, 67-72. doi:10.1016/j.parkreldis.2016.02.024 
Chahine, L. M., Weintraub, D., Hawkins, K. A., Siderowf, A., Eberly, S., Oakes, D., 
. . . Jennings, D. (2016). Cognition in individuals at risk for Parkinson's: 
Parkinson associated risk syndrome (PARS) study findings. Movement 
Disorders, 31, 86-94. doi:10.1002/mds.26373 
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. 
(2004). Empirical evidence for selective reporting of outcomes in randomized 
trials: Comparison of protocols to published articles. Journal of the American 
Medical Association, 291, 2457-2465. doi:10.1001/jama.291.20.2457 
Chand, P., & Litvan, I. (2007). Parkinson's disease. Encylopedia of Gerontology, 
332-333. doi:10.1016/B0-12-370870-2/0014 
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006). Non-motor symptoms of 
Parkinson's disease: Diagnosis and management. The Lancet Neurology, 5, 
235-245. doi:10.1016/S1474-4422(06)70373-8 
Chaudhuri, K. R., & Schapira, A. H. (2009). Non-motor symptoms of Parkinson's 
disease: Dopaminergic pathophysiology and treatment. The Lancet 
Neurology, 8, 464-474. doi:10.1016/S1474-4422(09)70068-7 
Chen, J. J., & Marsh, L. (2014). Anxiety in Parkinson’s disease: Identification and 
management. Therapeutic Advances in Neurological Disorders, 7, 52-59. 
doi:10.1177/1756285613495723 
Cholerton, B. A., Zabetian, C. P., Wan, J. Y., Montine, T. J., Quinn, J. F., Mata, I. F., 
. . . Revilla, F. J. (2014). Evaluation of mild cognitive impairment subtypes in 
Parkinson's disease. Movement Disorders, 29, 756-764. 
doi:10.1002/mds.25875 






Cockburn, J., & Keene, J. (2001). Are changes in everyday memory over time in 
autopsy-confirmed Alzheimer's disease related to changes in reported 
behaviour? Neuropsychological Rehabilitation, 11, 201-217. 
doi:10.1080/09602010042000015 
Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159. 
doi:10.1037//0033-2909.112.1.155 
Cohen, M. J., & Stanczak, D. E. (2000). On the reliability, validity, and cognitive 
structure of the Thurstone Word Fluency Test. Archives of Clinical 
Neuropsychology, 15, 267-279. doi:10.1016/S0887-6177(99)00017-7 
Collins, L., Cummins, G., & Barker, R. A. (2015). Parkinson's disease: Diagnosis 
and current management. Prescriber, 26, 16-23. doi:10.1002/psb.1316 
Compta, Y., Parkkinen, L., O'Sullivan, S. S., Vandrovcova, J., Holton, J. L., Collins, 
C., . . . de Silva, R. (2011). Lewy-and Alzheimer-type pathologies in 
Parkinson's disease dementia: Which is more important? Brain, 134, 1493-
1505. doi:10.1093/brain/awr031 
Copeland, J. N., Lieberman, A., Oravivattanakul, S., & Tröster, A. I. (2016). 
Accuracy of Patient and Care Partner Identification of Cognitive Impairments 
in Parkinson's Disease–Mild Cognitive Impairment. Movement Disorders, 
doi:10.1002/mds.26619 
Cortina, J. M. (1993). What is coefficient alpha? An examination of theory and 
applications. Journal of Applied Psychology, 78, 98. doi:10.1037/0021-
9010.78.1.98 
Cosgrove, J., Alty, J. E., & Jamieson, S. (2015). Cognitive impairment in Parkinson's 
disease. Postgraduate Medical Journal, 91, 212-220. 
doi:10.1136/postgradmedj-2015-133247 
Costa, A., Peppe, A., Serafini, F., Zabberoni, S., Barban, F., Caltagirone, C., & 
Carlesimo, G. (2014). Prospective Memory Performance of Patients with 
Parkinson's Disease Depends on Shifting Aptitude: Evidence from Cognitive 
Rehabilitation. Journal of the International Neuropsychological Society, 20, 
717-726. doi:10.1017/S1355617714000563 
Creutzfeldt, O. D., Fromm, G. H., & Kapp, H. (1962). Influence of transcortical dc 
currents on cortical neuronal activity. Experimental Neurology, 5, 436-452.  
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. 
Psychometrika, 16, 297-334. doi:10.1007/BF02310555 
168 
 
Cummings, J. L. (1988). Intellectual impairment in Parkinson's disease: Clinical, 
pathologic, and biochemical correlates. Journal of Geriatric Psychiatry and 
Neurology, 1, 24-36. doi:10.1177/089198878800100106 
Darweesh, S. K., Verlinden, V. J., Adams, H. H., Uitterlinden, A. G., Hofman, A., 
Stricker, B. H., . . . Ikram, M. A. (2016). Genetic risk of Parkinson’s disease 
in the general population. Parkinsonism & Related Disorders, 
doi:10.1016/j.parkreldis.2016.05.030 
Davis, K. L., Fitzgerald, T. P., Meyers, J., Kulkarni, A., Svarvar, P., & Hewitt, D. J. 
(2013). Incidence of adverse treatment effects in parkinson's disease: 
Evidence from a large employer population. The journal of the International 
Society for Pharmacoeconomics and Outcomes Research, 16, A100-A100.  
De Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson's disease. The 
Lancet Neurology, 5, 525-535. doi:10.1016/S1474-4422(06)70471-9 
Delgado‐Alvarado, M., Gago, B., Navalpotro‐Gomez, I., Jiménez‐Urbieta, H., & 
Rodriguez‐Oroz, M. C. (2016). Biomarkers for dementia and mild cognitive 
impairment in Parkinson's disease. Movement Disorders, 31, 861-881. 
doi:10.1002/mds.26662 
Demakis, G. J. (2004). Frontal lobe damage and tests of executive processing: a 
meta-analysis of the category test, stroop test, and trail-making test. Journal 
of Clinical and Experimental Neuropsychology, 26, 441-450. 
doi:10.1080/13803390490510149 
den Brok, M. G., van Dalen, J. W., van Gool, W. A., Moll van Charante, E. P., de 
Bie, R., & Richard, E. (2015). Apathy in Parkinson's disease: A systematic 
review and meta‐analysis. Movement Disorders, 30, 759-769. 
doi:10.1002/mds.26208 
DerSimonian, R., & Kacker, R. (2007). Random-effects model for meta-analysis of 
clinical trials: An update. Contemporary Clinical Trials, 28, 105-114. 
doi:10.1016/j.cct.2006.04.004 
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled 
Clinical Trials, 7, 177-188. doi:10.1016/0197-2456(86)90046-2 
Ding, D., Zhao, Q., Guo, Q., Meng, H., Wang, B., Luo, J., . . . Hong, Z. (2015). 
Prevalence of mild cognitive impairment in an urban community in China: A 
cross-sectional analysis of the Shanghai Aging Study. Alzheimer's & 
Dementia, 11, 300-309. doi:10.1016/j.jalz.2013.11.002 
169 
 
Disbrow, E., Russo, K., Higginson, C., Yund, E., Ventura, M., Zhang, L., . . . 
Sigvardt, K. (2012). Efficacy of tailored computer-based neurorehabilitation 
for improvement of movement initiation in Parkinson's disease. Brain 
Research, 1452, 151-164. doi:10.1016/j.brainres.2012.02.073 
Domellof, M., Ekman, U., Forsgren, L., & Elgh, E. (2015). Cognitive function in the 
early phase of Parkinson's disease, a five-year follow-up. Acta Neurologica 
Scandinavica, 1-10. doi:10.1111/ane.12375 
Dorsey, E., Constantinescu, R., Thompson, J., Biglan, K., Holloway, R., Kieburtz, 
K., . . . Siderowf, A. (2007). Projected number of people with Parkinson 
disease in the most populous nations, 2005 through 2030. Neurology, 68, 
384-386. doi:10.1212/01.wnl.0000247740.47667.03 
Doruk, D., Gray, Z., Bravo, G. L., Pascual-Leone, A., & Fregni, F. (2014). Effects of 
tDCS on executive function in Parkinson's disease. Neuroscience Letters, 
582, 27-31. doi:10.1016/j.neulet.2014.08.043 
Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G. A., . . . 
Gauthier, S. (2007). Diagnostic procedures for Parkinson's disease dementia: 
Recommendations from the movement disorder society task force. Movement 
Disorders, 22, 2314-2324. doi:10.1002/mds.21844 
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000). The FAB: A frontal 
assessment battery at bedside. Neurology, 55, 1621-1626. doi:10.1212/WNL.
55.11.1621  
Dujardin, K., Moonen, A. J., Behal, H., Defebvre, L., Duhamel, A., Duits, A. A., . . . 
Leentjens, A. F. (2015). Cognitive disorders in Parkinson's disease: 
Confirmation of a spectrum of severity. Parkinsonism & Related Disorders, 
21, 1299-1305. doi:10.1016/j.parkreldis.2015.08.032 
Dujardin, K., Sockeel, P., Delliaux, M., Destée, A., & Defebvre, L. (2009). Apathy 
may herald cognitive decline and dementia in Parkinson's disease. Movement 
Disorders, 24, 2391-2397. doi:10.1002/mds.22843 
Easterbrook, P. J., Gopalan, R., Berlin, J., & Matthews, D. R. (1991). Publication 






Edwards, J. D., Hauser, R. A., O'Connor, M. L., Valdés, E. G., Zesiewicz, T. A., & 
Uc, E. Y. (2013). Randomized trial of cognitive speed of processing training 
in Parkinson disease. Neurology, 81, 1284-1290. 
doi:10.1212/WNL.0b013e3182a823ba 
Elgh, E., Domellöf, M., Linder, J., Edström, M., Stenlund, H., & Forsgren, L. (2009). 
Cognitive function in early Parkinson’s disease: A population‐based study. 
European Journal of Neurology, 16, 1278-1284. doi:10.1111/j.1468-
1331.2009.02707.x 
Ell, S. W. (2013). Targeted training of the decision rule benefits rule-guided behavior 
in Parkinson’s disease. Cognitive, Affective, & Behavioral Neuroscience, 13, 
830-846. doi:10.3758/s13415-013-0176-4 
Epstein, C. M., Evatt, M. L., Funk, A., Girard-Siqueira, L., Lupei, N., Slaughter, L., . 
. . DeLong, M. R. (2007). An open study of repetitive transcranial magnetic 
stimulation in treatment-resistant depression with Parkinson’s disease. 
Clinical Neurophysiology, 118, 2189-2194. doi:10.1016/j.clinph.2007.07.010 
Fahn, S. (2015). The medical treatment of Parkinson disease from James Parkinson 
to George Cotzias. Movement Disorders, 30, 4-18. doi:10.1002/mds.26102 
Fahn, S., & Bressman, S. B. (1984). Should levodopa therapy for parkinsonism be 
started early or late? Evidence against early treatment. Canadian Journal of 
Neurological Sciences, 11(S1), 200-205. doi:10.1017/S0317167100046412 
Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., . . . Marek, K. 
(2004). Levodopa and the progression of Parkinson's disease. The New 
England Journal of Medicine, 351, 2498-2508. doi:10.1056/NEJMoa033447 
Fastenau, P. S., Denburg, N. L., & Mauer, B. A. (1998). Parallel short forms for the 
Boston Naming Test: Psychometric properties and norms for older adults. 
Journal of Clinical and Experimental Neuropsychology, 20, 828-834. 
doi:10.1076/jcen.20.6.828.1105 
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G* Power 3: A flexible 
statistical power analysis program for the social, behavioral, and biomedical 






Fennig, S., Mottes, A., Ricter-Levin, G., Treves, I., & Levkovitz, Y. (2002). 
Everyday memory and laboratory memory tests: General function predictors 
in schizophrenia and remitted depression. The Journal of Nervous and Mental 
Disease, 190, 677-682. doi:10.1097/00005053-200210000-00004 
Fernández-Ballesteros, Botella, J., Zamarrón, M. D., Molina, M. Á., Cabras, E., 
Schetinni, R., & Tárraga, L. (2012). Cognitive plasticity in normal and 
pathological aging. Clinical Interventions in Aging, 7, 15-25. 
doi:10.2147/CIA.S27008 
Fernández-Ballesteros, Zamarrón, M. D., Tárraga, L., Moya, R., & Iñiguez, J. 
(2003). Cognitive plasticity in healthy, mild cognitive impairment (MCI) 
subjects and Alzheimer's disease patients: A research project in Spain. 
European Psychologist, 8, 148-159. doi:10.1027//1016-9040.8.3.148 
Ferrucci, R., Mameli, F., Guidi, I., Mrakic-Sposta, S., Vergari, M., Marceglia, S., . . . 
Priori, A. (2008). Transcranial direct current stimulation improves 
recognition memory in Alzheimer disease. Neurology, 71, 493-498. doi:10.
1212/01.wnl.0000317060.43722.a3 
Field, A. (2013). Discovering statistics using IBM SPSS statistics (Trans. 4th ed ed. 
Vol.). California, USA: Sage. 
Finton, M. J., Lucas, J. A., Graff-Radford, N. R., & Uitti, R. J. (1998). Analysis of 
visuospatial errors in patients with Alzheimer's disease or Parkinson's disease. 
Journal of Clinical and Experimental Neuropsychology, 20, 186-193. 
doi:10.1076/jcen.20.2.186.1167 
Fisher, L. M., Freed, D. M., & Corkin, S. (1990). Stroop Color-Word Test 
performance in patients with Alzheimer's disease. Journal of Clinical and 
Experimental Neuropsychology, 12, 745-758. 
doi:10.1080/01688639008401016 
Fisk, J. E., & Sharp, C. A. (2004). Age-related impairment in executive functioning: 
Updating, inhibition, shifting, and access. Journal of Clinical and 
Experimental Neuropsychology, 26, 874-890. 
doi:10.1080/13803390490510680 
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”: A 
practical method for grading the cognitive state of patients for the clinician. 
Journal of Psychiatric Research, 12, 189-198.  
172 
 
Foltynie, T., Brayne, C. E., Robbins, T. W., & Barker, R. A. (2004). The cognitive 
ability of an incident cohort of Parkinson’s patients in the UK. The 
CamPaIGN study. Brain, 127, 550-560. doi:10.1093/brain/awh067 
Fong, T. G., Fearing, M. A., Jones, R. N., Shi, P., Marcantonio, E. R., Rudolph, J. L., 
. . . Inouye, S. K. (2009). Telephone interview for cognitive status: Creating a 
crosswalk with the Mini-Mental State Examination. Alzheimer's & Dementia, 
5, 492-497. doi:10.1016/j.jalz.2009.02.007 
Foster, P. S., Drago, V., Crucian, G. P., Skidmore, F., Rhodes, R. D., Shenal, B. V., . 
. . Heilman, K. M. (2010). Verbal and visuospatial memory in lateral onset 
Parkinson disease: Time is of the essence. Cognitive and Behavioral 
Neurology, 23, 19-25. doi:10.1097/WNN.0b013e3181c20de7 
Frakey, L., & Friedman, J. (2014). A-31The Effects of Rasagiline on Cognition in 
Mild to Moderate Stage Parkinson's Disease, A Double-Blind Placebo 
Controlled Study. Archives of Clinical Neuropsychology, 29, 514-514. 
doi:10.1093/arclin/acu038.31 
Fregni, F., Santos, C., Myczkowski, M., Rigolino, R., Gallucci-Neto, J., Barbosa, E., 
. . . Marcolin, M. (2004). Repetitive transcranial magnetic stimulation is as 
effective as fluoxetine in the treatment of depression in patients with 
Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 75, 
1171-1174. doi:10.1136/jnnp.2003.027060 
Fung, V. S., Herawati, L., & Wan, Y. (2009). Quality of life in early Parkinson's 
disease treated with levodopa/carbidopa/entacapone. Movement Disorders, 
24, 25-31. doi:10.1002/mds.21878 
Furukawa, T., Izumi, S., Toyokura, M., & Masakado, Y. (2009). Effects of low-
frequency repetitive transcranial magnetic stimulation in Parkinson's disease. 
Tokai Journal of Experimental and Clinical Medicine, 34, 63-71.  
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., . . . 
Chertkow, H. (2006). Mild cognitive impairment. The Lancet, 367, 1262-
1270. doi:10.1016/S0140-6736(06)68542-5 
Geurtsen, G. J., Hoogland, J., Goldman, J. G., Schmand, B. A., Tröster, A. I., Burn, 
D. J., & Litvan, I. (2014). Parkinson’s disease mild cognitive impairment: 




Glamser, F. D., & Turner, R. W. (1995). Youth sport participation and associated sex 
differences on a measure of spatial ability. Perceptual and Motor skills, 81, 
1099-1105. doi:10.2466/pms.1995.81.3f.1099 
Goetz, C. G., Blasucci, L., & Stebbins, G. T. (1999). Switching dopamine agonists in 
advanced Parkinson’s Disease: Is rapid titration preferable to slow? 
Neurology, 52, 1227-1227. doi:10.1212/WNL.52.6.1227 
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., . . . 
Wenning, G. K. (2004). Movement Disorder Society Task Force report on the 
Hoehn and Yahr staging scale: Status and recommendations the Movement 
Disorder Society Task Force on rating scales for Parkinson's disease. 
Movement Disorders, 19, 1020-1028. doi:10.1002/mds.20213 
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐
Martin, P., . . . Dodel, R. (2008). Movement Disorder Society‐sponsored 
revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): 
Scale presentation and clinimetric testing results. Movement Disorders, 23, 
2129-2170. doi:10.1002/mds.22340 
Goh, J. O., & Park, D. C. (2009). Neuroplasticity and cognitive aging: The 
scaffolding theory of aging and cognition. Restorative Neurology and 
Neuroscience, 27, 391-403. doi:10.3233/RNN-2009-0493 
Golden, C. J. (1975). A group version of the Stroop Color and Word Test. Journal of 
Personality Assessment, 39, 386-388. doi:10.1207/s15327752jpa3904_10 
Golden, C. J., & Freshwater, S. (2002). Stroop Colour and Word test: Revised 
examiner's manual (Trans. ed. Vol.). Wood dale, IL: Stoelting Co. 
Goldman, J. G., Holden, S., Bernard, B., Ouyang, B., Goetz, C. G., & Stebbins, G. T. 
(2013). Defining optimal cutoff scores for cognitive impairment using 
Movement Disorder Society Task Force criteria for mild cognitive 
impairment in Parkinson's disease. Movement Disorders, 28, 1972-1979. 
doi:10.1002/mds.25655 
Goldman, J. G., Holden, S., Ouyang, B., Bernard, B., Goetz, C. G., & Stebbins, G. T. 
(2015). Diagnosing PD‐MCI by MDS task force criteria: How many and 




Goldman, J. G., & Weintraub, D. (2015). Advances in the treatment of cognitive 
impairment in Parkinson's disease. Movement Disorders, 30, 1471-1489. 
doi:10.1002/mds.26352 
Goldman, J. G., Weis, H., Stebbins, G., Bernard, B., & Goetz, C. G. (2012). Clinical 
differences among mild cognitive impairment subtypes in Parkinson's 
disease. Movement Disorders, 27, 1129-1136. doi:10.1002/mds.25062 
Gur, R. C., Alsop, D., Glahn, D., Petty, R., Swanson, C. L., Maldjian, J. A., . . . Gur, 
R. E. (2000). An fMRI study of sex differences in regional activation to a 
verbal and a spatial task. Brain and Language, 74, 157-170. 
doi:10.1006/brln.2000.2325 
Guse, B., Falkai, P., & Wobrock, T. (2010). Cognitive effects of high-frequency 
repetitive transcranial magnetic stimulation: A systematic review. Journal of 
Neural Transmission, 117, 105-122. doi:10.1007/s00702-009-0333-7 
Haaxma, C., Helmich, R., Borm, G., Kappelle, A., Horstink, M., & Bloem, B. 
(2010). Side of symptom onset affects motor dysfunction in Parkinson's 
disease. Neuroscience, 170, 1282-1285. 
doi:10.1016/j.neuroscience.2010.07.030 
Hagell, P., & Nygren, C. (2007). The 39 item Parkinson’s disease questionnaire 
(PDQ-39) revisited: Implications for evidence based medicine. Journal of 
Neurology, Neurosurgery & Psychiatry, 78, 1191-1198. 
doi:10.1136/jnnp.2006.111161  
Hanakawa, T., Katsumi, Y., Fukuyama, H., Honda, M., Hayashi, T., Kimura, J., & 
Shibasaki, H. (1999). Mechanisms underlying gait disturbance in Parkinson's 
disease. Brain, 122, 1271-1282. doi:10.1093/brain/122.7.1271 
Hanes, K. R., Andrewes, D. G., Smith, D. J., & Pantelis, C. (1996). A brief 
assessment of executive control dysfunction: Discriminant validity and 
homogeneity of planning, set shift, and fluency measures. Archives of 
Clinical Neuropsychology, 11, 185-191. doi:10.1093/arclin/11.3.185 
Hardoy, M. C., Carta, M. G., Catena, M., Hardoy, M. J., Cadeddu, M., Dell'Osso, L., 
. . . Carpiniello, B. (2004). Impairment in visual and spatial perception in 
schizophrenia and delusional disorder. Psychiatry Research, 127, 163-166. 
doi:10.1016/j.psychres.2004.03.002 
Hedges, L. (1983). A random effects model for effect sizes. Psychological Bulletin, 
93, 388-395. doi:10.1037//0033-2909.93.2.388 
175 
 
Hedges, L., & Olkin, I. (1985). Statistical methods for meta-analysis (Trans. ed. 
Vol.). Orlando, FL: Academic. 
Hedges, L., & Vevea, J. L. (1998). Fixed-and random-effects models in meta-
analysis. Psychological Methods, 3, 486-504. doi:10.1037//1082-
989X.3.4.486 
Hennessy, M., & Mackenzie, B. (1995). AUSNART: The development of an 
Australian version of the NART. Paper presented at the The 18th Annual 
Brain Impairment Conference, Hobart 
Henry, J. D., & Crawford, J. R. (2004). Verbal fluency deficits in Parkinson's 
disease: A meta-analysis. Journal of the International Neuropsychological 
Society, 10, 608-622. doi:10.1017/S1355617704104141 
Henry, J. D., & Crawford, J. R. (2005). The short‐form version of the Depression 
Anxiety Stress Scales (DASS‐21): Construct validity and normative data in a 
large non‐clinical sample. British Journal of Clinical Psychology, 44, 227-
239. doi:10.1348/014466505X29657 
Henry, J. D., Crawford, J. R., & Phillips, L. H. (2004). Verbal fluency performance 
in dementia of the Alzheimer’s type: A meta-analysis. Neuropsychologia, 42, 
1212-1222.  
Herwig, U., Satrapi, P., & Schönfeldt-Lecuona, C. (2003). Using the international 
10-20 EEG system for positioning of transcranial magnetic stimulation. Brain 
Topography, 16(2), 95-99. doi:10.1023/B:BRAT.0000006333.93597.9d 
Hester, R. L., Kinsella, G. J., Ong, B., & Turner, M. (2004). Hopkins verbal learning 
test: Normative data for older Australian adults. Australian Psychologist, 39, 
251-255. doi:10.1080/00050060412331295063 
Higgins, J. P., & Green, S. (2008). Cochrane handbook for systematic reviews of 
interventions (Trans. ed. Vol. 5). Chichester: John Wiley & Sons Ltd. 
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring 
inconsistency in meta-analyses. British Medical Journal, 327, 557-560.  
Higginson, C. I., King, D. S., Levine, D., Wheelock, V. L., Khamphay, N. O., & 
Sigvardt, K. A. (2003). The relationship between executive function and 




Hill, N. L., Kolanowski, A. M., & Gill, D. J. (2011). Plasticity in Early Alzheimer’s 
Disease: An Opportunity for Intervention. Topics in Geriatric Rehabilitation, 
27, 257.  
Hindle, J. V., Martyr, A., & Clare, L. (2014). Cognitive reserve in Parkinson's 
disease: A systematic review and meta-analysis. Parkinsonism & Related 
Disorders, 20, 1-7. doi:10.1016/j.parkreldis.2013.08.010 
Hindle, J. V., Petrelli, A., Clare, L., & Kalbe, E. (2013). Nonpharmacological 
enhancement of cognitive function in Parkinson's disease: A systematic 
review. Movement Disorders, 28, 1034-1049. doi:10.1002/mds.25377 
Hobson, P. J., Meara, R. J., & Evans, R. (2013). A pilot evaluation of a brief non-
verbal executive function assessment in Parkinson's disease. International 
Journal of Geriatric Psychiatry, 29, 207-216. doi:10.1002/gps.3996 
Hogervorst, E., Combrinck, M., Lapuerta, P., Rue, J., Swales, K., & Budge, M. 
(2001). The Hopkins verbal learning test and screening for dementia. 
Dementia and Geriatric Cognitive Disorders, 13, 13-20. 
doi:10.1159/000048628 
Hooper, H. (1958). The Hooper Visual Organisation Test: Manual (Trans. ed. Vol.). 
Beverley Hills, Calif: Western Psychological Services. 
Hooper, H. (1983). Hooper Visual Organisation Test: Manual (Trans. ed. Vol.). Los 
Angeles: Western Psychological Services. 
Hoops, S., Nazem, S., Siderowf, A., Duda, J., Xie, S., Stern, M., & Weintraub, D. 
(2009). Validity of the MoCA and MMSE in the detection of MCI and 
dementia in Parkinson disease. Neurology, 73, 1738-1745. doi:10.1212/WNL.
0b013e3181c34b47 
Howell, D. (2013). Statistical Methods for Psychology (Trans. 8th ed ed. Vol.). 
California, USA: Cengage Learning. 
Hsu, W.-Y., Zanto, T. P., Anguera, J. A., Lin, Y.-Y., & Gazzaley, A. (2015). 
Delayed enhancement of multitasking performance: effects of anodal 
transcranial direct current stimulation on the prefrontal cortex. Cortex, 69, 
175-185. doi:10.1016/j.cortex.2015.05.014 
Hu, M., Szewczyk‐Królikowski, K., Tomlinson, P., Nithi, K., Rolinski, M., Murray, 
C., . . . Ben‐Shlomo, Y. (2014). Predictors of cognitive impairment in an 




Huang, Y.-Z., Edwards, M. J., Rounis, E., Bhatia, K. P., & Rothwell, J. C. (2005). 
Theta burst stimulation of the human motor cortex. Neuron, 45, 201-206. 
doi:10.1016/j.neuron.2004.12.033 
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006). 
Assessing heterogeneity in meta-analysis: Q statistic or I² index? 
Psychological Methods, 11, 193-206. doi:10.1037/1082-989X.11.2.193 
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical 
diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 
100 cases. Journal of Neurology, Neurosurgery & Psychiatry, 55, 181-184. 
doi:10.1136/jnnp.55.3.181 
Jankovic, J. (2008). Parkinson’s disease: Clinical features and diagnosis. Journal of 
Neurology, Neurosurgery & Psychiatry, 79, 368-376. 
doi:10.1136/jnnp.2007.131045 
Janvin, C. C., Aarsland, D., & Larsen, J. P. (2005). Cognitive predictors of dementia 
in Parkinson’s disease: A community-based, 4-year longitudinal study. 
Journal of Geriatric Psychiatry and Neurology, 18, 149-154. 
doi:10.1177/0891988705277540 
Janvin, C. C., Larsen, J. P., Aarsland, D., & Hugdahl, K. (2006). Subtypes of mild 
cognitive impairment in Parkinson's disease: Progression to dementia. 
Movement Disorders, 21, 1343-1349. doi:10.1002/mds.20974 
Jean, L., Bergeron, M.-È., Thivierge, S., & Simard, M. (2010). Cognitive 
intervention programs for individuals with mild cognitive impairment: 
Systematic review of the literature. The American Journal of Geriatric 
Psychiatry, 18, 281-296. doi:10.1097/JGP.0b013e3181c37ce9 
Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The 
Parkinson's Disease Questionnaire (PDQ-39): Development and validation of 
a Parkinson's disease summary index score. Age and Ageing, 26, 353-357. 
doi:10.1093/ageing/26.5.353 
Jensen, A. R., & Rohwer, W. D. (1966). The Stroop color-word test: A review. Acta 
Psychologica, 25, 36-93.  
Johnson, M. H. (2003). Development of human brain functions. Biological 





Kaci-Fairchild, J., & Scogin, F. (2010). Training to Enhance Adult Memory 
(TEAM): An investigation of the effectiveness of a memory training program 
with older adults. Aging & Mental Health, 14, 364-373. 
doi:10.1080/13607860903311733 
Kadastik-Eerme, L., Muldmaa, M., Lilles, S., Rosenthal, M., Taba, N., & Taba, P. 
(2016). Nonmotor Features in Parkinson’s Disease: What Are the Most 
Important Associated Factors? Parkinson’s Disease, 2016, 1-8. 
doi:10.1155/2016/4370674 
Kalbe, E., Rehberg, S. P., Heber, I., Kronenbuerger, M., Schulz, J. B., Storch, A., . . . 
Liepelt-Scarfone, I. (2016). Subtypes of mild cognitive impairment in 
patients with Parkinson's disease: evidence from the LANDSCAPE study. 
Journal of Neurology, Neurosurgery & Psychiatry, doi:10.1136/jnnp-2016-
313838 
Kaplan, E., Goodglass, H., & Weintraub, S. (2001). Boston naming test (Trans. 2nd 
ed. Vol.). Texas: Austin: Pro-Ed. 
Kasten, M., & Klein, C. (2015). Genetic risk loci for Parkinson's disease: Moving 
from state to trait? Movement Disorders, 30(6), 747-749. 
doi:10.1002/mds.26246 
Kaszás, B., Kovács, N., Balás, I., Kállai, J., Aschermann, Z., Kerekes, Z., . . . Lucza, 
T. (2012). Sensitivity and specificity of addenbrooke’s cognitive 
examination, mattis dementia rating scale, frontal assessment battery and 
mini mental state examination for diagnosing dementia in Parkinson’s 
disease. Parkinsonism & Related Disorders, 18, 553-556. 
doi:10.1016/j.parkreldis.2012.02.010 
Kaufman, A. S., & Lichtenberger, E. O. (1999). Essentials of WAIS-III Assessment 
(Trans. ed. Vol.). Hoboken, NJ, US: John Wiley & Sons Inc. 
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010). Neuropsychological and 
clinical heterogeneity of cognitive impairment and dementia in patients with 
Parkinson's disease. The Lancet Neurology, 9, 1200-1213. 
doi:10.1016/S1474-4422(10)70212-X 
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013). Cognitive impairment in 
Parkinson’s disease: The dual syndrome hypothesis. Neurodegenerative 
Diseases, 11, 79-92. doi:10.1159/000341998 
179 
 
Kelly, M. E., Loughrey, D., Lawlor, B. A., Robertson, I. H., Walsh, C., & Brennan, 
S. (2014). The impact of cognitive training and mental stimulation on 
cognitive and everyday functioning of healthy older adults: A systematic 
review and meta-analysis. Ageing Research Reviews, In press, 
doi:10.1016/j.arr.2014.02.004 
Kelly, V. E., Johnson, C., McGough, E. L., Shumway-Cook, A., Horak, F., Chung, 
K., . . . Wood-Siverio, C. (2015). Association of cognitive domains with 
postural instability/gait disturbance in Parkinson's disease. Parkinsonism & 
Related Disorders, 21, 692-697. doi:10.1016/j.parkreldis.2015.04.002 
Khoo, T. K., Yarnall, A. J., Duncan, G. W., Coleman, S., O’Brien, J. T., Brooks, D. 
J., . . . Burn, D. J. (2013). The spectrum of nonmotor symptoms in early 
Parkinson disease. Neurology, 80, 276-281. doi:10.1212/WNL.
0b013e31827deb74 
Kim, E. Y., & Kim, K. W. (2014). A theoretical framework for cognitive and non-
cognitive interventions for older adults: Stimulation versus compensation. 
Aging & Mental Health, 18, 304-315. doi:10.1080/13607863.2013.868404 
Kim, H. S., Cheon, S.-M., Seo, J.-W., Ryu, H.-J., Park, K.-W., & Kim, J. W. (2013). 
Nonmotor symptoms more closely related to Parkinson's disease: Comparison 
with normal elderly. Journal of the Neurological Sciences, 324, 70-73. 
doi:10.1016/j.jns.2012.10.004 
Kimura, H., Kurimura, M., Kurokawa, K., Nagaoka, U., Arawaka, S., Wada, M., . . . 
Kato, T. (2011). A Comprehensive Study of Repetitive Transcranial 
Magnetic Stimulation in Parkinson's Disease. International Scholarly 
Research Notices, 2011, 1-7. doi:10.5402/2011/845453 
Klepac, N., Trkulja, V., Relja, M., & Babić, T. (2008). Is quality of life in non‐
demented Parkinson’s disease patients related to cognitive performance? A 
clinic‐based cross‐sectional study. European Journal of Neurology, 15, 128-
133. doi:10.1111/j.1468-1331.2007.02011.x 
Kline, P. (1999). The Handbook of Psychological Testing (Trans. 2nd ed ed. Vol.). 
London: Routledge. 
Korczyn, A. D. (2016). Parkinson's and Alzheimer's diseases: Focus on mild 




Kramer, A. F., Erickson, K. I., & Colcombe, S. J. (2006). Exercise, cognition, and 
the aging brain. Journal of Applied Physiology, 101, 1237-1242. 
doi:10.1152/japplphysiol.000500.2006 
Krishnan, S., Sarma, G., Sarma, S., & Kishore, A. (2011). Do nonmotor symptoms in 
Parkinson's disease differ from normal aging? Movement Disorders, 26, 
2110-2113. doi:10.1002/mds.23826 
Krueger, C., & Tian, L. (2004). A comparison of the general linear mixed model and 
repeated measures ANOVA using a dataset with multiple missing data points. 
Biological Research for Nursing, 6, 151-157. 
doi:10.1177/1099800404267682 
Kudlicka, A., Clare, L., & Hindle, J. V. (2011). Executive functions in Parkinson's 
disease: Systematic review and meta‐analysis. Movement Disorders, 26, 
2305-2315. doi:10.1002/mds.23868 
Kulisevsky, J., & Pagonabarraga, J. (2009). Cognitive impairment in Parkinson's 
disease: Tools for diagnosis and assessment. Movement Disorders, 24, 1103-
1110. doi:10.1002/mds.22506 
Kulisevsky, J., Pagonabarraga, J., Pascual‐Sedano, B., García‐Sánchez, C., & 
Gironell, A. (2008). Prevalence and correlates of neuropsychiatric symptoms 
in Parkinson's disease without dementia. Movement disorders, 23, 1889-1896. 
doi:10.1002/mds.22246 
Lacritz, L. H., Cullum, C. M., Weiner, M. F., & Rosenberg, R. N. (2001). 
Comparison of the Hopkins Verbal Learning Test-Revised to the California 
Verbal Learning Test in Alzheimer's disease. Applied Neuropsychology, 8, 
180-184. doi:10.1207/S15324826AN0803_8 
Lai, S. W., Su, L. T., Lin, C. H., Tsai, C. H., Sung, F. C., & Hsieh, D. P. H. (2011). 
Polypharmacy increases the risk of Parkinson's disease in older people in 
Taiwan: A population‐based study. Psychogeriatrics, 11, 150-156. 
doi:10.1111/j.1479-8301.2011.00369.x 
Lampit, A., Hallock, H., & Valenzuela, M. (2014). Computerized cognitive training 
in cognitively healthy older adults: A systematic review and meta-analysis of 




Lawrence, B. J., Gasson, N., Kane, R., Bucks, R. S., & Loftus, A. M. (2014). 
Activities of daily living, depression, and quality of life in Parkinson's 
disease. PloS One, 9, e102294. doi:10.1371/journal.pone.0102294 
Lawson, R. A., Yarnall, A. J., Duncan, G. W., Breen, D. P., Khoo, T. K., Williams-
Gray, C. H., . . . Burn, D. J. (2016). Cognitive decline and quality of life in 
incident Parkinson's disease: The role of attention. Parkinsonism & Related 
Disorders, 27, 47-53. doi:10.1016/j.parkreldis.2016.04.009 
Lee, E.-Y., Sen, S., Eslinger, P. J., Wagner, D., Kong, L., Lewis, M. M., . . . Huang, 
X. (2015). Side of motor onset is associated with hemisphere-specific 
memory decline and lateralized gray matter loss in Parkinson's disease. 
Parkinsonism & Related Disorders, 21, 465-470. 
doi:10.1016/j.parkreldis.2015.02.008 
Leung, I. H., Walton, C. C., Hallock, H., Lewis, S. J., Valenzuela, M., & Lampit, A. 
(2015). Cognitive training in Parkinson disease: A systematic review and 
meta-analysis. Neurology, 1-8. doi:10.1212/WNL. 0000000000002145 
Levy, G., Jacobs, D. M., Tang, M. X., Côté, L. J., Louis, E. D., Alfaro, B., . . . 
Marder, K. (2002). Memory and executive function impairment predict 
dementia in Parkinson's disease. Movement Disorders, 17, 1221-1226. 
doi:10.1002/mds.10280 
Lewis, S. J., & Barker, R. A. (2009). Understanding the dopaminergic deficits in 
Parkinson’s disease: Insights into disease heterogeneity. Journal of Clinical 
Neuroscience, 16, 620-625. doi:10.1016/j.jocn.2008.08.020 
Lewis, S. J., Dove, A., Robbins, T. W., Barker, R. A., & Owen, A. M. (2003). 
Cognitive impairments in early Parkinson's disease are accompanied by 
reductions in activity in frontostriatal neural circuitry. The Journal of 
Neuroscience, 23, 6351-6356.  
Lewis, S. J., Foltynie, T., Blackwell, A., Robbins, T., Owen, A., & Barker, R. (2005). 
Heterogeneity of Parkinson’s disease in the early clinical stages using a data 
driven approach. Journal of Neurology, Neurosurgery & Psychiatry, 76, 343-
348. doi:10.1136/jnnp.2003.033530 
Lezak, M., Howieson, D., & Loring, D. (2004). Neuropsychological assessment 
(Trans. 4th ed ed. Vol.). New York: Oxford University Press. 
Lezak, M., Howieson, D., & Loring, D. (2012). Neuropsychological assessment 
(Trans. 5th ed. Vol.). UK: Oxford university press. 
182 
 
Li, H., Li, J., Li, N., Li, B., Wang, P., & Zhou, T. (2011). Cognitive intervention for 
persons with mild cognitive impairment: A meta-analysis. Ageing Research 
Reviews, 10, 285-296. doi:10.1016/j.arr.2010.11.003 
Liepelt-Scarfone, I., Graeber, S., Feseker, A., Baysal, G., Godau, J., Gaenslen, A., . . 
. Berg, D. (2011). Influence of different cut-off values on the diagnosis of 
mild cognitive impairment in Parkinson's disease. Parkinson’s Disease, 2011, 
1-7. doi:10.4061/2011/540843 
Lill, C. M., Hansen, J., Olsen, J. H., Binder, H., Ritz, B., & Bertram, L. (2015). 
Impact of Parkinson's disease risk loci on age at onset. Movement Disorders, 
30, 847-850. doi:10.1002/mds.26237 
Litvan, I., Aarsland, D., Adler, C. H., Goldman, J. G., Kulisevsky, J., Mollenhauer, 
B., . . . Weintraub, D. (2011). MDS task force on mild cognitive impairment 
in Parkinson's disease: Critical review of PD‐MCI. Movement Disorders, 26, 
1814-1824. doi:10.1002/mds.23823 
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, 
R. C., . . . Williams‐Gray, C. H. (2012). Diagnostic criteria for mild cognitive 
impairment in Parkinson's disease: Movement Disorder Society Task Force 
guidelines. Movement Disorders, 27, 349-356. doi:10.1002/mds.24893 
Loftus, A. M., Bucks, R. S., Thomas, M., Kane, R., Timms, C., Barker, R. A., & 
Gasson, N. (2015). Retrospective Assessment of Movement Disorder Society 
Criteria for Mild Cognitive Impairment in Parkinson’s Disease. Journal of the 
International Neuropsychological Society, 21, 137-145. 
doi:10.1017/S1355617715000041 
Lopez, M. N., Lazar, M. D., & Oh, S. (2003). Psychometric properties of the Hooper 
Visual Organization Test. Assessment, 10, 66-70. 
doi:10.1177/1073191102250183 
Louis, E. D., & Bennett, D. A. (2007). Mild Parkinsonian signs: An overview of an 
emerging concept. Movement Disorders, 22, 1681-1688. 
doi:10.1002/mds.21433 
Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional 
states: Comparison of the Depression Anxiety Stress Scales (DASS) with the 
Beck Depression and Anxiety Inventories. Behaviour Research and Therapy, 
33, 335-343. doi:10.1016/0005-7967(94)00075-U 
183 
 
Lowe, C., & Rabbitt, P. (1998). Test\ re-test reliability of the CANTAB and ISPOCD 
neuropsychological batteries: Theoretical and practical issues. 
Neuropsychologia, 36, 915-923. doi:10.1016/S0028-3932(98)00036-0 
Mack, W. J., Freed, D. M., Williams, B. W., & Henderson, V. W. (1992). Boston 
Naming Test: Shortened versions for use in Alzheimer's disease. Journal of 
Gerontology, 47, P154-P158. doi:10.1093/geronj/47.3.P154 
Macleod, A. D., Taylor, K. S., & Counsell, C. E. (2014). Mortality in Parkinson's 
disease: A systematic review and meta‐analysis. Movement Disorders, 29, 
1615-1622. doi:10.1002/mds.25898 
Maetzler, W., Liepelt, I., & Berg, D. (2009). Progression of Parkinson's disease in 
the clinical phase: Potential markers. The Lancet Neurology, 8, 1158-1171. 
doi:10.1016/S1474-4422(09)70291-1 
Mahieux, F., Fénelon, G., Flahault, A., Manifacier, M.-J., Michelet, D., & Boller, F. 
(1998). Neuropsychological prediction of dementia in Parkinson’s disease. 
Journal of Neurology, Neurosurgery & Psychiatry, 64, 178-183.  
Mahlknecht, P., Seppi, K., & Poewe, W. (2015). The concept of prodromal 
Parkinson’s Disease. Journal of Parkinson's Disease, 5, 681-697. 
doi:10.3233/JPD-150685 
Mally, J., & Stone, T. (1999). Therapeutic and “dose‐dependent” effect of repetitive 
microelectroshock induced by transcranial magnetic stimulation in 
Parkinson's disease. Journal of Neuroscience Research, 57, 935-940.  
Mamikonyan, E., Moberg, P. J., Siderowf, A., Duda, J. E., Have, T. T., Hurtig, H. I., 
. . . Weintraub, D. (2009). Mild cognitive impairment is common in 
Parkinson's disease patients with normal Mini-Mental State Examination 
(MMSE) scores. Parkinsonism & Related Disorders, 15, 226-231. 
doi:10.1016/j.parkreldis.2008.05.006 
Mamikonyan, E., Xie, S. X., Melvin, E., & Weintraub, D. (2015). Rivastigmine for 
mild cognitive impairment in Parkinson disease: A placebo‐controlled study. 
Movement Disorders, 30, 912-918. doi:10.1002/mds.26236 
Man, D. W.-k., & Li, R. (2002). Assessing Chinese adults' memory abilities: 
Validation of the Chinese version of the Rivermead Behavioral Memory Test. 
Clinical Gerontologist, 24, 27-36. doi:10.1300/J018v24n03_04 
184 
 
Manly, J. J., Tang, M. X., Schupf, N., Stern, Y., Vonsattel, J. P. G., & Mayeux, R. 
(2008). Frequency and course of mild cognitive impairment in a multiethnic 
community. Annals of Neurology, 63, 494-506. doi:10.1002/ana.21326 
Marconi, S., & Zwingers, T. (2014). Comparative efficacy of selegiline versus 
rasagiline in the treatment of early Parkinson’s disease. European Review for 
Medical and Pharmacological Sciences, 18, 1879-1882.  
Marras, C., Armstrong, M. J., Meaney, C. A., Fox, S., Rothberg, B., Reginold, W., . . 
. Zadikoff, C. (2013). Measuring mild cognitive impairment in patients with 
Parkinson's disease. Movement Disorders, 28, 626-633. 
doi:10.1002/mds.25426 
Marras, C., & Chaudhuri, K. (2016). Nonmotor features of Parkinson's disease 
subtypes. Movement Disorders, doi:10.1002/mds.26510 
Martin, M., Clare, L., Altgassen, A. M., Cameron, M. H., & Zehnder, F. (2011). 
Cognition-based interventions for healthy older people and people with mild 
cognitive impairment. Cochrane Database Systematic Review, 1, 
doi:10.1002/14651858.CD006220.pub2. 
Martinez‐Martin, P., Reddy, P., Katzenschlager, R., Antonini, A., Todorova, A., 
Odin, P., . . . Rizos, A. (2015). EuroInf: A multicenter comparative 
observational study of apomorphine and levodopa infusion in Parkinson's 
disease. Movement Disorders, 30, 510-516. doi:10.1002/mds.26067 
Matsumoto, M. (2015). Dopamine signals and physiological origin of cognitive 
dysfunction in Parkinson's Disease. Movement Disorders, 30, 472-483. 
doi:10.1002/mds.26177 
May, C. P., & Hasher, L. (1998). Synchrony effects in inhibitory control over 
thought and action. Journal of Experimental Psychology: Human Perception 
and Performance, 24, 363-379. doi:10.1037/0096-1523.24.2.363 
McCulloch, C. E. (2006). Generalized linear mixed models (Trans. ed. Vol.). John 
Wiley & Sons. 
McKinlay, A., Grace, R. C., Dalrymple-Alford, J. C., & Roger, D. (2010). 
Characteristics of executive function impairment in Parkinson’s disease 
patients without dementia. Journal of the International Neuropsychological 





Menza, M., Dobkin, R. D., Marin, H., Mark, M., Gara, M., Buyske, S., . . . Dicke, A. 
(2009). A controlled trial of antidepressants in patients with Parkinson 
Disease and depression. Neurology, 72, 886-892. doi:10.1212/01.wnl.
0000336340.89821.b3 
Milman, U., Atias, H., Weiss, A., Mirelman, A., & Hausdorff, J. M. (2014). Can 
Cognitive Remediation Improve Mobility in Patients with Parkinson's 
Disease? Findings from a 12 week Pilot Study. Journal of Parkinson's 
Disease, 4, 37-44. doi:10.3233/JPD-130321 
Mitchell, A. J., & Shiri‐Feshki, M. (2009). Rate of progression of mild cognitive 
impairment to dementia - Meta‐analysis of 41 robust inception cohort studies. 
Acta Psychiatrica Scandinavica, 119, 252-265. doi:10.1111/j.1600-
0447.2008.01326.x 
Mitrushina, M., Boone, K. B., Razani, J., & Delia, L. F. (2005). Handbook of 
normative data for neuropsychological assessment (Trans. ed. Vol.). USA: 
Oxford University Press. 
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, 
T. D. (2000). The unity and diversity of executive functions and their 
contributions to complex “frontal lobe” tasks: A latent variable analysis. 
Cognitive Psychology, 41, 49-100. doi:10.1006/cogp.1999.0734 
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting 
items for systematic reviews and meta-analyses: The PRISMA statement. 
Annals of Internal Medicine, 151, 264-269. 
doi:10.1016/j.jclinepi.2009.06.005 
Mohlman, J., Chazin, D., & Georgescu, B. (2011). Feasibility and acceptance of a 
nonpharmacological cognitive remediation intervention for patients with 
Parkinson disease. Journal of Geriatric Psychiatry and Neurology, 24, 91-97. 
doi:10.1177/0891988711402350 
Montse, A., Pere, V., Carme, J., Francesc, V., & Eduardo, T. (2001). Visuospatial 
deficits in Parkinson's disease assessed by Judgment of Line Orientation test: 
Error analyses and practice effects. Journal of Clinical and Experimental 





Mor, V., Branco, K., Fleishman, J., Hawes, C., Phillips, C., Morris, J., & Fries, B. 
(1995). The structure of social engagement among nursing home residents. 
The Journals of Gerontology Series B: Psychological Sciences and Social 
Sciences, 50, 1-8. doi:10.1111/j.1532-5415.2000.tb02624.x 
Mowszowski, L., Batchelor, J., & Naismith, S. L. (2010). Early intervention for 
cognitive decline: Can cognitive training be used as a selective prevention 
technique? International Psychogeriatrics, 22, 537-548. 
doi:10.1017/S1041610209991748 
Muscari, A., Giannoni, C., Pierpaoli, L., Berzigotti, A., Maietta, P., Foschi, E., . . . 
Magalotti, D. (2010). Chronic endurance exercise training prevents aging‐
related cognitive decline in healthy older adults: A randomized controlled 
trial. International Journal of Geriatric Psychiatry, 25, 1055-1064. 
doi:10.1002/gps.2462 
Muslimović, D., Post, B., Speelman, J. D., & Schmand, B. (2005). Cognitive profile 
of patients with newly diagnosed Parkinson disease. Neurology, 65, 1239-
1245. doi:10.1212/01.wnl.0000180516.69442.95 
Muslimović, D., Post, B., Speelman, J. D., Schmand, B., de Haan, R. J., & Group, C. 
S. (2008). Determinants of disability and quality of life in mild to moderate 
Parkinson disease. Neurology, 70, 2241-2247. doi:10.1212/01.wnl.
0000313835.33830.80 
Muslimovic, D., Schmand, B., Speelman, J. D., & De Haan, R. J. (2007). Course of 
cognitive decline in Parkinson's disease: A meta-analysis. Journal of the 
International Neuropsychological Society, 13, 920-932. 
doi:10.10170S1355617707071160 
Mylius, V., Ciampi de Andrade, D., Cury, R. G., Teepker, M., Ehrt, U., Eggert, K. 
M., . . . Oertel, W. H. (2015). Pain in Parkinson's Disease: Current Concepts 
and a New Diagnostic Algorithm. Movement Disorders Clinical Practice, 2, 
357-364. doi:10.1002/mdc3.12217 
Nadler, J. D., Grace, J., White, D. A., Butters, M. A., & Malloy, P. F. (1996). 
Laterality differences in quantitative and qualitative Hooper performance. 




Naismith, S. L., Mowszowski, L., Diamond, K., & Lewis, S. J. (2013). Improving 
memory in Parkinson's disease: A healthy brain ageing cognitive training 
program. Movement Disorders, 28, 1097-1103. doi:10.1002/mds.25457 
Nalls, M. A., Escott‐Price, V., Williams, N. M., Lubbe, S., Keller, M. F., Morris, H. 
R., & Singleton, A. B. (2015). Genetic risk and age in Parkinson's disease: 
Continuum not stratum. Movement Disorders, 30, 850-854. 
doi:10.1002/mds.26192 
Nardone, R., Bergmann, J., Christova, M., Caleri, F., Tezzon, F., Ladurner, G., . . . 
Golaszewski, S. (2012). Effect of transcranial brain stimulation for the 
treatment of Alzheimer disease: A review. International Journal of 
Alzheimer's Disease, 2012, 1-5. doi:10.1155/2012/687909 
Ng, V., Bullmore, E. T., De Zubicaray, G., Cooper, A., Suckling, J., & Williams, S. 
C. (2001). Identifying rate-limiting nodes in large-scale cortical networks for 
visuospatial processing: An illustration using fMRI. Journal of Cognitive 
Neuroscience, 13, 537-545. doi:10.1162/08989290152001943 
Ng, V., Eslinger, P. J., Williams, S. C., Brammer, M. J., Bullmore, E. T., Andrew, C. 
M., . . . Benton, A. L. (2000). Hemispheric preference in visuospatial 
processing: A complementary approach with fMRI and lesion studies. Human 
Brain Mapping, 10, 80-86. doi:10.1002/(SICI)1097-0193(200006) 
Nitsche, M., & Paulus, W. (2000). Excitability changes induced in the human motor 
cortex by weak transcranial direct current stimulation. The Journal of 
Physiology, 527, 633-639. doi:10.1111/j.1469-7793.2000.t01-1-00633.x  
Nombela, C., Bustillo, P. J., Castell, P. F., Sanchez, L., Medina, V., & Herrero, M. T. 
(2011). Cognitive rehabilitation in Parkinson’s disease: Evidence from 
neuroimaging. Frontiers in Neurology, 2, 1-11. 
doi:10.3389/fneur.2011.00082 
Nombela, C., Rowe, J. B., Winder-Rhodes, S. E., Hampshire, A., Owen, A. M., 
Breen, D. P., . . . Barker, R. A. (2014). Genetic impact on cognition and brain 
function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain, 
(10), 2743-2758. doi:10.1093/brain/awu201 
Nordlund, A., Rolstad, S., Hellström, P., Sjögren, M., Hansen, S., & Wallin, A. 
(2005). The Goteborg MCI study: Mild cognitive impairment is a 
heterogeneous condition. Journal of Neurology, Neurosurgery & Psychiatry, 
76, 1485-1490. doi:10.1136/jnnp.2004.050385 
188 
 
Nyholm, D. (2012). Duodopa® treatment for advanced Parkinson's disease: A review 
of efficacy and safety. Parkinsonism & Related Disorders, 18, 916-929. 
doi:10.1016/j.parkreldis.2012.06.022 
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., . . . 
Stocchi, F. (2009). A double-blind, delayed-start trial of rasagiline in 
Parkinson's Disease. New England Journal of Medicine, 361, 1268-1278. 
doi:10.1056/NEJMoa0809335 
Olkin, I., & Gleser, L. (2009). Stochastically dependent effect sizes. The Handbook 
of Research Synthesis and Meta-analysis,  
Olma, M. C., Dargie, R. A., Behrens, J. R., Kraft, A., Irlbacher, K., Fahle, M., & 
Brandt, S. A. (2013). Long-term effects of serial anodal tDCS on motion 
perception in subjects with occipital stroke measured in the unaffected visual 
hemifield. Frontiers in Human Neuroscience, 7, 1-10. 
doi:10.3389/fnhum.2013.00314 
Optale, G., Urgesi, C., Busato, V., Marin, S., Piron, L., Priftis, K., . . . Bordin, A. 
(2010). Controlling memory impairment in elderly adults using virtual reality 
memory training: A randomized controlled pilot study. Neurorehabilitation 
and Neural Repair, 24, 348-357. doi:10.1177/1545968309353328 
Pagonabarraga, J. (2010). Parkinson’s disease: Definition, diagnosis, and 
management. Encyclopedia of Movement Disorders, 405-412.  
Pagonabarraga, J., Kulisevsky, J., Llebaria, G., García‐Sánchez, C., Pascual‐Sedano, 
B., & Gironell, A. (2008). Parkinson's disease‐cognitive rating scale: A new 
cognitive scale specific for Parkinson's disease. Movement Disorders, 23, 
998-1005. doi:10.1002/mds.22007 
Pai, M. C., & Chan, S. H. (2001). Education and cognitive decline in Parkinson's 
disease: A study of 102 patients. Acta Neurologica Scandinavica, 103, 243-
247. doi:10.1034/j.1600-0404.2001.103004243.x 
Pal, E., Nagy, F., Aschermann, Z., Balazs, E., & Kovacs, N. (2010). The impact of 
left prefrontal repetitive transcranial magnetic stimulation on depression in 
Parkinson's disease: A randomized, double‐blind, placebo‐controlled study. 





Pankratz, V. S., Roberts, R. O., Mielke, M. M., Knopman, D. S., Jack, C. R., Geda, 
Y. E., . . . Petersen, R. C. (2015). Predicting the risk of mild cognitive 
impairment in the Mayo Clinic Study of Aging. Neurology, 84, 1433-1442. 
doi:10.1212/WNL.0000000000001437 
París, A. P., Saleta, H. G., de la Cruz Crespo Maraver, M., Silvestre, E., Freixa, M. 
G., Torrellas, C. P., . . . Bartolomé, M. V. P. (2011). Blind randomized 
controlled study of the efficacy of cognitive training in Parkinson's disease. 
Movement Disorders, 26, 1251-1258. doi:10.1002/mds.23688 
Park, D. C., & Reuter-Lorenz, P. (2009). The adaptive brain: Aging and 
neurocognitive scaffolding. Annual Review of Psychology, 60, 173-196. 
doi:10.1146/annurev.psych.59.103006.093656 
Parkinson, J. (1817). An Essay on the Shaking Palsy (Trans. ed. Vol.). London: 
Sherwood, Neely, and Jones. 
Parkinson Study Group. (2004). A controlled, randomized, delayed-start study of 
rasagiline in early Parkinson Disease. Archives of Neurology, 61, 561-566. 
doi:10.1001/archneur.61.4.561 
Pascual-Leone, A., Tormos, J. M., Keenan, J., Tarazona, F., Cañete, C., & Catalá, M. 
D. (1998). Study and modulation of human cortical excitability with 
transcranial magnetic stimulation. Journal of Clinical Neurophysiology, 15, 
333-343. doi:10.1097/00004691-199807000-00005 
Pascual-Leone, A., Wassermann, E. M., Grafman, J., & Hallett, M. (1996). The role 
of the dorsolateral prefrontal cortex in implicit procedural learning. 
Experimental Brain Research, 107, 479-485. doi:10.1007/BF00230427 
PD Med Collaborative Group. (2014). Long-term effectiveness of dopamine agonists 
and monoamine oxidase B inhibitors compared with levodopa as initial 
treatment for Parkinson's disease (PD MED): A large, open-label, pragmatic 
randomised trial. The Lancet, 384, 1196-1205. doi:10.1016/S0140-
6736(14)60683-8 
Pedersen, K. F., Larsen, J. P., Tysnes, O.-B., & Alves, G. (2013). Prognosis of mild 
cognitive impairment in early Parkinson disease: The Norwegian ParkWest 





Pena, J., Ibarretxe-Bilbao, N., Garcia-Gorostiaga, I., Gomez-Beldarrain, M. A., Diez-
Cirarda, M., & Ojeda, N. (2014). Improving functional disability and 
cognition in Parkinson disease. Neurology, 83, 1-8. 
doi:10.1212/WNL.0000000000001043 
Pereira, J. B., Junqué, C., Bartrés-Faz, D., Martí, M. J., Sala-Llonch, R., Compta, Y., 
. . . Valls-Solé, J. (2013). Modulation of verbal fluency networks by 
transcranial direct current stimulation (tDCS) in Parkinson’s disease. Brain 
Stimulation, 6, 16-24. doi:10.1016/j.brs.2012.01.006 
Pérez, M., & Godoy, J. (1998). Comparison between a “traditional” memory test and 
a “behavioral” memory battery in Spanish patients. Journal of Clinical and 
Experimental Neuropsychology, 20, 496-502. doi:10.1076/jcen.20.4.496.1478 
Petersen, R. C. (2000). Mild cognitive impairment: Transition between aging and 
Alzheimer's disease. Neurologia (Barcelona, Spain), 15, 93.  
Petersen, R. C. (2011). Mild cognitive impairment. New England Journal of 
Medicine, 364, 2227-2234. doi:10.1056/NEJMcp0910237 
Petersen, R. C., Roberts, R., Knopman, D., Geda, Y., Cha, R., Pankratz, V., . . . 
Rocca, W. (2010). Prevalence of mild cognitive impairment is higher in men: 
The Mayo Clinic Study of Aging. Neurology, 75, 889-897. 
doi:10.1212/WNL.0b013e3181f11d85 
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & 
Kokmen, E. (1999). Mild cognitive impairment: Clinical characterization and 
outcome. Archives of Neurology, 56, 303-308. doi:10.1001/archneur.56.3.303 
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., . . 
. Levey, A. (2005). Vitamin E and donepezil for the treatment of mild 
cognitive impairment. New England Journal of Medicine, 352, 2379-2388. 
doi:10.1056/NEJMoa050151 
Peto, V., Jenkinson, C., & Fitzpatrick, R. (1998). PDQ-39: A review of the 
development, validation and application of a Parkinson’s disease quality of 
life questionnaire and its associated measures. Journal of Neurology, 245, 10-
14. doi:10.1007/PL00007730 
Petrelli, A., Kaesberg, S., Barbe, M. T., Timmermann, L., Fink, G. R., Kessler, J., & 
Kalbe, E. (2014). Effects of cognitive training in Parkinson’s Disease: A 




Pfeiffer, R. F. (2016). Non-motor symptoms in Parkinson's disease. Parkinsonism & 
Related Disorders, 22, S119-S122. doi:10.1016/j.parkreldis.2015.09.004 
Poletti, M., Emre, M., & Bonuccelli, U. (2011). Mild cognitive impairment and 
cognitive reserve in Parkinson’s disease. Parkinsonism & Related Disorders, 
17, 579-586. doi:10.1016/j.parkreldis.2011.03.013 
Pompeu, J. E., Mendes, F. A. d. S., Silva, K. G. d., Lobo, A. M., Oliveira, T. d. P., 
Zomignani, A. P., & Piemonte, M. E. P. (2012). Effect of Nintendo Wii™-
based motor and cognitive training on activities of daily living in patients 
with Parkinson's disease: A randomised clinical trial. Physiotherapy, 98, 196-
204. doi:10.1016/j.physio.2012.06.004 
Ponti, G., Peretto, P., & Bonfanti, L. (2008). Genesis of neuronal and glial 
progenitors in the cerebellar cortex of peripuberal and adult rabbits. PLoS 
One, 3, e2366. doi:10.1371/journal.pone.0002366 
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., . . . 
Lang, A. E. (2015). MDS clinical diagnostic criteria for Parkinson's disease. 
Movement Disorders, 30, 1591-1601. doi:10.1002/mds.26424 
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. (2014). The prevalence of 
Parkinson's disease: A systematic review and meta‐analysis. Movement 
Disorders, 29, 1583-1590. doi:10.1002/mds.25945 
Qualls, C. E., Bliwise, N. G., & Stringer, A. Y. (2000). Short forms of the Benton 
judgment of line orientation test: Development and psychometric properties. 
Archives of Clinical Neuropsychology, 15, 159-163. doi:10.1016/S0887-
6177(98)00043-2 
Rabey, J. M., Dobronevsky, E., Aichenbaum, S., Gonen, O., Marton, R. G., & 
Khaigrekht, M. (2013). Repetitive transcranial magnetic stimulation 
combined with cognitive training is a safe and effective modality for the 
treatment of Alzheimer’s disease: A randomized, double-blind study. Journal 
of Neural Transmission, 120, 813-819. doi:10.1007/s00702-012-0902-z 
Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in 
Parkinson's disease: The relative importance of the symptoms. Movement 
Disorders, 23(10), 1428-1434. doi:10.1002/mds.21667 
Rajput, A., Rozdilsky, B., & Rajput, A. (1991). Accuracy of clinical diagnosis in 
parkinsonism: A prospective study. The Canadian Journal of Neurological 
Sciences, 18, 275-278.  
192 
 
Ramirez-Ruiz, B., Junque, C., Martí, M.-J., Valldeoriola, F., & Tolosa, E. (2007). 
Cognitive changes in Parkinson’s disease patients with visual hallucinations. 
Dementia and Geriatric Cognitive Disorders, 23, 281-288. 
doi:10.1159/000100850 
Rasquin, S., Lodder, J., Visser, P., Lousberg, R., & Verhey, F. (2005). Predictive 
accuracy of MCI subtypes for Alzheimer’s disease and vascular dementia in 
subjects with mild cognitive impairment: A 2-year follow-up study. Dementia 
and Geriatric Cognitive Disorders, 19, 113-119. doi:10.1159/000082662 
Ray, J. W., & Shadish, W. R. (1996). How interchangeable are different estimators 
of effect size? Journal of Consulting and Clinical Psychology, 64, 1316-
1325. doi:10.1037//0022-006X.64.6.1316 
Reid, W., Hely, M., Morris, J., Loy, C., & Halliday, G. (2011). Dementia in 
Parkinson's disease: A 20-year neuropsychological study (Sydney 
Multicentre Study). Journal of Neurology, Neurosurgery & Psychiatry, 82, 
1033-1037. doi:10.1136/jnnp.2010.232678 
Reijnders, J. S., Ehrt, U., Weber, W. E., Aarsland, D., & Leentjens, A. F. (2008). A 
systematic review of prevalence studies of depression in Parkinson's disease. 
Movement Disorders, 23, 183-189. doi:10.1002/mds.21803 
Reitan, R. M. (1992). Trail Making Test: Manual for administration and scoring 
(Trans. ed. Vol.). Reitan Neuropsychology Laboratory. 
Reuter, I., Mehnert, S., Sammer, G., Oechsner, M., & Engelhardt, M. (2012). 
Efficacy of a Multimodal Cognitive Rehabilitation Including Psychomotor 
and Endurance Training in Parkinson's Disease. Journal of Aging Research, 
2012, 1-15. doi:10.1155/2012/235765 
Ribeiro, F., De Mendonca, A., & Guerreiro, M. (2006). Mild cognitive impairment: 
Deficits in cognitive domains other than memory. Dementia and Geriatric 
Cognitive Disorders, 21, 284-290. doi:10.1159/000091435 
Ricker, J. H., & Axelrod, B. N. (1995). Hooper Visual Organization Test: Effects of 
object naming ability. The Clinical Neuropsychologist, 9, 57-62. 
doi:10.1080/13854049508402058 
Rosenthal, E., Brennan, L., Xie, S., Hurtig, H., Milber, J., Weintraub, D., . . . 
Siderowf, A. (2010). Association between cognition and function in patients 




Rosenthal, R. (1979). The file drawer problem and tolerance for null results. 
Psychological Bulletin, 86, 638-641. doi:10.1037//0033-2909.86.3.638 
Rothlind, J. C., York, M. K., Carlson, K., Luo, P., Marks, W. J., Weaver, F. M., . . . 
Ippolito, D. (2014). Neuropsychological changes following deep brain 
stimulation surgery for Parkinson's disease: Comparisons of treatment at 
pallidal and subthalamic targets versus best medical therapy. Journal of 
Neurology, Neurosurgery & Psychiatry, 1-9. doi:10.1136/jnnp-2014-308119 
Sales-Galán, A., Meléndez-Moral, J. C., & Mayordomo-Rodríguez, T. (2013). Using 
a cognitive plasticity measure to detect mild cognitive impairment. Archives 
of Clinical Neuropsychology, 28, 763-770. doi:10.1093/arclin/act064 
Sammer, G., Reuter, I., Hullmann, K., Kaps, M., & Vaitl, D. (2006). Training of 
executive functions in Parkinson's disease. Journal of the Neurological 
Sciences, 248, 115-119. doi:10.1016/j.jns.2006.05.028 
Saunders, N. L., & Summers, M. J. (2011). Longitudinal deficits to attention, 
executive, and working memory in subtypes of mild cognitive impairment. 
Neuropsychology, 25, 237-248. doi:10.1037/a0021134 
Schulz, K. F., & Grimes, D. A. (2002). Generation of allocation sequences in 
randomised trials: Chance, not choice. The Lancet, 359, 515-519. 
doi:10.1016/S0140-6736(02)07683-3 
Sedláčková, S., Rektorová, I., Srovnalová, H., & Rektor, I. (2009). Effect of high 
frequency repetitive transcranial magnetic stimulation on reaction time, 
clinical features and cognitive functions in patients with Parkinson’s disease. 
Journal of Neural Transmission, 116, 1093-1101. doi:10.1007/s00702-009-
0259-0 
Shapiro, A. M., Benedict, R. H., Schretlen, D., & Brandt, J. (1999). Construct and 
concurrent validity of the Hopkins Verbal Learning Test–revised. The 
Clinical Neuropsychologist, 13, 348-358. doi:10.1076/clin.13.3.348.1749 
Sindhi, A., & Leroi, I. (2013). Nonpharmacological therapies for cognitive 
enhancement in Parkison's disease: Applying old interventions in a new 
setting? Neurodegenerative Disease Management, 36, 539-547. 
doi:10.2217/NMT.13.67 
Sinforiani, E., Banchieri, L., Zucchella, C., Pacchetti, C., & Sandrini, G. (2004). 
Cognitive rehabilitation in Parkinson’s disease. Archives of Gerontology and 
Geriatrics, 38, 387-391. doi:10.1016/j.archger.2004.04.049 
194 
 
Ska, B., Poissant, A., & Joanette, Y. (1990). Line orientation judgment in normal 
elderly and subjects with dementia of Alzheimer's type. Journal of Clinical 
and Experimental Neuropsychology, 12, 695-702. 
doi:10.1080/01688639008401012 
Smith, E. E., & Jonides, J. (1999). Storage and executive processes in the frontal 
lobes. Science, 283, 1657-1661. doi:10.1126/science.283.5408.1657 
Sollinger, A. B., Goldstein, F. C., Lah, J. J., Levey, A. I., & Factor, S. A. (2010). 
Mild cognitive impairment in Parkinson's disease: Subtypes and motor 
characteristics. Parkinsonism & Related Disorders, 16, 177-180. 
doi:10.1016/j.parkreldis.2009.11.002 
Spreng, R. N., Wojtowicz, M., & Grady, C. L. (2010). Reliable differences in brain 
activity between young and old adults: A quantitative meta-analysis across 
multiple cognitive domains. Neuroscience & Biobehavioral Reviews, 34, 
1178-1194. doi:10.1016/j.neubiorev.2010.01.009 
Srovnalova, H., Marecek, R., Kubikova, R., & Rektorova, I. (2012). The role of the 
right dorsolateral prefrontal cortex in the Tower of London task performance: 
repetitive transcranial magnetic stimulation study in patients with Parkinson’s 
disease. Experimental brain research, 223(2), 251-257. doi:10.1007/s00221-
012-3255-9 
Srovnalova, H., Marecek, R., & Rektorova, I. (2011). The role of the inferior frontal 
gyri in cognitive processing of patients with Parkinson's disease: A pilot 
rTMS study. Movement Disorders, 26, 1545-1548. doi:10.1002/mds.23663 
Starkstein, S. E., Mayberg, H. S., Leiguarda, R., Preziosi, T. J., & Robinson, R. G. 
(1992). A prospective longitudinal study of depression, cognitive decline, and 
physical impairments in patients with Parkinson's disease. Journal of 
Neurology, Neurosurgery & Psychiatry, 55, 377-382. 
doi:10.1136/jnnp.55.5.377 
Stein, D. G., & Hoffman, S. W. (2003). Concepts of CNS plasticity in the context of 
brain damage and repair. The Journal of Head Trauma Rehabilitation, 18, 
317-341. doi:10.1097/00001199-200307000-00004 
Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer's disease. The Lancet 
Neurology, 11, 1006-1012.  
195 
 
Sterne, J. A., Egger, M., & Smith, G. D. (2001). Systematic reviews in health care: 
Investigating and dealing with publication and other biases in meta-analysis. 
British Medical Journal, 323, 101-105.  
Strauss, E., Sherman, E., & Spreen, O. (2006). A compendium of neuropsychological 
tests: Administration, norms, and commentary (Trans. ed. Vol.). UK: Oxford 
University Press. 
Stroop, J. R. (1935). The basis of Ligon's theory. The American Journal of 
Psychology, 47, 499-504. doi:10.2307/1416349  
Stuss, D. T., & Alexander, M. P. (2007). Is there a dysexecutive syndrome? 
Philosophical Transactions of the Royal Society B: Biological Sciences, 362, 
901-915. doi:10.1098/rstb.2007.2096 
Sullivan, R., Senior, G., & Scarcia, M. (2000). Australian age-education and 
premorbid cognitive intellectual stimates for the WAIS-III. Paper presented at 
the 6th National Conference of the APS College of Clinical 
Neuropsychologists, Hunter Valley, New South Wales, Australia 
Svenningsson, P., Westman, E., Ballard, C., & Aarsland, D. (2012). Cognitive 
impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and 
treatment. The Lancet Neurology, 11, 697-707. doi:10.1016/S1474-
4422(12)70152-7 
Tabachnick, B. G., & Fidell, L. S. (2013). Using Multivariate Statistics (Trans. 6th 
ed. Vol.). Boston, MA: Pearson/Allyn and Bacon. 
Tamkin, A. S., & Jacobsen, R. (1984). Age‐related norms for the Hooper Visual 
Organization Test. Journal of Clinical Psychology, 40, 1459-1463. 
doi:10.1002/1097-4679(198411)40:6<1459::AID-
JCLP2270400633>3.0.CO;2-3 
Tappen, R. M., & Hain, D. (2014). The effect of in-home cognitive training on 
functional performance of individuals with mild cognitive impairment and 
early-stage Alzheimer's disease. Research in Gerontological Nursing, 7, 14-
24. doi:10.3928/19404921-20131009-01 
Tárraga, L., Boada, M., Modinos, G., Espinosa, A., Diego, S., Morera, A., . . . 
Becker, J. T. (2006). A randomised pilot study to assess the efficacy of an 
interactive, multimedia tool of cognitive stimulation in Alzheimer’s disease. 




Taylor, A., Saint-Cyr, J., & Lang, A. (1986). Frontal lobe dysfunction in Parkinson's 
disease. Brain, 109, 845-883. doi:10.1093/brain/109.5.845 
Teixeira, C. V. L., Gobbi, L. T. B., Corazza, D. I., Stella, F., Costa, J. L. R., & 
Gobbi, S. (2012). Non-pharmacological interventions on cognitive functions 
in older people with mild cognitive impairment (MCI). Archives of 
Gerontology and Geriatrics, 54, 175-180. doi:10.1016/j.archger.2011.02.014 
Thornton, A., & Lee, P. (2000). Publication bias in meta-analysis: Its causes and 
consequences. Journal of Clinical Epidemiology, 53, 207-216. 
doi:10.1016/S0895-4356(99)00161-4 
Tombaugh, T. N., & Hubiey, A. M. (1997). The 60-item Boston Naming Test: 
Norms for cognitively intact adults aged 25 to 88 years. Journal of Clinical 
and Experimental Neuropsychology, 19, 922-932. 
doi:10.1080/01688639708403773 
Tombaugh, T. N., Kozak, J., & Rees, L. (1999). Normative data stratified by age and 
education for two measures of verbal fluency: FAS and animal naming. 
Archives of Clinical Neuropsychology, 14, 167-177.  
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010). 
Systematic review of levodopa dose equivalency reporting in Parkinson's 
disease. Movement Disorders, 25, 2649-2653. doi:10.1002/mds.23429 
Trahan, D. E. (1998). Judgment of line orientation in patients with unilateral 
cerebrovascular lesions. Assessment, 5, 227-235. 
doi:10.1177/107319119800500303 
Tröster, A. I., Woods, S. P., & Morgan, E. E. (2007). Assessing cognitive change in 
Parkinson's disease: Development of practice effect-corrected reliable change 
indices. Archives of Clinical Neuropsychology, 22, 711-718. 
doi:10.1016/j.acn.2004.12.003 
Troeung, L., Egan, S. J., & Gasson, N. (2013). A meta-analysis of randomised 
placebo-controlled treatment trials for depression and anxiety in Parkinson’s 
Disease. PloS one, (11), e79510. doi:10.1371/journal.pone.0079510 
van Uem, J. M., Marinus, J., Canning, C., van Lummel, R., Dodel, R., Liepelt-
Scarfone, I., . . . Maetzler, W. (2016). Health-related quality of life in patients 
with Parkinson's disease—a systematic review based on the ICF model. 




Verhaeghen, P. (2000). The interplay of growth and decline: Theoretical and 
empirical aspects of plasticity of intellectual and memory performance in 
normal old age. Cognitive Rehabilitation in Old Age, 3-22.  
Verleden, S., Vingerhoets, G., & Santens, P. (2007). Heterogeneity of cognitive 
dysfunction in Parkinson’s disease: A cohort study. European Neurology, 58, 
34-40. doi:10.1159/000102164 
Volkmann, J., Albanese, A., Antonini, A., Chaudhuri, K. R., Clarke, C. E., de Bie, R. 
M., . . . Kulisevsky, J. (2013). Selecting deep brain stimulation or infusion 
therapies in advanced Parkinson’s disease: An evidence-based review. 
Journal of Neurology, 260, 2701-2714. doi:10.1007/s00415-012-6798-6 
Wall, J., Xu, J., & Wang, X. (2002). Human brain plasticity: An emerging view of 
the multiple substrates and mechanisms that cause cortical changes and 
related sensory dysfunctions after injuries of sensory inputs from the body. 
Brain Research Reviews, 39, 181-215.  
Walton, C. C., Mowszowski, L., Lewis, S. J., & Naismith, S. L. (2014). Stuck in the 
mud: Time for change in the implementation of cognitive training research in 
ageing? Frontiers in Aging Neuroscience, 6, 1-4. 
doi:10.3389/fnagi.2014.00043 
Wang, H.-F., Yu, J.-T., Tang, S.-W., Jiang, T., Tan, C.-C., Meng, X.-F., . . . Tan, L. 
(2014). Efficacy and safety of cholinesterase inhibitors and memantine in 
cognitive impairment in Parkinson's disease, Parkinson's disease dementia, 
and dementia with Lew bobies: Systematice review with meta-analysis and 
trial sequential analysis. Journal of Neurology, Neurosurgery & Psychiatry, 
86, 135-143. doi:10.1136/jnnp-2014-307659 
Watts, R. L. (1997). The role of dopamine agonists in early Parkinson's Disease. 
Neurology, 49, S34-S48. doi:10.1212/WNL.49.1_Suppl_1.S34 
Wechsler, D. (2008). Wechsler Adult Intelligence Scale–Fourth Edition (WAIS–IV). 
San Antonio, TX: NCS Pearson,  
Weingarten, C. P., Sundman, M. H., Hickey, P., & Chen, N.-k. (2015). 
Neuroimaging of Parkinson's disease: Expanding views. Neuroscience & 
Biobehavioral Reviews, 59, 16-52. doi:10.1016/j.neubiorev.2015.09.007 
Weintraub, D., & Burn, D. J. (2011). Parkinson's disease: The quintessential 




Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., . . . 
Lang, A. E. (2010). Impulse control disorders in Parkinson disease: A cross-
sectional study of 3090 patients. Archives of neurology, 67, 589-595. 
doi:10.1001/archneurol.2010.65 
Weintraub, D., Moberg, P. J., Culbertson, W. C., Duda, J. E., & Stern, M. B. (2004). 
Evidence for impaired encoding and retrieval memory profiles in Parkinson 
disease. Cognitive and Behavioral Neurology, 17, 195-200.  
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2003). 
Recognition and treatment of depression in Parkinson's disease. Journal of 
Geriatric Psychiatry and Neurology, 16, 178-183. 
doi:10.1177/0891988703256053 
Weintraub, D., Simuni, T., Caspell‐Garcia, C., Coffey, C., Lasch, S., Siderowf, A., . . 
. Chahine, L. M. (2015). Cognitive performance and neuropsychiatric 
symptoms in early, untreated Parkinson's disease. Movement Disorders, 30, 
919-927. doi:10.1002/mds.26170 
Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., 
. . . Sawcer, S. J. (2009). The distinct cognitive syndromes of Parkinson's 
disease: 5 year follow-up of the CamPaIGN cohort. Brain, 132, 2958-2969. 
doi:10.1093/brain/awp245 
Williams-Gray, C. H., Foltynie, T., Brayne, C., Robbins, T., & Barker, R. (2007). 
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. 
Brain, 130, 1787-1798. doi:10.1093/brain/awm111  
Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, 
T. W., & Barker, R. A. (2013). The CamPaIGN study of Parkinson's disease: 
10-year outlook in an incident population-based cohort. Journal of 
Neurology, Neurosurgery & Psychiatry, 84, 1258-1264. doi:10.1136/jnnp-
2013-305277 
Williams, A., Gill, S., Varma, T., Jenkinson, C., Quinn, N., Mitchell, R., . . . Daniels, 
J. (2010). Deep brain stimulation plus best medical therapy versus best 
medical therapy alone for advanced Parkinson's disease (PD SURG trial): A 






Willis, S. L., Tennstedt, S. L., Marsiske, M., Ball, K., Elias, J., Koepke, K. M., . . . 
Stoddard, A. M. (2006). Long-term effects of cognitive training on everyday 
functional outcomes in older adults. Journal of the American Medical 
Association, 296, 2805-2814. doi:10.1001/jama.296.23.2805 
Wilson, B., Cockburn, J., Baddeley, A., & Hiorns, R. (1989). The development and 
validation of a test battery for detecting and monitoring everyday memory 
problems. Journal of Clinical and Experimental Neuropsychology, 11, 855-
870. doi:10.1080/01688638908400940 
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., . . . 
Almkvist, O. (2004). Mild cognitive impairment–beyond controversies, 
towards a consensus: Report of the International Working Group on mild 
cognitive impairment. Journal of Internal Medicine, 256, 240-246. 
doi:10.1111/j.1365-2796.2004.01380.x 
Witjas, T., Kaphan, E., Azulay, J., Blin, O., Ceccaldi, M., Pouget, J., . . . Chérif, A. 
A. (2002). Nonmotor fluctuations in Parkinson’s disease: Frequent and 
disabling. Neurology, 59, 408-413. doi:10.1212/WNL.59.3.408 
Woods, B., Aguirre, E., Spector, A. E., & Orrell, M. (2012). Cognitive stimulation to 
improve cognitive functioning in people with dementia. The Cochrane 
Library, 2, doi:10.1002/14651858.CD005562.pub2 
Woods, B., Thorgrimsen, L., Spector, A., Royan, L., & Orrell, M. (2006). Improved 
quality of life and cognitive stimulation therapy in dementia. Aging and 
Mental Health, 10, 219-226. doi:10.1080/13607860500431652 
World Health Organisation. (2015). Number of people over 60 years set to double by 
2050: Major societal changes required (Trans. ed. Vol.). Retrieved 9th 
August from, http://www.who.int/mediacentre/news/releases/2015/older-
persons-day/en/. 
Worth, P. F. (2013). When the going gets tough: How to select patients with 
Parkinson's disease for advanced therapies. Practical Neurology, 1-13. 
doi:10.1136/practneurol-2012-000463 
Xu, J., Zhang, J., Wang, J., Li, G., Hu, Q., & Zhang, Y. (2016). Abnormal fronto-
striatal functional connectivity in Parkinson’s disease. Neuroscience Letters, 
613, 66-71. doi:10.1016/j.neulet.2015.12.041 
200 
 
Yan, J. H. (2000). Effects of aging on linear and curvilinear aiming arm movements. 
Experimental Aging Research, 26, 393-407. 
doi:10.1080/036107300750015778 
Yarnall, A. J., Rochester, L., & Burn, D. J. (2013). Mild cognitive impairment in 
Parkinson's disease. Age and Ageing, 42, 567-576. doi:10.1093/ageing/aft085 
Zehnder, F., Martin, M., Altgassen, M., & Clare, L. (2009). Memory training effects 
in old age as markers of plasticity: A meta-analysis. Restorative Neurology 
and Neuroscience, 27, 507-520. doi:10.3233/RNN-2009-0491 
Zelazo, P. D., & Carlson, S. M. (2012). Hot and cool executive function in childhood 
and adolescence: Development and plasticity. Child Development 
Perspectives, 6, 354-360. doi:10.1111/j.1750-8606.2012.00246.x 
Zhang, S., Ou, R., Chen, X., Yang, J., Zhao, B., Yuan, X., . . . Shang, H.-F. (2016). 
Correlative factors of cognitive dysfunction in PD patients: a cross-sectional 
study from Southwest China. Neurological Research, 38, 434-440. 
doi:10.1080/01616412.2016.1139320 
Zimmermann, R., Gschwandtner, U., Benz, N., Hatz, F., Schindler, C., Taub, E., & 
Fuhr, P. (2014). Cognitive training in Parkinson disease: Cognition-specific 
vs nonspecific computer training. Neurology, 82, 1219-1226. 
doi:10.1212/WNL.0000000000000287 
Zis, P., Martinez‐Martin, P., Sauerbier, A., Rizos, A., Sharma, J., Worth, P., . . . 
Chaudhuri, K. (2015). Non‐motor symptoms burden in treated and untreated 
early Parkinson's disease patients: Argument for non‐motor subtypes. 













Every reasonable effort has been made to acknowledge the owners of copyright 
material. I would be pleased to hear from any copyright owner who has been omitted 

















































To Whom It May Concern 
I, Blake Justin Lawrence, contributed to the study design, recruiting participants, 
conducting neuropsychological assessments, analysing the data, writing the initial 
manuscript, and editing the final manuscript of the publication entitled ‘Lawrence, 
BJ, et al. Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s 
Disease. Scientific Reports, In Press, (2016).’ 
Candidate signature: ………………………. 
I, as a Co-Author, endorse that this level of contribution by the candidate indicated 
above is appropriate. 
Co-Author 1: ………………………. Signature:  …………………… 
















Stockings of Cambridge 
 
Cambridge Neuropsychological Test of 




Controlled Oral Word 
Association 
 
Tombaugh, T. N., & Hubiey, A. M. 
(1997). The 60-item Boston Naming Test: 
Norms for cognitively intact adults aged 
25 to 88 years. Journal of Clinical and 
Experimental Neuropsychology, 19, 922-
932. doi:10.1080/01688639708403773 
 







Wechsler, D. (2008). Wechsler Adult 
Intelligence Scale–Fourth Edition (WAIS–





Fisher, L. M., Freed, D. M., & Corkin, S. 
(1990). Stroop Color-Word Test 
performance in patients with Alzheimer's 
disease. Journal of Clinical and 






Learning Test – Revised  
 
Brandt, J., & Benedict, R. H. (2001). 
Hopkins Verbal Learning Test-Revised: 
Professional Manual. Lutz, FL: 
Psychological Assessment Resources. 
 
Hester, R. L., Kinsella, G. J., Ong, B., & 
Turner, M. (2004). Hopkins verbal 
learning test: Normative data for older 






Wilson, B., Cockburn, J., Baddeley, A., & 
Hiorns, R. (1989). The development and 
validation of a test battery for detecting 
and monitoring everyday memory 
problems. Journal of Clinical and 
Experimental Neuropsychology, 11, 855-
870. doi:10.1080/01688638908400940 
 
Strauss, E., Sherman, E., & Spreen, O. 
(2006). A compendium of 
neuropsychological tests: Administration, 







Judgement of Line 
Orientation 
 
Glamser, F. D., & Turner, R. W. (1995). 
Youth sport participation and associated 
sex differences on a measure of spatial 




Ska, B., Poissant, A., & Joanette, Y. 
(1990). Line orientation judgment in 
normal elderly and subjects with dementia 
of Alzheimer's type. Journal of Clinical 







Tamkin, A. S., & Jacobsen, R. (1984). 
Age‐related norms for the Hooper Visual 
Organization Test. Journal of clinical 







Boston Naming Test – 
Short  
 
Fastenau, P. S., Denburg, N. L., & Mauer, 
B. A. (1998). Parallel short forms for the 
Boston Naming Test: Psychometric 
properties and norms for older adults. 
Journal of Clinical and Experimental 






Wechsler, D. (2008). Wechsler Adult 
Intelligence Scale–Fourth Edition (WAIS–













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pre-intervention neuropsychological test results for intervention groups 
  Standard CT Tailored CT tDCS  
Domain Outcome M SD M SD M SD  
EF COWAT 38.86 14.98 32.43 17.89 30.86 17.39  
 SOC 7.85 1.07 6.43 2.51 5.42 1.27  
Atten.WM LNS 18.86 2.41 17.86 4.60 14.71 6.75  
 Stroop Test 34.29 8.38 31.43 11.83 20 8.49  
Memory HVLT 22.14 6.52 22.86 6.41 19.42 9.25  
 Paragraph Recall 5 2.36 5.64 2.36 4 2.40  
Language BNT 14.14 1.86 13.14 1.35 12.57 1.13  
 Similarities 21.71 3.50 22.29 3.45 22.57 3.16  
VS JLO 24.57 2.94 20.14 4.41 21.43 8.44  
 HVOT 24.57 4.08 20.29 4.54 21 3.87  
Global MMSE 26.29 2.14 25.86 3.13 24.14 1.77 
 PD-CRS 89.57 12.08 88.29 15.82 72.57 19.03 
ADL UPDRS-II .95 .83 .68 .34 1.27 .59  
QOL PDQ-39 23.50 11.35 18.89 9.82 23.62 11.93  
  
Standard CT + 
tDCS 
Tailored CT + 
tDCS 
Control  
Domain Outcome M SD M SD M SD 
EF COWAT 37.71 10.66 32.14 9.96 30.14 16.65 
 SOC 7.43 1.51 5.29 1.11 6 3.06 
Atten.WM LNS 18.42 2.82 17.43 3.60 14.29 7.04 
 Stroop Test 23.14 9.46 28.57 11.97 18.57 10.01 
Memory HVLT 27.71 3.25 21.29 2.98 20.29 6.87 
 Paragraph Recall 6 2.24 3.21 1.55 4.07 2.59 
Language BNT 13.29 1.70 14 1.53 12.43 2.15 
 Similarities 21.86 2.41 23.14 3.85 18.43 2.70 
VS JLO 23.86 5.76 23.14 8.25 20.14 8.53 
 HVOT 23.43 3.69 21.86 3.81 23.57 2.37 
Global MMSE 27.86 .69 26.71 2.36 24.71 2.63 
 PD-CRS 90 13.22 86.14 15.46 74.14 23.23 
ADL UPDRS-II 1 .52 1.17 .61 1.17 .75 




Post-intervention neuropsychological test results for intervention groups 
  Standard CT Tailored CT tDCS  
Domain Outcome M SD M SD M SD  
EF COWAT 44.14 12.28 34.71 13.14 36 16.29  
 SOC 6.43 2.70 5.43 3.05 5.57 2.88  
Atten.WM LNS 18.71 4.68 19 4.16 15.86 6.82  
 Stroop Test 36.57 10.13 34.71 12.89 26.29 12.57  
Memory HVLT 27 6.73 25.29 7.52 24.43 7.18  
 Paragraph Recall 6.36 2.46 7.36 3.78 6.29 2.20  
Language BNT 13.86 1.07 13.86 1.35 13.71 1.98  
 Similarities 23.14 3.19 22.14 3.29 23.57 2.64  
VS JLO 23.86 4.30 22.86 4.49 22.57 5.77  
 HVOT 25.19 3.86 23.14 4.67 22.43 4.58  
Global MMSE 26.14 2.19 27.28 3.40 25.86 2.27 
 PD-CRS 96.29 12.89 97 24.39 82.86 19.39 
ADL UPDRS-II .73 .80 .80 .43 1.06 .71  
QOL PDQ-39 22.30 10.08 17.38 13.93 21.28 13.77  
  
Standard CT + 
tDCS 
Tailored CT + 
tDCS 
Control  
Domain Outcome M SD M SD M SD 
EF COWAT 46.14 5.24 36.29 9.12 27.42 10.71 
 SOC 8.43 3.99 7 2.24 5.57 4.20 
Atten.WM LNS 19 2.45 18.43 2.07 14.71 7.09 
 Stroop Test 29.14 9.28 29.29 8.12 18.14 9.14 
Memory HVLT 29.71 3.94 25.14 3.48 22.43 7.41 
 Paragraph Recall 8.21 1.50 5.71 1.78 4.07 1.95 
Language BNT 14.43 .79 14.29 1.11 13 1.92 
 Similarities 23.86 1.46 25.57 3.91 19.14 2.34 
VS JLO 25.57 5.03 23.29 6.68 19.86 9.19 
 HVOT 24.71 3.04 24.43 3.60 23.86 2.67 
Global MMSE 27.71 1.60 26.86 1.35 23.71 2.81 
 PD-CRS 101.71 12.23 94.43 14.01 75.14 18.73 
ADL UPDRS-II .62 .56 .97 .52 1.25 1.02 




Follow-up neuropsychological test results for intervention groups 
  Standard CT Tailored CT tDCS  
Domain Outcome M SD M SD M SD  
EF COWAT 20.72 7.66 31.86 25.48 30.57 18.95  
 SOC 4.99 4.71 4.29 3.20 6 3.16  
Atten.WM LNS 11.04 8.68 17.29 8.28 15.71 5.96  
 Stroop Test 28.05 20.48 27.29 16.57 25.14 8.15  
Memory HVLT 19.17 14.51 23 12.57 22.43 8.44  
 Paragraph Recall 4.99 3.91 6.36 4.16 4.36 2.70  
Language BNT 9.57 6.63 11.71 5.28 13.29 1.80  
 Similarities 13.89 9.94 20 9.15 21.57 3.10  
VS JLO 13.16 10.16 18.71 8.90 24.71 4.92  
 HVOT 18.50 12.89 19.29 9.50 21 4.87  
Global MMSE 19.69 13.58 22.29 10.08 25.29 2.87 
 PD-CRS 73.23 51.39 84.86 43.80 76.86 22.73 
ADL UPDRS-II .71 .97 .66 .38 1.23 .72  
QOL PDQ-39 26.65 21.08 11.74 16.96 11.99 9.57  
  
Standard CT + 
tDCS 
Tailored CT + 
tDCS 
Control  
Domain Outcome M SD M SD M SD 
EF COWAT 39.85 12.13 35.86 12.39 30.86 23.49 
 SOC 9.14 2.27 8.57 2.37 4.43 4.39 
Atten.WM LNS 18.71 2.56 19.57 1.99 13.57 8.30 
 Stroop Test 32.43 9.47 31 6.98 19.86 19.07 
Memory HVLT 31.14 4.22 25.43 6.21 19.57 11.53 
 Paragraph Recall 6.64 1.95 6.43 2.41 2.93 1.64 
Language BNT 14 1 14.57 .53 10.29 4.92 
 Similarities 21.57 1.90 21.71 4.27 17.86 8.03 
VS JLO 24 7.55 22.86 7.54 19.57 13.18 
 HVOT 23.71 3.04 24.71 3.09 20.57 9.41 
Global MMSE 28.57 .98 26.71 1.80 21.57 10.11 
 PD-CRS 97.86 16.75 91.57 12.25 68.43 39.26 
ADL UPDRS-II .77 .35 1.16 .52 1.03 1.06 





Between group effect sizes based on change scores 
     Comparison Group Effect Sizes (g)** 






 Control EF COWAT Post .70 .42 .58 1.33 .70 
    Follow-up -.13 -.06 -.30 -.22 -.12 
   SOC Post  -1.19 -.51 -.13 .41 .19 
    Follow-up -.66 -.91 .14 .23 .92 
  Atten./WM LNS Post  -.04 .19 .12 -.04 .02 
    Follow-up -.42 .34 .13 -.14 .22 
   Stroop Test Post  .35 .34 .65 .60  .14  
    Follow-up -.15 -.25 .01 .24 -.17 
  Memory HVLT Post  .46 .05 .45 -.03 .37 
    Follow-up .51 .24 .03 .09 .22 
   Para. Recall Post  .62 .58 1.11 1.29 1.36 
    Follow-up 1.30 .70 .28 .57 1.75 





     Comparison Group Effect Sizes (g)** 





 Control   Follow-up .01 .69 .65 .77 .73 
   Similarities Post  .28 -.36 .13 .59 1.06 
    Follow-up -.98 -.55 -1.25 -.95 -1.58 
  VS JLO Post  -.08 .49 .24 .37 .06 
    Follow-up -.32 .04 .18 -.23 -.28 
   HVOT Post  .06 .61 .24 .21 .54 
    Follow-up .33 .60 -.01 .05 .62 
  GC MMSE Post  .41 .98 1.36 .46 .61 
    Follow-up .59 .35 .55 .50 .19 
   PDCRS Post  .44 .39 .53 .71 .51 
    Follow-up .27 .28 -.06 .10 -.02 
  QOL PDQ39 Post  .24 .26 .22 .27 -.14 
    Follow-up -.24 .12 .37 -.09 .27 
  ADL UPDRS-II Post  .33 -.06 .32 .55 .34 







     Comparison Group Effect Sizes (g)** 






 Standard CT EF COWAT Post – -.24 -.01 .34 -.11 
     Follow-up – .05 -.20 -.09 .03 
   SOC Post  – .76 1.21 1.71 1.40 
    Follow-up – -.23 .79 .84 1.41 
  Atten./WM LNS Post  – .28 .17 .01 .09 
    Follow-up – .86 .59 .40 .83 
   Stroop Test Post  – .10 .45 .39  -.24  
    Follow-up – -.22 .34 .66 -.05 
  Memory HVLT Post  – -.40 .02 -.62 -.23 
    Follow-up – -.19 -.39 -.48 -.27 
   Para. Recall Post  – .11 .40 .42 .54 
    Follow-up – -.18 -.72 -.77 .50 
  Language BNT Post  – .83 .91 1.53 .53 
    Follow-up – .87 .77 .99 1 






     Comparison Group Effect Sizes (g)** 





 Standard CT   Follow-up – .52 -.45 -.16 -.96 
  VS JLO Post  – .65 .38 .55 .15 
    Follow-up – .53 .65 .10 .03 
   HVOT Post  – .58 .19 .16 .50 
    Follow-up – .34 -.44 -.36 .35 
  GC MMSE Post  – .67 1.02 .00 .17 
    Follow-up – -.40 -.04 -.24 -.54 
   PDCRS Post  – .11 .23 .41 .14 
    Follow-up – .08 -.37 -.18 -.50 
  QOL PDQ39 Post  – -.02 -.04 .02 -.45 
    Follow-up – .41 .67 .16 .53 
  ADL UPDRS-II Post  – -.55 -.03 .22 -.05 








     Comparison Group Effect Sizes (g)** 






 Tailored CT EF COWAT Post – – .20 .62 .17 
     Follow-up – – -.22 -.13 -.04 
   SOC Post  – – .44 1.02 .72 
    Follow-up – – 1.04 1.08 1.64 
  Atten./WM LNS Post  – – -.04 -.38 -.31 
    Follow-up – – -.23 -.66 -.24 
   Stroop Test Post  – – .25 .22  -.25  
    Follow-up – – .52 .78 .17 
  Memory HVLT Post  – – .39 -.08 .29 
    Follow-up – – -.19 -.17 -.04 
   Para. Recall Post  – – .19 .17 .27 
    Follow-up – – -.40 -.35 .55 
  Language BNT Post  – – .25 .38 -.35 
    Follow-up – – .05 .06 -.07 







     Comparison Group Effect Sizes (g)** 





 Tailored CT   Follow-up – – -.88 -.54 -1.30 
  VS JLO Post  – – -.28 -.20 -.41 
    Follow-up – – .21 -.37 -.42 
   HVOT Post  – – -.39 -.42 -.08 
    Follow-up – – -.80 -.71 .01 
  GC MMSE Post  – – .12 -.73 -.59 
    Follow-up – – .35 .25 -.24 
   PDCRS Post  – – .07 .16 -.02 
    Follow-up – – -.36 -.21 -.40 
  QOL PDQ39 Post  – – -.03 .06 -.56 
    Follow-up – – .30 -.24 .18 
  ADL UPDRS-II Post  – – .57 1 .68 








     Comparison Group Effect Sizes (g)** 






 tDCS EF COWAT Post – – – .27 -.08 
     Follow-up – – – .14 .25 
   SOC Post  – – – .66 .36 
    Follow-up – – – .10 .81 
  Atten./WM LNS Post  – – – -.19 -.13 
    Follow-up – – – -.33 .07 
   Stroop Test Post  – – – -.03  -.59  
    Follow-up – – – .42 -.38 
  Memory HVLT Post  – – – -.59 -.23 
    Follow-up – – – .05 .17 
   Para. Recall Post  – – – -.04 .11 
    Follow-up – – – .13 1.13 
  Language BNT Post  – – – .00 -.54 
    Follow-up – – – -.01 -.11 







     Comparison Group Effect Sizes (g)** 





 tDCS   Follow-up – – – .20 -.55 
  VS JLO Post  – – – .12 -.17 
    Follow-up – – – -.50 -.55 
   HVOT Post  – – – -.04 .31 
    Follow-up – – – .08 .82 
  GC MMSE Post  – – – -1.18 -.97 
    Follow-up – – – -.19 -.50 
   PDCRS Post  – – – .08 -.12 
    Follow-up – – – .17 .07 
  QOL PDQ39 Post  – – – .07 -.45 
    Follow-up – – – -.52 -.09 
  ADL UPDRS-II Post  – – – .27 -.02 







     Comparison Group Effect Sizes (g)** 







Standard CT + 
tDCS 
EF COWAT Post – – – – -.58 
     Follow-up – – – – .14 
   SOC Post  – – – – -.22 
    Follow-up – – – – .69 
  Atten./WM LNS Post  – – – – .12 
    Follow-up – – – – .65 
   Stroop Test Post  – – – –  -.53  
    Follow-up – – – – -.68 
  Memory HVLT Post  – – – – .67 
    Follow-up – – – – .15 
   Para. Recall Post  – – – – .18 
    Follow-up – – – – 1.26 
  Language BNT Post  – – – – -.89 
    Follow-up – – – – -.18 







     Comparison Group Effect Sizes (g)** 






Standard CT + 
tDCS 
  Follow-up – – – – -.65 
  VS JLO Post  – – – – -.28 
    Follow-up – – – – -.06 
   HVOT Post  – – – – .34 
    Follow-up – – – – .73 
  GC MMSE Post  – – – – .20 
    Follow-up – – – – -.46 
   PDCRS Post  – – – – -.26 
    Follow-up – – – – -.16 
  QOL PDQ39 Post  – – – – -.54 
    Follow-up – – – – .39 
  ADL UPDRS-II Post  – – – – -.33 
    Follow-up – – – – -.51 
Note. Bolded effect sizes correspond with results reported in text.  H = hypothesis; g = Hedge’s g; CT = cognitive training; tDCS = transcranial 
direct current stimulation; * = post changes scores calculated using ‘pre-intervention mean – post-intervention mean’ and follow-up change 
scores calculated using ‘pre-intervention mean – follow-up intervention mean’; ** = positive effect sizes favour comparison group.  24
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